Compounds and methods for the targeted degradation of androgen receptor

ABSTRACT

The present disclosure relates to bifunctional compounds, which find utility to degrade and (inhibit) Androgen Receptor. In particular, the present disclosure is directed to compounds, which contain on one end a cereblon ligand which binds to the E3 ubiquitin ligase and on the other end a moiety which binds Androgen Receptor, such that Androgen Receptor is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of Androgen Receptor. The present disclosure exhibits a broad range of pharmacological activities associated with compounds according to the present disclosure, consistent with the degradation/inhibition of Androgen Receptor.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. patent application Ser. No.16/888,484, filed 29 May 2020, which is a continuation of U.S. patentapplication Ser. No. 16/577,901, filed 20 Sep. 2019, which is adivisional of U.S. patent application Ser. No. 15/730,728, filed 11 Oct.2017, now U.S. Pat. No. 10,584,101, which claims priority to and thebenefit of U.S. Provisional Application No. 62/528,385, filed 3 Jul.2017, and U.S. Provisional Application No. 62/406,888, filed 11 Oct.2016, each of which is incorporated by reference herein in its entiretyfor all purposes.

INCORPORATION BY REFERENCE

U.S. patent application Ser. No. 14/686,640, filed on Apr. 14, 2015,published as U.S. Patent Application Publication No. 2016/0058872; U.S.patent application Ser. No. 14/792,414, filed on Jul. 6, 2015, publishedas U.S. Patent Application Pulbication No. 2015/0291562; U.S. patentapplication Ser. No. 14/371,956, filed on Jul. 11, 2014, published asU.S. Patent Application Publication No. 2014/0356322; U.S. patentapplication Ser. No. 15/074,820, filed on Mar. 18, 2016, published asU.S. Patent Application Publication No. 2016/0272639, are incorporatedherein in their entireties. Furthermore, all references cited herein areincorporated by reference herein in their entirety.

STATEMENT REGARDING FEDERALLY FUNDED RESEARCH

This invention was made with government support under grant number1R44CA203199-01 by the National Cancer Institute. The government hascertain rights in the invention.

FIELD OF THE INVENTION

The present description provides imide-based compounds, includingbifunctional compounds comprising the same, and associated methods ofuse. The bifunctional compounds are useful as modulators of targetedubiquitination, especially with respect to a variety of polypeptides andother proteins, which are degraded and/or otherwise inhibited bybifunctional compounds according to the present disclosure. In certainaspects, the bifunctional compounds comprise a Cereblon E3 UbiquitinLigase (CRBN) binding moiety, which binds to the cereblon E3 ubiquitinligase, a target protein binding moiety, which binds to the targetprotein (e.g., androgen receptor), and optionally a linker moiety whichlinks the cereblon binding moiety and target protein binding moiety.These compounds work in such a way that the target protein/polypeptideis placed in proximity to the ubiquitin ligase to effect degradation(and inhibition) of that protein (e.g., androgen receptor).

BACKGROUND

Most small molecule drugs bind enzymes or receptors in tight andwell-defined pockets. On the other hand, protein-protein interactionsare notoriously difficult to target using small molecules due to theirlarge contact surfaces and the shallow grooves or flat interfacesinvolved. E3 ubiquitin ligases (of which hundreds are know in humans)confer substrate specificity for ubiquitination, and therefore, are moreattractive therapeutic targets than general proteasome inhibitors due totheir specificity for certain protein substrates. The development ofligands of E3 ligases has proven challenging, in part due to the factthat they must disrupt protein-protein interactions. However, recentdevelopments have provided specific ligands which bind to these ligases.For example, since the discovery of nutlins, the first small molecule E3ligase inhibitors, additional compounds have been reported that targetE3 ligases, but the field remains underdeveloped.

One E3 ligase with therapeutic potential is Cereblon, a protein that inhumans is encoded by the CRBN gene. CRBN orthologs are highly conservedfrom plants to humans, which underscores its physiological importance.Cereblon forms an E3 ubiquitin ligase complex with damaged DNA bindingprotein 1 (DDB1), Cullin-4A (CUL4A), and regulator of cullins 1 (ROC1).This complex ubiquitinates a number of other proteins. Through amechanism which has not been completely elucidated, cereblonubquitination of target proteins results in increased levels offibroblast growth factor 8 (FGF8) and fibroblast growth factor 10(FGF10). FGF8 in turn regulates a number of developmental processes,such as limb and auditory vesicle formation. The net result is that thisubiquitin ligase complex is important for limb outgrowth in embryos. Inthe absence of cereblon, DDB1 forms a complex with DDB2 that functionsas a DNA damage-binding protein.

Thalidomide, which has been approved for the treatment of a number ofimmunological indications, has also been approved for the treatment ofcertain neoplastic diseases, including multiple myeloma. In addition tomultiple myeloma, thalidomide and several of its analogs are alsocurrently under investigation for use in treating a variety of othertypes of cancer. While the precise mechanism of thalidomide's anti-tumoractivity is still emerging, it is known to inhibit angiogenesis. Recentliterature discussing the biology of the imides includes Lu et al.Science 343, 305 (2014) and Krönke et al. Science 343, 301 (2014).

Significantly, thalidomide and its analogs e.g. pomolinamiode andlenalinomide, are known to bind cereblon. These agents bind to cereblon,altering the specificity of the complex to induce the ubiquitination anddegradation of Ikaros (IKZF1) and Aiolos (IKZF3), transcription factorsessential for multiple myeloma growth. Indeed, higher expression ofcereblon has been linked to an increase in efficacy of imide drugs inthe treatment of multiple myeloma.

Androgen Receptor (AR) belongs to a nuclear hormone receptor family thatis activated by androgens, such as testosterone and dihydrotestosterone(Pharmacol. Rev. 2006, 58(4), 782-97; Vitam. Horm. 1999, 55:309-52.). Inthe absence of androgens, AR is bound by Heat Shock Protein 90 (Hsp90)in the cytosol. When an androgen binds AR, its conformation changes torelease AR from Hsp90 and to expose the Nuclear Localization Signal(NLS). The latter enables AR to translocate into the nucleus where ARacts as a transcription factor to promote gene expression responsiblefor male sexual characteristics (Endocr. Rev. 1987, 8(1):1-28; Mol.Endocrinol. 2002, 16(10), 2181-7). AR deficiency leads to AndrogenInsensitivity Syndrome, formerly termed testicular feminization.

While AR is responsible for development of male sexual characteristics,it is also a well-documented oncogene in certain forms cancers includingprostate cancers (Endocr. Rev. 2004, 25(2), 276-308). A commonlymeasured target gene of AR activity is the secreted Prostate SpecificAntigen (PSA) protein. The current treatment regimen for prostate cancerinvolves inhibiting the androgen-AR axis by two methods. The firstapproach relies on reduction of androgens, while the second strategyaims to inhibit AR function (Nat. Rev. Drug Discovery, 2013, 12,823-824). Despite the development of effective targeted therapies, mostpatients develop resistance and the disease progresses. An alternativeapproach for the treatment of prostate cancer involves eliminating theAR protein. Because AR is a critical driver of tumorigenesis in manyforms of prostate cancers, its elimination should lead totherapeutically beneficial response.

There exists an ongoing need in the art for effective treatments fordiseases, especially cancer, prostate cancer, and Kennedy's Disease.However, non-specific effects, and the inability to target and modulatecertain classes of proteins altogether, such as transcription factors,remain as obstacles to the development of effective anti-cancer agents.As such, small molecule therapeutic agents that leverage or potentiatecereblon's substrate specificity and, at the same time, are “tunable”such that a wide range of protein classes can be targeted and modulatedwith specificity would be very useful as a therapeutic.

BRIEF SUMMARY OF THE INVENTION

The present disclosure describes bi-functional compounds, which functionto recruit endogenous proteins to an E3 Ubiquitin Ligase fordegradation, and methods of using the same. In particular, the presentdisclosure provides bifunctional or proteolysis targeting chimeric(PROTAC) compounds, which find utility as modulators of targetedubiquitination of a variety of polypeptides and other proteins (such asandrogen receptor), which are then degraded and/or otherwise inhibitedby the bifunctional compounds as described herein. An advantage of thecompounds provided herein is that a broad range of pharmacologicalactivities is possible, consistent with the degradation/inhibition oftargeted polypeptides from virtually any protein class or family. Inaddition, the description provides methods of using an effective amountof the compounds as described herein for the treatment or ameliorationof a disease condition including cancer, e.g., prostate cancer, andKennedy's Disease.

Thus, in one aspect, the disclosure provides novel imide-based compoundsas described herein.

In an additional aspect, the disclosure provides bifunctional or PROTACcompounds, which comprise an E3 Ubiqutin Ligase binding moiety (i.e. aligand for an E3 Ubiquitin Ligase or “ULM” group), and a moiety thatbinds a target protein (i.e. a protein/polypeptide targeting ligand or“PTM” group) such that the target protein/polypeptide is placed inproximity to the ubiquitin ligase to effect degrataion (and inhibition)of that protein. In a preferred embodiment the ULM is a cereblon E3Ubiquitin Ligase binding moiety (i.e. a “CLM”). For example, thestructure of the bifunctional compound can be depicted as:

PTM-CLM.

The respective positions of the PTM and CLM moieties as well as theirnumber as illustrated herein is provided by way of example only and isnot intended to limit the compounds in any way. As would be understoodby the skilled artisan, the bifunctional compounds as described hereincan be synthesized such that the number and position of the respectivefunctional moieties can be varied as desired.

In certain embodiments the bifunctional compound may further comprise achemical linker (“L”). In this example, the structure of thebifunctional compounds can be depicted as:

PTM-L-CLM,

wherein the PTM is a protein/polypeptide targeting moiety, the L is achemical linker moiety or bond that links the PTM and the CLM, and theCLM is a cereblon E3 ubiquitin ligase binding moiety.

In certain preferred embodiments, the E3 Ubiquitin Ligase is cereblon.As such, in certain additional embodiments, the CLM of the bifunctionalcompound comprises chemistries such as imide, amide, thioamide,thioimide derived moieties. In additional embodiments, the CLM comprisesa phthalimido group or an analog or derivative thereof. In stilladditional embodiments, the CLM comprises a phthalimido-glutarimidegroup or an analog or derivative thereof. In still other embodiments,the CLM comprises a member of the group consisting of thalidomide,lenalidomide, pomalidomide, and analogs or derivatives thereof.

In certain embodiments, the compounds as described herein comprisemultiple CLMs, multiple PTMs, multiple chemical linkers or a combinationthereof.

It will be understood that the general structures are exemplary and therespective moieties can be arranged spatially in any desired order orconfiguration, e.g., CLM-L-PTM, and PTM-L-CLM respectively.

In certain embodiments, the PTM is an AR binding moieties (ABM). Inparticular embodiments, the ABM is selected from following structures:

wherein:

-   -   W¹ is aryl, heteroaryl, bicyclic, or biheterocyclic, each        independently substituted by 1 or more H, halo, hydroxyl, nitro,        CN, C≡CH, C₁₋₆ alkyl (linear, branched, optionally substituted;        for example, optionally substituted by 1 or more halo, C₁₋₆        alkoxyl), C₁₋₆ alkoxyl (linear, branched, optionally        substituted; for example, optionally substituted by by 1 or more        halo), C₂₋₆ alkenyl, C₂₋₆ alkynyl, or CF₃;    -   Y¹, Y² are each independently NR^(Y1), O, S;    -   Y³, Y⁴, Y⁵ are each independently a bond, O, NR^(Y2),        CR^(Y1)R^(Y2), C═O, C═S, SO, SO₂ heteroaryl, or aryl;    -   Q is a 3-6 membered alicyclic or aromatic ring with 0-4        heteroatoms, optionally substituted with 0-6 R^(Q), each R^(Q),        is independently H, C₁₋₆ alkyl (linear, branched, optionally        substituted; for example, optionally substituted by 1 or more        halo, C₁₋₆ alkoxyl), halogen, C₁₋₆ alkoxy, or 2 R^(Q) groups        taken together with the atom they are attached to, form a 3-8        membered ring system containing 0-2 heteroatoms);    -   R¹, R², R^(a), R^(b), R^(Y1), R^(Y2) are each independently H,        C₁₋₆ alkyl (linear, branched, optionally substituted; for        example, optionally substituted by 1 or more halo, C₁₋₆        alkoxyl), halogen, C₁₋₆ alkoxy, cyclic, heterocyclic, or R¹, R²        together with the atom they are attached to, form a 3-8 membered        ring system containing 0-2 heteroatoms);    -   W² is a bond, C₁₋₆ alkyl, C₁₋₆ heteroalkyl, O, C₁₋₆ alicyclic,        heterocyclic, aryl, heteroaryl, biheterocyclic, biaryl, or        biheteroaryl, each optionally substituted by 1-10 R^(W2); each        R^(W2) is independently H, halo, C₁₋₆ alkyl (linear, branched,        optionally substituted; for example, optionally substituted by 1        or more F), C₁₋₆ heteroalkyl (linear, branched, optionally        substituted), —OR^(W2A), C₃₋₆ cycloalkyl, C₄₋₆ cycloheteroalkyl,        OC₁₋₃alkyl (optionally substituted; for example, optionally        substituted by 1 or more —F), C₁₋₆ alicyclic (optionally        substituted), heterocyclic (optionally substituted), aryl        (optionally substituted), or heteroaryl (optionally        substituted), bicyclic hereoaryl or aryl, OH, NH₂,        NR^(Y1)R^(Y2), CN; and    -   R^(W2A) is H, C₁₋₆ alkyl (linear, branched), or C₁₋₆ heteroalkyl        (linear, branched), each optionally substituted by a cycloalkyl,        cycloheteroalkyl, aryl, heterocyclic, heteroaryl, halo, or        OC₁₋₃alkyl.

In an additional aspect, the description provides therapeuticcompositions comprising an effective amount of a compound as describedherein or salt form thereof, and a pharmaceutically acceptable carrier.The therapeutic compositions modulate protein degradation in a patientor subject, for example, an animal such as a human, and can be used fortreating or ameliorating disease states or conditions which aremodulated through the degraded protein. In certain embodiments, thetherapeutic compositions as described herein may be used to effectuatethe degradation and/or inhibition of proteins of interest for thetreatment or amelioration of a disease, e.g., cancer. In yet anotheraspect, the present disclosure provides a method ofubiquitinating/degrading a target protein in a cell. In certainembodiments, the method comprises administering a bifunctional compoundas described herein comprising an CLM and a PTM, preferably linkedthrough a linker moiety, as otherwise described herein, wherein the CLMis coupled to the PTM and wherein the CLM recognizes a ubiquitin pathwayprotein (e.g., a ubiquitin ligase, preferably an E3 ubiquitin ligasesuch as cereblon) and the PTM recognizes the target protein such thatdegradation of the target protein will occur when the target protein isplaced in proximity to the ubiquitin ligase, thus resulting indegradation/inhibition of the effects of the target protein and thecontrol of protein levels. The control of protein levels afforded by thepresent disclosure provides treatment of a disease state or condition,which is modulated through the target protein by lowering the level ofthat protein in the cells of a patient.

In an additional aspect, the description provides a method for assessing(i.e., determining and/or measuring) a CLM's binding affinity. Incertain embodiments, the method comprises providing a test agent orcompound of interest, for example, an agent or compound having an imidemoiety, e.g., a phthalimido group, phthalimido-glutarimide group,derivatized thalidomide, derivatized lenalidomide or derivatizedpomalidomide, and comparing the cereblon binding affinity and/orinhibitory activity of the test agent or compound as compared to anagent or compound known to bind and/or inhibit the activity of cereblon.

In still another aspect, the description provides methods for treatingor emeliorating a disease, disorder or symptom thereof in a subject or apatient, e.g., an animal such as a human, comprising administering to asubject in need thereof a composition comprising an effective amount,e.g., a therapeutically effective amount, of a compound as describedherein or salt form thereof, and a pharmaceutically acceptable carrier,wherein the composition is effective for treating or ameliorating thedisease or disorder or symptom thereof in the subject.

In another aspect, the description provides methods for identifying theeffects of the degradation of proteins of interest in a biologicalsystem using compounds according to the present disclosure.

The preceding general areas of utility are given by way of example onlyand are not intended to be limiting on the scope of the presentdisclosure and appended claims. Additional objects and advantagesassociated with the compositions, methods, and processes of the presentdisclosure will be appreciated by one of ordinary skill in the art inlight of the instant claims, description, and examples. For example, thevarious aspects and embodiments of the invention may be utilized innumerous combinations, all of which are expressly contemplated by thepresent description. These additional advantages objects and embodimentsare expressly included within the scope of the present disclosure. Thepublications and other materials used herein to illuminate thebackground of the invention, and in particular cases, to provideadditional details respecting the practice, are incorporated byreference.

Where applicable or not specifically disclaimed, any one of theembodiments described herein are contemplated to be able to combine withany other one or more embodiments, even though the embodiments aredescribed under different aspects of the disclosure. As such, thepreceding general areas of utility are given by way of example only andare not intended to be limiting on the scope of the present disclosureand appended claims. Additional objects and advantages associated withthe compositions, methods, and processes of the present disclosure willbe appreciated by one of ordinary skill in the art in light of theinstant claims, description, and examples. For example, the variousaspects and embodiments of the disclosure may be utilized in numerouscombinations, all of which are expressly contemplated by the presentdescription. These additional advantages objects and embodiments areexpressly included within the scope of the present disclosure. Thepublications and other materials used herein to illuminate thebackground of the disclosure, and in particular cases, to provideadditional details respecting the practice, are incorporated byreference.

BRIEF DESCRIPTION OF THE DRAWINGS

The accompanying drawings, which are incorporated into and form a partof the specification, illustrate several embodiments of the presentdisclosure and, together with the description, serve to explain theprinciples of the present disclosure. The drawings are only for thepurpose of illustrating an embodiment of the disclosure and are not tobe construed as limiting the invention. Further objects, features andadvantages of the invention will become apparent from the followingdetailed description taken in conjunction with the accompanying figuresshowing illustrative embodiments of the disclosure, in which:

FIG. 1A and FIG. 1B. Illustration of general principle for PROTACfunction. FIG. 1A: Exemplary PROTACs comprise an androgen receptortargeting moiety (ABM; darkly shaded rectangle), a E3 ubiquitin Ligasebinding moiety, such as a cereblon E3 ubiquitin ligase binding moiety(CLM; lightly shaded triangle), and a linker moiety (L; black line)coupling or tethering the ABM to the CLM (as described herein, L can beabsent or a bond or a chemical linker moiety). FIG. 1B Illustrates thefunctional use of the PROTACs as described herein. Briefly, the CLMrecognizes and binds to cereblon E3 ubiquitin ligase, and the ABM bindsand recruits androgen receptor and brings it into close proximity to thecereblon E3 ubiquitin ligase. Typically, the E3 ubiquitin ligase iscomplexed with an E2 ubiquitin-conjugating protein, and either alone orvia the E2 protein catalyzes attachment of ubiquitin (dark circles) to alysine on the target protein via an isopeptide bond. Thepoly-ubiquitinated protein (far right) is then targeted for degradationby the proteosomal machinery of the cell.

FIG. 2. Table 2 that include Exemplary Compounds 1-75, as well as theGeneral Scheme that may be used to produce each of the ExemplaryCompounds. Table 2 also includes the DC50, Dmax, M/Z+, and 1H NMR datafor each of the Exemplary Compounds. DC50 (μM) categories (degradationof AR ELISA in LNCaP and/or VCaP cells): A<1 nM; B: 1-10 nM; C: 10-100nM; D: >100 nM. Dmax categories (degradation of AR-maximum inhibition(%) AR ELISA in LNCaP and/or VCaP cells): A>50%; B<50%.

FIG. 3. Table 3 that include Exemplary Compounds 76-398, as well as theGeneral Scheme that may be used to produce each of the ExemplaryCompounds. Table 3 also includes the DC50, M/Z+, and 1H NMR data foreach of the Exemplary Compounds. DC50 (μM) categories (degradation of ARELISA in LNCaP and/or VCaP cells): A<1 nM; B: 1-10 nM; C: 10-100 nM;D: >100 nM.

FIG. 4. Table 4 that include Exemplary Compounds 399-427, as well as theGeneral Scheme that may be used to produce each of the ExemplaryCompounds. Table 4 also includes the DC50, Dmax (%), M/Z+, and 1H NMRdata for each of the Exemplary Compounds. DC50 (μM) categories(degradation of AR ELISA in LNCaP and/or VCaP cells): A<1 nM; B: 1-10nM; C: 10-100 nM; D: >100 nM.

FIG. 5. Table 5 that include Exemplary Compounds 428-452. Table 5 alsoincludes the DC50, Dmax (%), M/Z+, and 1H NMR data for each of theExemplary Compounds. DC50 (μM) categories (degradation of AR ELISA inLNCaP and/or VCaP cells): A<1 nM; B: 1-10 nM; C: 10-100 nM; D: >100 nM.

FIG. 6. Table 6 that include Exemplary Compound 528. Table 6 alsoincludes the DC50, Dmax, M/Z+, and 1H NMR data for each of the ExemplaryCompounds. DC50 (μM) categories (degradation of AR ELISA in LNCaP and/orVCaP cells): A<1 nM; B: 1-10 nM; C: 10-100 nM; D: >100 nM. Dmaxcategories (degradation of AR-maximum inhibition (%) AR ELISA in LNCaPand/or VCaP cells): A>50%; B<50%.

FIG. 7. Table 7 that include Exemplary Compounds 529-625. Table 7 alsoincludes the DC50, M/Z+, and 1H NMR data for each of the ExemplaryCompounds. DC50 (M) categories (degradation of AR ELISA in LNCaP and/orVCaP cells): A<1 nM; B: 1-10 nM; C: 10-100 nM; D: >100 nM.

DETAILED DESCRIPTION

The following is a detailed description provided to aid those skilled inthe art in practicing the present invention. Those of ordinary skill inthe art may make modifications and variations in the embodimentsdescribed herein without departing from the spirit or scope of thepresent disclosure. All publications, patent applications, patents,figures and other references mentioned herein are expressly incorporatedby reference in their entirety.

The present description relates to the surprising and unexpecteddiscovery that an E3 ubiquitin ligase protein can ubiquitinate a targetprotein, in particular androgen receptor, once the E3 ubiquitin ligaseprotein and the target protein are brought into proximity by a chimericconstruct (e.g., PROTAC) as described herein, in which a moiety thatbinds the E3 ubiquitin ligase protein is coupled, e.g., covalently, to amoiety that bind the androgen receptor target protein. Accordingly, thepresent description provides compounds, compositions comprising thesame, and associated methods of use for ubiquitination and degradationof a chosen target protein, e.g., androgen receptor (See FIG. 1A andFIG. 1B).

The present description is related in certain aspects to U.S. PatentPublications 2014/0356322A1, 2015/0291562A1, and 2016/0214972A1, all ofwhich are incorporated herein by reference in its entirety for allpurposes.

Unless otherwise defined, all technical and scientific terms used hereinhave the same meaning as commonly understood by one of ordinary skill inthe art to which this disclosure belongs. The terminology used in thedescription is for describing particular embodiments only and is notintended to be limiting of the invention.

Where a range of values is provided, it is understood that eachintervening value, to the tenth of the unit of the lower limit unlessthe context clearly dictates otherwise (such as in the case of a groupcontaining a number of carbon atoms in which case each carbon atomnumber falling within the range is provided), between the upper andlower limit of that range and any other stated or intervening value inthat stated range is encompassed within the invention. The upper andlower limits of these smaller ranges may independently be included inthe smaller ranges is also encompassed within the invention, subject toany specifically excluded limit in the stated range. Where the statedrange includes one or both of the limits, ranges excluding either bothof those included limits are also included in the invention.

The following terms are used to describe the present disclosure. Ininstances where a term is not specifically defined herein, that term isgiven an art-recognized meaning by those of ordinary skill applying thatterm in context to its use in describing the present invention.

The articles “a” and “an” as used herein and in the appended claims areused herein to refer to one or to more than one (i.e., to at least one)of the grammatical object of the article unless the context clearlyindicates otherwise. By way of example, “an element” means one elementor more than one element.

The phrase “and/or,” as used herein in the specification and in theclaims, should be understood to mean “either or both” of the elements soconjoined, i.e., elements that are conjunctively present in some casesand disjunctively present in other cases. Multiple elements listed with“and/or” should be construed in the same fashion, i.e., “one or more” ofthe elements so conjoined. Other elements may optionally be presentother than the elements specifically identified by the “and/or” clause,whether related or unrelated to those elements specifically identified.Thus, as a non-limiting example, a reference to “A and/or B”, when usedin conjunction with open-ended language such as “comprising” can refer,in one embodiment, to A only (optionally including elements other thanB); in another embodiment, to B only (optionally including elementsother than A); in yet another embodiment, to both A and B (optionallyincluding other elements); etc.

As used herein in the specification and in the claims, “or” should beunderstood to have the same meaning as “and/or” as defined above. Forexample, when separating items in a list, “or” or “and/or” shall beinterpreted as being inclusive, i.e., the inclusion of at least one, butalso including more than one, of a number or list of elements, and,optionally, additional unlisted items. Only terms clearly indicated tothe contrary, such as “only one of” or “exactly one of,” or, when usedin the claims, “consisting of,” will refer to the inclusion of exactlyone element of a number or list of elements. In general, the term “or”as used herein shall only be interpreted as indicating exclusivealternatives (i.e., “one or the other but not both”) when preceded byterms of exclusivity, such as “either,” “one of,” “only one of,” or“exactly one of.”

The term “about” and the like, as used herein, in association withnumeric values or ranges, reflects the fact that there is a certainlevel of variation that is recognized and tolerated in the art due topractical and/or theoretical limitations. For example, minor variationis tolerated due to inherent variances in the manner in which certaindevices operate and/or measurements are taken. In accordance with theabove, the phrase “about” is normally used to encompass values withinthe standard deviation or standard error.

In the claims, as well as in the specification above, all transitionalphrases such as “comprising,” “including,” “carrying,” “having,”“containing,” “involving,” “holding,” “composed of,” and the like are tobe understood to be open-ended, i.e., to mean including but not limitedto. Only the transitional phrases “consisting of” and “consistingessentially of” shall be closed or semi-closed transitional phrases,respectively, as set forth in the United States Patent Office Manual ofPatent Examining Procedures, Section 2111.03.

As used herein in the specification and in the claims, the phrase “atleast one,” in reference to a list of one or more elements, should beunderstood to mean at least one element selected from anyone or more ofthe elements in the list of elements, but not necessarily including atleast one of each and every element specifically listed within the listof elements and not excluding any combinations of elements in the listof elements. This definition also allows that elements may optionally bepresent other than the elements specifically identified within the listof elements to which the phrase “at least one” refers, whether relatedor unrelated to those elements specifically identified. Thus, as anonlimiting example, “at least one of A and B” (or, equivalently, “atleast one of A or B,” or, equivalently “at least one of A and/or B”) canrefer, in one embodiment, to at least one, optionally including morethan one, A, with no B present (and optionally including elements otherthan B); in another embodiment, to at least one, optionally includingmore than one, B, with no A present (and optionally including elementsother than A); in yet another embodiment, to at least one, optionallyincluding more than one, A, and at least one, optionally including morethan one, B (and optionally including other elements); etc.

It should also be understood that, in certain methods described hereinthat include more than one step or act, the order of the steps or actsof the method is not necessarily limited to the order in which the stepsor acts of the method are recited unless the context indicatesotherwise.

The terms “co-administration” and “co-administering” or “combinationtherapy” can refer to both concurrent administration (administration oftwo or more therapeutic agents at the same time) and time variedadministration (administration of one or more therapeutic agents at atime different from that of the administration of an additionaltherapeutic agent or agents), as long as the therapeutic agents arepresent in the patient to some extent, preferably at effective amounts,at the same time. In certain preferred aspects, one or more of thepresent compounds described herein, are coadministered in combinationwith at least one additional bioactive agent, especially including ananticancer agent. In particularly preferred aspects, theco-administration of compounds results in synergistic activity and/ortherapy, including anticancer activity.

The term “effective” can mean, but is in no way limited to, thatamount/dose of the active pharmaceutical ingredient, which, when used inthe context of its intended use, effectuates or is sufficient toprevent, inhibit the occurrence, ameliorate, delay or treat (alleviate asymptom to some extent, preferably all) the symptoms of a condition,disorder or disease state in a subject in need of such treatment orreceiving such treatment. The term effective subsumes all othereffective amount or effective concentration terms, e.g., “effectiveamount/dose,” “pharmaceutically effective amount/dose” or“therapeutically effective amount/dose,” which are otherwise describedor used in the present application.

The effective amount depends on the type and severity of disease, thecomposition used, the route of administration, the type of mammal beingtreated, the physical characteristics of the specific mammal underconsideration, concurrent medication, and other factors which thoseskilled in the medical arts will recognize. The exact amount can beascertainable by one skilled in the art using known techniques (see,e.g., Lieberman, Pharmaceutical Dosage Forms (vols. 1-3, 1992); Lloyd,The Art, Science and Technology of Pharmaceutical Compounding (1999);Pickar, Dosage Calculations (1999); and Remington: The Science andPractice of Pharmacy, 20th Edition, 2003, Gennaro, Ed., Lippincott,Williams & Wilkins).

The term “pharmacological composition,” “therapeutic composition,”“therapeutic formulation” or “pharmaceutically acceptable formulation”can mean, but is in no way limited to, a composition or formulation thatallows for the effective distribution of an agent provided by thepresent disclosure, which is in a form suitable for administration tothe physical location most suitable for their desired activity, e.g.,systemic administration.

The term “pharmaceutically acceptable” or “pharmacologically acceptable”can mean, but is in no way limited to, entities and compositions that donot produce an adverse, allergic or other untoward reaction whenadministered to an animal, or a human, as appropriate.

The term “pharmaceutically acceptable carrier” or “pharmacologicallyacceptable carrier” can mean, but is in no way limited to, any and allsolvents, dispersion media, coatings, antibacterial and antifungalagents, isotonic and absorption delaying agents, and the like,compatible with pharmaceutical administration. Suitable carriers aredescribed in the most recent edition of Remington's PharmaceuticalSciences, a standard reference text in the field, which is incorporatedherein by reference. Preferred examples of such carriers or diluentsinclude, but are not limited to, water, saline, finger's solutions,dextrose solution, and 5% human serum albumin. Liposomes and non-aqueousvehicles such as fixed oils may also be used. The use of such media andagents for pharmaceutically active substances is well known in the art.Except insofar as any conventional media or agent is incompatible withthe active compound, use thereof in the compositions is contemplated.Supplementary active compounds can also be incorporated into thecompositions.

The term “systemic administration” refers to a route of administrationthat is, e.g., enteral or parenteral, and results in the systemicdistribution of an agent leading to systemic absorption or accumulationof drugs in the blood stream followed by distribution throughout theentire body. Suitable forms, in part, depend upon the use or the routeof entry, for example oral, transdermal, or by injection. Such formsshould not prevent the composition or formulation from reaching a targetcell (i.e., a cell to which the negatively charged polymer is desired tobe delivered to). For example, pharmacological compositions injectedinto the blood stream should be soluble. Other factors are known in theart, and include considerations such as toxicity and forms which preventthe composition or formulation from exerting its effect. Administrationroutes which lead to systemic absorption include, without limitations:intravenous, subcutaneous, intraperitoneal, inhalation, oral,intrapulmonary and intramuscular. The rate of entry of a drug into thecirculation has been shown to be a function of molecular weight or size.The use of a liposome or other drug carrier comprising the compounds ofthe instant disclosure can potentially localize the drug, for example,in certain tissue types, such as the tissues of the reticularendothelial system (RES). A liposome formulation which can facilitatethe association of drug with the surface of cells, such as, lymphocytesand macrophages is also useful.

The term “local administration” refers to a route of administration inwhich the agent is delivered to a site that is apposite or proximal,e.g., within about 10 cm, to the site of the lesion or disease.

The term “compound”, as used herein, unless otherwise indicated, refersto any specific chemical compound disclosed herein and includestautomers, regioisomers, geometric isomers, and where applicable,stereoisomers, including optical isomers (enantiomers) and othersteroisomers (diastereomers) thereof, as well as pharmaceuticallyacceptable salts and derivatives (including prodrug forms) thereof whereapplicable, in context. Within its use in context, the term compoundgenerally refers to a single compound, but also may include othercompounds such as stereoisomers, regioisomers and/or optical isomers(including racemic mixtures) as well as specific enantiomers orenantiomerically enriched mixtures of disclosed compounds. The term alsorefers, in context to prodrug forms of compounds which have beenmodified to facilitate the administration and delivery of compounds to asite of activity. It is noted that in describing the present compounds,numerous substituents and variables associated with same, among others,are described.

It is understood by those of ordinary skill that molecules which aredescribed herein are stable compounds as generally described hereunder.When the bond

is shown, both a double bond and single bond are represented orunderstood within the context of the compound shown and well-known rulesfor valence interactions.

As used herein, “derivatives” can mean compositions formed from thenative compounds either directly, by modification, or by partialsubstitution. As used herein, “analogs” can mean compositions that havea structure similar to, but not identical to, the native compound.

The term “Ubiquitin Ligase” refers to a family of proteins thatfacilitate the transfer of ubiquitin to a specific substrate protein,targeting the substrate protein for degradation. For example, cereblonis an E3 Ubiquitin Ligase protein that alone or in combination with anE2 ubiquitin-conjugating enzyme causes the attachment of ubiquitin to alysine on a target protein, and subsequently targets the specificprotein substrates for degradation by the proteasome. Thus, E3 ubiquitinligase alone or in complex with an E2 ubiquitin conjugating enzyme isresponsible for the transfer of ubiquitin to targeted proteins. Ingeneral, the ubiquitin ligase is involved in polyubiquitination suchthat a second ubiquitin is attached to the first; a third is attached tothe second, and so forth. Polyubiquitination marks proteins fordegradation by the proteasome. However, there are some ubiquitinationevents that are limited to mono-ubiquitination, in which only a singleubiquitin is added by the ubiquitin ligase to a substrate molecule.Mono-ubiquitinated proteins are not targeted to the proteasome fordegradation, but may instead be altered in their cellular location orfunction, for example, via binding other proteins that have domainscapable of binding ubiquitin. Further complicating matters, differentlysines on ubiquitin can be targeted by an E3 to make chains. The mostcommon lysine is Lys48 on the ubiquitin chain. This is the lysine usedto make polyubiquitin, which is recognized by the proteasome.

The term “patient” or “subject” is used throughout the specification todescribe a cell, tissue, or animal, preferably a mammal, e.g., a humanor a domesticated animal, to whom treatment, including prophylactictreatment, with the compositions according to the present disclosure isprovided. For treatment of those infections, conditions or diseasestates which are specific for a specific animal such as a human patient,the term patient refers to that specific animal, including adomesticated animal such as a dog or cat or a farm animal such as ahorse, cow, sheep, etc. In general, in the present disclosure, the termpatient refers to a human patient unless otherwise stated or impliedfrom the context of the use of the term.

Compounds and Compositions

In one aspect, the present disclosure provides compounds useful forregulating protein activity. The composition comprises a ubiquitinpathway protein binding moiety (preferably for an E3 ubiquitin ligase,alone or in complex with an E2 ubiquitin conjugating enzyme which isresponsible for the transfer of ubiquitin to targeted proteins)according to a defined chemical structure and a protein targeting moietywhich are linked or coupled together, preferably through a linker,wherein the ubiquitin pathway protein binding moiety recognizes aubiquitin pathway protein and the targeting moiety recognizes a targetprotein (e.g., androgen receptor). Such compounds may be referred toherein as PROTAC compounds or PROTACs.

In one aspect, the description provides compounds comprising an E3Ubiquitin Ligase binding moiety (“ULM”) that is a cereblon E3 UbiquitinLigase binding moiety (“CLM”). In one embodiment, the CLM is coupled toa chemical linker group (L) according to the structure:

L-CLM  (I)

wherein L is a chemical linker group and CLM is a cereblon E3 UbiquitinLigase binding moiety. The number and/or relative positions of themoieties in the compounds illustrated herein is provided by way ofexample only. As would be understood by the skilled artisan, compoundsas described herein can be synthesized with any desired number and/orrelative position of the respective functional moieties.

The terms ULM and CLM are used in their inclusive sense unless thecontext indicates otherwise. For example, the term ULM is inclusive ofall ULMs, including those that bind cereblon (i.e., CLMs). Further, theterm CLM is inclusive of all possible cereblon E3 Ubiquitin Ligasebinding moieties.

In another embodiment, the description provides a compound whichcomprises a plurality of CLMs coupled directly or via a chemical linkermoiety (L). For example, a compound having two CLMs can be depicted as:

CLM-CLM  (II) or

CLM-L-CLM  (III).

In certain embodiments, where the compound comprises multiple CLMs, theCLMs are identical. In additional embodiments, the compound comprising aplurality of CLMs further comprises at least one PTM coupled to a CLMdirectly or via a chemical linker (L) or both. In certain additionalembodiments, the compound comprising a plurality of CLMs furthercomprises multiple PTMs. In still additional embodiments, the PTMs arethe same or, optionally, different. In still further embodiments,wherein the PTMs are different the respective PTMs may bind the sameprotein target or bind specifically to a different protein target.

In additional embodiments, the description provides a compoundcomprising at least two different CLMs coupled directly or via achemical linker (L) or both. For example, such a compound having twodifferent CLMs can be depicted as:

CLM-CLM′  (IV) or

CLM-L-CLM′  (V)

wherein CLM′ indicates a cereblon E3 Ubiquitin Ligase binding moietythat is structurally different from CLM. In certain embodiments, thecompound may comprise a plurality of CLMs and/or a plurality of CLM's.In further embodiments, the compound comprising at least two differentCLMs, a plurality of CLMs, and/or a plurality of CLM's further comprisesat least one PTM coupled to a CLM or a CLM′ directly or via a chemicallinker or both. In any of the embodiments described herein, a compoundcomprising at least two different CLMs can further comprise multiplePTMs. In still additional embodiments, the PTMs are the same or,optionally, different. In still further embodiments, wherein the PTMsare different the respective PTMs may bind the same protein target orbind specifically to a different protein target. In still furtherembodiments, the PTM itself is a ULM or CLM (or ULM′ or CLM′)

In another aspect, the description provides bifunctional or PROTACcompounds, which comprise an E3 Ubiqutin Ligase binding moiety (“ULM”)that is a cereblon E3 Ubiquitin Ligase binding moiety (“CLM”), and amoiety that binds a target protein (i.e. a protein/polypeptide targetingligand or “PTM” group) that is an AR binding moiety (“ABM”). In oneembodiment the structure of the bifunctional compound can be depictedas:

ABM-CLM  (VI),

The respective positions of the ABM and CLM moieties as well as theirnumber as illustrated herein is provided by way of example only and isnot intended to limit the compounds in any way. As would be understoodby the skilled artisan, the bifunctional compounds as described hereincan be synthesized such that the number and position of the respectivefunctional moieties can be varied as desired.

In certain embodiments, the compounds having the following generalstructure: ABM-L, wherein ABM is an AR binding moiety as describedherein, and L is a chemical linker moiety, e.g., a linker as describedherein, or optionally a bond.

In certain embodiments the bifunctional compound further comprises achemical linker (“L”). In this example, the structure of thebifunctional compounds can be depicted as:

ABM-L-CLM  (VII)

where ABM is an AR binding moiety as described herein, CLM is a cereblonE3 ligase binding moiety as described herein, and L is a chemical linkermoiety, e.g., a linker as described herein, or optionally a bond, thatlinks the ABM and CLM.

Further, CLM is inclusive of all possible cereblon E3 Ubiquitin Ligasebinding moieties. The CLM group and ABM group may be covalently linkedto the linker group through any covalent bond which is appropriate andstable to the chemistry of the linker.

In certain embodiments, the CLM comprises a moiety that is a ligand ofthe cereblon E3 Ubiquitin Ligase (CRBN). In certain embodiments, the CLMcomprises a chemotype from the “imide” class of molecules. In certainadditional embodiments, the CLM comprises a phthalimido group or ananalog or derivative thereof. In still additional embodiments, the CLMcomprises a phthalimido-glutarimide group or an analog or derivativethereof. In still other embodiments, the CLM comprises a member of thegroup consisting of thalidomide, lenalidomide, pomalidomide, and analogsor derivatives thereof.

It will be understood that the general structures are exemplary and therespective moieties can be arranged in any desired order orconfiguration, e.g., CLM-L-ABM, and CLM-L-ABM respectively. In certainadditional embodiments, the compounds comprise a plurality of E3 ligasebinding moieties and/or a plurality of ABMs.

In certain embodiments, the compounds as described herein comprisemultiple ABMs (targeting the same or different locations of the AR),multiple CLMs, one or more ULMs (i.e., moieties that bind specificallyto another E3 Ubiquitin Ligase, e.g., VHL) or a combination thereof. Inany of the aspects of embodiments described herein, the ABMs, CLMs, andULMs can be coupled directly or via one or more chemical linkers or acombination thereof. In additional embodiments, where a compound hasmultiple ULMs, the ULMs can be for the same E3 Ubiquitin Ligase or eachrespective ULM can bind specifically to a different E3 Ubiquitin Ligase.In still further embodiments, where a compound has multiple ABMs, theABMs are the same or, optionally, different.

In certain embodiments, where the compound comprises multiple CLMs, theCLMs are identical or, optionally, different. In additional embodiments,the compound comprising a plurality of CLMs further comprises at leastone ABM coupled to a CLM directly or via a chemical linker (L) or both.In certain additional embodiments, the compound comprising a pluralityof CLMs further comprises multiple ABMs. In still additionalembodiments, the ABMs are the same or, optionally, different.

In certain embodiments, ABM alone, without forming ABM-L-CLM, providesdesired properties in regulating protein activity.

In any of the aspects or embodiments of compounds described herein,unless indicated otherwise, the compounds are intended to encompasspharmaceutically acceptable salts, enantiomers, stereoisomers, solvatesor polymorphs thereof.

In certain embodiments, the compounds as described herein comprisemultiple PTMs (targeting the same or different protein targets),multiple ABMs, multiple CLMs, one or more ULMs (i.e., moieties that bindspecifically to another E3 Ubiquitin Ligase, e.g., cereblon) or acombination thereof. In any of the aspects of embodiments describedherein, the PTMs, ABMs, CLMs, and ULMs can be coupled directly or viaone or more chemical linkers or a combination thereof. In additionalembodiments, where a compound has multiple ULMs, the ULMs can be for thesame E3 Ubiquintin Ligase or each respective ULM can bind specificallyto a different E3 Ubiquitin Ligase. In still further embodiments, wherea compound has multiple PTMs, the PTMs can bind the same target proteinor each respective PTM can bind specifically to a different targetprotein.

In any aspect or embodiment described herein, the compound of thepresent disclosure has the chemical structure:

wherein:

-   -   CLM is a thalidomide analog comprising a substituted glutaramide        moiety;    -   L is a chemical linker group that is covalently bound to the PTM        and the CLM and has the chemical structure -(A^(L))_(q)-,        wherein:        -   q is greater than or equal to 1;        -   each A^(L) is selected from the group consisting of            CR^(L1)R^(L2), O, NR^(L3), CONR^(L3), CO, C₃₋₁₁ cycloalkyl            optionally substituted with 1-6 R^(L1) and/or R^(L2) groups,            and C₃₋₁₁ heterocyclyl optionally substituted with 1-6            R^(L1) and/or R^(L2) groups, where R^(L1) and R, together            with the carbon they are linked optionally form a cycloalkyl            and/or heterocyclyl group; and        -   R^(L1), R^(L2), R^(L3), R^(L4) and R^(L5) are, each            independently, H, halo, C₁₋₈alkyl, OC₁₋₈alkyl, NHC₁₋₈alkyl,            OH, or NH₂;    -   W¹ is aryl or heteroaryl, each independently substituted by 1 or        more: H; halo; hydroxyl; nitro; CN; C≡CH; CF₃; linear or        branched C₁₋₆ alkyl optionally substituted by 1 or more halo or        C₁₋₆ alkoxyl; or linear or branched C₁₋₆ alkoxyl optionally        substituted by 1 or more halo;    -   Y¹ and Y² are each independently O or S;    -   R¹, R², R^(Y1), and R^(Y2) are each independently: H; halogen;        C₁₋₆ alkoxy, linear or branched C₁₋₆ alkyl optionally        substituted by 1 or more halo; or R¹ and R² together with the        atom they are attached to, form a 3-8 membered ring system        containing 0-2 heteroatoms;    -   W² is aryl or heteroaryl, each optionally substituted by 1-10        R^(W2); and    -   each R^(W2) is independently: H; halo; C₁₋₆ alkyl optionally        substituted by 1 or more F; C₃₋₆ cycloalkyl; C₄₋₆        cycloheteroalkyl; OH; NH₂; NR^(Y1)R^(Y2); CN; or OC₁₋₃alkyl        optionally substituted by 1 or more —F.

In any aspect or embodiment described herein, the linker comprises atleast one group selected from an optionally substituted:

or a combination thereof,wherein m, and n are each independently 0, 1, 2, 3, 4, 5, or 6.

In any aspect or embodiment described herein, the compound has thechemical structure:

wherein:

-   -   CLM is a cereblon E3 ubiquitin ligase binding moiety;    -   L is a chemical linker group that is covalently bound to the PTM        and the CLM and has the chemical structure

-   -   W¹ is an aryl or heteroaryl substituted with CN and optionally        substituted with CF₃;    -   R¹ and R² are each a C1 alkyl, or R¹ and R², together with the        atom to which they are attached, form a 4 membered cycloalkyl;        and    -   W² is aryl substituted with an ethyl.

Exemplary CLMs

Neo-Imide Compounds

In one aspect the description provides compounds useful for bindingand/or inhibiting cereblon. In certain embodiments, the compound or CLMis selected from the group consisting of chemical structures:

wherein:

W is independently selected from the group consisting of CH₂, CHR, C═O,SO₂, NH, and N-alkyl (linear, branched, optionally substituted);

Y is independently selected from the group consisting of CH₂, —C═CR′,NH, N-alkyl, N-aryl, N-hetaryl, N-cycloalkyl, N-heterocyclyl, O, and S;

X and Z are each independently O, S, or H₂, except that both X and Zcannot be H₂;

G and G′ are independently selected from the group consisting of H,alkyl (linear, branched, optionally substituted with R′), OH, R′OCOOR,R′OCONRR″, CH₂-heterocyclyl optionally substituted with R′, and benzyloptionally substituted with R′;

Q1-Q4 are each independently C optionally substituted with R′, N, orN-oxide;

A is independently selected from the group consisting of alkyl (linear,branched, optionally substituted), cycloalkyl (optionally substituted),Cl, H and F;

R comprises, but is not limited to: —CONR′R″, —OR′, —NR′R″, —SR′,—SO₂R′, —SO₂NR′R″, —CR′R″—, —CR′NR′R″—, -aryl, -hetaryl, -alkyl (linear,branched, optionally substituted), -cycloalkyl, -heterocyclyl,—P(O)(OR′)R″, —P(O)R′R″, —OP(O)(OR′)R″, —OP(O)R′R″, —Cl, —F, —Br, —I,—CF₃, —CN, —NR′SO₂NR′R″, —NR′CONR′R″, —CONR′COR″, —NR′C(═N—CN)NR′R″,—C(═N—CN)NR′R″, —NR′C(═N—CN)R″, —NR′C(═C—NO₂)NR′R″, —S₂NR′COR″, —NO₂,—CO₂R′, —C(C═N—OR′)R″, —CR′═CR′R″, —CCR′, —S(C═O)(C═N—R′)R″, —SF₅,—R′NR′R″, (—R′O)_(n)R″, or —OCF₃

R′ and R″ are each independently a bond, H, alkyl (linear, branched),cycloalkyl, aryl, hetaryl, heterocyclyl, or —C(═O)R, each of which isoptionally substituted;

n is an integer from 1-10 (e.g., 1-4, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10);

represents a bond that may be stereospecific ((R) or (S)) ornon-stereospecific; and

R_(n) comprises 1-4 independent functional groups or atoms, andoptionally, one of which is modified to be covalently joined to an ABM,a chemical linker group (L), a ULM, a CLM (CLM′), or combinationthereof.

Exemplary CLMs

In any of the compounds described herein, the CLM comprises a chemicalstructure selected from the group:

wherein:

-   -   W is CH₂, CHR, C═O, SO₂, NH, or N-alkyl (linear, branched,        optionally substituted);    -   X and Z are each independently O, S or H₂, except that both X        and Z cannot be H₂;    -   Y is independently selected from the group CH₂, —C═CR′, NH,        N-alkyl, N-aryl, N-hetaryl, N-cycloalkyl, N-heterocyclyl, O, and        S;    -   G is H, alkyl (linear, branched), OH, R′OCOOR, R′OCONRR″,        CH₂-heterocyclyl, heterocyclic, aryl, or benzyl, each optionally        substituted with R′;    -   Q1-Q4 are each independently C is optionally substituted with        R′, N, or N-oxide;    -   A is C₁-C₆ alkyl (linear, branched, optionally substituted),        cycloalkyl (optionally substituted), H, Cl or F;    -   R is —CONR′R″, —OR′, —NR′R″, —SR′, —SO2R′, —S2NR′R″, —CR′R″—,        —CR′NR′R″—, (—CR′O)_(n)R″, -aryl, -heteroaryl, -alkyl (linear,        branched, optionally substituted), -cycloalkyl, -heterocyclyl,        —P(O)(OR′)R″, —P(O)R′R″, —OP(O)(OR′)R″, —OP(O)R′R″, —Cl, —F,        —Br, —I, —CF3, —CN, —NR′SO2NR′R″, —NR′CONR′R″, —CONR′COR″,        —NR′C(═N—CN)NR′R″, —C(═N—CN)NR′R″, —NR′C(═N—CN)R″,        —NR′C(═C—NO2)NR′R″, —SO₂NR′COR″, —NO2, —CO2R′, —C(C═N—OR′)R″,        —CR′═CR′R″, —CCR′, —S(C═O)(C═N—R′)R″, alicylic, heterocyclic,        —SF5, or —OCF3;    -   R′ and R″ are each independently a bond, H, N, N-oxide, alkyl        (linear, branched), cycloalkyl, aryl, heteroaryl, heterocyclic,        —C(═O)R, or, heterocyclyl, each of which is optionally        substituted;    -   n is an integer from 1-10;    -   represents a bond that may be stereospecific ((R) or (S)) or        non-stereospecific; and    -   R_(n) comprises 1-4 independent functional groups or atoms, and        optionally, one of which is modified to be covalently joined to        an ABM, a chemical linker group (L), a ULM, a CLM (CLM′), or        combination thereof.

In certain embodiments described herein, the CLM or ULM comprises achemical structure selected from the group:

wherein:

-   -   W is independently selected from the group consisting of CH₂,        C═O, NH, and N-alkyl;    -   R is a H, methyl, or C1-C6 alkyl (linear, branched, optionally        substituted);    -   represents a bond that may be stereospecific ((R) or (S)) or        non-stereospecific; and    -   Rn comprises 1-4 independently selected functional groups or        atoms, and optionally, one of which is modified to be covalently        joined to an ABM, a chemical linker group (L), a ULM, CLM (or        CLM′) or combination thereof.

The term “independently” is used herein to indicate that the variable,which is independently applied, varies independently from application toapplication.

The term “alkyl” shall mean within its context a linear, branch-chainedor cyclic fully saturated hydrocarbon radical or alkyl group, preferablya C₁-C₁₀, more preferably a C₁-C₆, alternatively a C₁-C₃ alkyl group,which may be optionally substituted. Examples of alkyl groups aremethyl, ethyl, n-butyl, sec-butyl, n-hexyl, n-heptyl, n-octyl, n-nonyl,n-decyl, isopropyl, 2-methylpropyl, cyclopropyl, cyclopropylmethyl,cyclobutyl, cyclopentyl, cyclopentylethyl, cyclohexylethyl andcyclohexyl, among others. In certain embodiments, the alkyl group isend-capped with a halogen group (At, Br, Cl, F, or I). In certainpreferred embodiments, compounds according to the present disclosure,which may be used to covalently bind to dehalogenase enzymes. Thesecompounds generally contain a side chain (often linked through apolyethylene glycol group) which terminates in an alkyl group which hasa halogen substituent (often chlorine or bromine) on its distal endwhich results in covalent binding of the compound containing such amoiety to the protein.

The term “Alkenyl” refers to linear, branch-chained or cyclic C₂-C₁₀(preferably C₂-C₆) hydrocarbon radicals containing at least one C≡Cbond.

The term “Alkynyl” refers to linear, branch-chained or cyclic C₂-C₁₀(preferably C₂-C₆) hydrocarbon radicals containing at least one C≡Cbond.

The term “alkylene” when used, refers to a —(CH₂)_(n)— group (n is aninteger generally from 0-6), which may be optionally substituted. Whensubstituted, the alkylene group preferably is substituted on one or moreof the methylene groups with a C₁-C₆ alkyl group (including acyclopropyl group or a t-butyl group), but may also be substituted withone or more halo groups, preferably from 1 to 3 halo groups or one ortwo hydroxyl groups, O—(C₁-C₆ alkyl) groups or amino acid sidechains asotherwise disclosed herein. In certain embodiments, an alkylene groupmay be substituted with a urethane or alkoxy group (or other group)which is further substituted with a polyethylene glycol chain (of from 1to 10, preferably 1 to 6, often 1 to 4 ethylene glycol units) to whichis substituted (preferably, but not exclusively on the distal end of thepolyethylene glycol chain) an alkyl chain substituted with a singlehalogen group, preferably a chlorine group. In still other embodiments,the alkylene (often, a methylene) group, may be substituted with anamino acid sidechain group such as a sidechain group of a natural orunnatural amino acid, for example, alanine, β-alanine, arginine,asparagine, aspartic acid, cysteine, cystine, glutamic acid, glutamine,glycine, phenylalanine, histidine, isoleucine, lysine, leucine,methionine, proline, serine, threonine, valine, tryptophan or tyrosine.

The term “unsubstituted” shall mean substituted only with hydrogenatoms. A range of carbon atoms which includes C₀ means that carbon isabsent and is replaced with H. Thus, a range of carbon atoms which isC₀-C₆ includes carbons atoms of 1, 2, 3, 4, 5 and 6 and for C₀, H standsin place of carbon.

The term “substituted” or “optionally substituted” shall meanindependently (i.e., where more than substituent occurs, eachsubstituent is independent of another substituent) one or moresubstituents (independently up to five substituents, preferably up tothree substituents, often 1 or 2 substituents on a moiety in a compoundaccording to the present disclosure and may include substituents whichthemselves may be further substituted) at a carbon (or nitrogen)position anywhere on a molecule within context, and includes assubstituents hydroxyl, thiol, carboxyl, cyano (C≡N), nitro (NO₂),halogen (preferably, 1, 2 or 3 halogens, especially on an alkyl,especially a methyl group such as a trifluoromethyl), an alkyl group(preferably, C₁-C₁₀, more preferably, C₁-C₆), aryl (especially phenyland substituted phenyl for example benzyl or benzoyl), alkoxy group(preferably, C₁-C₆ alkyl or aryl, including phenyl and substitutedphenyl), thioether (C₁-C₆ alkyl or aryl), acyl (preferably, C₁-C₆ acyl),ester or thioester (preferably, C₁-C₆ alkyl or aryl) including alkyleneester (such that attachment is on the alkylene group, rather than at theester function which is preferably substituted with a C₁-C₆ alkyl oraryl group), preferably, C₁-C₆ alkyl or aryl, halogen (preferably, F orCl), amine (including a five- or six-membered cyclic alkylene amine,further including a C₁-C₆ alkyl amine or a C₁-C₆ dialkyl amine whichalkyl groups may be substituted with one or two hydroxyl groups) or anoptionally substituted —N(C₀-C₆ alkyl)C(O)(O—C₁-C₆ alkyl) group (whichmay be optionally substituted with a polyethylene glycol chain to whichis further bound an alkyl group containing a single halogen, preferablychlorine substituent), hydrazine, amido, which is preferably substitutedwith one or two C₁-C₆ alkyl groups (including a carboxamide which isoptionally substituted with one or two C₁-C₆ alkyl groups), alkanol(preferably, C₁-C₆ alkyl or aryl), or alkanoic acid (preferably, C₁-C₆alkyl or aryl). Substituents according to the present disclosure mayinclude, for example —SiR₁R₂R₃ groups where each of R₁ and R₂ is asotherwise described herein and R₃ is H or a C₁-C₆ alkyl group,preferably R₁, R₂, R₃ in this context is a C₁-C₃ alkyl group (includingan isopropyl or t-butyl group). Each of the above-described groups maybe linked directly to the substituted moiety or alternatively, thesubstituent may be linked to the substituted moiety (preferably in thecase of an aryl or heteraryl moiety) through an optionally substituted—(CH₂)_(m)— or alternatively an optionally substituted —(OCH₂)_(m)—,—(OCH₂CH₂)_(m)— or —(CH₂CH₂O)_(m)— group, which may be substituted withany one or more of the above-described substituents. Alkylene groups—(CH₂)_(m)— or —(CH₂)_(n)— groups or other chains such as ethyleneglycol chains, as identified above, may be substituted anywhere on thechain. Preferred substituents on alkylene groups include halogen orC₁-C₆ (preferably C₁-C₃) alkyl groups, which may be optionallysubstituted with one or two hydroxyl groups, one or two ether groups(O—C₁-C₆ groups), up to three halo groups (preferably F), or a sideshainof an amino acid as otherwise described herein and optionallysubstituted amide (preferably carboxamide substituted as describedabove) or urethane groups (often with one or two C₀-C₆ alkylsubstitutents, which group(s) may be further substituted). In certainembodiments, the alkylene group (often a single methylene group) issubstituted with one or two optionally substituted C₁-C₆ alkyl groups,preferably C₁-C₄ alkyl group, most often methyl or O-methyl groups or asidechain of an amino acid as otherwise described herein. In the presentdisclosure, a moiety in a molecule may be optionally substituted with upto five substituents, preferably up to three substituents. Most often,in the present disclosure moieties which are substituted are substitutedwith one or two substituents.

The term “substituted” (each substituent being independent of any othersubstituent) shall also mean within its context of use C₁-C₆ alkyl,C₁-C₆ alkoxy, halogen, amido, carboxamido, sulfone, includingsulfonamide, keto, carboxy, C₁-C₆ ester (oxyester or carbonylester),C₁-C₆ keto, urethane —O—C(O)—NR₁R₂ or —N(R₁)—C(O)—O—R₁, nitro, cyano andamine (especially including a C₁-C₆ alkylene-NR₁R₂, a mono- or di-C₁-C₆alkyl substituted amines which may be optionally substituted with one ortwo hydroxyl groups). Each of these groups contain unless otherwiseindicated, within context, between 1 and 6 carbon atoms. In certainembodiments, preferred substituents will include for example, —NH—,—NHC(O)—, —O—, ═O, —(CH₂)_(m)— (here, m and n are in context, 1, 2, 3,4, 5 or 6), —S—, —S(O)—, SO₂— or —NH—C(O)—NH—, —(CH₂)_(n)OH,—(CH₂)_(n)SH, —(CH₂)_(n)COOH, C₁-C₆ alkyl, —(CH₂)_(n)O—(C₁-C₆ alkyl),—(CH₂)_(n)C(O)—(C₁-C₆ alkyl), —(CH₂)_(n)OC(O)—(C₁-C₆ alkyl),—(CH₂)_(n)C(O)O—(C₁-C₆ alkyl), —(CH₂)_(n)NHC(O)—R₁,—(CH₂)_(n)C(O)—NR₁R₂, —(OCH₂)_(n)OH, —(CH₂O)_(n)COOH, C₁-C₆ alkyl,—(OCH₂)_(n)O—(C₁-C₆ alkyl), —(CH₂O)_(n)C(O)—(C₁-C₆ alkyl),—(OCH₂)_(n)NHC(O)—R₁, —(CH₂O)_(n)C(O)—NR₁R₂, —S(O)₂—R₂, —S(O)—R_(S)(R_(S) is C₁-C₆ alkyl or a —(CH₂)_(m)—NR₁R₂ group), NO₂, CN or halogen(F, Cl, Br, I, preferably F or Cl), depending on the context of the useof the substituent. R and R² are each, within context, H or a C₁-C₆alkyl group (which may be optionally substituted with one or twohydroxyl groups or up to three halogen groups, preferably fluorine). Theterm “substituted” shall also mean, within the chemical context of thecompound defined and substituent used, an optionally substituted aryl orheteroaryl group or an optionally substituted heterocyclic group asotherwise described herein. Alkylene groups may also be substituted asotherwise disclosed herein, preferably with optionally substituted C₁-C₆alkyl groups (methyl, ethyl or hydroxymethyl or hydroxyethyl ispreferred, thus providing a chiral center), a sidechain of an amino acidgroup as otherwise described herein, an amido group as describedhereinabove, or a urethane group O—C(O)—NR₁R₂ group where R₁ and R₂ areas otherwise described herein, although numerous other groups may alsobe used as substituents. Various optionally substituted moieties may besubstituted with 3 or more substituents, preferably no more than 3substituents and preferably with 1 or 2 substituents. It is noted thatin instances where, in a compound at a particular position of themolecule substitution is required (principally, because of valency), butno substitution is indicated, then that substituent is construed orunderstood to be H, unless the context of the substitution suggestsotherwise.

The term “aryl” or “aromatic”, in context, refers to a substituted (asotherwise described herein) or unsubstituted monovalent aromatic radicalhaving a single ring (e.g., benzene, phenyl, benzyl) or condensed rings(e.g., naphthyl, anthracenyl, phenanthrenyl, etc.) and can be bound tothe compound according to the present disclosure at any available stableposition on the ring(s) or as otherwise indicated in the chemicalstructure presented. Other examples of aryl groups, in context, mayinclude heterocyclic aromatic ring systems, “heteroaryl” groups havingone or more nitrogen, oxygen, or sulfur atoms in the ring (moncyclic)such as imidazole, furyl, pyrrole, furanyl, thiene, thiazole, pyridine,pyrimidine, pyrazine, triazole, oxazole or fused ring systems such asindole, quinoline, indolizine, azaindolizine, benzofurazan, etc., amongothers, which may be optionally substituted as described above. Amongthe heteroaryl groups which may be mentioned include nitrogen-containingheteroaryl groups such as pyrrole, pyridine, pyridone, pyridazine,pyrimidine, pyrazine, pyrazole, imidazole, triazole, triazine,tetrazole, indole, isoindole, indolizine, azaindolizine, purine,indazole, quinoline, dihydroquinoline, tetrahydroquinoline,isoquinoline, dihydroisoquinoline, tetrahydroisoquinoline, quinolizine,phthalazine, naphthyridine, quinoxaline, quinazoline, cinnoline,pteridine, imidazopyridine, imidazotriazine, pyrazinopyridazine,acridine, phenanthridine, carbazole, carbazoline, pyrimidine,phenanthroline, phenacene, oxadiazole, benzimidazole, pyrrolopyridine,pyrrolopyrimidine and pyridopyrimidine; sulfur-containing aromaticheterocycles such as thiophene and benzothiophene; oxygen-containingaromatic heterocycles such as furan, pyran, cyclopentapyran, benzofuranand isobenzofuran; and aromatic heterocycles comprising 2 or more heteroatoms selected from among nitrogen, sulfur and oxygen, such as thiazole,thiadizole, isothiazole, benzoxazole, benzothiazole, benzothiadiazole,phenothiazine, isoxazole, furazan, phenoxazine, pyrazoloxazole,imidazothiazole, thienofuran, furopyrrole, pyridoxazine, furopyridine,furopyrimidine, thienopyrimidine and oxazole, among others, all of whichmay be optionally substituted.

The term “substituted aryl” refers to an aromatic carbocyclic groupcomprised of at least one aromatic ring or of multiple condensed ringsat least one of which being aromatic, wherein the ring(s) aresubstituted with one or more substituents. For example, an aryl groupcan comprise a substituent(s) selected from: —(CH₂)_(n)OH,—(CH₂)_(n)—O—(C₁-C₆)alkyl, —(CH₂)—O—(CH₂)_(n)—(C₁-C₆)alkyl,—(CH₂)_(n)—C(O)(C₀-C₆) alkyl, —(CH₂)_(n)—C(O)O(C₀-C₆)alkyl,—(CH₂)_(n)—OC(O)(C₀-C₆)alkyl, amine, mono- or di-(C₁-C₆ alkyl) aminewherein the alkyl group on the amine is optionally substituted with 1 or2 hydroxyl groups or up to three halo (preferably F, Cl) groups, OH,COOH, C₁-C₆ alkyl, preferably CH₃, CF₃, OMe, OCF₃, NO₂, or CN group(each of which may be substituted in ortho-, meta- and/or para-positionsof the phenyl ring, preferably para-), an optionally substituted phenylgroup (the phenyl group itself is preferably substituted with a linkergroup attached to a ABM group, including a ULM group), and/or at leastone of F, Cl, OH, COOH, CH₃, CF₃, OMe, OCF₃, NO₂, or CN group (inortho-, meta- and/or para-positions of the phenyl ring, preferablypara-), a naphthyl group, which may be optionally substituted, anoptionally substituted heteroaryl, preferably an optionally substitutedisoxazole including a methylsubstituted isoxazole, an optionallysubstituted oxazole including a methylsubstituted oxazole, an optionallysubstituted thiazole including a methyl substituted thiazole, anoptionally substituted isothiazole including a methyl substitutedisothiazole, an optionally substituted pyrrole including amethylsubstituted pyrrole, an optionally substituted imidazole includinga methylimidazole, an optionally substituted benzimidazole ormethoxybenzylimidazole, an optionally substituted oximidazole ormethyloximidazole, an optionally substituted diazole group, including amethyldiazole group, an optionally substituted triazole group, includinga methylsubstituted triazole group, an optionally substituted pyridinegroup, including a halo-(preferably, F) or methylsubstitutedpyridinegroup or an oxapyridine group (where the pyridine group is linked to thephenyl group by an oxygen), an optionally substituted furan, anoptionally substituted benzofuran, an optionally substituteddihydrobenzofuran, an optionally substituted indole, indolizine orazaindolizine (2, 3, or 4-azaindolizine), an optionally substitutedquinoline, and combinations thereof.

“Carboxyl” denotes the group —C(O)OR, where R is hydrogen, alkyl,substituted alkyl, aryl, substituted aryl, heteroaryl or substitutedheteroaryl, whereas these generic substituents have meanings which areidentical with definitions of the corresponding groups defined herein.

The term “heteroaryl” or “hetaryl” can mean but is in no way limited toan optionally substituted quinoline (which may be attached to thepharmacophore or substituted on any carbon atom within the quinolinering), an optionally substituted indole (including dihydroindole), anoptionally substituted indolizine, an optionally substitutedazaindolizine (2, 3 or 4-azaindolizine) an optionally substitutedbenzimidazole, benzodiazole, benzoxofuran, an optionally substitutedimidazole, an optionally substituted isoxazole, an optionallysubstituted oxazole (preferably methyl substituted), an optionallysubstituted diazole, an optionally substituted triazole, a tetrazole, anoptionally substituted benzofuran, an optionally substituted thiophene,an optionally substituted thiazole (preferably methyl and/or thiolsubstituted), an optionally substituted isothiazole, an optionallysubstituted triazole (preferably a 1,2,3-triazole substituted with amethyl group, a triisopropylsilyl group, an optionally substituted—(CH₂)_(m)—O—C₁-C₆ alkyl group or an optionally substituted—(CH₂)_(m)—C(O)—O—C₁-C₆ alkyl group), an optionally substituted pyridine(2-, 3, or 4-pyridine) or a group according to the chemical structure:

wherein

-   -   S^(c) is CHR^(SS), NR^(URE), or O;    -   R^(HET) is H, CN, NO₂, halo (preferably Cl or F), optionally        substituted C₁-C₆ alkyl (preferably substituted with one or two        hydroxyl groups or up to three halo groups (e.g. CF₃),        optionally substituted O(C₁-C₆ alkyl) (preferably substituted        with one or two hydroxyl groups or up to three halo groups) or        an optionally substituted acetylenic group —C≡C—R_(a) where        R_(a) is H or a C₁-C₆ alkyl group (preferably C₁-C₃ alkyl);    -   R^(SS) is H, CN, NO₂, halo (preferably F or Cl), optionally        substituted C₁-C₆ alkyl (preferably substituted with one or two        hydroxyl groups or up to three halo groups), optionally        substituted O—(C₁-C₆ alkyl) (preferably substituted with one or        two hydroxyl groups or up to three halo groups) or an optionally        substituted —C(O)(C₁-C₆ alkyl)(preferably substituted with one        or two hydroxyl groups or up to three halo groups);    -   R^(URE) is H, a C₁-C₆ alkyl (preferably H or C₁-C₃ alkyl) or a        —C(O)(C₁-C₆ alkyl), each of which groups is optionally        substituted with one or two hydroxyl groups or up to three        halogen, preferably fluorine groups, or an optionally        substituted heterocycle, for example piperidine, morpholine,        pyrrolidine, tetrahydrofuran, tetrahydrothiophene, piperidine,        piperazine, each of which is optionally substituted, and    -   Y^(C) is N or C—R^(YC), where R^(YC) is H, OH, CN, NO₂, halo        (preferably Cl or F), optionally substituted C₁-C₆ alkyl        (preferably substituted with one or two hydroxyl groups or up to        three halo groups (e.g. CF₃), optionally substituted O(C₁-C₆        alkyl) (preferably substituted with one or two hydroxyl groups        or up to three halo groups) or an optionally substituted        acetylenic group —C≡C—R_(a) where R_(a) is H or a C₁-C₆ alkyl        group (preferably C₁-C₃ alkyl).

The terms “aralkyl” and “heteroarylalkyl” refer to groups that compriseboth aryl or, respectively, heteroaryl as well as alkyl and/orheteroalkyl and/or carbocyclic and/or heterocycloalkyl ring systemsaccording to the above definitions.

The term “arylalkyl” as used herein refers to an aryl group as definedabove appended to an alkyl group defined above. The arylalkyl group isattached to the parent moiety through an alkyl group wherein the alkylgroup is one to six carbon atoms. The aryl group in the arylalkyl groupmay be substituted as defined above.

The term “Heterocycle” refers to a cyclic group which contains at leastone heteroatom, e.g., N, O or S, and may be aromatic (heteroaryl) ornon-aromatic. Thus, the heteroaryl moieties are subsumed under thedefinition of heterocycle, depending on the context of its use.Exemplary heteroaryl groups are described hereinabove.

Exemplary heterocyclics include: azetidinyl, benzimidazolyl,1,4-benzodioxanyl, 1,3-benzodioxolyl, benzoxazolyl, benzothiazolyl,benzothienyl, dihydroimidazolyl, dihydropyranyl, dihydrofuranyl,dioxanyl, dioxolanyl, ethyleneurea, 1,3-dioxolane, 1,3-dioxane,1,4-dioxane, furyl, homopiperidinyl, imidazolyl, imidazolinyl,imidazolidinyl, indolinyl, indolyl, isoquinolinyl isothiazolidinyl,isothiazolyl, isoxazolidinyl, isoxazolyl, morpholinyl, naphthyridinyl,oxazolidinyl, oxazolyl, pyridone, 2-pyrrolidone, pyridine, piperazinyl,N-methylpiperazinyl, piperidinyl, phthalimide, succinimide, pyrazinyl,pyrazolinyl, pyridyl, pyrimidinyl, pyrrolidinyl, pyrrolinyl, pyrrolyl,quinolinyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydroquinoline,thiazolidinyl, thiazolyl, thienyl, tetrahydrothiophene, oxane, oxetanyl,oxathiolanyl, thiane among others.

Heterocyclic groups can be optionally substituted with a member selectedfrom the group consisting of alkoxy, substituted alkoxy, cycloalkyl,substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, acyl,acylamino, acyloxy, amino, substituted amino, aminoacyl, aminoacyloxy,oxyaminoacyl, azido, cyano, halogen, hydroxyl, keto, thioketo, carboxy,carboxyalkyl, thioaryloxy, thioheteroaryloxy, thioheterocyclooxy, thiol,thioalkoxy, substituted thioalkoxy, aryl, aryloxy, heteroaryl,heteroaryloxy, heterocyclic, heterocyclooxy, hydroxyamino, alkoxyamino,nitro, —SO-alkyl, —SO-substituted alkyl, —SOaryl, —SO-heteroaryl,—SO2-alkyl, —SO2-substituted alkyl, —SO2-aryl, oxo (═O), and—SO2-heteroaryl. Such heterocyclic groups can have a single ring ormultiple condensed rings. Examples of nitrogen heterocycles andheteroaryls include, but are not limited to, pyrrole, imidazole,pyrazole, pyridine, pyrazine, pyrimidine, pyridazine, indolizine,isoindole, indole, indazole, purine, quinolizine, isoquinoline,quinoline, phthalazine, naphthylpyridine, quinoxaline, quinazoline,cinnoline, pteridine, carbazole, carboline, phenanthridine, acridine,phenanthroline, isothiazole, phenazine, isoxazole, phenoxazine,phenothiazine, imidazolidine, imidazoline, piperidine, piperazine,indoline, morpholino, piperidinyl, tetrahydrofuranyl, and the like aswell as N-alkoxy-nitrogen containing heterocycles. The term“heterocyclic” also includes bicyclic groups in which any of theheterocyclic rings is fused to a benzene ring or a cyclohexane ring oranother heterocyclic ring (for example, indolyl, quinolyl, isoquinolyl,tetrahydroquinolyl, and the like).

The term “cycloalkyl” can mean but is in no way limited to univalentgroups derived from monocyclic or polycyclic alkyl groups orcycloalkanes, as defined herein, e.g., saturated monocyclic hydrocarbongroups having from three to twenty carbon atoms in the ring, including,but not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl,cycloheptyl and the like. The term “substituted cycloalkyl” can mean butis in no way limited to a monocyclic or polycyclic alkyl group and beingsubstituted by one or more substituents, for example, amino, halogen,alkyl, substituted alkyl, carbyloxy, carbylmercapto, aryl, nitro,mercapto or sulfo, whereas these generic substituent groups havemeanings which are identical with definitions of the correspondinggroups as defined in this legend.

“Heterocycloalkyl” refers to a monocyclic or polycyclic alkyl group inwhich at least one ring carbon atom of its cyclic structure beingreplaced with a heteroatom selected from the group consisting of N, O, Sor P. “Substituted heterocycloalkyl” refers to a monocyclic orpolycyclic alkyl group in which at least one ring carbon atom of itscyclic structure being replaced with a heteroatom selected from thegroup consisting of N, O, S or P and the group is containing one or moresubstituents selected from the group consisting of halogen, alkyl,substituted alkyl, carbyloxy, carbylmercapto, aryl, nitro, mercapto orsulfo, whereas these generic substituent group have meanings which areidentical with definitions of the corresponding groups as defined inthis legend.

The term “hydrocarbyl” shall mean a compound which contains carbon andhydrogen and which may be fully saturated, partially unsaturated oraromatic and includes aryl groups, alkyl groups, alkenyl groups andalkynyl groups.

In any of the embodiments described herein, the W, X, Y, Z, G, G′, R,R′, R″, Q1-Q4, A, and Rn can independently be covalently coupled to alinker and/or a linker to which is attached one or more ABM, ULM, CLM orCLM′ groups.

More specifically, non-limiting examples of CLMs include those shownbelow as well as those ‘hybrid’ molecules that arise from thecombination of 1 or more of the different features shown in themolecules below, wherein Rn comprises 1-4 independently selectedfunctional groups or atoms, and optionally, one of which is modified tobe covalently joined to a ABM, a chemical linker group (L), a ULM, CLM(or CLM′) or combination thereof.

Exemplary Linkers

In certain embodiments, the compounds as described herein include one ormore ABM chemically linked or coupled to one or more ULMs or CLMs via achemical linker (L). In certain embodiments, the linker group L is agroup comprising one or more covalently connected structural units(e.g., -A₁ . . . A_(q)- or -A_(q)-), wherein A₁ is a group coupled toABM, and A_(q) is a group coupled to ULM.

In certain embodiments, the linker group L is selected from A_(q)-;

A_(q) is a group which is connected to a ULM or ABM moiety; and

q is an integer greater than or equal to 1,

wherein A_(q) is selected from the group consisting of, a bond,CR^(L1)R^(L2), O, S, SO, SO₂, NR^(L3), SO₂NR^(L3), SONR^(L3), CONR^(L3),NR^(L3)CONR^(L4), NR^(L3)SO₂NR^(L4), CO, CR^(L1)═CR^(L2), C≡C,SiR^(L1)R^(L2), P(O)R^(L1), P(O)OR^(L1), NR^(L3)C(═NCN)NR^(L4),NR^(L3)C(═NCN), NR^(L3)C(═CNO₂)NR^(L4), C₃₋₁₁cycloalkyl optionallysubstituted with 0-6 R^(L1) and/or R^(L2) groups, C₅₋₁₃ spirocycloalkyloptionally substituted with 0-9 R^(L1) and/or R^(L2) groups,C₃₋₁₁heterocyclyl optionally substituted with 0-6 R^(L1) and/or R^(L2)groups, C₅₋₁₃ spiroheterocycloalkyl optionally substituted with 0-8R^(L1) and/or R^(L2) groups, aryl optionally substituted with 0-6 R^(L1)and/or R^(L2) groups, heteroaryl optionally substituted with 0-6 R^(L1)and/or R^(L2) groups, where R^(L) or R, each independently areoptionally linked to other groups to form cycloalkyl and/or heterocyclylmoiety, optionally substituted with 0-4 R^(L5) groups;

R^(L1), R^(L2), R^(L3), R^(L4) and R^(L5) are, each independently, H,halo, C₁₋₈alkyl, OC₁₋₈alkyl, SC₁₋₈alkyl, NHC₁₋₈alkyl, N(C₁₋₈alkyl)₂,C₃₋₁₁cycloalkyl, aryl, heteroaryl, C₃₋₁₁heterocyclyl, OC₁₋₈cycloalkyl,SC₁₋₈cycloalkyl, NHC₁₋₈cycloalkyl, N(C₁₋₈cycloalkyl)₂,N(C₁₋₈cycloalkyl)(C₁₋₈alkyl), OH, NH₂, SH, SO₂C₁₋₈alkyl,P(O)(OC₁₋₈alkyl)(C₁₋₈alkyl), P(O)(OC₁₋₈alkyl)₂, CC—C₁₋₈alkyl, CCH,CH═CH(C₁₋₈alkyl), C(C₁₋₈alkyl)═CH(C₁₋₈alkyl),C(C₁₋₈alkyl)═C(C₁₋₈alkyl)₂, Si(OH)₃, Si(C₁₋₈alkyl)₃, Si(OH)(C₁₋₈alkyl)₂,COC₁₋₈alkyl, CO₂H, halogen, CN, CF₃, CHF₂, CH₂F, NO₂, SF₅,SO₂NHC₁₋₈alkyl, SO₂N(C₁₋₈alkyl)₂, SONHC₁₋₈alkyl, SON(C₁₋₈alkyl)₂,CONHC₁₋₈alkyl, CON(C₁₋₈alkyl)₂, N(C₁₋₈alkyl)CONH(C₁₋₈alkyl),N(C₁₋₈alkyl)CON(C₁₋₈alkyl)₂, NHCONH(C₁₋₈alkyl), NHCON(C₁₋₈alkyl)₂,NHCONH₂, N(C₁₋₈alkyl)SO₂NH(C₁₋₈alkyl), N(C₁₋₈alkyl) SO₂N(C₁₋₈alkyl)₂, NHSO₂NH(C₁₋₈alkyl), NH SO₂N(C₁₋₈alkyl)₂, NH SO₂NH₂.

In certain embodiments, q is an integer greater than or equal to 0. Incertain embodiments, q is an integer greater than or equal to 1.

In certain embodiments, e.g., where q is greater than 2, A_(q) is agroup which is connected to ULM, and A₁ and A_(q) are connected viastructural units of the linker (L).

In certain embodiments, e.g., where q is 2, A_(q) is a group which isconnected to A and to a ULM.

In certain embodiments, e.g., where q is 1, the structure of the linkergroup L is -A₁-, and A₁ is a group which is connected to a ULM moietyand a ABM moiety.

In certain embodiments, the linker (L) comprises a group represented bya general structure selected from the group consisting of:

—NR(CH₂)_(n)-(lower alkyl)-, —NR(CH₂)_(n)-(lower alkoxyl)-,—NR(CH₂)_(n)-(lower alkoxyl)-OCH₂—, —NR(CH₂)_(n)-(lower alkoxyl)-(loweralkyl)-OCH₂—, —NR(CH₂)_(n)-(cycloalkyl)-(lower alkyl)-OCH₂—,—NR(CH₂)_(n)-(hetero cycloalkyl)-, —NR(CH₂CH₂O)_(n)-(loweralkyl)-O—CH₂—, —NR(CH₂CH₂O)_(n)-(heterocycloalkyl)-O—CH₂—,—NR(CH₂CH₂O)_(n)-Aryl-O—CH₂—, —NR(CH₂CH₂O)_(n)-(hetero aryl)-O—CH₂—,—NR(CH₂CH₂O)_(n)-(cyclo alkyl)-O-(hetero aryl)-O—CH₂—,—NR(CH₂CH₂O)_(n)-(cyclo alkyl)-O-Aryl-O—CH₂—, —NR(CH₂CH₂O)_(n)-(loweralkyl)-NH-Aryl-O—CH₂-, —NR(CH₂CH₂O)_(n)-(lower alkyl)-O-Aryl-CH₂,—NR(CH₂CH₂O)_(n)-cycloalkyl-O-Aryl-,—NR(CH₂CH₂O)_(n)-cycloalkyl-O-(hetero aryl)l-,—NR(CH2CH2)n-(cycloalkyl)-O-(heterocycle)-CH₂,—NR(CH2CH2)n-(heterocycle)-(heterocycle)-CH₂,—N(R1R2)-(heterocycle)-CH2; where

n can be 0 to 10;

R can be H, lower alkyl;

R1 and R2 can form a ring with the connecting N.

In certain embodiments, the linker (L) comprises a group represented bya general structure selected from the group consisting of:—N(R)—(CH2)_(m)-O(CH2)_(n)-O(CH2)_(o)-O(CH2)_(p)-O(CH2)_(q)-O(CH2)_(r)-OCH2-,—O—(CH2)_(m)-O(CH2)_(n)-O(CH2)_(o)-O(CH2)_(p)-O(CH2)_(q)-O(CH2)_(r)-OCH2-,—O—(CH2)_(m)-O(CH2)_(n)-O(CH2)_(o)-O(CH2)_(p)-O(CH2)_(q)-O(CH2)_(r)-O—;—N(R)—(CH2)_(m)-O(CH2)_(n)-O(CH2)_(o)-O(CH2)_(p)-O(CH2)_(q)-O(CH2)_(r)-O—;—(CH2)_(m)-O(CH2)_(n)-O(CH2)_(o)-O(CH2)_(p)-O(CH2)_(q)-O(CH2)_(r)-O—;—(CH2)_(m)-O(CH2)_(n)-O(CH2)_(o)-O(CH2)_(p)-O(CH2)_(q)-O(CH2)_(r)-OCH2-;

whereinm, n, o, p, q, and r are each independently 0, 1, 2, 3, 4, 5, 6;when the number is zero, there is no N—O or O—O bondR is H, methyl or ethyl; and

X is H or F.

In certain embodiments, the linker (L) comprises a group represented bya general structure:

wherein m can be 2, 3, 4, 5.

In certain embodiments, the linker (L) comprises a group represented bya general structure selected from the group consisting of:

wherein n and m are each independently 0, 1, 2, 3, 4, 5, 6; and X is H,or F.

In additional embodiments, the linker group is optionally substituted(poly)ethyleneglycol having between 1 and about 100 ethylene glycolunits, between about 1 and about 50 ethylene glycol units, between 1 andabout 25 ethylene glycol units, between about 1 and 10 ethylene glycolunits, between 1 and about 8 ethylene glycol units and 1 and 6 ethyleneglycol units, between 2 and 4 ethylene glycol units, or optionallysubstituted alkyl groups interdispersed with optionally substituted, O,N, S, P or Si atoms. In certain embodiments, the linker is substitutedwith an aryl, phenyl, benzyl, alkyl, alkylene, or heterocycle group. Incertain embodiments, the linker may be asymmetric or symmetrical.

In any of the embodiments of the compounds described herein, the linkergroup may be any suitable moiety as described herein. In one embodiment,the linker is a substituted or unsubstituted polyethylene glycol groupranging in size from about 1 to about 12 ethylene glycol units, between1 and about 10 ethylene glycol units, about 2 about 6 ethylene glycolunits, between about 2 and 5 ethylene glycol units, between about 2 and4 ethylene glycol units.

In another embodiment, the present disclosure is directed to a compoundwhich comprises a ABM group as described above which binds to a targetprotein (e.g., Androgen Receptor) or polypeptide, which is ubiquitinatedby an ubiquitin ligase and is chemically linked directly to the ULMgroup or through a linker moiety L, or ABM is alternatively a ULM′ groupwhich is also an ubiquitin ligase binding moiety, which may be the sameor different than the ULM group as described above and is linkeddirectly to the ULM group directly or through the linker moiety; and Lis a linker moiety as described above which may be present or absent andwhich chemically (covalently) links ULM to ABM, or a pharmaceuticallyacceptable salt, enantiomer, stereoisomer, solvate or polymorph thereof.

In certain embodiments, the ULM shows activity or binds to an E3ubiquitin ligase with an IC₅₀ of less than about 200 μM. The IC₅₀ can bedetermined according to any method known in the art, e.g., a fluorescentpolarization assay.

In certain additional embodiments, the bifunctional compounds describedherein demonstrate an activity with an IC₅₀ of less than about 100, 50,10, 1, 0.5, 0.1, 0.05, 0.01, 0.005, 0.001 mM, or less than about 100,50, 10, 1, 0.5, 0.1, 0.05, 0.01, 0.005, 0.001 μM, or less than about100, 50, 10, 1, 0.5, 0.1, 0.05, 0.01, 0.005, 0.001 nM.

Although the ULM group and ABM group may be covalently linked to thelinker group through any group which is appropriate and stable to thechemistry of the linker, in preferred aspects of the present disclosure,the linker is independently covalently bonded to the ULM group and theABM group preferably through an amide, ester, thioester, keto group,carbamate (urethane), carbon or ether, each of which groups may beinserted anywhere on the ULM group and ABM group to provide maximumbinding of the ULM group on the ubiquitin ligase and the ABM group onthe target protein to be degraded. In certain preferred aspects, thelinker may be linked to an optionally substituted alkyl, alkylene,alkene or alkyne group, an aryl group or a heterocyclic group on the ULMand/or ABM groups.

Exemplary Androgen Binding Moieties (ABMs)

In another aspect, the description provides AR binding moieties (ABM),which in certain aspects and embodiments are coupled to a linker and/ora ULM as described herein.

In any of the compounds described herein, the ABM comprises a chemicalmoiety that binds to the androgen receptor (AR). Various androgenreceptor binding compounds have been described in literature, includingvarious androgen derivatives such as testosterone, dihydrotestosterone,and metribolone (also known as methyltrienolone or R1881), andnon-steroidal compounds such as bicalutamide, enzalutamide. Those ofordinary skill in the art would appreciate that these androgen receptorbinding compounds could be potentially used as an ABM moiety in a PROTACcompound. Such literature includes, but not limited to, G. F. Allan et.al, Nuclear Receptor Signaling, 2003, 1, e009; R. H. Bradbury et. al,Bioorganic & Medicinal Chemistry Letters, 20115442-5445; C. Guo et. al,Bioorganic & Medicinal Chemistry Letters, 2012 2572-2578; P. K.Poutiainen et. al, J. Med. Chem. 2012, 55, 6316-6327 A. Pepe et. al, J.Med. Chem. 2013, 56, 8280-8297; M. E. Jung et al, J. Med. Chem. 2010,53, 2779-2796, which are incorporated by reference herein

In certain embodiments, the ABM comprises a structure selected from, butnot limited to the structures shown below, where a dashed line indicatesthe attachment point of a linker moiety or a ULM:

wherein:

-   -   W¹ is aryl, heteroaryl, bicyclic, or biheterocyclic, each        independently substituted by 1 or more H, halo, hydroxyl, nitro,        CN, C≡CH, C₁₋₆ alkyl (linear, branched, optionally substituted;        for example, optionally substituted by 1 or more halo, C₁₋₆        alkoxyl), C₁₋₆ alkoxyl (linear, branched, optionally        substituted; for example, optionally substituted by 1 or more        halo), C₂₋₆ alkenyl, C₂₋₆ alkynyl, or CF₃;    -   Y¹, Y² are each independently NR^(Y1), O, S;    -   Y³, Y⁴, Y⁵ are each independently a bond, O, NR^(Y2),        CR^(Y1)R^(Y2), C═O, C═S, SO, SO₂, heteroaryl, or aryl;    -   Q is a 3-6 membered ring with 0-4 heteroatoms, optionally        substituted with 0-6 R^(Q), each R^(Q), is independently H, C₁₋₆        alkyl (linear, branched, optionally substituted; for example,        optionally substituted by 1 or more halo, C₁₋₆ alkoxyl),        halogen, C₁₋₆ alkoxy, or 2 R^(Q) groups taken together with the        atom they are attached to, form a 3-8 membered ring system        containing 0-2 heteroatoms);    -   R¹, R², R^(a), R^(b), R^(Y1), R^(Y2) are each independently H,        C₁₋₆ alkyl (linear, branched, optionally substituted; for        example, optionally substituted by 1 or more halo, C₁₋₆        alkoxyl), halogen, C₁₋₆ alkoxy, cyclic, heterocyclic, or R¹, R²        together with the atom they are attached to, form a 3-8 membered        ring system containing 0-2 heteroatoms);    -   W² is a bond, C₁₋₆ alkyl, C₁₋₆ heteroalkyl, O, aryl, heteroaryl,        alicyclic, heterocyclic, biheterocyclic, biaryl, or        biheteroaryl, each optionally substituted by 1-10 R^(W2);    -   each R^(W2) is independently H, halo, C₁₋₆ alkyl (linear,        branched, optionally substituted; for example, optionally        substituted by 1 or more F), —OR^(W2A), C₃₋₆ cycloalkyl, C₄₋₆        cycloheteroalkyl, C₁₋₆ alicyclic (optionally substituted),        heterocyclic (optionally substituted), aryl (optionally        substituted), or heteroaryl (optionally substituted), bicyclic        hereoaryl or aryl, OC₁₋₃alkyl (optionally substituted), OH, NH₂,        NR^(Y1)R^(Y2), CN; and    -   R^(W2A) is H, C₁₋₆ alkyl (linear, branched), or C₁₋₆ heteroalkyl        (linear, branched), each optionally substituted by a cycloalkyl,        cycloheteroalkyl, aryl, heterocyclic, heteroaryl, halo, or        OC₁₋₃alkyl.

In any of the embodiments described herein, the W² is covalently coupledto one or more ULM or CLM groups, or a linker to which is attached oneor more ULM or CLM groups as described herein.

In certain embodiments, W¹ is

wherein each R₂₂ is independently halo, H, optionally substituted alkyl,haloalkyl, cyano, or nitro; andeach R₂₃ is independently H, halo, CF₃, optionally substituted alkyl,alkoxy, haloalkyl, cyano, or nitro.

In certain additional embodiments, W¹ is selected from the groupconsisting of:

In particular embodiments, the ABM comprises a structure selected fromthe following structures shown below, where a

indicates the attachment point of a linker or a ULM:

wherein:

-   -   R^(Q2) is a H, halogen, CH₃ or CF₃;    -   R^(Q3) is H, halo, hydroxyl, nitro, CN, C≡CH, C₁₋₆ alkyl        (linear, branched, optionally substituted by 1 or more halo,        C₁₋₆ alkoxyl), C₁₋₆ alkoxyl (linear, branched, optionally        substituted by 1 or more halo), C₂₋₆ alkenyl, C₂₋₆ alkynyl, or        CF₃;    -   Y³, Y⁴, Y⁵ are each independently a bond, O, NR^(Y2),        CR^(Y1)R^(Y2), C═O, heteroaryl, or aryl;    -   R^(Y1), R^(Y2) are each independently H, or C₁₋₆ alkyl (linear,        branched, optionally substituted by 1 or more halo, C₁₋₆        alkoxyl, cyclic, or heterocyclic); and    -   R^(Q) each independently is H, C₁-C₆ alkyl (linear, branched,        optionally substituted by 1 or more halo, or C₁₋₆ alkoxyl), or        two R^(Q) together with the atom they are attached to, form a        3-8 membered ring system containing 0-2 heteroatoms.

In a particular embodiment, each R^(Q) is independently H or CH₃. Inanother embodiment R^(Q3) is CN.

In particular embodiments, the ABM comprises a structure selected fromthe following structures shown below, where a

indicates the attachment point of a linker or a ULM:

wherein:

-   -   R^(Q2) is a H, halogen, CN, CH₃ or CF₃; and    -   R^(Q3) is H, halo, hydroxyl, nitro, CN, C≡CH, C₁₋₆ alkyl        (linear, branched, optionally substituted by 1 or more halo,        C₁₋₆ alkoxyl), C₁₋₆ alkoxyl (linear, branched, optionally        substituted by 1 or more halo), C₂₋₆ alkenyl, C₂₋₆ alkynyl, or        CF₃;    -   Y³, Y⁴, Y⁵ are each independently a bond, O, NR^(Y2),        CR^(Y1)R^(Y2), C═O, heteroaryl, or aryl; and    -   R^(Y1), R^(Y2) are each independently H or C₁₋₆ alkyl (linear,        branched, optionally substituted by 1 or more halo, C₁₋₆        alkoxyl, cyclic, or heterocyclic); and    -   X is N or C.

In a particular embodiment R^(Q3) is a CN.

In certain additional embodiments, the ABM comprises a structure shownbelow, where a dashed line indicates the attachment point of a linkermoiety or a ULM or a CLM:

wherein:

-   -   W¹ is

-   -   each R₂₂ is independently H or —CN;    -   each R₂₃ is independently H, halo, C₁-C₆ alkyl (linear,        branched, optionally substituted), C₁-C₆ alkoxy, or —CF₃;    -   Y³ is a bond or O;    -   Y⁴ is a bond or NH;    -   Y⁵ is a bond, C═O, C₁-C₆ heteroaryl, or C₁-C₆ aryl;    -   R¹, R², are each independently H, or C₁-C₆ alkyl (linear or        branched, optionally substituted; for example, optionally        substituted by 1 or more halo, or C₁₋₆alkoxyl);    -   W² is a bond, C₁₋₆aryl, C₁₋₆ heteroaryl, C₁₋₆alicyclic, or C₁₋₆        heterocyclic, biheterocyclic, biaryl, or biheteroaryl, each        optionally substituted by 1-10 R^(W2); and    -   each R^(W2) is independently H, or halo; and

represents a bond that may be stereospecific ((R) or (S)) ornon-stereospecific.

In any of the embodiments described herein, the W² is covalently coupledto one or more ULM or CLM groups, or a linker to which is attached oneor more ULM or CLM groups as described herein.

In certain additional embodiments, W¹ is selected from the groupconsisting of:

In any aspect or embodiment described herein, W² is selected from thegroup consisting of:

In certain embodiments, the ABM comprises a structure selected from, butnot limited to the structures shown below, where a dashed line indicatesthe attachment point of a linker moiety or a ULM:

wherein W¹ is

-   -   each R₂₂ is independently H or —CN;    -   each R₂₃ is independently H, halo, or —CF₃;    -   Y¹, Y² are each independently O or S;    -   R¹, R², are each independently H or a methyl group;    -   W² is a bond, C₁₋₆ aryl, or heteroaryl, each optionally        substituted by 1, 2 or 3 R^(W2); and    -   each R^(W2) is independently H, halo, C₁₋₆ alkyl (optionally        substituted by 1 or more F), OC₁₋₃alkyl (optionally substituted        by 1 or more —F).

In any of the embodiments described herein, the W² is covalently coupledto one or more ULM or CLM groups, or a linker to which is attached oneor more ULM or CLM groups as described herein.

In certain additional embodiments, W¹ is selected from the groupconsisting of:

In certain additional embodiments, W2 is selected from the groupconsisting of:

In certain embodiments, ABM is selected from the group consisting of:

In certain embodiments, the ABM comprises the structure:

wherein W¹ is aryl, or heteroaryl, each independently substituted by 1or more H, halo, hydroxyl, nitro, CN, C≡CH, C₁₋₆ alkyl (linear,branched, optionally substituted by 1 or more halo, C₁₋₆ alkoxyl), C₁₋₆alkoxyl (linear, branched, optionally substituted by 1 or more halo),C₂₋₆ alkenyl, C₂₋₆ alkynyl, or CF₃;

Y³, Y⁴, Y⁵ are each independently a bond, O, NR^(Y2), CR^(Y1)R^(Y2),C═O, C═S, SO, SO₂, heteroaryl, or aryl;

Q is a 4 membered alicyclic ring with 0-2 heteroatoms, optionallysubstituted with 0-6 R^(Q), each R^(Q) is independently H, C₁₋₆ alkyl(linear, branched, optionally substituted by 1 or more halo, C₁₋₆alkoxyl), or 2 R^(Q) groups taken together with the atom they areattached to, form a 3-8 membered ring system containing 0-2heteroatoms);

R^(Y1), R^(Y2) are each independently H, C₁₋₆ alkyl (linear, branched,optionally substituted by 1 or more halo, C₁₋₆ alkoxyl);

W² is a bond, C₁₋₆ alkyl, C₁₋₆ heteroalkyl, O, C₁₋₆ alicyclic,heterocyclic, aryl, biheterocyclic, biaryl, or biheteroaryl, orheteroaryl, each optionally substituted by 1, 2 or 3 R^(W2); and

each R^(W2) is independently H, halo, C₁₋₆ alkyl (linear, branched,optionally substituted by 1 or more F), C₁₋₆ heteroalkyl (linear,branched, optionally substituted), —OR^(W2A) OC₁₋₃alkyl (optionallysubstituted by 1 or more —F), C₃₋₆ cycloalkyl, C₄₋₆ cycloheteroalkyl(optionally substituted), C₁₋₆ alkyl (optionally substituted), C₁₋₆alicyclic (optionally substituted), heterocyclic (optionallysubstituted), aryl (optionally substituted), heteroaryl (optionallysubstituted), bicyclic hereoaryl (optionally substituted), bicyclicaryl, OH, NH₂, NR^(Y1)R^(Y2), or CN; and R^(W2A) is H, C₁₋₆ alkyl(linear, branched), or C₁₋₆ heteroalkyl (linear, branched), eachoptionally substituted by a cycloalkyl, cycloheteroalkyl, aryl,heterocyclic, heteroaryl, halo, or OC₁₋₃alkyl.

In an additional aspect, the description provides an androgen receptorbinding compound comprising a structure of:

wherein W¹ is aryl, heteroaryl, bicyclic, or biheterocyclic, eachindependently substituted by 1 or more H, halo, hydroxyl, nitro, CN,C≡CH, C₁₋₆ alkyl (linear, branched, optionally substituted by 1 or morehalo, C₁₋₆ alkoxyl), C₁₋₆ alkoxyl (linear, branched, optionallysubstituted by 1 or more halo), C₂₋₆ alkenyl, C₂₋₆ alkynyl, or CF₃;

Y¹, Y² are each independently NR^(Y1), O, or S;

Y³, Y⁴, Y⁵ are each independently a bond, O, NR^(Y2), CR^(Y1)R^(Y2),C═O, C═S, SO, SO₂, heteroaryl, or aryl;

Q is a 3-6 membered alicyclic or aromatic ring with 0-4 heteroatoms,optionally substituted with 0-6 R^(Q), each R^(Q), is independently H,C₁₋₆ alkyl (linear, branched, optionally substituted by 1 or more halo,C₁₋₆ alkoxyl), or 2 R^(Q) groups taken together with the atom they areattached to, form a 3-8 membered ring system containing 0-2heteroatoms);

R¹, R², R^(a), R^(b), R^(Y1), R^(Y2) are each independently H, C₁₋₆alkyl (linear, branched, optionally substituted by 1 or more halo, C₁₋₆alkoxyl), or R¹, R² together with the atom they are attached to, form a3-8 membered ring system containing 0-2 heteroatoms);

W² is a bond, C₁₋₆ alkyl, C₁₋₆ heteroalkyl, O, C₁₋₆ alicyclic,heterocyclic, aryl, biheterocyclic, biaryl, or biheteroaryl, orheteroaryl, each optionally substituted by 1, 2 or 3 R^(W2);

each R^(W2) is independently H, halo, C₁₋₆ alkyl (linear, branched,optionally substituted by 1 or more F), C₁₋₆heteroalkyl (linear,branched, optionally substituted), —OR^(W2A), OC₁₋₃alkyl (optionallysubstituted by 1 or more —F), C₃₋₆ cycloalkyl, C₄₋₆ cycloheteroalkyl,C₁₋₆ alkyl (optionally substituted), C₁₋₆ alicyclic (optionallysubstituted), heterocyclic (optionally substituted), aryl (optionallysubstituted), or heteroaryl (optionally substituted), bicyclic hereoarylor aryl, OH, NH₂, NR^(Y1)R^(Y2), CN; and

R^(W2A) is H, C₁₋₆ alkyl (linear, branched), or C₁₋₆ heteroalkyl(linear, branched), each optionally substituted by a cycloalkyl,cycloheteroalkyl, aryl, heterocyclic, heteroaryl, halo, or OC₁₋₃alkyl.

In certain embodiments, an androgen receptor binding moiety has astructure of:

wherein W¹ is

each R₂₂ is independently H or —CN;each R₂₃ is independently H, halo, or —CF₃;Y³ is a bond or O;Q is a 4 member ring, optionally substituted with 0-4 R^(Q), each R^(Q)is independently H or methyl;Y4 is a bond or NH;Y5 is a bond, a C═O, or a C═S;each W² is independently a bond, C1-6 aryl or heteroaryl, eachoptionally substituted by 1, 2 or 3 R^(W2), each R^(W2) is independentlyH, halo, a 6 member alicyclic ring with 1 or 2 heteroatoms or a 5 memberaromatic ring with 1 or 2 or 3 heteroatoms.

In certain additional embodiments, W² is selected from the groupconsisting of:

In any of the embodiments described herein, the W² is covalently coupledto one or more ULM or CLM groups, or a linker to which is attached oneor more ULM or CLM groups as described herein.

In certain additional embodiments, W¹ is selected from the groupconsisting of:

In certain embodiments, an androgen binding moiety has a structure of:

wherein W¹ is aryl, independently substituted by 1 or more halo, CN;

-   -   Y³ are each independently a bond, NR^(Y2), CR^(Y1)R^(Y2), C═O;    -   Q is a 5 membered aromatic ring with 1 or 2 heteroatoms;    -   R^(Y1), R^(Y2) are each independently H, C₁₋₆ alkyl (linear,        branched);    -   W² is a bond, aryl, or heteroaryl, each optionally substituted        by 1, 2 or 3 R^(W2); and    -   each R^(W2) is independently H, halo, C₁₋₆ alkyl (optionally        substituted by 1 or more F), OC₁₋₃alkyl (optionally substituted        by 1 or more —F).

In any of the embodiments described herein, the W² is covalently coupledto one or more ULM or CLM groups, or a linker to which is attached oneor more ULM or CLM groups as described herein.

In certain embodiments, W¹ is

wherein each R₂₂ is independently halo or CN; andeach R₂₃ is independently H or halo.

In certain additional embodiments, W¹ is selected from the groupconsisting of:

In certain additional embodiments, Q is

In certain additional embodiments, W² is

In certain additional embodiments, (Y³)₀₋₅ is

In certain embodiments, the ABM comprises a structure selected from, butnot limited to the structures shown below, where a dashed line indicatesthe attachment point of a linker moiety or a ULM:

wherein:

-   -   W¹ is

-   -   each R₂₂ is independently H or —CN;    -   each R₂₃ is independently H, halo, or —CF₃;    -   Y¹, Y² are each independently O or S;    -   Y³, Y⁴, Y⁵ are each independently a bond, O, NR^(Y2),        CR^(Y1)R^(Y2), C═O, C═S, SO, or SO₂;    -   R¹, R², are each independently H or a methyl group;    -   W² is a bond, C₁₋₆ aryl, or heteroaryl, each optionally        substituted by 1, 2 or 3 R^(W2); and    -   each R^(W2) is independently H, halo, C₁₋₆ alkyl (optionally        substituted by 1 or more F), C₃₋₆ cycloalkyl, C₄₋₆        cycloheteroalkyl, OC₁₋₃alkyl (optionally substituted by 1 or        more —F).

In any of the embodiments described herein, the W² is covalently coupledto one or more ULM or CLM groups, or a linker to which is attached oneor more ULM or CLM groups as described herein.

In certain additional embodiments, W¹ is selected from the groupconsisting of:

In certain additional embodiments, W2 is selected from the groupconsisting of:

In certain embodiments, the ABM comprises a structure shown below, wherea dashed line indicates the attachment point of a linker moiety or a ULMor a CLM:

wherein:

W¹ is

-   -   each R₂₂ is independently H or —CN;    -   each R₂₃ is independently H, halo, or —CF₃;    -   Y³ is a bond or O;    -   Y⁴ is a bond or NH;    -   Y⁵ is a bond, C═O, C₁-C₆ heteroaryl, or C₁-C₆ aryl;    -   R¹, R², are each independently H, or C₁-C₆ alkyl (linear or        branched, optionally substituted by 1 or more halo, or C₁₋₆        alkoxyl);    -   W² is a bond, C₁₋₆ aryl, C₁₋₆ heteroaryl, C₁₋₆ alicyclic, or        C₁₋₆ heterocyclic, each optionally substituted by 1-10 R^(W2);        and        -   each R^(W2) is independently H, or halo; and        -   represents a bond that may be stereospecific ((R) or (S)) or            non-stereospecific.

In any of the embodiments described herein, the W² is covalently coupledto one or more ULM or CLM groups, or a linker to which is attached oneor more ULM or CLM groups as described herein.

In certain additional embodiments, W¹ is selected from the groupconsisting of:

In certain additional embodiments, W² is selected from the groupconsisting of:

In certain embodiments, the androgen receptor binding compound of ABM isselected from the group consisting of:

-   trans-2-Chloro-4-[3-amino-2,2,4,4-tetramethylcyclobutoxy]benzonitrile;-   cis-2-Chloro-4-[3-amino-2,2,4,4-tetramethylcyclobutoxy]benzonitrile;-   trans    6-Amino-N-[3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl]pyridazine-3-carboxamide;-   trans tert-Butyl    N-[3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl]carbamate;-   trans    4-Amino-N-[3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl]benzamide;-   trans    5-Amino-N-[3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl]pyrazine-2-carboxamide;-   trans    2-Amino-N-[3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl]pyrimidine-5-carboxamide;-   4-Methoxy-N-[(1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl]benzamide;-   trans    1-(2-Hydroxyethyl)-N-[3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl]-1H-pyrazole-4-carboxamide;-   trans    6-Amino-N-[3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl]pyridine-3-carboxamide;-   trans    4-[(5-Hydroxypentyl)amino]-N-[3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl]benzamide;    and-   trans tert-Butyl    2-({5-[(4-{[3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl]carbamoyl}phenyl)aminopentyl}oxy)acetate;    and-   N-((1r,3r)-3-(4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-methylbenzamide.

The term “hydrocarbyl” shall mean a compound which contains carbon andhydrogen and which may be fully saturated, partially unsaturated oraromatic and includes aryl groups, alkyl groups, alkenyl groups andalkynyl groups.

The term “unsubstituted” shall mean substituted only with hydrogenatoms. A range of carbon atoms which includes Co means that carbon isabsent and is replaced with H. Thus, a range of carbon atoms which isCo-C6 includes carbons atoms of 1, 2, 3, 4, 5 and 6 and for C₀, H standsin place of carbon. The term “substituted” or “optionally substituted”shall mean independently (i.e., where more than substituent occurs, eachsubstituent is independent of another substituent) one or moresubstituents (independently up to five substitutents, preferably up tothree substituents, often 1 or 2 substituents on a moiety in a compoundaccording to the present disclosure and may include substituents whichthemselves may be further substituted) at a carbon (or nitrogen)position anywhere on a molecule within context, and includes assubstituents hydroxyl, thiol, carboxyl, cyano (C≡N), nitro (NO₂),halogen (preferably, 1, 2 or 3 halogens, especially on an alkyl,especially a methyl group such as a trifluoromethyl), an alkyl group(preferably, C₁-C₁₀, more preferably, C₁-C₆), aryl (especially phenyland substituted phenyl for example benzyl or benzoyl), alkoxy group(preferably, C₁-C₆ alkyl or aryl, including phenyl and substitutedphenyl), thioether (C₁-C₆ alkyl or aryl), acyl (preferably, C₁-C₆ acyl),ester or thioester (preferably, C₁-C₆ alkyl or aryl) including alkyleneester (such that attachment is on the alkylene group, rather than at theester function which is preferably substituted with a C₁-C₆ alkyl oraryl group), preferably, C₁-C₆ alkyl or aryl, halogen (preferably, F orCl), amine (including a five- or six-membered cyclic alkylene amine,further including a C₁-C₆ alkyl amine or a C₁-C₆ dialkyl amine whichalkyl groups may be substituted with one or two hydroxyl groups) or anoptionally substituted —N(C₀-C₆ alkyl)C(O)(O—C₁-C6 alkyl) group (whichmay be optionally substituted with a polyethylene glycol chain to whichis further bound an alkyl group containing a single halogen, preferablychlorine substituent), hydrazine, amido, which is preferably substitutedwith one or two C₁-C₆ alkyl groups (including a carboxamide which isoptionally substituted with one or two C₁-C₆ alkyl groups), alkanol(preferably, C₁-C₆ alkyl or aryl), or alkanoic acid (preferably, C₁-C₆alkyl or aryl). Substituents according to the present disclosure mayinclude, for example —SiR₁R₂R₃ groups where each of R₁ and R₂ is asotherwise described herein and R₃ is H or a C₁-C₆ alkyl group,preferably R₁, R₂, R₃ in this context is a C₁-C₃ alkyl group (includingan isopropyl or t-butyl group). Each of the above-described groups maybe linked directly to the substituted moiety or alternatively, thesubstituent may be linked to the substituted moiety (preferably in thecase of an aryl or heteraryl moiety) through an optionally substituted—(CH₂)_(m)— or alternatively an optionally substituted —(OCH₂)_(m)—,—(OCH₂CH₂)_(m)— or —(CH₂CH₂O)_(m)— group, which may be substituted withany one or more of the above-described substituents. Alkylene groups—(CH₂)_(m)— or —(CH₂)_(n)— groups or other chains such as ethyleneglycol chains, as identified above, may be substituted anywhere on thechain. Preferred substituents on alkylene groups include halogen orC₁-C₆ (preferably C₁-C₃) alkyl groups, which may be optionallysubstituted with one or two hydroxyl groups, one or two ether groups(O—C₁-C₆ groups), up to three halo groups (preferably F), or a sidechainof an amino acid as otherwise described herein and optionallysubstituted amide (preferably carboxamide substituted as describedabove) or urethane groups (often with one or two C₀-C₆ alkylsubstituents, which group(s) may be further substituted). In certainembodiments, the alkylene group (often a single methylene group) issubstituted with one or two optionally substituted C₁-C₆ alkyl groups,preferably C₁-C₄ alkyl group, most often methyl or O-methyl groups or asidechain of an amino acid as otherwise described herein. In the presentdisclosure, a moiety in a molecule may be optionally substituted with upto five substituents, preferably up to three substituents. Most often,in the present disclosure moieties that are substituted, are substitutedwith one or two substituents.

The term “substituted” (each substituent being independent of any othersubstituent) shall also mean within its context of use C₁-C₆ alkyl,C₁-C₆ alkoxy, halogen, amido, carboxamido, sulfone, includingsulfonamide, keto, carboxy, C₁-C₆ ester (oxyester or carbonylester),C₁-C₆ keto, urethane —O—C(O)—NR₁R₂ or —N(R₁)—C(O)—O—R₁, nitro, cyano andamine (especially including a C₁-C₆ alkylene-NR₁R₂, a mono- or di-C₁-C₆alkyl substituted amines which may be optionally substituted with one ortwo hydroxyl groups). Each of these groups contain unless otherwiseindicated, within context, between 1 and 6 carbon atoms. In certainembodiments, preferred substituents will include for example, —NH—,—NHC(O)—, —O—, ═O, —(CH₂)_(m)— (here, m and n are in context, 1, 2, 3,4, 5 or 6), —S—, —S(O)—, SO₂— or —NH—C(O)—NH—, —(CH₂)_(n)OH,—(CH₂)_(n)SH, —(CH₂)_(n)COOH, C₁-C₆ alkyl, —(CH₂)_(n)O—(C₁-C₆ alkyl),—(CH₂)_(n)C(O)—(C₁-C₆ alkyl), —(CH₂)_(n)OC(O)—(C₁-C₆ alkyl),—(CH₂)_(n)C(O)O—(C₁-C₆ alkyl), —(CH₂)_(n)NHC(O)—R₁,—(CH₂)_(n)C(O)—NR₁R₂, —(OCH₂)_(n)OH, —(CH₂O)_(n)COOH, C₁-C₆ alkyl,—(OCH₂)_(n)O—(C₁-C₆ alkyl), —(CH₂O)_(n)C(O)—(C₁-C₆ alkyl),—(OCH₂)_(n)NHC(O)—R₁, —(CH₂O)_(n)C(O)—NR₁R₂, —S(O)₂—R_(S), —S(O)—R_(S)(R_(S) is C₁-C₆ alkyl or a —(CH₂)_(m)—NR₁R₂ group), NO₂, CN or halogen(F, Cl, Br, I, preferably F or Cl), depending on the context of the useof the substituent. R₁ and R₂ are each, within context, H or a C₁-C₆alkyl group (which may be optionally substituted with one or twohydroxyl groups or up to three halogen groups, preferably fluorine). Theterm “substituted” shall also mean, within the chemical context of thecompound defined and substituent used, an optionally substituted aryl orheteroaryl group or an optionally substituted heterocyclic group asotherwise described herein. Alkylene groups may also be substituted asotherwise disclosed herein, preferably with optionally substituted C₁-C₆alkyl groups (methyl, ethyl or hydroxymethyl or hydroxyethyl ispreferred, thus providing a chiral center), a sidechain of an amino acidgroup as otherwise described herein, an amido group as describedhereinabove, or a urethane group O—C(O)—NR₁R₂ group where R₁ and R₂ areas otherwise described herein, although numerous other groups may alsobe used as substituents. Various optionally substituted moieties may besubstituted with 3 or more substituents, preferably no more than 3substituents and preferably with 1 or 2 substituents. It is noted thatin instances where, in a compound at a particular position of themolecule substitution is required (principally, because of valency), butno substitution is indicated, then that substituent is construed orunderstood to be H, unless the context of the substitution suggestsotherwise.

Exemplary AR-PROTAC Compounds

As described above, in certain aspects, the description providesbifunctional PROTAC compounds comprising at least one ABM group, alinker, and at least one ULM (or CLM) group as described herein.

In certain embodiments, the compound is selected from the groupconsisting of compounds 1-625 (i.e., the chemical structures describedin Table 2, Table 3, Table 4, Table 5, Table 6, and Table 7 of FIGS. 2,3, 4, 5, 6, and 7, respectively), and salts and polymorphs thereof.

In additional embodiments, the compound is selected from the groupconsisting of:4-{3-[4-({1-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl]-4,7,10-trioxa-1-azadodecan-12-yl}oxy)phenyl]-4,4-dimethyl-5-oxo-2-sulfanylideneimidazolidin-1-yl}-2-(trifluoromethyl)benzonitrile(1);4-(3-{4-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl]amino}ethoxy)ethoxy]phenyl}-4,4-dimethyl-5-oxo-2-sulfanylideneimidazolidin-1-yl)-2-(trifluoromethyl)benzonitrile(2);4-{3-[4-({1-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl]-4,7,10,13,16-pentaoxa-1-azaoctadecan-18-yl}oxy)phenyl]-4,4-dimethyl-5-oxo-2-sulfanylideneimidazolidin-1-yl}-2-(trifluoromethyl)benzonitrile(3);4-[3-(4-{2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl]amino}ethoxy)ethoxy]ethoxy}phenyl)-4,4-dimethyl-5-oxo-2-sulfanylideneimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile(4);4-[3-(4-{3-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl]amino}ethoxy)ethoxy]propoxy}phenyl)-4,4-dimethyl-5-oxo-2-sulfanylideneimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile(5);4-{3-[4-({1-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl]-4,7,10-trioxa-1-azatetradecan-14-yl}oxy)phenyl]-4,4-dimethyl-5-oxo-2-sulfanylideneimidazolidin-1-yl}-2-(trifluoromethyl)benzonitrile(6);4-{3-[4-({1-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl]-4,7,10-trioxa-1-azatridecan-13-yl}oxy)phenyl]-4,4-dimethyl-5-oxo-2-sulfanylideneimidazolidin-1-yl}-2-(trifluoromethyl)benzonitrile(7);4-(3-{4-[(1-{2-[(3R)-2,6-dioxopiperidin-3-yl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl}-4,7,10-trioxa-1-azadodecan-12-yl)oxy]phenyl}-4,4-dimethyl-5-oxo-2-sulfanylideneimidazolidin-1-yl)-2-(trifluoromethyl)benzonitrile(8);4-(3-{4-[(1-{2-[(3S)-2,6-dioxopiperidin-3-yl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl}-4,7,10-trioxa-1-azadodecan-12-yl)oxy]phenyl}-4,4-dimethyl-5-oxo-2-sulfanylideneimidazolidin-1-yl)-2-(trifluoromethyl)benzonitrile(9);4-[3-(4-{3-[3-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl]amino}ethoxy)propoxy]propoxy}phenyl)-4,4-dimethyl-5-oxo-2-sulfanylideneimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile(10);4-{4,4-dimethyl-3-[4-({1-[2-(3-methyl-2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl]-4,7,10-trioxa-1-azatridecan-13-yl}oxy)phenyl]-5-oxo-2-sulfanylideneimidazolidin-1-yl}-2-(trifluoromethyl)benzonitrile(11);4-[3-(4-{4-[(5-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl]amino}pentyl)oxy]phenyl}phenyl)-4,4-dimethyl-5-oxo-2-sulfanylideneimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile(12);4-{[5-(3-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl]amino}propoxy)pentyl]oxy}-N-[(1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl]benzamide(13);4-{3-[4-({1-[2-(2,6-dioxopiperidin-3-yl)-1-oxo-2,3-dihydro-1H-isoindol-4-yl]-1,4,7,10-tetraoxatridecan-13-yl}oxy)phenyl]-4,4-dimethyl-5-oxo-2-sulfanylideneimidazolidin-1-yl}-2-(trifluoromethyl)benzonitrile(14);6-[4-(2-{[2-(2,6-dioxopiperidin-3-yl)-1-oxo-2,3-dihydro-1H-isoindol-4-yl]amino}ethyl)piperazin-1-yl]-N-[(1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl]pyridine-3-carboxamide(15);6-{4-[2-(3-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl]amino}propoxy)ethyl]piperazin-1-yl}-N-[(1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl]pyridine-3-carboxamide(16);4-(3-{4-[1-(2-{[2-(2,6-dioxopiperidin-3-yl)-1-oxo-2,3-dihydro-1H-isoindol-4-yl]oxy}ethyl)-1H-1,3-benzodiazol-5-yl]phenyl}-4,4-dimethyl-5-oxo-2-sulfanylideneimidazolidin-1-yl)-2-(trifluoromethyl)benzonitrile(17);4-{[5-(3-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl]amino}propoxy)pentyl]amino}-3-fluoro-N-[(1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl]benzamide(18);6-[4-(2-{[2-(2,6-dioxopiperidin-3-yl)-1-oxo-2,3-dihydro-1H-isoindol-4-yl]oxy}ethyl)piperazin-1-yl]-N-[(1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl]pyridine-3-carboxamide(19);6-[4-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl]amino}ethyl)piperazin-1-yl]-N-[(1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl]pyridine-3-carboxamide(20);6-(4-{3-[2-(2,6-dioxopiperidin-3-yl)-1-oxo-2,3-dihydro-1H-isoindol-4-yl]propyl}piperazin-1-yl)-N-[(1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl]pyridine-3-carboxamide(21);6-{4-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1-oxo-2,3-dihydro-1H-isoindol-4-yl]oxy}ethoxy)ethyl]piperazin-1-yl}-N-[(1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl]pyridine-3-carboxamide(22);4-{4-[4-(2-{[2-(2,6-dioxopiperidin-3-yl)-1-oxo-2,3-dihydro-1H-isoindol-4-yl]oxy}ethyl)piperazin-1-yl]butyl}-N-[(1r,3r)-3-[4-cyano-3-(trifluoromethyl)phenoxy]-2,2,4,4-tetramethylcyclobutyl]benzamide(23);6-{4-[2-(3-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl]amino}propoxy)ethyl]piperazin-1-yl}-N-[(1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl]pyridine-3-carboxamide(24);6-{4-[2-(3-{[2-(2,6-dioxopiperidin-3-yl)-7-fluoro-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl]amino}propoxy)ethyl]piperazin-1-yl}-N-[(1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl]pyridine-3-carboxamide(25);4-(6-{4-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl]piperazin-1-yl}hexyl)-N-[(1r,3r)-3-[4-cyano-3-(trifluoromethyl)phenoxy]-2,2,4,4-tetramethylcyclobutyl]benzamide(26);4-{3-[4-(3-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl]amino}propyl)piperazin-1-yl]propyl}-N-[(1r,3r)-3-[4-cyano-3-(trifluoromethyl)phenoxy]-2,2,4,4-tetramethylcyclobutyl]benzamide(27);4-[5-(3-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl]amino}propoxy)pentyl]-N-[(1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl]benzamide(28);6-{4-[2-(3-{[2-(2,6-dioxopiperidin-3-yl)-5-fluoro-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl]amino}propoxy)ethyl]piperazin-1-yl}-N-[(1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl]pyridine-3-carboxamide(29);4-(4-{4-[2-({2-[(3S)-2,6-dioxopiperidin-3-yl]-1-oxo-2,3-dihydro-1H-isoindol-5-yl}oxy)ethyl]piperazin-1-yl}butyl)-N-[(1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl]benzamide(30);4-(4-{4-[2-({2-[(3S)-2,6-dioxopiperidin-3-yl]-1-oxo-2,3-dihydro-1H-isoindol-4-yl}oxy)ethyl]piperazin-1-yl}butyl)-N-[(1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl]benzamide(31);4-{4-[4-(2-{[2-(2,6-dioxopiperidin-3-yl)-7-fluoro-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl]amino}ethyl)piperazin-1-yl]butyl}-N-[(1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl]benzamide(32);6-{4-[5-({2-[(3S)-2,6-dioxopiperidin-3-yl]-1-oxo-2,3-dihydro-1H-isoindol-4-yl}oxy)pentyl]piperazin-1-yl}-N-[(1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl]pyridine-3-carboxamide(33);4-(4-{4-[2-({2-[(3S)-2,6-dioxopiperidin-3-yl]-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl}oxy)ethyl]piperazin-1-yl}butyl)-N-[(1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl]benzamide(34);6-{4-[5-({2-[(3S)-2,6-dioxopiperidin-3-yl]-1-oxo-2,3-dihydro-1H-isoindol-5-yl}oxy)pentyl]piperazin-1-yl}-N-[(1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl]pyridine-3-carboxamide(35);4-(4-{4-[2-(2,6-dioxopiperidin-3-yl)-5-fluoro-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl]piperazin-1-yl}butyl)-N-[(1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl]benzamide(36);4-{4-[4-(2-{[2-(2,6-dioxopiperidin-3-yl)-5-fluoro-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl]amino}ethyl)piperazin-1-yl]butyl}-N-[(1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl]benzamide(37);6-(4-{6-[2-(2,6-dioxopiperidin-3-yl)-1-oxo-2,3-dihydro-1H-isoindol-4-yl]hexyl}piperazin-1-yl)-N-[(1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl]pyridine-3-carboxamide(38);4-(4-{4-[2-(2,6-dioxopiperidin-3-yl)-4-fluoro-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl]piperazin-1-yl}butyl)-N-[(1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl]benzamide(39);4-(6-{4-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl]piperazin-1-yl}hexyl)-N-[(1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl]benzamide(40);6-{4-[5-({2-[(3S)-2,6-dioxopiperidin-3-yl]-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl}oxy)pentyl]piperazin-1-yl}-N-[(1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl]pyridine-3-carboxamide(41);6-[4-(5-{[2-(2,6-dioxopiperidin-3-yl)-1-oxo-2,3-dihydro-1H-isoindol-4-yl]oxy}pentyl)piperazin-1-yl]-N-[(1r,3r)-3-(3-chloro-4-cyanophenoxy)cyclobutyl]pyridine-3-carboxamide(42);4-[4-(5-{[2-(2,6-dioxopiperidin-3-yl)-1-oxo-2,3-dihydro-1H-isoindol-4-yl]oxy}pentyl)piperazin-1-yl]-N-[(1r,3r)-3-(3-chloro-4-cyanophenoxy)cyclobutyl]benzamide(43);4-(5-{4-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl]piperazin-1-yl}pentyl)-N-[(1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl]benzamide(44);4-(4-{4-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl]piperazin-1-yl}butyl)-N-[(1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl]benzamide(45);4-(6-{4-[2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl]piperazin-1-yl}hexyl)-N-[(1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl]benzamide(46);4-(4-{[2-(2,6-dioxopiperidin-3-yl)-1-oxo-2,3-dihydro-1H-isoindol-4-yl]oxy}butyl)-N-[(1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl]benzamide(47);4-(5-{[2-(2,6-dioxopiperidin-3-yl)-1-oxo-2,3-dihydro-1H-isoindol-4-yl]oxy}pentyl)-N-[(1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl]benzamide(48);4-[3-(2-{[2-(2,6-dioxopiperidin-3-yl)-1-oxo-2,3-dihydro-1H-isoindol-4-yl]oxy}ethoxy)propyl]-N-[(1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl]benzamide(49);4-[4-(2-{[2-(2,6-dioxopiperidin-3-yl)-1-oxo-2,3-dihydro-1H-isoindol-4-yl]oxy}ethoxy)butyl]-N-[(1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl]benzamide(50);4-[5-(2-{[2-(2,6-dioxopiperidin-3-yl)-1-oxo-2,3-dihydro-1H-isoindol-4-yl]oxy}ethoxy)pentyl]-N-[(1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl]benzamide(51);4-[6-(2-{[2-(2,6-dioxopiperidin-3-yl)-1-oxo-2,3-dihydro-1H-isoindol-4-yl]oxy}ethoxy)hexyl]-N-[(1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl]benzamide(52);N-[(2R)-1-[3-(3-chloro-4-cyanophenyl)-1H-pyrazol-1-yl]propan-2-yl]-5-{[4-(4-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl]amino}butyl)piperazin-1-yl]methyl}-1H-pyrazole-3-carboxamide(53);4-(4-{6-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl]hexyl}piperazin-1-yl)-N-[(1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl]benzamide(54);4-(3-{[2-(2,6-dioxopiperidin-3-yl)-1-oxo-2,3-dihydro-1H-isoindol-4-yl]oxy}propyl)-N-[(1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl]benzamide(55);N-[(2R)-1-[3-(3-chloro-4-cyanophenyl)-1H-pyrazol-1-yl]propan-2-yl]-5-[(3-{4-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl]piperazin-1-yl}propoxy)methyl]-1H-pyrazole-3-carboxamide(56);4-[4-(3-{[2-(2,6-dioxopiperidin-3-yl)-1-oxo-2,3-dihydro-1H-isoindol-4-yl]oxy}propyl)-1H-1,2,3-triazol-1-yl]-N-[(1r,3r)-3-(3-chloro-4-cyanophenoxy)cyclobutyl]benzamide(57);6-[4-(6-{[2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl]amino}hexyl)piperazin-1-yl]-N-[(1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl]pyridine-3-carboxamide(58);N-[(2R)-1-[3-(3-chloro-4-cyanophenyl)-1H-pyrazol-1-yl]propan-2-yl]-5-({3-[4-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl]amino}ethyl)piperazin-1-yl]propoxy}methyl)-1H-pyrazole-3-carboxamide(59); (60);4-[4-(5-{[2-(2,6-dioxopiperidin-3-yl)-1-oxo-2,3-dihydro-1H-isoindol-4-yl]oxy}pentyl)-1H-1,2,3-triazol-1-yl]-N-[(1r,3r)-3-(3-chloro-4-cyanophenoxy)cyclobutyl]benzamide(61);6-{4-[2-(4-{2-[(3S)-2,6-dioxopiperidin-3-yl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl}butoxy)ethyl]piperazin-1-yl}-N-[(1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl]pyridine-3-carboxamide(62);6-{4-[2-(4-{2-[(3R)-2,6-dioxopiperidin-3-yl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl}butoxy)ethyl]piperazin-1-yl}-N-[(1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl]pyridine-3-carboxamide(63);6-(4-{2-[(5-{2-[(3S)-2,6-dioxopiperidin-3-yl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl}pentyl)oxy]ethyl}piperazin-1-yl)-N-[(1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl]pyridine-3-carboxamide(64);6-(4-{2-[(5-{2-[(3R)-2,6-dioxopiperidin-3-yl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl}pentyl)oxy]ethyl}piperazin-1-yl)-N-[(1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl]pyridine-3-carboxamide(65);4-(4-{2-[(5-{2-[(3S)-2,6-dioxopiperidin-3-yl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl}pentyl)oxy]ethyl}piperazin-1-yl)-N-[(1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl]benzamide(66);4-(4-{2-[(5-{2-[(3R)-2,6-dioxopiperidin-3-yl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl}pentyl)oxy]ethyl}piperazin-1-yl)-N-[(1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl]benzamide(67);4-(4-{6-[2-(2,6-dioxopiperidin-3-yl)-1-oxo-2,3-dihydro-1H-isoindol-5-yl]hexyl}piperazin-1-yl)-N-[(1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl]benzamide(68);4-(3-{4-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl]piperazin-1-yl}propyl)-N-[(1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl]benzamide(69);4-[6-(4-{2-[(3S)-2,6-dioxopiperidin-3-yl]-1-oxo-2,3-dihydro-1H-isoindol-5-yl}piperazin-1-yl)hexyl]-N-[(1r,3r)-3-[4-cyano-3-(trifluoromethyl)phenoxy]-2,2,4,4-tetramethylcyclobutyl]benzamide(70);4-[6-(4-{2-[(3R)-2,6-dioxopiperidin-3-yl]-1-oxo-2,3-dihydro-1H-isoindol-5-yl}piperazin-1-yl)hexyl]-N-[(1r,3r)-3-[4-cyano-3-(trifluoromethyl)phenoxy]-2,2,4,4-tetramethylcyclobutyl]benzamide(71);6-[4-(6-{[2-(2,6-dioxopiperidin-3-yl)-5-fluoro-1-oxo-2,3-dihydro-1H-isoindol-4-yl]oxy}hexyl)piperazin-1-yl]-N-[(1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl]pyridine-3-carboxamide(72);6-[4-(6-{[2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl]oxy}hexyl)piperazin-1-yl]-N-[(1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl]pyridine-3-carboxamide(73);4-[6-(4-{2-[(3S)-2,6-dioxopiperidin-3-yl]-3-oxo-2,3-dihydro-1H-isoindol-5-yl}piperazin-1-yl)hexyl]-N-[(1r,3r)-3-[4-cyano-3-(trifluoromethyl)phenoxy]-2,2,4,4-tetramethylcyclobutyl]benzamide(74); and4-[6-(4-{2-[(3R)-2,6-dioxopiperidin-3-yl]-3-oxo-2,3-dihydro-1H-isoindol-5-yl}piperazin-1-yl)hexyl]-N-[(1r,3r)-3-[4-cyano-3-(trifluoromethyl)phenoxy]-2,2,4,4-tetramethylcyclobutyl]benzamide(75);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-6-(4-(6-((2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1-oxoisoindolin-5-yl)amino)hexyl)piperazin-1-yl)nicotinamide(76);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-6-(4-(2-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)ethyl)piperazin-1-yl)nicotinamide(77);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-6-(4-(2-(1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperidin-4-yl)ethyl)piperazin-1-yl)nicotinamide(78);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-6-(4-(2-((5-(2-((S)-2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)pentyl)oxy)ethyl)piperazin-1-yl)nicotinamide(79);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4-(2-((5-(2-((R)-2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)pentyl)oxy)ethyl)piperazin-1-yl)benzamide(80);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(6-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)-3,6-dihydropyridin-1(2H)-yl)hexyl)benzamide(81);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(6-(4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)-3,6-dihydropyridin-1(2H)-yl)hexyl)benzamide(82);N-((1r,3R)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-6-((1R,4R)-5-(5-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)pentyl)-2,5-diazabicyclo[2.2.1]heptan-2-yl)nicotinamide(83);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4-(5-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)oxy)pentyl)piperazin-1-yl)benzamide(84);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(1-(5-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)pentyl)-1,2,3,6-tetrahydropyridin-4-yl)benzamide(85);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(5-(4-(2-((S)-2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)piperazin-1-yl)pentyl)benzamide(86);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(5-(4-(2-((R)-2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)piperazin-1-yl)pentyl)benzamide(87);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(6-(4-(2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1-oxoisoindolin-5-yl)piperazin-1-yl)hexyl)benzamide(88);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(6-(4-(2-(2,6-dioxopiperidin-3-yl)-6-fluoro-3-oxoisoindolin-5-yl)piperazin-1-yl)hexyl)benzamide(89);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-6-(4-(6-((2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1-oxoisoindolin-5-yl)oxy)hexyl)piperazin-1-yl)nicotinamide(90);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4-(3-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)propyl)piperazin-1-yl)benzamide(91);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4-(4-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)butyl)piperazin-1-yl)benzamide(92);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(6-(4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)piperidin-1-yl)hexyl)benzamide(93);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-6-(6-(4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)piperidin-1-yl)hexyl)nicotinamide(94);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(5-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)-3,6-dihydropyridin-1(2H)-yl)pentyl)benzamide(95);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-6-(4-(5-((2-(2,6-dioxopiperidin-3-yl)-3-oxoisoindolin-5-yl)oxy)pentyl)piperazin-1-yl)nicotinamide(96);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)-3,6-dihydropyridin-1(2H)-yl)butyl)benzamide(97);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(5-(4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)-3,6-dihydropyridin-1(2H)-yl)pentyl)benzamide(98);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(1-(5-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)pentyl)piperidin-4-yl)benzamide(99);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4-(5-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)oxy)pentyl)-1H-1,2,3-triazol-1-yl)benzamide(100);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(6-((1S,4S)-5-(2-((R)-2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)-2,5-diazabicyclo[2.2.1]heptan-2-yl)hexyl)benzamide(101);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-6-(4-(5-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)oxy)pentyl)-1H-1,2,3-triazol-1-yl)nicotinamide(102);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-6-(6-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperidin-1-yl)hexyl)nicotinamide(103);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4-(4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)-3,6-dihydropyridin-1(2H)-yl)butyl)benzamide(104);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4-(3-(4-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)oxy)piperidin-1-yl)propyl)-1H-1,2,3-triazol-1-yl)benzamide(105);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4-(3-(3-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)oxy)azetidin-1-yl)propyl)-1H-1,2,3-triazol-1-yl)benzamide(106);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-6-(4-(2-(1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)-1H-1,2,3-triazol-4-yl)ethyl)piperazin-1-yl)nicotinamide(107);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-6-(4-(3-(1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)-1H-1,2,3-triazol-4-yl)propyl)piperazin-1-yl)nicotinamide(108);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-6-(6-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)hexyl)nicotinamide(109);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-6-(6-(4-(2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)hexyl)nicotinamide(110);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-6-(4-(3-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)propyl)piperazin-1-yl)nicotinamide(111);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-6-(1-(5-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)pentyl)piperidin-4-yl)nicotinamide(112);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-6-(1-(3-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)propyl)piperidin-4-yl)nicotinamide(113);N-((1r,3r)-3-(4-cyano-3-(trifluoromethyl)phenoxy)-2,2,4,4-tetramethylcyclobutyl)-6-(4-(5-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)pentyl)piperazin-1-yl)nicotinamide(114);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-6-(4-(4-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)butyl)piperazin-1-yl)nicotinamide(115);N-((1r,3S)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-((3S)-4-(5-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)pentyl)-3-(hydroxymethyl)piperazin-1-yl)benzamide(116);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-6-(4-(3-(3-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)oxy)azetidin-1-yl)propyl)-1H-1,2,3-triazol-1-yl)nicotinamide(117);N-((1r,3r)-3-(4-cyano-3-(trifluoromethyl)phenoxy)-2,2,4,4-tetramethylcyclobutyl)-6-(6-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)hexyl)nicotinamide(118);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-6-(3-(4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)piperazin-1-yl)propyl)nicotinamide(119);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-6-(3-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)propyl)nicotinamide(120);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-6-(4-(4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)piperidin-1-yl)butyl)nicotinamide(121);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-6-(4-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)ethyl)piperazin-1-yl)nicotinamide(122);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-6-(4-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperidin-1-yl)butyl)nicotinamide(123);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-6-(4-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)butyl)nicotinamide(124);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-6-(4-(4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)piperazin-1-yl)butyl)nicotinamide(125);N-((1r,3r)-3-(4-cyano-3-methylphenoxy)-2,2,4,4-tetramethylcyclobutyl)-6-(4-(5-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)pentyl)piperazin-1-yl)nicotinamide(126);N-((1r,3r)-3-(3,4-dicyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-6-(4-(5-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)pentyl)piperazin-1-yl)nicotinamide(127);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-6-(5-(3-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)azetidin-1-yl)pentyl)nicotinamide(128);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-6-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)nicotinamide(129);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-6-(4-(4-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)piperidin-1-yl)butyl)nicotinamide(130);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-6-(4-(2-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)ethyl)piperidin-1-yl)nicotinamide(131);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-2-(4-(5-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)pentyl)piperazin-1-yl)pyrimidine-5-carboxamide(132);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(2-(3-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)propoxy)ethyl)-3,5-difluorobenzamide(133);N-((1r,3R)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-((3S,5R)-4-(5-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)pentyl)-3,5-dimethylpiperazin-1-yl)benzamide(134);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-6-(2-(4-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)butyl)-2,6-dihydropyrrolo[3,4-c]pyrazol-5(4H)-yl)nicotinamide(135);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-6-(1-(4-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)butyl)-4,6-dihydropyrrolo[3,4-c]pyrazol-5(1H)-yl)nicotinamide(136);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-6-(5-(4-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)butyl)-5,6-dihydropyrrolo[3,4-c]pyrazol-2(4H)-yl)nicotinamide(137);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-6-(5-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)pentyl)nicotinamide(138);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-6-(6-(4-(2-((S)-2,6-dioxopiperidin-3-yl)-6-fluoro-3-oxoisoindolin-5-yl)piperazin-1-yl)hexyl)nicotinamide(139);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-6-(6-(4-(2-((S)-2,6-dioxopiperidin-3-yl)-6-fluoro-1-oxoisoindolin-5-yl)piperazin-1-yl)hexyl)nicotinamide(140);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(2-(9-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)-1-oxa-4,9-diazaspiro[5.5]undecan-4-yl)ethyl)benzamide(141);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-2-(4-(4-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)butyl)piperazin-1-yl)pyrimidine-5-carboxamide(142);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-2-(4-(3-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)propyl)piperazin-1-yl)pyrimidine-5-carboxamide(143);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-2-(4-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)ethyl)piperazin-1-yl)pyrimidine-5-carboxamide(144);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-2-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)pyrimidine-5-carboxamide(145);N-((1r,3r)-3-(4-cyano-3-(trifluoromethyl)phenoxy)-2,2,4,4-tetramethylcyclobutyl)-6-(3-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)propyl)nicotinamide(146);N—((R)-1-(3-(3-chloro-4-cyanophenyl)-1H-pyrazol-1-yl)propan-2-yl)-5-((4-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)butoxy)methyl)-1H-pyrazole-3-carboxamide(147);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(3-(9-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)-1-oxa-4,9-diazaspiro[5.5]undecan-4-yl)propyl)benzamide(148);N-((1r,3r)-3-(4-cyano-3-methylphenoxy)-2,2,4,4-tetramethylcyclobutyl)-6-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)nicotinamide(149);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-2-(4-(2-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)ethyl)piperidin-1-yl)pyrimidine-5-carboxamide(150);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-6-(4-(5-((2-((S)-2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)pentyl)piperazin-1-yl)nicotinamide(151);N-((1r,3r)-3-(4-cyano-3-methylphenoxy)-2,2,4,4-tetramethylcyclobutyl)-6-(4-(2-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)ethyl)piperidin-1-yl)nicotinamide(152);N-((1r,3r)-3-(4-cyano-3-(trifluoromethyl)phenoxy)-2,2,4,4-tetramethylcyclobutyl)-6-(4-(2-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)ethyl)piperidin-1-yl)nicotinamide(153);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-6-(4-(5-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)pentyl)-3-oxopiperazin-1-yl)nicotinamide(154);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-2-(4-(4-(3-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)azetidin-1-yl)butyl)piperazin-1-yl)pyrimidine-5-carboxamide(155);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-2-(4-(3-(3-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)azetidin-1-yl)propyl)piperazin-1-yl)pyrimidine-5-carboxamide(156);2-chloro-4-(3-(4-(5-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)pentyl)-3-fluorophenyl)-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl)benzonitrile(157);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)benzamide(158);2-chloro-4-(5-(4-(5-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)pentyl)-3-fluorophenyl)-8-oxo-6-thioxo-5,7-diazaspiro[3.4]octan-7-yl)benzonitrile(159);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-6-(4-(2-(4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)piperazin-1-yl)ethyl)piperidin-1-yl)nicotinamide(160);N-((1r,3r)-3-(3,4-dicyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-2-(4-(2-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)ethyl)piperidin-1-yl)pyrimidine-5-carboxamide(161);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-6-(2-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)-2,7-diazaspiro[3.5]nonan-7-yl)nicotinamide(162);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-6-(7-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)-2,7-diazaspiro[3.5]nonan-2-yl)nicotinamide(163);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-6-(2-(5-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)pentyl)-2,6-dihydropyrrolo[3,4-c]pyrazol-5(4H)-yl)nicotinamide(164);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-2-(3-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)ethyl)azetidin-1-yl)pyrimidine-5-carboxamide(165);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4-(4-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)butyl)piperazin-1-yl)-2,6-difluorobenzamide(166);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-2-(4-((1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperidin-4-yl)methyl)-1,4-diazepan-1-yl)pyrimidine-5-carboxamide(167);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)ethyl)-1-oxa-4,9-diazaspiro[5.5]undecan-9-yl)benzamide(168);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4-(3-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)propyl)-1-oxa-4,9-diazaspiro[5.5]undecan-9-yl)benzamide(169);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(2-(4-(2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)ethyl)benzamide(170);N-((1r,3R)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(2-((1R,4R)-5-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)-2,5-diazabicyclo[2.2.1]heptan-2-yl)ethyl)benzamide(171);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazine-1-carbonyl)piperidin-1-yl)benzamide(172);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)-3,5-difluorobenzamide(173);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4-(2-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)ethyl)piperidin-1-yl)benzamide(174);N-((1r,3R)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4-(((1R,4R)-5-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)-2,5-diazabicyclo[2.2.1]heptan-2-yl)methyl)piperidin-1-yl)benzamide(175);N-((1r,3S)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4-(((1S,4S)-5-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)-2,5-diazabicyclo[2.2.1]heptan-2-yl)methyl)piperidin-1-yl)benzamide(176);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)-3-fluorobenzamide(177);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4-((((1r,3r)-3-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)cyclobutyl)(methyl)amino)methyl)piperidin-1-yl)benzamide(178);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-6-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)-5-fluoronicotinamide(179);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-4-fluoro-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)benzamide(180);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-4,6-difluoro-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)benzamide(181);N-((1r,3R)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-((3R)-3-((4-(2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl)pyrrolidin-1-yl)benzamide(182);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl)cyclohexyl)benzamide(183);N-((1r,3r)-3-(4-cyano-3-methylphenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl)cyclohexyl)benzamide(184);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-6-fluoro-3-oxoisoindolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)benzamide(185);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1-oxoisoindolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)benzamide(186);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4-(2-(4-(2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1-oxoisoindolin-5-yl)piperazin-1-yl)ethyl)piperidin-1-yl)benzamide(187);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4-(2-(4-(2-(2,6-dioxopiperidin-3-yl)-6-fluoro-3-oxoisoindolin-5-yl)piperazin-1-yl)ethyl)piperidin-1-yl)benzamide(188);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(3-(2-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)ethyl)azetidin-1-yl)benzamide(189);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4-(2-(3-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)azetidin-1-yl)ethyl)piperidin-1-yl)benzamide(190);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-2-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl)azepan-1-yl)pyrimidine-5-carboxamide(191);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)cyclohexyl)benzamide(192);N-((1r,3R)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-6-((3S,5R)-4-(3-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)propyl)-3,5-dimethylpiperazin-1-yl)nicotinamide(193);N-((1r,3R)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-((3S,5R)-4-(3-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)propyl)-3,5-dimethylpiperazin-1-yl)benzamide(194);N-((1r,3R)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-2-((3S,5R)-4-(3-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)propyl)-3,5-dimethylpiperazin-1-yl)pyrimidine-5-carboxamide(195);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4-((1s,3S)-3-(((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)methyl)cyclobutyl)piperazin-1-yl)benzamide(196);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(2-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)ethyl)-2-fluorobenzamide(197);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4-(3-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)azetidin-1-yl)piperidin-1-yl)benzamide(198);N-((1r,3R)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-((3R)-3-(((1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperidin-4-yl)methyl)(methyl)amino)pyrrolidin-1-yl)benzamide(199);N-((1r,3S)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-((3S)-3-(((1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperidin-4-yl)methyl)(methyl)amino)pyrrolidin-1-yl)benzamide(200);N-((1r,3R)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-((3R)-3-(((1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperidin-4-yl)(methyl)amino)methyl)pyrrolidin-1-yl)benzamide(201);N-((1r,3R)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(2-((2S,6R)-4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)-2,6-dimethylpiperazin-1-yl)ethyl)benzamide(202);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(3-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)-[1,3′-biazetidin]-1′-yl)benzamide(203);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4-(2-(((1r,3r)-3-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)cyclobutyl)(methyl)amino)ethyl)piperazin-1-yl)benzamide(204);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4-(1-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)ethyl)azetidin-3-yl)piperazin-1-yl)benzamide(205);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(2-(4-(1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)azetidin-3-yl)piperazin-1-yl)ethyl)benzamide(206);N-((1r,3R)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(2-((2R,6R)-4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)-2,6-dimethylpiperazin-1-yl)ethyl)benzamide(207);N-((1r,3S)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-((3S)-3-((4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl)pyrrolidin-1-yl)benzamide(208);N-((1r,3S)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(2-((2S,6S)-4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)-2,6-dimethylpiperazin-1-yl)ethyl)benzamide(209);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(3-((4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl)azetidin-1-yl)benzamide(210);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(3-(2-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)ethyl)pyrrolidin-1-yl)benzamide(211);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4-(2-(4-(6-(2,6-dioxopiperidin-3-yl)-5,7-dioxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazin-2-yl)piperazin-1-yl)ethyl)piperidin-1-yl)benzamide(212);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-7-fluoro-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)benzamide(213);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-4-fluoro-1-oxoisoindolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)benzamide(214);N-((1r,3S)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-6-((4aR,6R,8aS)-6-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)octahydroisoquinolin-2(1H)-yl)nicotinamide(215);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(3-(2-(((1r,3r)-3-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)cyclobutyl)(methyl)amino)ethyl)azetidin-1-yl)benzamide(216);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4-(3-((2-(2,6-dioxopiperidin-3-yl)-4-fluoro-1,3-dioxoisoindolin-5-yl)oxy)propyl)piperazin-1-yl)benzamide(217);N-((1r,3R)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-((1r,3R)-3-((4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl)cyclobutyl)benzamide(218);N-((1r,3R)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-((1s,3S)-3-((4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl)cyclobutyl)benzamide(219);N-((1r,3R)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-6-((4aR,6S,8aR)-6-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)octahydroisoquinolin-2(1H)-yl)nicotinamide(220);N-((1r,3R)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-6-((4aR,6R,8aR)-6-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)octahydroisoquinolin-2(1H)-yl)nicotinamide(221);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-6-(4-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)piperidin-1-yl)pyridazine-3-carboxamide(222);N-((1r,3R)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-((3R)-3-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)pyrrolidin-1-yl)benzamide(223);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4-(1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)azetidin-3-yl)piperazin-1-yl)benzamide(224);N-((1r,3R)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-((3R)-3-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazine-1-carbonyl)pyrrolidin-1-yl)benzamide(225);N-((1r,3R)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-((3R)-3-(4-(2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1,3-dioxoisoindolin-5-yl)piperazine-1-carbonyl)pyrrolidin-1-yl)benzamide(226);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(3-((4-(2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl)pyrrolidin-1-yl)benzamide(227);N-((1r,3R)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4-(((3R)-1-(2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1,3-dioxoisoindolin-5-yl)pyrrolidin-3-yl)methyl)piperazin-1-yl)benzamide(228);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(6-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)ethyl)-2,6-diazaspiro[3.3]heptan-2-yl)benzamide(229);(3R)-N-(1-(4-(((1r,3R)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)carbamoyl)phenyl)piperidin-4-yl)-1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)-N-methylpyrrolidine-3-carboxamide(230);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-6-(4-(2-(4-(2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)ethyl)piperidin-1-yl)pyridazine-3-carboxamide(231);N-((1r,3R)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-2-((2S,4R,6R)-4-((4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl)-2,6-dimethylpiperidin-1-yl)pyrimidine-5-carboxamide(232);N-((1r,3R)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-2-((2S,4S,6R)-4-((4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl)-2,6-dimethylpiperidin-1-yl)pyrimidine-5-carboxamide(233);N-((1r,3S)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-2-((2S,6S)-4-((4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl)-2,6-dimethylpiperidin-1-yl)pyrimidine-5-carboxamide(234);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(3-(3-(3-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)azetidin-1-yl)propyl)azetidin-1-yl)benzamide(235);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-6-(7-((3-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperidin-1-yl)methyl)octahydro-2H-pyrido[1,2-a]pyrazin-2-yl)nicotinamide(236);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4-((((1r,3r)-3-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)cyclobutyl)methyl)(methyl)amino)piperidin-1-yl)benzamide(237);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-((1′-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)-[1,4′-bipiperidin]-4-yl)amino)benzamide(238);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4-(2-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)ethyl)piperazin-1-yl)benzamide(239);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4-((((1r,3r)-3-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)cyclobutyl)(isopropyl)amino)methyl)piperidin-1-yl)benzamide(240);N-((1r,3S)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-2-((1S,4S,5R)-5-((4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl)-2-azabicyclo[2.2.1]heptan-2-yl)pyrimidine-5-carboxamide(241);N-((1r,3S)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-2-((1S,4S,5S)-5-((4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl)-2-azabicyclo[2.2.1]heptan-2-yl)pyrimidine-5-carboxamide(242);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-2-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)pyrimidine-5-carboxamide(243);N-((1r,3R)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-((3R)-3-((2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)ethyl)(methyl)amino)pyrrolidin-1-yl)benzamide(244);N-((1r,3R)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-((3R)-3-(3-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)azetidin-1-yl)pyrrolidin-1-yl)benzamide(245);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(5-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)ethyl)hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)benzamide(246);N-((1r,3r)-3-(4-cyano-3-methylphenoxy)-2,2,4,4-tetramethylcyclobutyl)-2-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)pyrimidine-5-carboxamide(247);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4-(4-(2-((S)-2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)piperazin-1-yl)butyl)benzamide(248);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4-(4-(2-((R)-2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)piperazin-1-yl)butyl)benzamide(249);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(6-(4-(2-((S)-2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)piperazin-1-yl)hexyl)benzamide(250);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(6-(4-(2-((R)-2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)piperazin-1-yl)hexyl)benzamide(251);N-((1r,3r)-3-(4-cyano-3-(trifluoromethyl)phenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4-(5-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)pentyl)piperazin-1-yl)benzamide(252);N-((1r,3r)-3-(4-cyano-3-(trifluoromethyl)phenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(6-((2S,6R)-4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)-2,6-dimethylpiperazin-1-yl)hexyl)benzamide(253);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-((3-(2-(4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)-3,6-dihydropyridin-1(2H)-yl)ethyl)oxetan-3-yl)methyl)benzamide(254);N-((1r,3r)-3-(4-cyano-3-(trifluoromethyl)phenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)ethyl)piperazin-1-yl)benzamide(255);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(6-((1S,4S)-5-(2-((S)-2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)-2,5-diazabicyclo[2.2.1]heptan-2-yl)hexyl)benzamide(256);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)ethyl)piperazin-1-yl)benzamide(257);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(6-((1R,4R)-5-(2-((S)-2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)-2,5-diazabicyclo[2.2.1]heptan-2-yl)hexyl)benzamide(258);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(6-((1R,4R)-5-(2-((R)-2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)-2,5-diazabicyclo[2.2.1]heptan-2-yl)hexyl)benzamide(259);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-((3-(2-(4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)piperazin-1-yl)ethyl)oxetan-3-yl)methyl)benzamide(260);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-6-(1-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)ethyl)piperidin-4-yl)nicotinamide(261);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-6-(1-(4-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)butyl)piperidin-4-yl)nicotinamide(262);N-((1r,3r)-3-((5-cyano-6-methylpyridin-2-yl)oxy)-2,2,4,4-tetramethylcyclobutyl)-6-(4-(5-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)pentyl)piperazin-1-yl)nicotinamide(263);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-5-(4-(5-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)pentyl)piperazin-1-yl)pyrazine-2-carboxamide(264);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-6-(4-(5-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)pentyl)piperazin-1-yl)pyridazine-3-carboxamide(265);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-5-(4-(5-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)pentyl)piperazin-1-yl)picolinamide(266);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-1-(1-(5-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)pentyl)piperidin-4-yl)-1H-pyrazole-4-carboxamide(267);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-1-(1-(5-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)pentyl)piperidin-4-yl)-1H-pyrazole-3-carboxamide(268);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-1-(1-(4-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)butyl)pyrrolidin-3-yl)-1H-pyrazole-4-carboxamide(269);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(2-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)ethyl)benzamide(270);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-6-(6-(4-(2-((R)-2,6-dioxopiperidin-3-yl)-6-fluoro-3-oxoisoindolin-5-yl)piperazin-1-yl)hexyl)nicotinamide(271);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-6-(6-(4-(2-((R)-2,6-dioxopiperidin-3-yl)-6-fluoro-1-oxoisoindolin-5-yl)piperazin-1-yl)hexyl)nicotinamide(272);N-((1r,3r)-3-(4-cyano-3-(trifluoromethyl)phenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(3-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)propyl)benzamide(273);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-6-(4-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)-3,6-dihydropyridin-1(2H)-yl)butyl)nicotinamide(274);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-1′-(5-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)pentyl)-1′,2′,3′,6′-tetrahydro-[3,4′-bipyridine]-6-carboxamide(275);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-6-(5-(5-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)pentyl)-5,6-dihydropyrrolo[3,4-c]pyrazol-2(4H)-yl)nicotinamide(276);N—((S)-1-(3-(3-chloro-4-cyanophenyl)-1H-pyrazol-1-yl)propan-2-yl)-5-((3-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)propoxy)methyl)-1H-pyrazole-3-carboxamide(277);N—((R)-1-(3-(3-chloro-4-cyanophenyl)-1H-pyrazol-1-yl)propan-2-yl)-5-((4-(4-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)butyl)piperazin-1-yl)methyl)-1H-pyrazole-3-carboxamide(278);N-((1r,3R)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-6-((2R)-4-(5-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)pentyl)-2-(hydroxymethyl)piperazin-1-yl)nicotinamide(279);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-1′-(5-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)pentyl)-1′,2′,3′,6′-tetrahydro-[2,4′-bipyridine]-5-carboxamide(280);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-6-(4-(5-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)pentyl)-2-oxopiperazin-1-yl)nicotinamide(281);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(1-(4-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)butyl)piperidin-4-yl)benzamide(282);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(1-(3-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)propyl)piperidin-4-yl)benzamide(283);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(3-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)-3-oxopropyl)benzamide(284);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-6-(4-(5-((2-((R)-2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)pentyl)piperazin-1-yl)nicotinamide(285);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-6-(3-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)ethyl)azetidin-1-yl)nicotinamide(286);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-6-(3-(4-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)butyl)azetidin-1-yl)nicotinamide(287);4-(3-(4-(5-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)pentyl)-3-fluorophenyl)-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl)-2-(trifluoromethyl)benzonitrile(288);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-6-(4-(2-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)ethyl)piperidin-1-yl)pyridazine-3-carboxamide(289);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-5-(4-(2-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)ethyl)piperidin-1-yl)pyrazine-2-carboxamide(290);N—((S)-1-(3-(3-chloro-4-cyanophenyl)-1H-pyrazol-1-yl)propan-2-yl)-5-(1-(3-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)propoxy)ethyl)-1H-pyrazole-3-carboxamide(291);N-((1r,3S)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-5-((3S)-4-(5-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)pentyl)-3-(hydroxymethyl)piperazin-1-yl)picolinamide(292);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-6-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)pyridazine-3-carboxamide(293);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-6-(9-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)-3,9-diazaspiro[5.5]undecan-3-yl)nicotinamide(294);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-2-(9-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)-3,9-diazaspiro[5.5]undecan-3-yl)pyrimidine-5-carboxamide(295);N-((1r,3R)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(2-((1R,4R)-5-(2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1,3-dioxoisoindolin-5-yl)-2,5-diazabicyclo[2.2.1]heptan-2-yl)ethyl)benzamide(296);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4-(3-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)propyl)piperazin-1-yl)-2,6-difluorobenzamide(297);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4-(5-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)pentyl)piperazin-1-yl)-2,6-difluorobenzamide(298);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4-(4-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)butyl)piperazin-1-yl)-2-fluorobenzamide(299);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-2-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)-4-(trifluoromethyl)pyrimidine-5-carboxamide(300);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-3′-((4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl)-[1,1′-biphenyl]-4-carboxamide(301);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)-3-(trifluoromethyl)benzamide(302);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-3′-(2-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)ethyl)-[1,1′-biphenyl]-4-carboxamide(303);N-((1r,3R)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-((3S,5R)-4-(2-(1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperidin-4-yl)ethyl)-3,5-dimethylpiperazin-1-yl)benzamide(304);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-5-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)pyrimidine-2-carboxamide(305);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-5-(4-(2-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)ethyl)piperidin-1-yl)pyrimidine-2-carboxamide(306);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4-((1-(2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1,3-dioxoisoindolin-5-yl)piperidin-4-yl)methyl)piperazin-1-yl)benzamide(307);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(3-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)azetidin-1-yl)benzamide(308);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4-(2-(3-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)azetidin-1-yl)ethyl)piperazin-1-yl)benzamide(309);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-2-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)-4-methylpyrimidine-5-carboxamide(310);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-2-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)-4,6-dimethylpyrimidine-5-carboxamide(311);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(2-(4-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)ethyl)piperazin-1-yl)ethyl)benzamide(312);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-3′-(2-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)ethoxy)-[1,1′-biphenyl]-4-carboxamide(313);N-((1r,3R)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-((3S,5R)-4-(4-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)butyl)-3,5-dimethylpiperazin-1-yl)benzamide(314);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4-((1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)azetidin-3-yl)methyl)piperazin-1-yl)benzamide(315);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4-((1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperidin-4-yl)methyl)piperazin-1-yl)benzamide(316);N-((1r,3S)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-6-((3S)-4-(5-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)pentyl)-3-(hydroxymethyl)piperazin-1-yl)nicotinamide(317);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-6-(4-(4-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)butyl)piperazin-1-yl)-4-fluoronicotinamide(318);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(2-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)ethyl)-2,6-difluorobenzamide(319);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(3-(3-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)propyl)azetidin-1-yl)benzamide(320);N-((1r,3S)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-((3S)-3-((1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperidin-4-yl)methoxy)pyrrolidin-1-yl)benzamide(321);N-((1r,3S)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4-(((3S)-1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)pyrrolidin-3-yl)methyl)piperazin-1-yl)benzamide(322);N-((1r,3R)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4-(((3R)-1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)pyrrolidin-3-yl)methyl)piperazin-1-yl)benzamide(323);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-3-(4-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)butyl)benzamide(324);N-((1r,3R)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-((3R)-3-((1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperidin-4-yl)methoxy)pyrrolidin-1-yl)benzamide(325);N-((1r,3R)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-2-((3R,5R)-4-(3-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)propyl)-3,5-dimethylpiperazin-1-yl)pyrimidine-5-carboxamide(326);N-((1r,3R)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-((3R)-3-((4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl)pyrrolidin-1-yl)benzamide(327);N-((1r,3S)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-((3S)-3-((4-(2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl)pyrrolidin-1-yl)benzamide(328);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4-(4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)butyl)piperazin-1-yl)benzamide(329);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(3-(1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)azetidin-3-yl)propyl)benzamide(330);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)butyl)piperazin-1-yl)benzamide(331);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-3-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)cyclobutane-1-carboxamide(332);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-5-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)pyrazine-2-carboxamide(333);N-((1r,3R)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-((3R)-3-((((1r,3R)-3-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)cyclobutyl)(methyl)amino)methyl)pyrrolidin-1-yl)benzamide(334);N-((1r,3R)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4-(((3R)-1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)pyrrolidin-3-yl)methoxy)piperidin-1-yl)benzamide(335);N-((1r,3S)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4-(((3S)-1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)pyrrolidin-3-yl)methoxy)piperidin-1-yl)benzamide(336);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(3-((((1r,3r)-3-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)cyclobutyl)(methyl)amino)methyl)azetidin-1-yl)benzamide(337);N-((1r,3S)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-((3S)-3-((((1r,3S)-3-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)cyclobutyl)(methyl)amino)methyl)pyrrolidin-1-yl)benzamide(338);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-6-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)-4-fluoronicotinamide(339);N-((1r,3S)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4-((((3S)-1-(2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1,3-dioxoisoindolin-5-yl)pyrrolidin-3-yl)methyl)(methyl)amino)piperidin-1-yl)benzamide(340);N-((1r,3R)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4-((((3R)-1-(2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1,3-dioxoisoindolin-5-yl)pyrrolidin-3-yl)methyl)(methyl)amino)piperidin-1-yl)benzamide(341);N-((1r,3S)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-6-((4aR,6S,8aS)-6-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)octahydroisoquinolin-2(1H)-yl)nicotinamide(342);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)-3-fluorobenzamide(343);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)piperidin-1-yl)benzamide(344);N-((1r,3S)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4-(((3S)-1-(2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1,3-dioxoisoindolin-5-yl)pyrrolidin-3-yl)methyl)piperazin-1-yl)benzamide(345);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-6-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)pyridazine-3-carboxamide(346);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)-3-(2-(2-methoxyethoxy)ethoxy)benzamide(347);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4-((1-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)azetidin-3-yl)methyl)piperidin-1-yl)benzamide(348);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4-((1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperidin-4-yl)oxy)piperidin-1-yl)benzamide(349);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-6-(4-((1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperidin-4-yl)methyl)piperazin-1-yl)-4-fluoronicotinamide(350);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(3-((1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)azetidin-3-yl)methyl)azetidin-1-yl)benzamide(351);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl)-3,6-dihydropyridin-1(2H)-yl)benzamide(352);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-((1′-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)-[1,4′-bipiperidin]-4-yl)oxy)benzamide(353);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-2-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)-4,6-dimethylpyrimidine-5-carboxamide(354);N-((1r,3r)-3-(4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)benzamide(355);N-((1r,3r)-3-(4-cyano-3-(trifluoromethyl)phenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)benzamide(356);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(6-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)ethyl)-2-azaspiro[3.3]heptan-2-yl)benzamide(357);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-2-(4-(3-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)propyl)piperazin-1-yl)-4,6-dimethylpyrimidine-5-carboxamide(358);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-5-(4-(3-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)propyl)piperazin-1-yl)pyrazine-2-carboxamide(359);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-6-(4-(3-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)propyl)piperazin-1-yl)pyridazine-3-carboxamide(360);2-chloro-N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)benzamide(361);2-chloro-N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)benzamide(362);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-5-(4-(5-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)pentyl)piperazin-1-yl)pyrimidine-2-carboxamide(363);N-((1r,3r)-3-(4-cyano-3-(trifluoromethyl)phenoxy)-2,2,4,4-tetramethylcyclobutyl)-5-(4-(5-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)pentyl)piperazin-1-yl)picolinamide(364);N-((1r,3S)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-2-((3S,5S)-4-(3-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)propyl)-3,5-dimethylpiperazin-1-yl)pyrimidine-5-carboxamide(365);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(3-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)ethoxy)propyl)benzamide(366);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)cyclobutyl)-4-(4-(4-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)butyl)-1H-1,2,3-triazol-1-yl)benzamide(367);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-6-(4-(2-((5-(2-((R)-2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)pentyl)oxy)ethyl)piperazin-1-yl)nicotinamide(368);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4-(2-((5-(2-((S)-2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)pentyl)oxy)ethyl)piperazin-1-yl)benzamide(369);(2S)-1-(4-(((r,3S)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)carbamoyl)phenyl)-N-(4-(4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)piperazin-1-yl)butyl)-N-methylpyrrolidine-2-carboxamide(370);(2R)-1-(4-(((1r,3R)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)carbamoyl)benzyl)-N-(2-(4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)piperazin-1-yl)ethyl)-N-methylpyrrolidine-2-carboxamide(371);(2S)-1-(4-(((1r,3S)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)carbamoyl)benzyl)-N-(2-(4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)piperazin-1-yl)ethyl)-N-methylpyrrolidine-2-carboxamide(372);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)ethoxy)ethyl)benzamide(373);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-1-(1-(5-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)pentyl)pyrrolidin-3-yl)-1H-pyrazole-4-carboxamide(374);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-1-(2-(3-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)propoxy)ethyl)-1H-pyrazole-4-carboxamide(375);4-(3-(4-(4-(5-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)pentyl)piperazin-1-yl)phenyl)-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl)-2-(trifluoromethyl)benzonitrile(376);2-chloro-4-(3-(4-(4-(5-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)pentyl)piperazin-1-yl)phenyl)-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl)benzonitrile(377);4-(5-(4-(4-(5-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)pentyl)piperazin-1-yl)phenyl)-8-oxo-6-thioxo-5,7-diazaspiro[3.4]octan-7-yl)-2-(trifluoromethyl)benzonitrile(378);N—((R)-1-(3-(3-chloro-4-cyanophenyl)-1H-pyrazol-1-yl)propan-2-yl)-5-((2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)ethoxy)ethoxy)methyl)-1H-pyrazole-3-carboxamide(379);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-5-(3-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)propyl)picolinamide(380);N-((1r,3r)-3-(4-cyano-3-(trifluoromethyl)phenoxy)-2,2,4,4-tetramethylcyclobutyl)-5-(3-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)propyl)picolinamide(381);4-(3-(6-(4-(5-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)pentyl)piperazin-1-yl)pyridin-3-yl)-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl)-2-(trifluoromethyl)benzonitrile(382);4-(3-(4-(4-(4-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)butyl)piperazine-1-carbonyl)-3-fluorophenyl)-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl)-2-(trifluoromethyl)benzonitrile(383);N-((1r,3S)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(2-((1S,4S)-5-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)-2,5-diazabicyclo[2.2.1]heptan-2-yl)ethyl)benzamide(384);4-(5-(((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)carbamoyl)pyridin-2-yl)-1-(5-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)pentyl)-1-methylpiperazin-1-ium(385);4-(3-(2-((5-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)pentyl)oxy)phenyl)-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl)-2-(trifluoromethyl)benzonitrile(386);4-(3-(2-((6-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)hexyl)oxy)phenyl)-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl)-2-(trifluoromethyl)benzonitrile(387);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)-2-fluorobenzamide(388);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4-(3-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)propyl)piperazin-1-yl)benzamide(389);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(2-(1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)azetidin-3-yl)ethyl)benzamide(390);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)-2,6-difluorobenzamide(391);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4-(3-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)propyl)piperazin-1-yl)benzamide(392);4-(3-(2-(2-(4-((1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperidin-4-yl)methyl)piperazin-1-yl)ethyl)phenyl)-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl)-2-(trifluoromethyl)benzonitrile(393);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(3-(1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)azetidin-3-yl)propyl)benzamide(394);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4-((1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)azetidin-3-yl)methyl)piperidin-1-yl)benzamide(395);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-1-(1-((1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperidin-4-yl)methyl)piperidin-4-yl)-1H-pyrazole-3-carboxamide(396);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-1-(1-(2-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)ethyl)piperidin-4-yl)-1H-pyrazole-3-carboxamide(397);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(2-(dimethylamino)ethoxy)-6-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)nicotinamide(398);N-((1s,4s)-4-(3-chloro-4-cyanophenoxy)cyclohexyl)-6-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)nicotinamide(399);N-((1r,4r)-4-(3-chloro-4-cyanophenoxy)cyclohexyl)-6-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)nicotinamide(400);N-((1r,4r)-4-(3-chloro-4-cyanophenoxy)cyclohexyl)-4-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)benzamide(401);N-((1s,4s)-4-(3-chloro-4-cyanophenoxy)cyclohexyl)-4-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)benzamide(402);N-((1r,4r)-4-(3-chloro-4-cyanophenoxy)cyclohexyl)-2-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)pyrimidine-5-carboxamide(403);N-((1r,4r)-4-(3-chloro-4-cyanophenoxy)cyclohexyl)-5-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)pyrazine-2-carboxamide(404);N-((1r,4r)-4-(3-chloro-4-cyanophenoxy)cyclohexyl)-6-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)pyridazine-3-carboxamide(405);N-((1r,4r)-4-(3-chloro-4-cyanophenoxy)cyclohexyl)-6-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)pyridazine-3-carboxamide(406);N-((1r,4r)-4-(3-chloro-4-cyanophenoxy)cyclohexyl)-2-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)pyrimidine-5-carboxamide(407);N-((1r,4r)-4-(3-chloro-4-cyanophenoxy)cyclohexyl)-5-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)pyrazine-2-carboxamide(408);N-((1r,4r)-4-(3-chloro-4-cyanophenoxy)cyclohexyl)-4-(4-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)piperidin-1-yl)benzamide(409);N-((1r,4r)-4-(3-chloro-4-cyanophenoxy)cyclohexyl)-4-(4-(1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperidin-4-yl)piperazin-1-yl)benzamide(410);N-((1r,4r)-4-(3-chloro-4-cyanophenoxy)cyclohexyl)-6-(4-(1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperidin-4-yl)piperazin-1-yl)pyridazine-3-carboxamide(411);N-((1r,4r)-4-(3-chloro-4-cyanophenoxy)cyclohexyl)-2-(4-(1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperidin-4-yl)piperazin-1-yl)pyrimidine-5-carboxamide(412);N-((1r,4r)-4-(3-chloro-4-cyanophenoxy)cyclohexyl)-6-(4-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)piperidin-1-yl)pyridazine-3-carboxamide(413);N-((1r,4S)-4-(3-chloro-4-cyanophenoxy)cyclohexyl)-2-((3S)-3-((4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl)pyrrolidin-1-yl)pyrimidine-5-carboxamide(414);N-((1r,4r)-4-(3-chloro-4-cyanophenoxy)cyclohexyl)-6-(4-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)ethyl)piperazin-1-yl)pyridazine-3-carboxamide(415);N-((1r,4r)-4-(3-chloro-4-cyanophenoxy)cyclohexyl)-4-(4-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)ethyl)piperazin-1-yl)benzamide(416);N-((1r,4r)-4-(3-chloro-4-cyanophenoxy)cyclohexyl)-2-(4-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)ethyl)piperazin-1-yl)pyrimidine-5-carboxamide(417);N-((1r,4r)-4-(3-chloro-4-cyanophenoxy)cyclohexyl)-2-(4-(3-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)propyl)piperazin-1-yl)pyrimidine-5-carboxamide(418);N-((1r,4r)-4-(3-chloro-4-cyanophenoxy)-4-methylcyclohexyl)-4-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)benzamide(419);N-((1r,4r)-4-(3-chloro-4-cyanophenoxy)cyclohexyl)-5-(4-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)ethyl)piperazin-1-yl)pyrazine-2-carboxamide(420);N-((1r,4r)-4-(3-chloro-4-cyanophenoxy)cyclohexyl)-5-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)picolinamide(421);N-((1r,4r)-4-(3-chloro-4-cyanophenoxy)cyclohexyl)-6-(4-(2-((2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1,3-dioxoisoindolin-5-yl)oxy)ethyl)piperazin-1-yl)-5-fluoronicotinamide(422);N-((1r,4r)-4-(3-chloro-4-cyanophenoxy)cyclohexyl)-5-(4-(3-((2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1,3-dioxoisoindolin-5-yl)oxy)propyl)piperazin-1-yl)pyrazine-2-carboxamide(423);N-((1r,4r)-4-(3-chloro-4-cyanophenoxy)cyclohexyl)-2-(4-(2-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)ethyl)piperidin-1-yl)pyrimidine-5-carboxamide(424);N-((1r,4r)-4-(3-chloro-4-cyanophenoxy)cyclohexyl)-4-(4-(2-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)ethyl)piperidin-1-yl)benzamide(425);N-((1r,4r)-4-(3-chloro-4-cyanophenoxy)cyclohexyl)-5-(4-(3-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)propyl)piperazin-1-yl)pyrazine-2-carboxamide(426);N-((1r,4r)-4-(3-chloro-4-cyanophenoxy)cyclohexyl)-6-(4-(2-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)ethyl)piperidin-1-yl)pyridazine-3-carboxamide(427);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-6-(4-(5-((2-(1-methyl-2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)pentyl)piperazin-1-yl)nicotinamide(428);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-1-(1-(5-((2-(1-methyl-2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)pentyl)piperidin-4-yl)-1H-pyrazole-4-carboxamide(429);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-1-(1-(5-((2-(1-methyl-2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)pentyl)piperidin-4-yl)-1H-pyrazole-3-carboxamide(430);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-1-(1-(4-((2-(1-methyl-2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)butyl)pyrrolidin-3-yl)-1H-pyrazole-4-carboxamide(431);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-1-(1-(5-((2-(1-methyl-2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)pentyl)pyrrolidin-3-yl)-1H-pyrazole-4-carboxamide(432);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-1-(2-(3-(4-(2-(1-methyl-2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)propoxy)ethyl)-1H-pyrazole-4-carboxamide(433);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-5-(4-(5-((2-(1-methyl-2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)pentyl)piperazin-1-yl)picolinamide(434);N-((1r,3r)-3-(4-cyano-3-(trifluoromethyl)phenoxy)-2,2,4,4-tetramethylcyclobutyl)-5-(4-(5-((2-(1-methyl-2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)pentyl)piperazin-1-yl)picolinamide(435);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-5-(3-(4-(2-(1-methyl-2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)propyl)picolinamide(436);6-(4-(4-((2-(1-butyl-2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)butyl)piperazin-1-yl)-N,N-dimethylpyridazine-3-carboxamide(437);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-2-(4-(4-((2-(1-methyl-2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)butyl)piperazin-1-yl)pyrimidine-5-carboxamide(438);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4-((4-(2-(1-methyl-2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)benzamide(439);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-2-(4-((4-(2-(1-methyl-2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)pyrimidine-5-carboxamide(440);(3-(5-(4-((1-(4-(((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)carbamoyl)phenyl)piperidin-4-yl)methyl)piperazin-1-yl)-1,3-dioxoisoindolin-2-yl)-2,6-dioxopiperidin-1-yl)methylmethyl carbonate (441);(3-(5-(4-((1-(4-(((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)carbamoyl)phenyl)piperidin-4-yl)methyl)piperazin-1-yl)-1,3-dioxoisoindolin-2-yl)-2,6-dioxopiperidin-1-yl)methylethyl carbonate (442);(3-(5-(4-((1-(4-(((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)carbamoyl)phenyl)piperidin-4-yl)methyl)piperazin-1-yl)-1,3-dioxoisoindolin-2-yl)-2,6-dioxopiperidin-1-yl)methylisopropyl carbonate (443);(3-(5-(4-((1-(4-(((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)carbamoyl)phenyl)piperidin-4-yl)methyl)piperazin-1-yl)-1,3-dioxoisoindolin-2-yl)-2,6-dioxopiperidin-1-yl)methyl(tetrahydro-2H-pyran-4-yl) carbonate (444);(3-(5-(4-((1-(4-(((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)carbamoyl)phenyl)piperidin-4-yl)methyl)piperazin-1-yl)-1,3-dioxoisoindolin-2-yl)-2,6-dioxopiperidin-1-yl)methyl(2-acetamidoethyl)carbamate (445);(3-(5-(4-((1-(4-(((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)carbamoyl)phenyl)piperidin-4-yl)methyl)piperazin-1-yl)-1,3-dioxoisoindolin-2-yl)-2,6-dioxopiperidin-1-yl)methyl(2-(2-aminoacetamido)ethyl)carbamate (446);(3-(5-(4-((1-(4-(((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)carbamoyl)phenyl)piperidin-4-yl)methyl)piperazin-1-yl)-1,3-dioxoisoindolin-2-yl)-2,6-dioxopiperidin-1-yl)methyl(2-((S)-2-aminopropanamido)ethyl)carbamate (447);(3-(5-(4-((1-(4-(((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)carbamoyl)phenyl)piperidin-4-yl)methyl)piperazin-1-yl)-1,3-dioxoisoindolin-2-yl)-2,6-dioxopiperidin-1-yl)methyl(2-((S)-2-amino-3-methylbutanamido)ethyl)carbamate (448);(3-(5-(4-((1-(4-(((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)carbamoyl)phenyl)piperidin-4-yl)methyl)piperazin-1-yl)-1,3-dioxoisoindolin-2-yl)-2,6-dioxopiperidin-1-yl)methyl(2-((S)-2-((S)-2-amino-3-methylbutanamido)-3-methylbutanamido)ethyl)carbamate(449);(3-(5-(4-((1-(4-(((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)carbamoyl)phenyl)piperidin-4-yl)methyl)piperazin-1-yl)-1,3-dioxoisoindolin-2-yl)-2,6-dioxopiperidin-1-yl)methyl(2,5,8,11-tetraoxatridecan-13-yl) carbonate (450);2-chloro-4-(3-(3-fluoro-4-(5-(4-(2-(1-methyl-2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)pentyl)phenyl)-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl)benzonitrile(451);2-chloro-4-(5-(3-fluoro-4-(5-(4-(2-(1-methyl-2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)pentyl)phenyl)-8-oxo-6-thioxo-5,7-diazaspiro[3.4]octan-7-yl)benzonitrile(452);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-3-oxo-2,3-dihydro-[1,2,4]triazolo[4,3-a]pyridin-6-yl)piperazin-1-yl)methyl)piperidin-1-yl)benzamide(528);rac-N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-4-methylene-1-oxo-1,2,3,4-tetrahydroisoquinolin-6-yl)piperazin-1-yl)methyl)piperidin-1-yl)benzamide(529);rac-N-(1-(4-(((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)carbamoyl)phenyl)azetidin-3-yl)-1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)-N-methylpiperidine-4-carboxamide(530);rac-N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-6-(4-(3-((2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1,3-dioxoisoindolin-5-yl)oxy)propyl)piperazin-1-yl)pyridazine-3-carboxamide(531);rac-N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-5-(4-(3-((2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1,3-dioxoisoindolin-5-yl)oxy)propyl)piperazin-1-yl)pyrazine-2-carboxamide(532);rac-N-((1r,4r)-4-(3-chloro-4-cyanophenoxy)cyclohexyl)-2-(4-(3-((2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1,3-dioxoisoindolin-5-yl)oxy)propyl)piperazin-1-yl)pyrimidine-5-carboxamide(533);rac-N-((1r,4r)-4-(3-chloro-4-cyanophenoxy)cyclohexyl)-2-(4-(2-(4-(2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)ethyl)piperidin-1-yl)pyrimidine-5-carboxamide(534);rac-N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-6-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)-4-(2-(2-methoxyethoxy)ethoxy)nicotinamide(535);rac-N-((1r,4R)-4-(3-chloro-4-cyanophenoxy)cyclohexyl)-4-(2-((2R,6R)-4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)-2,6-dimethylpiperazin-1-yl)ethyl)benzamide(536);rac-N-((1r,3r)-3-(3,4-dicyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)benzamide(537);rac-N-((1r,3r)-3-(4-cyano-2-methylphenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)benzamide(538);rac-N-((1r,3r)-3-(2,4-dicyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)benzamide(539);rac-N-((1r,3r)-3-(4-cyano-2,6-dimethylphenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)benzamide(540);rac-N-((1r,3r)-3-(4-cyano-3-methoxyphenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)benzamide(541);N-((1r,4r)-4-(4-cyano-3-methylphenoxy)cyclohexyl)-5-(4-((((1r,3r)-3-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)cyclobutyl)(isopropyl)amino)methyl)piperidin-1-yl)pyrazine-2-carboxamide(542);rac-N-((1r,4r)-4-(3-chloro-4-cyanophenoxy)cyclohexyl)-4-(4-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)thio)ethyl)piperazin-1-yl)benzamide(543);rac-N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-2-(4-(3-((2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1,3-dioxoisoindolin-5-yl)oxy)propyl)piperazin-1-yl)-4,6-dimethylpyrimidine-5-carboxamide(544);rac-N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-2-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-6,7-difluoro-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)-4,6-dimethylpyrimidine-5-carboxamide(545);rac-2-chloro-4-(((r,4r)-4-(5-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)-1H-benzo[d]imidazol-2-yl)cyclohexyl)oxy)benzonitrile(546);rac-N-((1r,4r)-4-(3-chloro-4-cyanophenoxy)cyclohexyl)-6-(4-(2-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)ethyl)piperidin-1-yl)nicotinamide(547);rac-N-((1r,4r)-4-(3-chloro-4-cyano-2-methylphenoxy)cyclohexyl)-6-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)pyridazine-3-carboxamide(548);rac-N-((1r,4r)-4-(4-cyano-3-methylphenoxy)cyclohexyl)-6-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)pyridazine-3-carboxamide(549);rac-N-((1r,3r)-3-(4-cyano-3-methylphenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)benzamide(550);rac-N-((1r,3r)-3-((5-cyano-6-methylpyridin-2-yl)oxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)benzamide(551);rac-N-((1r,3r)-3-((5-cyanopyridin-2-yl)oxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)benzamide(552);rac-N-((1r,3r)-3-(3,4-dicyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-2-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)pyrimidine-5-carboxamide(553);rac-N-((1r,3r)-3-((5-cyano-6-methylpyridin-2-yl)oxy)-2,2,4,4-tetramethylcyclobutyl)-2-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)pyrimidine-5-carboxamide(554);rac-N-((1r,3R)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-2-((1R,4R,5S)-5-((4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl)-2-azabicyclo[2.2.1]heptan-2-yl)pyrimidine-5-carboxamide(555);rac-N-((1r,3r)-3-((5-cyano-3-methylpyridin-2-yl)oxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)benzamide(556);rac-N-((1r,3r)-3-((5-cyanopyrimidin-2-yl)oxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)benzamide(557);rac-N-((1r,3r)-3-(4-cyano-3,5-dimethylphenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)benzamide(558);rac-N-((1r,4r)-4-(3-chloro-4-cyanophenoxy)cyclohexyl)-5-(4-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)piperidin-1-yl)pyrazine-2-carboxamide(559);rac-N-((1r,4r)-4-(3-chloro-4-cyanophenoxy)cyclohexyl)-2-(4-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)piperidin-1-yl)pyrimidine-5-carboxamide(560);rac-N-((1r,3R)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-2-((1R,4R,5R)-5-((4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl)-2-azabicyclo[2.2.1]heptan-2-yl)pyrimidine-5-carboxamide(561);rac-N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(3-((2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)ethyl)(methyl)amino)pyrrolidin-1-yl)benzamide(562);rac-N-((1r,3R)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4-((1R,3S)-3-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)cyclopentyl)piperazin-1-yl)benzamide(563);rac-N-((1r,3r)-3-((6-cyano-5-methylpyridin-3-yl)oxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)benzamide(564);rac-N-((1r,3r)-3-((6-cyano-5-(trifluoromethyl)pyridin-3-yl)oxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)benzamide(565);rac-N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-5-(3-((4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl)azetidin-1-yl)pyrazine-2-carboxamide(566);rac-N-((1r,4r)-4-(3-chloro-4-cyanophenoxy)cyclohexyl)-5-(3-((4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl)azetidin-1-yl)pyrazine-2-carboxamide(567);rac-N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)benzamide(568);rac-N-((1r,4r)-4-(3-chloro-4-cyanophenoxy)cyclohexyl)-6-(4-(2-((2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1,3-dioxoisoindolin-5-yl)oxy)ethyl)piperazin-1-yl)-4-fluoronicotinamide(569);rac-N-((1r,4r)-4-(3-chloro-4-cyanophenoxy)cyclohexyl)-6-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-7-fluoro-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)pyridazine-3-carboxamide(570);rac-N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-2-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-7-fluoro-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)pyrimidine-5-carboxamide(571);rac-N-((1r,3r)-3-(4-cyano-3-methylphenoxy)-2,2,4,4-tetramethylcyclobutyl)-2-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)-4,6-dimethylpyrimidine-5-carboxamide(572);rac-N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-6-(3-((4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl)azetidin-1-yl)pyridazine-3-carboxamide(573);rac-N-((1r,4r)-4-(3-chloro-4-cyanophenoxy)cyclohexyl)-2-(3-((4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl)azetidin-1-yl)pyrimidine-5-carboxamide(574);rac-N-((1r,4r)-4-(4-cyano-3-methylphenoxy)cyclohexyl)-2-(3-((4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl)azetidin-1-yl)pyrimidine-5-carboxamide(575);rac-N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-6-(3-((4-(2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl)azetidin-1-yl)pyridazine-3-carboxamide(576);rac-N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-6-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-7-fluoro-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)pyridazine-3-carboxamide(577);rac-N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-2-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)pyrimidine-5-carboxamide(578);rac-N-((1r,4r)-4-(3-chloro-4-cyanophenoxy)cyclohexyl)-5-(4-((((1r,3r)-3-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)cyclobutylxisopropyl)amino)methyl)piperidin-1-yl)pyrazine-2-carboxamide(579);rac-N-((1r,4r)-4-(3-chloro-4-cyanophenoxy)cyclohexyl)-2-(4-((((1r,3r)-3-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)cyclobutyl)(isopropyl)amino)methyl)piperidin-1-yl)pyrimidine-5-carboxamide(580);rac-N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-2-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-4,6-difluoro-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)-4,6-dimethylpyrimidine-5-carboxamide(581);rac-N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-6-(4-(2-(4-(2-(2,6-dioxopiperidin-3-yl)-4,6-difluoro-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)ethyl)piperidin-1-yl)pyridazine-3-carboxamide(582);rac-N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-6-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)-4-(2-morpholinoethoxy)nicotinamide(583);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-2-(3-((((1r,3r)-3-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)cyclobutyl)(isopropyl)amino)methyl)azetidin-1-yl)pyrimidine-5-carboxamide(584);rac-N-((1r,3r)-3-((5-cyano-6-ethylpyridin-2-yl)oxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)benzamide(585);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-6-(3-((((1r,3r)-3-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)cyclobutylxisopropyl)amino)methyl)azetidin-1-yl)pyridazine-3-carboxamide(586);rac-N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(3-((4-(2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl)azetidin-1-yl)benzamide(587);rac-N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(1-((1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperidin-4-yl)methyl)piperidin-4-yl)benzamide(588);rac-N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(3-(((1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperidin-4-yl)oxy)methyl)pyrrolidin-1-yl)benzamide(589);rac-N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4-((1-(2-(2,6-dioxopiperidin-3-yl)-6-fluoro-3-oxoisoindolin-5-yl)piperidin-4-yl)methyl)piperazin-1-yl)benzamide(590);rac-N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4-((1-(2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1-oxoisoindolin-5-yl)piperidin-4-yl)methyl)piperazin-1-yl)benzamide(591);rac-N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-6-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-4,6-difluoro-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)pyridazine-3-carboxamide(592);rac-2-chloro-4-(((r,4r)-4-(5-(4′-(2-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)-1-methyl-1H-imidazol-5-yl)-[1,1′-biphenyl]-4-yl)-1-methyl-1H-imidazol-2-yl)cyclohexyl)oxy)benzonitrile(593);rac-N-((1r,4r)-4-(3-chloro-4-cyanophenoxy)cyclohexyl)-6-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-4,6-difluoro-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)pyridazine-3-carboxamide(594);rac-N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-2-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-4,6-difluoro-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)pyrimidine-5-carboxamide(595);rac-N-((1r,4r)-4-(3-chloro-4-cyanophenoxy)cyclohexyl)-4-(3-((4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl)azetidin-1-yl)benzamide(596);rac-N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-5-(4-((((1r,3r)-3-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)cyclobutyl)(isopropyl)amino)methyl)piperidin-1-yl)pyrazine-2-carboxamide(597);rac-N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-2-(1-((1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperidin-4-yl)methyl)piperidin-4-yl)pyrimidine-5-carboxamide(598);rac-N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-6-(4-(4-(2-(2,6-dioxopiperidin-3-yl)-7-fluoro-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)piperidin-1-yl)pyridazine-3-carboxamide(599);rac-N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-6-(4-((((1r,3r)-3-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)cyclobutyl)(isopropyl)amino)methyl)piperidin-1-yl)pyridazine-3-carboxamide(600);rac-N-((1r,4r)-4-(3-chloro-4-cyanophenoxy)cyclohexyl)-5-(4-((((1r,3r)-3-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)cyclobutylxisopropyl)amino)methyl)piperidin-1-yl)picolinamide(601);rac-N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-6-(6-(4-(2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1-oxoisoindolin-5-yl)piperazin-1-yl)hexyl)nicotinamide(602);rac-2-chloro-4-(((r,4r)-4-(2-(4-(3-((4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl)azetidin-1-yl)phenyl)-1H-imidazol-5-yl)cyclohexyl)oxy)benzonitrile(603);rac-N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-1-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl)cyclohexyl)-1H-pyrazole-3-carboxamide(604);rac-N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-1-(3-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)propyl)-1H-pyrazole-3-carboxamide(605);rac-N-((1r,4r)-4-(3-chloro-4-cyanophenoxy)cyclohexyl)-1-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl)cyclohexyl)-1H-pyrazole-3-carboxamide(606);3-chloro-5-(5-(4-(1-((1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperidin-4-yl)methyl)piperidin-4-yl)-3-fluorophenyl)-8-oxo-6-thioxo-5,7-diazaspiro[3.4]octan-7-yl)picolinonitrile(607);3-chloro-5-(5-(4-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)phenyl)-8-oxo-6-thioxo-5,7-diazaspiro[3.4]octan-7-yl)picolinonitrile(608);rac-N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-3-methyl-1-oxoisoindolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)benzamide(609);rac-N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-1-methyl-3-oxoisoindolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)benzamide(610);rac-N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-6-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-4-fluoro-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)pyridazine-3-carboxamide(611);3-chloro-5-(5-(4-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)-3-fluorophenyl)-8-oxo-6-thioxo-5,7-diazaspiro[3.4]octan-7-yl)picolinonitrile(612);3-chloro-5-(5-(4-(1-((1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperidin-4-yl)methyl)piperidin-4-yl)phenyl)-8-oxo-6-thioxo-5,7-diazaspiro[3.4]octan-7-yl)picolinonitrile(613);5-(4-((1-(2-(4-(6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-3-yl)phenoxy)ethyl)piperidin-4-yl)methyl)piperazin-1-yl)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione(614);rac-N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-2-(4-((((1r,3r)-3-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)cyclobutylxisopropyl)amino)methyl)piperidin-1-yl)pyrimidine-5-carboxamide(615);rac-N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(5-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazine-1-carbonyl)hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)benzamide(616);rac-N-((1r,3R)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-1-((1r,4R)-4-((1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperidin-4-yl)(methyl)amino)cyclohexyl)-1H-pyrazole-3-carboxamide(617);5-(4-((1-(4-(6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-3-yl)phenyl)piperidin-4-yl)methyl)piperazin-1-yl)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione(618);rac-N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-5-(3-((((1r,3r)-3-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)cyclobutyl)(isopropyl)amino)methyl)azetidin-1-yl)pyrazine-2-carboxamide(619);N-((1r,3R)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-1-((1R,4R)-4-((((1r,3R)-3-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)cyclobutylxisopropyl)amino)methyl)cyclohexyl)-1H-pyrazole-3-carboxamide(620);N-((1r,3r)-3-(4-cyano-3-methoxyphenoxy)-2,2,4,4-tetramethylcyclobutyl)-2-(4-((((1r,3r)-3-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)cyclobutyl)(isopropyl)amino)methyl)piperidin-1-yl)pyrimidine-5-carboxamide(621);N-((1r,3r)-3-(4-cyano-3-methylphenoxy)-2,2,4,4-tetramethylcyclobutyl)-2-(4-((((1r,3r)-3-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)cyclobutylxisopropyl)amino)methyl)piperidin-1-yl)pyrimidine-5-carboxamide(622);N-((1r,3r)-3-(4-cyano-3,5-dimethylphenoxy)-2,2,4,4-tetramethylcyclobutyl)-2-(4-((((1r,3r)-3-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)cyclobutylxisopropyl)amino)methyl)piperidin-1-yl)pyrimidine-5-carboxamide(623);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-3-oxoisoindolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)benzamide(624); andN-((1r,4r)-4-(3-chloro-4-cyanophenoxy)cyclohexyl)-2-(4-((((1r,3r)-3-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)oxy)cyclobutylxisopropyl)amino)methyl)piperidin-1-yl)pyrimidine-5-carboxamide(625).

In another embodiment, the present disclosure provides a library ofcompounds. The library comprises more than one compound wherein eachcompound has a formula of ABM-L-ULM, wherein ULM is a ubiquitin pathwayprotein binding moiety (preferably, an E3 ubiquitin ligase moiety asotherwise disclosed herein), e.g., a CLM, and ABM is an AR proteinbinding moiety, wherein ABM is coupled (preferably, through a linkermoiety) to ULM, and wherein the ubiquitin pathway protein binding moietyrecognizes an ubiquitin pathway protein, in particular, an E3 ubiquitinligase.

The present description includes, where applicable, the compositionscomprising the pharmaceutically acceptable salts, in particular, acid orbase addition salts of compounds of the present disclosure.

The term “pharmaceutically acceptable salt” is used throughout thespecification to describe, where applicable, a salt form of one or moreof the compounds described herein which are presented to increase thesolubility of the compound in the gastic juices of the patient'sgastrointestinal tract in order to promote dissolution and thebioavailability of the compounds. Pharmaceutically acceptable saltsinclude those derived from pharmaceutically acceptable inorganic ororganic bases and acids, where applicable. Suitable salts include thosederived from alkali metals such as potassium and sodium, alkaline earthmetals such as calcium, magnesium and ammonium salts, among numerousother acids and bases well known in the pharmaceutical art. Sodium andpotassium salts are particularly preferred as neutralization salts ofthe phosphates according to the present disclosure.

The acids which are used to prepare the pharmaceutically acceptable acidaddition salts of the aforementioned base compounds useful in thisdisclosure are those which form non-toxic acid addition salts, i.e.,salts containing pharmacologically acceptable anions, such as thehydrochloride, hydrobromide, hydroiodide, nitrate, sulfate, bisulfate,phosphate, acid phosphate, acetate, lactate, citrate, acid citrate,tartrate, bitartrate, succinate, maleate, fumarate, gluconate,saccharate, benzoate, methanesulfonate, ethanesulfonate,benzenesulfonate, p-toluenesulfonate and pamoate [i.e.,1,1′-methylene-bis-(2-hydroxy-3 naphthoate)]salts, among numerousothers.

Pharmaceutically acceptable base addition salts may also be used toproduce pharmaceutically acceptable salt forms of the compounds orderivatives according to the present disclosure. The chemical bases thatmay be used as reagents to prepare pharmaceutically acceptable basesalts of the present compounds that are acidic in nature are those thatform non-toxic base salts with such compounds. Such non-toxic base saltsinclude, but are not limited to those derived from suchpharmacologically acceptable cations such as alkali metal cations (e.g.,potassium and sodium) and alkaline earth metal cations (e.g., calcium,zinc and magnesium), ammonium or water-soluble amine addition salts suchas N-methylglucamine-(meglumine), and the lower alkanolammonium andother base salts of pharmaceutically acceptable organic amines, amongothers.

Compositions

In another aspect, the description provides compositions comprisingcompounds as described herein, including salts thereof, and apharmaceutically acceptable carrier. In certain embodiments, thecompositions are therapeutic or pharmaceutical compositions comprisingan effective amount of a compound as described herein and apharmaceutically acceptable carrier.

The amount of compound in a pharmaceutical composition of the instantdisclosure that may be combined with the carrier materials to produce asingle dosage form will vary depending upon the host and diseasetreated, the particular mode of administration. Generally, an amountbetween 0.1 mg/kg and 1000 mg/kg body weight/day of active ingredientsis administered dependent upon potency of the agent. Toxicity andtherapeutic efficacy of such compounds can be determined by standardpharmaceutical procedures in cell cultures or experimental animals,e.g., for determining the LD50 (the dose lethal to 50% of thepopulation) and the ED50 (the dose therapeutically effective in 50% ofthe population). The dose ratio between toxic and therapeutic effects isthe therapeutic index and it can be expressed as the ratio LD50/ED50.Compounds that exhibit large therapeutic indices are preferred. Whilecompounds that exhibit toxic side effects may be used, care should betaken to design a delivery system that targets such compounds to thesite of affected tissue in order to minimize potential damage touninfected cells and, thereby, reduce side effects. The data obtainedfrom the cell culture assays and animal studies can be used informulating a range of dosage for use in humans. The dosage of suchcompounds lies preferably within a range of circulating concentrationsthat include the ED50 with little or no toxicity. The dosage may varywithin this range depending upon the dosage form employed and the routeof administration utilized. For any compound used in the method of thepresent disclosure, the therapeutically effective dose can be estimatedinitially from cell culture assays. A dose may be formulated in animalmodels to achieve a circulating plasma concentration range that includesthe IC50 (i.e., the concentration of the test compound which achieves ahalf-maximal inhibition of symptoms) as determined in cell culture. Suchinformation can be used to more accurately determine useful doses inhumans. Levels in plasma may be measured, for example, by highperformance liquid chromatography.

The compositions of the present disclosure may be formulated in aconventional manner using one or more pharmaceutically acceptablecarriers and may also be administered in controlled-releaseformulations. Pharmaceutically acceptable carriers that may be used inthese pharmaceutical compositions include, but are not limited to, ionexchangers, alumina, aluminum stearate, lecithin, serum proteins, suchas human serum albumin, buffer substances such as phosphates, glycine,sorbic acid, potassium sorbate, partial glyceride mixtures of saturatedvegetable fatty acids, water, salts or electrolytes, such as prolaminesulfate, disodium hydrogen phosphate, potassium hydrogen phosphate,sodium chloride, zinc salts, colloidal silica, magnesium trisilicate,polyvinyl pyrrolidone, cellulose-based substances, polyethylene glycol,sodium carboxymethylcellulose, polyacrylates, waxes,polyethylene-polyoxypropylene-block polymers, polyethylene glycol andwool fat.

The active compound is included in the pharmaceutically acceptablecarrier or diluent in an amount sufficient to deliver to a patient atherapeutically effective amount for the desired indication, withoutcausing serious toxic effects in the patient treated. A preferred doseof the active compound for all of the herein-mentioned conditions is inthe range from about 10 ng/kg to 300 mg/kg, preferably 0.1 to 100 mg/kgper day, more generally 0.5 to about 25 mg per kilogram body weight ofthe recipient/patient per day. A typical topical dosage will range from0.01-5% wt/wt in a suitable carrier.

The compound is conveniently administered in any suitable unit dosageform, including but not limited to one containing less than 1 mg, 1 mgto 3000 mg, preferably 5 to 500 mg of active ingredient per unit dosageform. An oral dosage of about 25-250 mg is often convenient.

The active ingredient is preferably administered to achieve peak plasmaconcentrations of the active compound of about 0.00001-30 mM, preferablyabout 0.1-30 μM. This may be achieved, for example, by the intravenousinjection of a solution or formulation of the active ingredient,optionally in saline, or an aqueous medium or administered as a bolus ofthe active ingredient. Oral administration is also appropriate togenerate effective plasma concentrations of active agent.

The concentration of active compound in the drug composition will dependon absorption, distribution, inactivation, and excretion rates of thedrug as well as other factors known to those of skill in the art. It isto be noted that dosage values will also vary with the severity of thecondition to be alleviated. It is to be further understood that for anyparticular subject, specific dosage regimens should be adjusted overtime according to the individual need and the professional judgment ofthe person administering or supervising the administration of thecompositions, and that the concentration ranges set forth herein areexemplary only and are not intended to limit the scope or practice ofthe claimed composition. The active ingredient may be administered atonce, or may be divided into a number of smaller doses to beadministered at varying intervals of time.

If administered intravenously, preferred carriers are physiologicalsaline or phosphate buffered saline (PBS).

In one embodiment, the active compounds are prepared with carriers thatwill protect the compound against rapid elimination from the body, suchas a controlled release formulation, including implants andmicroencapsulated delivery systems. Biodegradable, biocompatiblepolymers can be used, such as ethylene vinyl acetate, polyanhydrides,polyglycolic acid, collagen, polyorthoesters, and polylactic acid.Methods for preparation of such formulations will be apparent to thoseskilled in the art.

Liposomal suspensions may also be pharmaceutically acceptable carriers.These may be prepared according to methods known to those skilled in theart, for example, as described in U.S. Pat. No. 4,522,811 (which isincorporated herein by reference in its entirety). For example, liposomeformulations may be prepared by dissolving appropriate lipid(s) (such asstearoyl phosphatidyl ethanolamine, stearoyl phosphatidyl choline,arachadoyl phosphatidyl choline, and cholesterol) in an inorganicsolvent that is then evaporated, leaving behind a thin film of driedlipid on the surface of the container. An aqueous solution of the activecompound are then introduced into the container. The container is thenswirled by hand to free lipid material from the sides of the containerand to disperse lipid aggregates, thereby forming the liposomalsuspension.

Modes of Administration

In any of the aspects or embodiments described herein, the therapeuticcompositions comprising compounds described herein can be in anysuitable dosage form configured to be delivered by any suitable route.For example, the compounds can be administered by any appropriate route,for example, orally, parenterally, intravenously, intradermally,subcutaneously, or topically, including transdermally, in liquid, cream,gel, or solid form, rectally, nasally, buccally, vaginally or via animplanted reservoir or by aerosol form.

The term “parenteral” as used herein includes subcutaneous, intravenous,intramuscular, intra-articular, intra-synovial, intrasternal,intrathecal, intrahepatic, intralesional and intracranial injection orinfusion techniques. Preferably, the compositions are administeredorally, intraperitoneally or intravenously.

The compounds as described herein may be administered in single ordivided doses by the oral, parenteral or topical routes. Administrationof the active compound may range from continuous (intravenous drip) toseveral oral administrations per day (for example, Q.I.D.) and mayinclude oral, topical, parenteral, intramuscular, intravenous,sub-cutaneous, transdermal (which may include a penetration enhancementagent), buccal, sublingual and suppository administration, among otherroutes of administration. Enteric coated oral tablets may also be usedto enhance bioavailability of the compounds from an oral route ofadministration. The most effective dosage form will depend upon thepharmacokinetics of the particular agent chosen as well as the severityof disease in the patient.

Administration of compounds as sprays, mists, or aerosols forintra-nasal, intra-tracheal or pulmonary administration may also beused. Compounds as described herein may be administered in immediaterelease, intermediate release or sustained or controlled release forms.Sustained or controlled release forms are preferably administeredorally, but also in suppository and transdermal or other topical forms.Intramuscular injections in liposomal form may also be used to controlor sustain the release of compound at an injection site.

Sterile injectable forms of the compositions as described herein may beaqueous or oleaginous suspension. These suspensions may be formulatedaccording to techniques known in the art using suitable dispersing orwetting agents and suspending agents. The sterile injectable preparationmay also be a sterile injectable solution or suspension in a non-toxicparenterally-acceptable diluent or solvent, for example as a solution in1, 3-butanediol. Among the acceptable vehicles and solvents that may beemployed are water, Ringer's solution and isotonic sodium chloridesolution. In addition, sterile, fixed oils are conventionally employedas a solvent or suspending medium. For this purpose, any bland fixed oilmay be employed including synthetic mono- or di-glycerides. Fatty acids,such as oleic acid and its glyceride derivatives are useful in thepreparation of injectables, as are natural pharmaceutically-acceptableoils, such as olive oil or castor oil, especially in theirpolyoxyethylated versions. These oil solutions or suspensions may alsocontain a long-chain alcohol diluent or dispersant, such as Ph. Helv orsimilar alcohol.

The pharmaceutical compositions as described herein may be orallyadministered in any orally acceptable dosage form including, but notlimited to, capsules, tablets, aqueous suspensions or solutions. In thecase of tablets for oral use, carriers which are commonly used includelactose and corn starch. Lubricating agents, such as magnesium stearate,are also typically added. For oral administration in a capsule form,useful diluents include lactose and dried corn starch. When aqueoussuspensions are required for oral use, the active ingredient is combinedwith emulsifying and suspending agents. If desired, certain sweetening,flavoring or coloring agents may also be added. Oral compositions willgenerally include an inert diluent or an edible carrier. They may beenclosed in gelatin capsules or compressed into tablets. For the purposeof oral therapeutic administration, the active compound or its prodrugderivative can be incorporated with excipients and used in the form oftablets, troches, or capsules. Pharmaceutically compatible bindingagents, and/or adjuvant materials are included as part of thecomposition.

The tablets, pills, capsules, troches and the like can contain any ofthe following ingredients, or compounds of a similar nature: a bindersuch as microcrystalline cellulose, gum tragacanth or gelatin; anexcipient such as starch or lactose, a dispersing agent such as alginicacid, Primogel, or corn starch; a lubricant such as magnesium stearateor Sterotes; a glidant such as colloidal silicon dioxide; a sweeteningagent such as sucrose or saccharin; or a flavoring agent such aspeppermint, methyl salicylate, or orange flavoring. When the dosage unitform is a capsule, it can contain, in addition to material of the abovetype, a liquid carrier such as a fatty oil. In addition, dosage unitforms can contain various other materials which modify the physical formof the dosage unit, for example, coatings of sugar, shellac, or entericagents.

The active compound or pharmaceutically acceptable salt thereof can beadministered as a component of an elixir, suspension, syrup, wafer,chewing gum or the like. A syrup may contain, in addition to the activecompounds, sucrose as a sweetening agent and certain preservatives, dyesand colorings and flavors.

Alternatively, the pharmaceutical compositions as described herein maybe administered in the form of suppositories for rectal administration.These can be prepared by mixing the agent with a suitable non-irritatingexcipient, which is solid at room temperature but liquid at rectaltemperature and therefore will melt in the rectum to release the drug.Such materials include cocoa butter, beeswax and polyethylene glycols.

The pharmaceutical compositions of the disclosure may also beadministered topically. Suitable topical formulations are readilyprepared for each of these areas or organs. Topical application for thelower intestinal tract can be effected in a rectal suppositoryformulation (see above) or in a suitable enema formulation.Topically-acceptable transdermal patches may also be used. For topicalapplications, the pharmaceutical compositions may be formulated in asuitable ointment containing the active component suspended or dissolvedin one or more carriers. Carriers for topical administration of thecompounds of this disclosure include, but are not limited to, mineraloil, liquid petrolatum, white petrolatum, propylene glycol,polyoxyethylene, polyoxypropylene compound, emulsifying wax and water.In certain preferred aspects of the disclosure, the compounds may becoated onto a stent which is to be surgically implanted into a patientin order to inhibit or reduce the likelihood of occlusion occurring inthe stent in the patient.

Alternatively, the pharmaceutical compositions can be formulated in asuitable lotion or cream containing the active components suspended ordissolved in one or more pharmaceutically acceptable carriers. Suitablecarriers include, but are not limited to, mineral oil, sorbitanmonostearate, polysorbate 60, cetyl esters wax, cetearyl alcohol,2-octyldodecanol, benzyl alcohol and water.

For ophthalmic use, the pharmaceutical compositions may be formulated asmicronized suspensions in isotonic, pH adjusted sterile saline, or,preferably, as solutions in isotonic, pH adjusted sterile saline, eitherwith our without a preservative such as benzylalkonium chloride.Alternatively, for ophthalmic uses, the pharmaceutical compositions maybe formulated in an ointment such as petrolatum.

The pharmaceutical compositions of this disclosure may also beadministered by nasal aerosol or inhalation. Such compositions areprepared according to techniques well-known in the art of pharmaceuticalformulation and may be prepared as solutions in saline, employing benzylalcohol or other suitable preservatives, absorption promoters to enhancebioavailability, fluorocarbons, and/or other conventional solubilizingor dispersing agents.

Solutions or suspensions used for parenteral, intradermal, subcutaneous,or topical application can include the following components: a sterilediluent such as water for injection, saline solution, fixed oils,polyethylene glycols, glycerine, propylene glycol or other syntheticsolvents; antibacterial agents such as benzyl alcohol or methylparabens; antioxidants such as ascorbic acid or sodium bisulfite;chelating agents such as ethylenediaminetetraacetic acid; buffers suchas acetates, citrates or phosphates and agents for the adjustment oftonicity such as sodium chloride or dextrose. The parental preparationcan be enclosed in ampoules, disposable syringes or multiple dose vialsmade of glass or plastic.

It should also be understood that a specific dosage and treatmentregimen for any particular patient will depend upon a variety offactors, including the activity of the specific compound employed, theage, body weight, general health, sex, diet, time of administration,rate of excretion, drug combination, and the judgment of the treatingphysician and the severity of the particular disease or condition beingtreated.

A patient or subject in need of therapy using compounds as describedherein can be treated by administering to the patient (subject) aneffective amount of the compound including pharmaceutically acceptablesalts, solvates or polymorphs, thereof optionally in a pharmaceuticallyacceptable carrier or diluent, either alone, or in combination withother known agents.

Co-Administration

Disease states of conditions which may be treated using compounds orcompositions according to the present description include, but notlimited to, for example, cancer (e.g., prostate cancer), and Kennedy'sdisease. In certain embodiments, the therapeutic or pharmaceuticalcompositions comprise an effective amount of an additional biologicallyor bioactive active agent, e.g., an agent effective for the treatment ofcancer, that is co-administered.

The term “coadministration” or “combination therapy” shall mean that atleast two compounds or compositions are administered to the patient atthe same time, such that effective amounts or concentrations of each ofthe two or more compounds may be found in the patient at a given pointin time. Although compounds according to the present disclosure may beco-administered to a patient at the same time, the term embraces bothadministration of two or more agents at the same time or at differenttimes, provided that effective concentrations of all coadministeredcompounds or compositions are found in the subject at a given time. Incertain preferred aspects of the present disclosure, one or more of thepresent compounds described above, are coadministered in combinationwith at least one additional bioactive agent, especially including ananticancer agent. In particularly preferred aspects of the disclosure,the co-administration of compounds results in synergistic therapeutic,including anticancer therapy.

In another aspect, the description provides a composition comprising aneffective amount of two or more of the PROTAC compounds as describedherein, and a pharmaceutically acceptable carrier. In certainembodiments, the composition further comprises an effective orsynergistic amount of another bioactive agent that is not a PROTACcompound.

Pharmaceutical compositions comprising combinations of an effectiveamount of at least one bifunctional compound according to the presentdisclosure, and one or more of the compounds otherwise described herein,all in effective amounts, in combination with a pharmaceuticallyeffective amount of a carrier, additive or excipient, represents afurther aspect of the present disclosure.

The term “bioactive agent” is used to describe an agent, other than thePROTAC compounds described herein, which is used in combination with thepresent compounds as an agent with biological activity to assist ineffecting an intended therapy, inhibition and/or prevention/prophylaxisfor which the present compounds are used. Preferred bioactive agents foruse herein include those agents which have pharmacological activitysimilar to that for which the present compounds are used or administeredand include for example, anti-cancer agents.

The term “additional anti-cancer agent” is used to describe ananti-cancer agent, which may be combined with PROTAC compounds accordingto the present description to treat cancer. These agents include, forexample, everolimus, trabectedin, abraxane, TLK 286, AV-299, DN-101,pazopanib, GSK690693, RTA 744, ON 0910.Na, AZD 6244 (ARRY-142886),AMN-107, TKI-258, GSK461364, AZD 1152, enzastaurin, vandetanib, ARQ-197,MK-0457, MLN8054, PHA-739358, R-763, AT-9263, a FLT-3 inhibitor, anandrogen receptor inhibitor, a VEGFR inhibitor, an EGFR TK inhibitor, anaurora kinase inhibitor, a PIK-1 modulator, a Bcl-2 inhibitor, an HDACinhbitor, a c-MET inhibitor, a PARP inhibitor, a Cdk inhibitor, an EGFRTK inhibitor, an IGFR-TK inhibitor, an anti-HGF antibody, a PI3 kinaseinhibitors, an AKT inhibitor, a JAK/STAT inhibitor, a checkpoint-1 or 2inhibitor, a focal adhesion kinase inhibitor, a Map kinase kinase (mek)inhibitor, a VEGF trap antibody, pemetrexed, erlotinib, dasatanib,nilotinib, decatanib, panitumumab, amrubicin, oregovomab, Lep-etu,nolatrexed, azd2171, batabulin, ofatumumab, zanolimumab, edotecarin,tetrandrine, rubitecan, tesmilifene, oblimersen, ticilimumab,ipilimumab, gossypol, Bio 111, 131-I-TM-601, ALT-110, BIO 140, CC 8490,cilengitide, gimatecan, IL13-PE38QQR, INO 1001, IPdRI KRX-0402,lucanthone, LY317615, neuradiab, vitespan, Rta 744, Sdx 102, talampanel,atrasentan, Xr 311, romidepsin, ADS-100380, sunitinib, 5-fluorouracil,vorinostat, etoposide, gemcitabine, doxorubicin, liposomal doxorubicin,5′-deoxy-5-fluorouridine, vincristine, temozolomide, ZK-304709,seliciclib; PD0325901, AZD-6244, capecitabine, L-Glutamic acid,N-[4-[2-(2-amino-4,7-dihydro-4-oxo-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-,disodium salt, heptahydrate, camptothecin, PEG-labeled irinotecan,tamoxifen, toremifene citrate, anastrazole, exemestane, letrozole,DES(diethylstilbestrol), estradiol, estrogen, conjugated estrogen,bevacizumab, IMC-1C11, CHIR-258);3-[5-(methylsulfonylpiperadinemethyl)-indolylj-quinolone, vatalanib,AG-013736, AVE-0005, the acetate salt of [D-Ser(Bu t) 6, Azgly 10](pyro-Glu-His-Trp-Ser-Tyr-D-Ser(Bu t)-Leu-Arg-Pro-Azgly-NH₂ acetate[C₅₉H₈₄N₁₈Oi₄-(C₂H₄O₂)_(x) where x=1 to 2.4], goserelin acetate,leuprolide acetate, triptorelin pamoate, medroxyprogesterone acetate,hydroxyprogesterone caproate, megestrol acetate, raloxifene,bicalutamide, flutamide, nilutamide, megestrol acetate, CP-724714;TAK-165, HKI-272, erlotinib, lapatanib, canertinib, ABX-EGF antibody,erbitux, EKB-569, PKI-166, GW-572016, Ionafarnib, BMS-214662,tipifarnib; amifostine, NVP-LAQ824, suberoyl analide hydroxamic acid,valproic acid, trichostatin A, FK-228, SU11248, sorafenib, KRN951,aminoglutethimide, arnsacrine, anagrelide, L-asparaginase, BacillusCalmette-Guerin (BCG) vaccine, adriamycin, bleomycin, buserelin,busulfan, carboplatin, carmustine, chlorambucil, cisplatin, cladribine,clodronate, cyproterone, cytarabine, dacarbazine, dactinomycin,daunorubicin, diethylstilbestrol, epirubicin, fludarabine,fludrocortisone, fluoxymesterone, flutamide, gleevec, gemcitabine,hydroxyurea, idarubicin, ifosfamide, imatinib, leuprolide, levamisole,lomustine, mechlorethamine, melphalan, 6-mercaptopurine, mesna,methotrexate, mitomycin, mitotane, mitoxantrone, nilutamide, octreotide,oxaliplatin, pamidronate, pentostatin, plicamycin, porfimer,procarbazine, raltitrexed, rituximab, streptozocin, teniposide,testosterone, thalidomide, thioguanine, thiotepa, tretinoin, vindesine,13-cis-retinoic acid, phenylalanine mustard, uracil mustard,estramustine, altretamine, floxuridine, 5-deooxyuridine, cytosinearabinoside, 6-mecaptopurine, deoxycoformycin, calcitriol, valrubicin,mithramycin, vinblastine, vinorelbine, topotecan, razoxin, marimastat,COL-3, neovastat, BMS-275291, squalamine, endostatin, SU5416, SU6668,EMD121974, interleukin-12, IM862, angiostatin, vitaxin, droloxifene,idoxyfene, spironolactone, finasteride, cimitidine, trastuzumab,denileukin diftitox, gefitinib, bortezimib, paclitaxel, cremophor-freepaclitaxel, docetaxel, epithilone B, BMS-247550, BMS-310705,droloxifene, 4-hydroxytamoxifen, pipendoxifene, ERA-923, arzoxifene,fulvestrant, acolbifene, lasofoxifene, idoxifene, TSE-424, HMR-3339,ZK186619, topotecan, PTK787/ZK 222584, VX-745, PD 184352, rapamycin,40-O-(2-hydroxyethyl)-rapamycin, temsirolimus, AP-23573, RAD001,ABT-578, BC-210, LY294002, LY292223, LY292696, LY293684, LY293646,wortmannin, ZM336372, L-779,450, PEG-filgrastim, darbepoetin,erythropoietin, granulocyte colony-stimulating factor, zolendronate,prednisone, cetuximab, granulocyte macrophage colony-stimulating factor,histrelin, pegylated interferon alfa-2a, interferon alfa-2a, pegylatedinterferon alfa-2b, interferon alfa-2b, azacitidine, PEG-L-asparaginase,lenalidomide, gemtuzumab, hydrocortisone, interleukin-11, dexrazoxane,alemtuzumab, all-transretinoic acid, ketoconazole, interleukin-2,megestrol, immune globulin, nitrogen mustard, methylprednisolone,ibritgumomab tiuxetan, androgens, decitabine, hexamethylmelamine,bexarotene, tositumomab, arsenic trioxide, cortisone, editronate,mitotane, cyclosporine, liposomal daunorubicin, Edwina-asparaginase,strontium 89, casopitant, netupitant, an NK-1 receptor antagonist,palonosetron, aprepitant, diphenhydramine, hydroxyzine, metoclopramide,lorazepam, alprazolam, haloperidol, droperidol, dronabinol,dexamethasone, methylprednisolone, prochlorperazine, granisetron,ondansetron, dolasetron, tropisetron, pegfilgrastim, erythropoietin,epoetin alfa, darbepoetin alfa and mixtures thereof.

Methods of Treatment

In another aspect, the disclosure provides methods of modulating proteinubiquitination and degradation in a subject, e.g., a cell, a tissue,mammal, or human patient, the method comprising administering aneffective amount of a PROTAC compound as described herein or acomposition comprising an effective amount of the same to a subject,wherein the compound or composition comprising the same is effective inmodulating protein ubquitination and degradation of the protein in thesubject. In certain embodiments, the protein is androgen receptor (AR).

In certain embodiments, the description provides a method for regulatingprotein activity of the androgen receptor in a patient in needcomprising administering to said patient an amount of a compound asdescribed herein to a patient.

In still additional embodiments, the description provides a method oftreating a disease state or condition in a patient wherein dysregulatedprotein activity is responsible for said disease state or condition,said method comprising administering to said patient an effective amountof a compound as described herein to said patient in order to regulatesaid protein activity in said patient. In certain embodiments, theprotein is AR.

The terms “treat”, “treating”, and “treatment”, etc., as used herein,refer to any action providing a benefit to a patient for which thepresent compounds may be administered, including the treatment of anydisease state or condition which is modulated through the protein towhich the present compounds bind. Disease states or conditions,including cancer, which may be treated using compounds according to thepresent disclosure are set forth hereinabove.

In another aspect, the disclosure provides methods of modulating ARprotein ubiquitination and degradation in a subject, e.g., a cell, atissue, mammal, or human patient, the method comprising administering aneffective amount of a compound as described herein or a compositioncomprising an effective amount of a compound as described herein to asubject, wherein the compound or composition comprising the same iseffective in modulating AR protein ubquitination and degradation of theprotein in the subject.

In another aspect, the disclosure provides methods of treating orameliorating a symptom of a disease related to AR activity in a subject,e.g., a cell, a tissue, mammal, or human patient, the method comprisingadministering an effective amount of a compound as described herein or acomposition comprising an effective amount of the same to a subject inneed thereof, wherein the compound or composition comprising the same iseffective in treating or ameliorating a symptom of a disease related toAR activity in the subject.

In certain embodiments, the disease or disorder is asthma, multiplesclerosis, cancer, prostate cancer, Kenney's disease, ciliopathies,cleft palate, diabetes, heart disease, hypertension, inflammatory boweldisease, mental retardation, mood disorder, obesity, refractive error,infertility, Angelman syndrome, Canavan disease, Coeliac disease,Charcot-Marie-Tooth disease, Cystic fibrosis, Duchenne musculardystrophy, Haemochromatosis, Haemophilia, Klinefelter's syndrome,Neurofibromatosis, Phenylketonuria, Polycystic kidney disease, (PKD1) or4 (PKD2) Prader-Willi syndrome, Sickle-cell disease, Tay-Sachs disease,Turner syndrome. The method according to claim 48 wherein said cancer issquamous-cell carcinoma, basal cell carcinoma, adenocarcinoma,hepatocellular carcinomas, and renal cell carcinomas, cancer of thebladder, bowel, breast, cervix, colon, esophagus, head, kidney, liver,lung, neck, ovary, pancreas, prostate, and stomach; leukemias; benignand malignant lymphomas, particularly Burkitt's lymphoma andNon-Hodgkin's lymphoma; benign and malignant melanomas;myeloproliferative diseases; sarcomas, including Ewing's sarcoma,hemangiosarcoma, Kaposi's sarcoma, liposarcoma, myosarcomas, peripheralneuroepithelioma, synovial sarcoma, gliomas, astrocytomas,oligodendrogliomas, ependymomas, gliobastomas, neuroblastomas,ganglioneuromas, gangliogliomas, medulloblastomas, pineal cell tumors,meningiomas, meningeal sarcomas, neurofibromas, and Schwannomas; bowelcancer, breast cancer, prostate cancer, cervical cancer, uterine cancer,lung cancer, ovarian cancer, testicular cancer, thyroid cancer,astrocytoma, esophageal cancer, pancreatic cancer, stomach cancer, livercancer, colon cancer, melanoma; carcinosarcoma, Hodgkin's disease,Wilms' tumor or teratocarcinomas. In certain embodiments, the disease tobe treated is cancer, e.g., prostate cancer, or Kennedy's Disease. In apreferred embodiment, the subject is a human.

In another aspect, the disclosure provides methods of treating orameliorating a symptom of a disease related to AR activity in a subject,e.g., a cell, a tissue, mammal, or human patient, the method comprisingadministering an effective amount of a compound as described herein or acomposition comprising an effective amount of the same and an effectiveor synergistic amount of another bioactive agent to a subject in needthereof, wherein the composition comprising the same is effective intreating or ameliorating a symptom of a disease related to AR activityin the subject. In certain embodiments, the disease to be treated iscancer, e.g., prostate cancer, or Kennedy's Disease. In a preferredembodiment, the subject is a human. In certain additional embodiments,the additional bioactive agent is an anti-cancer agent.

In alternative aspects, the present disclosure relates to a method fortreating a disease state by degrading a protein or polypeptide throughwhich a disease state or condition is modulated comprising administeringto said patient or subject an effective amount of at least one compoundas described hereinabove, optionally in combination with an additionalbioactive agent. The method according to the present disclosure may beused to treat a large number of disease states or conditions includingcancer, by virtue of the administration of effective amounts of at leastone compound described herein.

In another aspect, the disclosure provides methods for identifying theeffects of the degradation of proteins of interest in a biologicalsystem using compounds according to the present disclosure.

Kits

In another aspect, the description provides kits comprising compounds orcompositions as described herein. The kit may be promoted, distributed,or sold as a unit for performing the methods of the present disclosure.In addition, the kits of the present disclosure may preferably containinstructions, which describe a suitable use. Such kits can beconveniently used, e.g., in clinical settings, to treat patientsexhibiting symptoms of, e.g., cancer, prostate cancer or Kennedy'sDisease.

EXAMPLES

General Chemistry—Analysis and Synthesis

Unless otherwise noted, all materials/reagents were obtained fromcommercial suppliers and used without further purification. Reactionswere monitored by LC-MS and/or thin layer chromatography (TLC) on silicagel 60 F₂₅₄ (0.2 mm) pre-coated aluminum foil or glass-backed andvisualized using UV light. Flash chromatography (alternatively called“ISCO chromatography”) was performed using an ISCO CombiFiash RF 75 PSIor equivalent with RediSep normal-phase silica gel cartridges.Preparative TLC was performed on Whatman LK6F Silica Gel 60A size 20×20cm plates with a thickness of 1000 μm or equivalent.

¹HNMR (300 or 400 MHz) and ¹³CNMR (100.6 MHz) spectra were recorded onBruker spectrometers at room temperature with TMS or the residualsolvent peak as the internal standard. The line positions or multiplesare given in (δ) and the coupling constants (J) are given as absolutevalues in Hertz (Hz). The multiplicities in ¹HNMR spectra areabbreviated as follows: s (singlet), d (doublet), t (triplet), q(quartet), m (multiplet), br or broad (broadened).

Preparative HPLC purifications were performed on a Waters® UV-DirectedPurification System equipped with 2545 Binary Gradient Module, 2767Sample Manager and 2489 UV/Visible Detector, controlled by MassLynx V4.1software. All purification work was completed using the followingcolumns: Atlantis Prep T3 OBD Column, SunFire Prep C18 OBD Column andXBridge Prep Phenyl OBD Column. The mobile phases were water (with 0.1%TFA or 0.01% NH₄HCO₃) and acetonitrile; all reagents used were of HPLCgrade. The flow rate was 30 ml/min. After the columns, a 1:1000 LCpackings flow splitter allowed transfer of a small portion of the eluentinto the UV detector. The electrospray source was set at 3.0 kVcapillary voltage, 30 V conevoltage, 110° C. source temperature, 350° C.desolvation temperature, 600 L/h desolvation gas flow, and 601.h conegas flow. For the analyzer, the multiplier was set at 550 forpreparative tune method.

Analytical LC-MS data was collected on a Shimadzu LCMS-2020 with amobile phase of 0.05% TFA in Acetonitrile (A) and 0.05% TFA in HPLCgrade water (B); 0.1% FA in Acetonitrile (A) and 0.1% FA in HPLC gradewater (B); Acetonitrile (A) and 5 mM ammonium bicarbonate in HPLC gradewater (B).

Shimadzu LCMS-2020 equipped with LC-20AD or 30AD pumps, SPD-M20A PDA andAlltech 3300 ELSD. The system uses the following conditions for 2.0 min,2.6 min, 3 min, 3.6 min, 5 min or 5.6 min run time.

2.0 minute run: Kinetex XB-C 18 100A column, 2.6 μm, 30×50 mm. The flowrate is 1.5 mL/min, the run time is 2.0 min, and the gradient profilesare 0.01 min 10% A, 1.10 min 100% A, 1.60 min 100% A, 1.70 min 10% A,2.00 min 10% A.

2.6 minute run: Shim-pack VP-ODS column, 2.2 μm, 3×50 mm. The flow rateis 1.5 mL/min, the run time is 2.6 min, and the gradient profiles are0.01 min 5% A, 1.20 min 100% A, 2.20 min 100% A, 2.30 min 5% A, 2.60 min5% A.

3.0 minute run: ACE UltraCore Super C18 column, 2.5 μm, 3×50 mm. Theflow rate is 1.5 mL/min, the run time is 3.0 min, and the gradientprofiles are 0.01 min 10% A, 2.00 min 95% A, 2.60 min 95% A, 2.70 min10% A, 3.00 min 10% A.

3.6 minute run: Shim-pack VP-ODS column, 2.2 μm, 3×50 mm. The flow rateis 1.5 mL/min, the run time is 3.6 min, and the gradient profiles are0.01 min 5% A, 2.20 min 100% A, 3.20 min 100% A, 3.30 min 5% A, 3.60 min5% A.

5.0 minute run: ACE UltraCore Super C18 column, 2.5 μm, 3×50 mm. Theflow rate is 1.5 mL/min, the run time is 5.0 min, and the gradientprofiles are 0.01 min 10% A, 4.00 min 60% A, 4.70 min 60% A, 4.80 min10% A, 5.00 min 10% A.

5.6 minute run: Shim-pack VP-ODS column, 2.2 μm, 3×50 mm. The flow rateis 1.5 mL/min, the run time is 5.6 min, and the gradient profiles are0.01 min 5% A, 3.00 min 50% A, 5.00 min 50% A, 5.20 min 5% A, 5.60 min5% A

Alternatively, analytical LC-MS data was collected on Agilent infinity1260 LC, Agilent 6230 TOF mass spectrometer. The analysis is conductedon a Poroshell 120 EC C18 column (50 mm×3.0 mm internal diameter 2.7 μmpacking diameter) at 45° C.

The solvents employed are:

A=0.1% v/v solution of formic acid in water.B=0.1% v/v solution of formic acid in acetonitrile.

The gradient employed are as follows:

TABLE 1 Exemplary Column Gradients. Time Flow Rate (minutes) (mL/min) %A % B 0 1 95 5 0.5 1 95 5 3.0 1 1 99 4.0 1 1 99 4.1 1 95 5 4.5 1 95 5

The UV detection is an averaged signal from wavelength of 210 nm to 350nm and mass spectra are recorded on a mass spectrometer using positivemode electrospray ionization.

Unless otherwise noted, all compounds were prepared with LC-MS purity>95%.

Chemical Synthesis

A PROTAC of ABM-L-ULM, or their pharmaceutically acceptable salts,polymorphic forms, prodrugs, solvate forms and isotope containingderivatives thereof, may be prepared by the general approaches describedin FIGS. 8a and 8b and below in General Schemes 1-122, 1A-22A, and1B-25B, together with synthetic methods known in the art of organicchemistry, or modifications and derivatizations that are familiar tothose of ordinary skill in the art.

To a solution of tert-butyl 4-(4-(hydroxymethyl)piperidin-1-yl)benzoate3 (15 g, 51.4 mmol) in DCM (100 mL) was added Dess-Martin periodinane(26.1 g, 61.6 mmol) in ice-water bath and the clear solution was stirredat room temperature for 2 hours. The solvent was evaporated and EtOAcwas added. The mixture was passed through a pad of silica gel, washedwith EtOAc, and the solvent was evaporated to give crude. (It wascombined with another batch of crude which started from 10 g startingmaterial for purification.) The crude was dry loaded to ISCO (0-10%MeOH/DCM) for separation. Light yellow solid 16.11 g 4 (yield 65%) wasobtained as product.

To a mixture of tert-butyl 4-(4-formylpiperidin-1-yl)benzoate 4 (15.79g, 54.2 mmol) and2-(2,6-dioxopiperidin-3-yl)-5-(piperazin-1-yl)isoindoline-1,3-dionedihydrochloride 5 (22.5 g, 54.2 mmol) in DCM (500 mL) was added sodiumacetate (4.44 g, 54.2 mmol). The reaction mixture was allowed to stirfor 3 mins and lowered into ice-water bath. NaBH(OAc)₃ (20.0 g, 94.8mmol) was added over 10 mins and the bath was removed after anadditional 10 mins. After 21h, water (500 mL) and DCM (150 mL) wereadded, the organic layer was removed and the aqueous layer was extractedwith DCM (150 ml), the combined organics were dried with Na₂SO₄, andevaporated the to give crude 6 which was dry-loaded with silica gel toISCO (0-10% MeOH/DCM, 750 g column) for separation. The fractions werecollected and dried, exchanged with DCM twice, and dried under highvacuum for 26 hours to provide 18.15 g 6 (yield 60%) as a yellow solid.

4N HCl in dioxane (40 mL, 29.3 mmol) was added to tert-butyl4-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)benzoate6 (18.15 g, 29.3 mmol) and the reaction mixture was heated to 50° C. for7 hours. The solvent was evaporated and DCM exchanged twice, dried underhigh vacuum for overnight. It was exchanged with DCM again twice, driedunder high vacuum for 8 hours to provide 18.77 g (yield 101%) 7 as alight brown solid.

To a solution of4-((1r,3r)-3-amino-2,2,4,4-tetramethylcyclobutoxy)-2-chlorobenzonitrilehydrochloride 8 (8.9 g, 28.2 mmol) and4-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)benzoicacid dihydrochloride 7 (18.7 g, 29.6 mmol) in DCM (300 mL) was addedHunig's base (24.2 mL, 140 mmol), and HATU (11.0 g, 29.0 mmol) wasadded. The reaction mixture was allowed to stir at ambient temperaturefor 17h at which time it was washed with sat. NaHCO₃(250 mL) twice,dried with Na₂SO₄, and evaporated to dryness. The crude was dry-loadedwith silica gel to column. ISCO (0% 3CV, 0-10% MeOH/DCM 30 CV, 750 gcolumn) separated the mixture. The product was dried in heated vacuumoven at 40° C. for 16 hours to give 9 19.6 g (yield 85%, 99.55% pure by18 mins analytical method) as a yellow solid.

Synthetic Procedure for Compound 406 Synthesis of tert-butylN-[(1r,4r)-4-(3-chloro-4-cyanophenoxy)cyclohexyl]carbamate

Into a 50.0-mL round-bottom flask, was placed tert-butylN-[(1r,4r)-4-hydroxycyclohexyl]carbamate (500.0 mg, 2.32 mmol, 1.00equiv), N,N-dimethylformamide (10.0 mL), sodium hydride (82.8 mg, 3.45mmol, 1.50 equiv), 2-chloro-4-fluorobenzonitrile (432.6 mg, 2.78 mmol,1.20 equiv). The resulting solution was stirred for 2 hours at 0° C. ina water/ice bath. The reaction was then quenched by the addition of 20.0mL of water. The resulting solution was extracted with ethyl acetate(40.0 mL) and the organic layers combined. The resulting mixture waswashed with sodium chloride (40.0 mL). The mixture was dried overanhydrous sodium sulfate. The residue was applied onto a silica gelcolumn with ethyl acetate/petroleum ether (1/2). The collected fractionswere combined and concentrated under vacuum. This resulted in 470.0 mg(58%) of tert-butylN-[(1r,4r)-4-(3-chloro-4-cyanophenoxy)cyclohexyl]carbamate as yellowoil.

LC-MS (ES⁺): m/z 295.0 [MH⁺], t_(R)=1.199 min, (1.90 minute run).

C₁₈H₂₃ClN₂O₃[350.14].  Chemical formula:

Synthesis of 4-(((1r,4r)-4-aminocyclohexyl)oxy)-2-chlorobenzonitrile

Into a 50.0-mL round-bottom flask, was placed tert-butylN-[(1r,4r)-4-(3-chloro-4-cyanophenoxy)cyclohexyl]carbamate (470.0 mg,1.34 mmol, 1.00 equiv), methanol (5.0 mL), hydrogen chloride. Theresulting solution was stirred for 2 hours at room temperature. Theresulting mixture was concentrated under vacuum. This resulted in 340.0mg (88%) of 2-chloro-4-[[(1r,4r)-4-aminocyclohexyl]oxy]benzonitrilehydrochloride as a yellow solid.

LC-MS (ES⁺): m/z 250.90 [MH⁺], t_(R)=0.537 min, (1.90 minute run).

C₁₃H₁₅ClN₂O[250.09].  Chemical formula:

Synthesis of6-[4-(hydroxymethyl)piperidin-1-yl]-N-[(1r,4r)-4-(3-chloro-4-cyanophenoxy)cyclohexyl]pyridazine-3-carboxamide)

Into a 100-mL round-bottom flask, was placed6-[4-(hydroxymethyl)piperidin-1-yl]pyridazine-3-carboxylic acid (1.0 g,4.21 mmol, 1.00 equiv),2-chloro-4-[(1r,4r)-4-aminocyclohexyl]oxybenzonitrile hydrochloride (1.2g, 4.18 mmol, 1.00 equiv), N,N-dimethylformamide (30 mL),N,N,N′,N′-Tetramethyl-O-(7-azabenzotriazol-1-yl)uroniumhexafluorophospate (2.4 g, 6.31 mmol, 1.50 equiv),N,N-diisopropylethylamine (1.6 g, 12.38 mmol, 3.00 equiv). The resultingsolution was stirred for 1 hour at room temperature. The reaction wasthen quenched by the addition of water (50 mL) and extracted with ethylacetate (50 mL×3). The combined organic layers was washed with brine (50mL), dried over anhydrous sodium sulfate and concentrated under vacuum.The residue was applied onto a silica gel column withdichloromethane/methanol (v:v=12:1). This resulted in 1.1 g (56%) of6-[4-(hydroxymethyl)piperidin-1-yl]-N-[(1r,4r)-4-(3-chloro-4-cyanophenoxy)cyclohexyl]pyridazine-3-carboxamideas yellow oil.

LC-MS (ES⁺): m/z 470.0 [MH⁺], t_(R)=0.90 min (1.8 minute run).

Synthesis of6-(4-formylpiperidin-1-yl)-N-[(1r,4r)-4-(3-chloro-4-cyanophenoxy)cyclohexyl]pyridazine-3-carboxamide

Into a 100-mL round-bottom flask, was placed6-[4-(hydroxymethyl)piperidin-1-yl]-N-[(1r,4r)-4-(3-chloro-4-cyanophenoxy)cyclohexyl]pyridazine-3-carboxamide(700.0 mg, 1.49 mmol, 1.00 equiv), dichloromethane (20 mL),(1,1,1-Triacetoxy)-1,1-dihydro-1,2-benziodoxol-3(1H)-one (947.2 mg, 2.23mmol, 1.50 equiv). The resulting solution was stirred for 3 hours atroom temperature. The resulting mixture was concentrated under vacuum.The residue was applied onto a silica gel column with ethylacetate/petroleum ether (v:v=1:3). This resulted in 390.0 mg (56%) of6-(4-formylpiperidin-1-yl)-N-[(1r,4r)-4-(3-chloro-4-cyanophenoxy)cyclohexyl]pyridazine-3-carboxamideas a yellow solid.

LC-MS (ES⁺): m/z 468.2 [MH⁺], t_(R)=1.06 min (2.0 minute run).

Synthesis of6-[4-([4-[2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl]piperazin-1-yl]methyl)piperidin-1-yl]-N-[(1r,4r)-4-(3-chloro-4-cyanophenoxy)cyclohexyl]pyridazine-3-carboxamide

Into a 100-mL round-bottom flask, was placed6-(4-formylpiperidin-1-yl)-N-[(1r,4r)-4-(3-chloro-4-cyanophenoxy)cyclohexyl]pyridazine-3-carboxamide(180.0 mg, 0.38 mmol, 1.00 equiv), dichloromethane (10 mL),2-(2,6-dioxopiperidin-3-yl)-5-fluoro-6-(piperazin-1-yl)-2,3-dihydro-1H-isoindole-1,3-dionehydrochloride (152.7 mg, 0.38 mmol, 1.00 equiv), sodiumtriacetoxyborohydride (244.6 mg, 3.00 equiv). The resulting solution wasstirred for 3 hours at room temperature. The reaction was then quenchedby water (30 mL), extracted with ethyl acetate (30 mL×3), washed withbrine (30 mL) and concentrated under reduced pressure. The solid wasfiltered out. The crude product was purified by Prep-HPLC with thefollowing conditions: Column, XBridge Prep C18 OBD Column, 19*150 mm 5um; mobile phase, water (10 mmol/L ammonium bicarbonate) andacetonitrile (48.0% acetonitrile up to 73.0% in 8 min); Detector, UV 254nm. This resulted in 146.1 mg (47%) of6-[4-([4-[2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl]piperazin-1-yl]methyl)piperidin-1-yl]-N-[(1r,4r)-4-(3-chloro-4-cyanophenoxy)cyclohexyl]pyridazine-3-carboxamideas a yellow solid.

¹H NMR (400 MHz, DMSO): δ 11.11 (s, 1H), 8.58 (d, J=8.2 Hz, 1H), 7.86(d, J=8.8 Hz, 1H), 7.81 (d, J=9.5 Hz, 1H), 7.73 (d, J=11.4 Hz, 1H), 7.46(d, J=7.4 Hz, 1H), 7.39 (d, J=2.4 Hz, 1H), 7.34 (d, J=9.7 Hz, 1H),7.15-7.12 (m, 1H), 5.13-5.08 (m, 1H), 4.59-4.45 (m, 3H), 3.90-3.83 (m,1H), 3.27 (s, 4H), 3.03 (m, 2H), 2.97-2.82 (m, 1H), 2.64-2.53 (m, 5H),2.46 (m, 1H), 2.23 (m, 2H), 2.14-2.09 (m, 2H), 2.07-2.02 (m, 1H),1.96-1.79 (m, 5H), 1.65 (m, 2H), 1.52 (m, 2H), 1.19-10.09 (m, 2H); LC-MS(ES⁺): m/z 812.25 [MH⁺], t_(R)=1.57 min (3.0 minute run).

C41H43ClFN9O6 [811.30].  Chemical Formula:

Total H count from HNMR data: 43.

Synthetic Procedure for Compound 109 1. Synthesis of benzyl6-(6-hydroxyhex-1-yn-1-yl)pyridine-3-carboxylate)

Into a 250-mL round-bottom flask, was placed a solution of benzyl6-chloropyridine-3-carboxylate (2.8 g, 11.31 mmol, 1.00 equiv) intriethylamine (50 mL), Cuprous iodide (1.2 g, 6.30 mmol, 1.50 equiv),four (triphenylphosphine) palladium (2.5 g, 0.50 equiv), hex-5-yn-1-ol(1.3 g, 13.25 mmol, 1.00 equiv). The resulting solution was stirred for3 hours at 90° C. in an oil bath. The resulting solution was extractedwith ethyl acetate and the organic layers combined. The resultingmixture was washed with brine. The mixture was dried over anhydroussodium sulfate. The residue was applied onto a silica gel column withethyl acetate/petroleum ether (1:1). The collected fractions werecombined and concentrated under vacuum. This resulted in 1.1 g (31%) ofbenzyl 6-(6-hydroxyhex-1-yn-1-yl)pyridine-3-carboxylate as yellow oil.LC-MS (ES⁺): m/z 309.95 [MH⁺], t_(R)=0.873 min (1.90 minute run).

2. Synthesis of 6-(6-hydroxyhexyl)pyridine-3-carboxylic

Into a 250-mL round-bottom flask, was placed a solution of benzyl6-(6-hydroxyhex-1-yn-1-yl)pyridine-3-carboxylate (1.1 g, 3.56 mmol, 1.00equiv) in methanol (40 mL), Palladium carbon (2 g, 10.00 equiv),hydrogen (g). The resulting solution was stirred for 48 hours at roomtemperature. The resulting solution was diluted with 200 mL of methanol.The resulting mixture was concentrated under vacuum. This resulted in700 mg (88%) of 6-(6-hydroxyhexyl)pyridine-3-carboxylic acid as yellowoil.

LC-MS (ES⁺): m/z 223.95 [MH⁺], t_(R)=0.377 min (1.90 minute run).

3. Synthesis of6-(6-hydroxyhexyl)-N-[(1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl]pyridine-3-carboxamide

Into a 100-mL round-bottom flask, was placed a solution of6-(6-hydroxyhexyl)pyridine-3-carboxylic acid (430 mg, 1.93 mmol, 1.00equiv) in N,N-dimethylformamide (20 mL),N,N,N′,N′-Tetramethyl-O-(7-azabenzotriazol-1-yl)uroniumhexafluorophospate (1.5 g, 3.94 mmol, 2.00 equiv),N,N-diisopropylethylamine (1 mL, 0.30 equiv),2-chloro-4-[(1r,3r)-3-amino-2,2,4,4-tetramethylcyclobutoxy]benzonitrile(690 mg, 2.48 mmol, 1.30 equiv). The resulting solution was stirred for2 hours at room temperature. The reaction was then quenched by theaddition of 50 mL of water. The resulting solution was extracted withethyl acetate and the organic layers combined. The resulting mixture waswashed with brine. The mixture was dried over anhydrous sodium sulfateand concentrated under vacuum. The residue was applied onto a silica gelcolumn with ethyl acetate/hexane (1/3). The collected fractions werecombined and concentrated under vacuum. This resulted in 580 mg (62%) of6-(6-hydroxyhexyl)-N-[(1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl]pyridine-3-carboxamideas a yellow solid.

LC-MS (ES⁺): m/z 484.10/486.10 [MH⁺], t_(R)=0.927 min (1.90 minute run).

4. Synthesis of6-(5-[[(1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl]carbamoyl]pyridin-2-yl)hexyl4-methylbenzene-1-sulfonate

Into a 100-mL round-bottom flask, was placed a solution of6-(6-hydroxyhexyl)-N-[(1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl]pyridine-3-carboxamide(580 mg, 1.20 mmol, 1.00 equiv) in dichloromethane (20 mL), 4-toluenesulfonyl chloride (750 mg, 3.93 mmol, 1.50 equiv), triethylamine (690mg, 6.82 mmol, 3.00 equiv), 4-dimethylaminopyridine (35 mg, 0.29 mmol,0.10 equiv). The resulting solution was stirred for 20 hours at roomtemperature. The reaction was then quenched by the addition of water.The resulting solution was extracted with ethyl acetate and the organiclayers combined. The resulting mixture was washed with brine. The solidwas dried in an oven under reduced pressure. The residue was appliedonto a silica gel column with ethyl acetate/petroleum ether (1:1). Thisresulted in 430 mg (56%) of6-(5-[[(1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl]carbamoyl]pyridin-2-yl)hexyl4-methylbenzene-1-sulfonate as a yellow solid.

LC-MS (ES⁺): m/z 638.40/640.40[MH⁺], t_(R)=1.336 min (2.00 minute run).

5. Synthesis of6-(6-[4-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl]piperazin-1-yl]hexyl)-N-[(1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl]pyridine-3-carboxamide

Into a 25-mL round-bottom flask, was placed a solution of6-(5-[(1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl]carbamoylpyridin-2-yl)hexyl4-methylbenzene-1-sulfonate (220 mg, 0.34 mmol, 1.00 equiv) inacetonitrile (5 mL),2-(2,6-dioxopiperidin-3-yl)-5-(piperazin-1-yl)-2,3-dihydro-1H-isoindole-1,3-dione;trifluoroacetic acid (162 mg, 0.35 mmol, 1.50 equiv), potassiumcarbonate (25 mg, 0.18 mmol, 3.00 equiv), sodium iodide (25 mg, 0.50equiv). The resulting solution was stirred for 12 hours at 70° C. in anoil bath. The resulting mixture was concentrated under vacuum. The crudeproduct (3 mL) was purified by Prep-HPLC with the following conditions:Column, XBridge Shield RP18 OBD Column, 5 um, 19*150 mm; mobile phase,water (10 mmol/L ammonium bicarbonate) and acetonitrile (56.0%acetonitrile up to 65.0% in 8 min); Detector, UV 254 nm. 41.3 mg productwas obtained. This resulted in 41.3 mg (15%) of6-(6-[4-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl]piperazin-1-yl]hexyl)-N-[(1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl]pyridine-3-carboxamideas a yellow solid.

¹HNMR (300 MHz, CD₃OD): δ 8.86 (s, 1H), 8.16-8.09 (m, 1H), 7.72-7.64 (m,2H), 7.47-7.33 (m, 2H), 7.24-7.17 (m, 1H), 7.12 (s, 1H), 6.98-6.89 (m,1H), 5.09-5.02 (m, 1H), 4.26 (s, 1H), 4.15 (s, 1H), 3.48-3.42 (m, 4H),2.92-2.49 (m, 9H), 2.46-2.35 (m, 2H), 2.16-2.01 (m, 1H), 1.81-1.71 (m,2H), 1.59-1.47 (m, 2H), 1.42-1.36 (m, 4H), 1.27-1.18 (m, 12H); LC-MS(ES⁺): m/z 808.85/810.85 [MH⁺], t_(R)=4.79 min (8.0 minute run).

Chemical formula: C₄₄H₅₀ClN₇O₆ [807.35/809.35].

Total H count from HNMR data: 48.

Synthetic Procedure for Compound 158 1. Synthesis of benzyl4-fluorobenzoate

Into a 500-mL round-bottom flask, was placed 4-fluorobenzoic acid (14 g,99.9 mmol, 1.0 equiv), N,N-dimethylformamide (150.0 mL),(bromomethyl)benzene (18.7 g, 109.3 mmol, 1.1 equiv), dicesium carbonate(27.6 g, 84.7 mmol, 2.0 equiv). The resulting solution was stirred for 4hours at room temperature. The reaction was then quenched by theaddition of 150 mL of water. The resulting solution was extracted withethyl acetate (100 mL×3) and the organic layers combined andconcentrated under vacuum. The residue was applied onto a silica gelcolumn with ethyl acetate/petroleum ether (1/6). This resulted in 18.0 g(78%) of benzyl 4-fluorobenzoate as a solid.

2. Synthesis of benzyl 4-[4-(hydroxymethyl)piperidin-1-yl]benzoate

Into a 100-mL round-bottom flask, was placed benzyl 4-fluorobenzoate(5.0 g, 21.7 mmol, 1.1 equiv), N,N-Dimethylformamide (30.0 mL),piperidin-4-ylmethanol (2.3 g, 19.9 mmol, 1.0 equiv),N,N-Diisopropylethylamine (7.6 g, 59.1 mmol, 3.0 equiv). The resultingsolution was stirred for 2 hours at 100° C. The reaction was thenquenched by the addition of 60.0 mL of water. The resulting solution wasextracted with ethyl acetate (60 mL×3) and the organic layers combinedand concentrated under vacuum. The residue was applied onto a silica gelcolumn with ethyl acetate/petroleum ether (1/1). This resulted in 3.6 g(55%) of benzyl 4-[4-(hydroxymethyl)piperidin-1-yl]benzoate as whiteoil.

LC-MS (ES⁺): 326.30m/z [MH⁺], t_(R)=1.18 min, (1.90 minute run).

3. Synthesis of benzyl 4-(4-formylpiperidin-1-yl)benzoate

Into a 100-mL round-bottom flask, was placed benzyl4-[4-(hydroxymethyl)piperidin-1-yl]benzoate (500 mg, 1.54 mmol, 1.00equiv), dichloromethane (15.0 mL),(1,1,1-Triacetoxy)-1,1-dihydro-1,2-benziodoxol-3(1H)-one (978 mg, 2.31mmol, 1.5 equiv). The resulting solution was stirred for 4 hours at roomtemperature. The resulting mixture was concentrated under vacuum. Theresidue was applied onto a silica gel column with ethylacetate/petroleum ether (1:4). This resulted in 420.0 mg (85%) of benzyl4-(4-formylpiperidin-1-yl)benzoate as a yellow solid.

LC-MS (ES⁺): 323.95m/z [MH⁺], t_(R)=1.04 min, (1.80 minute run).

4. Synthesis of benzyl4-[4-([4-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl]piperazin-1-yl]methyl)piperidin-1-yl]benzoate

Into a 150-mL round-bottom flask, was placed benzyl4-(4-formylpiperidin-1-yl)benzoate (500.0 mg, 1.5 mmol, 1.0 equiv),dichloromethane (20.0 mL),2-(2,6-dioxopiperidin-3-yl)-5-(piperazin-1-yl)-2,3-dihydro-1H-isoindole-1,3-dione,trifluoroacetyl (747 mg, 1.7 mmol, 1.1 equiv), Sodiumtriacetoxyborohydride (1.39 g, 6.5 mmol, 4.0 equiv). The resultingsolution was stirred for 4 hours at room temperature. The reaction wasthen quenched by the addition of water (100.0 mL). The resultingsolution was extracted with ethyl acetate (30 mL×3) and the organiclayers combined and dried over anhydrous sodium sulfate and concentratedunder vacuum. The residue was applied onto a silica gel column withethyl acetate/petroleum ether (1:1). This resulted in 500.0 mg (50%) ofbenzyl4-[4-([4-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl]piperazin-1-yl]methyl)piperidin-1-yl]benzoateas a yellow solid.

LC-MS (ES⁺): 650.45m/z [MH⁺], t_(R)=1.37 min, (1.90 minute run).

5. Synthesis of4-[4-([4-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl]piperazin-1-yl]methyl)piperidin-1-yl]benzoicacid

To a solution of benzyl4-[4-([4-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl]piperazin-1-yl]methyl)piperidin-1-yl]benzoate(500.0 mg, 0.8 mmol, 1.0 equiv) in 20.0 mL methyl alcohol (30.0 mL) wasadded Pd/C (10%, 300 mg) under nitrogen atmosphere in a 100.0 mL roundbottom flask. The flask was then vacuumed and flushed with hydrogen. Thereaction mixture was hydrogenated at room temperature for 12 hours underhydrogen atmosphere using a hydrogen balloon, then filtered through aCelite pad and concentrated under reduced pressure. This resulted in300.0 mg (69.0%) of4-[4-([4-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl]piperazin-1-yl]methyl)piperidin-1-yl]benzoicacid as a yellow solid.

LC-MS (ES⁺): 560.35m/z [MH⁺], t_(R)=0.74 min, (1.90 minute run).

6. Synthesis of4-[4-([4-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl]piperazin-1-yl]methyl)piperidin-1-yl]-N-[(1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl]benzamide

Into a 100-mL round-bottom flask, was placed4-[4-([4-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl]piperazin-1-yl]methyl)piperidin-1-yl]benzoicacid (300.0 mg, 0.5 mmol, 1.0 equiv), N,N-dimethylformamide (15.0 mL),N,N,N′,N′-Tetramethyl-O-(7-azabenzotriazol-1-yl)uroniumhexafluorophospate (307.0 mg, 0.8 mmol, 1.5 equiv),2-chloro-4-[(1r,3r)-3-amino-2,2,4,4-tetramethylcyclobutoxy]benzonitrilehydrochloride (170.0 mg, 0.5 mmol, 1.0 equiv), N,N-Diisopropylethylamine(207.0 mg, 1.6 mmol, 3.0 equiv). The resulting solution was stirred for1 hour at room temperature. The reaction was then quenched by theaddition of water (80 mL). The resulting solution was extracted withethyl acetate (30 mL×3) and the organic layers combined and concentratedunder vacuum. The crude product (5 mL) was purified by Prep-HPLC withthe following conditions: Column, XBridge Prep C18 OBD Column, 5 um,19*150 mm; mobile phase, Water (10 MMOUL ammonium bicarbonate) andacetonitrile (59.0% acetonitrile up to 80.0% in 8 min); Detector, UV 220nm. 4 mL product was obtained. This resulted in 114 g (25921%) of4-[4-([4-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl]piperazin-1-yl]methyl)piperidin-1-yl]-N-[(1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl]benzamideas a yellow solid.

1H NMR (300 MHz, DMSO-d6) δ 11.05 (s, 1H), 7.86 (d, J=8.7 Hz, 1H), 7.67(dd, J=17.8, 8.4 Hz, 3H), 7.44 (d, J=9.2 Hz, 1H), 7.34-7.13 (m, 3H),7.02-6.87 (m, 3H), 5.04 (dd, J=12.6, 5.3 Hz, 1H), 4.28 (s, 1H), 4.02 (d,J=9.0 Hz, 1H), 3.82 (d, J=12.5 Hz, 2H), 3.58-3.30 (m, 5H), 2.90-2.66 (m,3H), 2.6-2.47 (m, 3H), 2.50-2.42 (m, 4H), 2.17 (d, J=6.5 Hz, 2H), 1.98(dt, J=10.0, 4.5 Hz, 1H), 1.77 (d, J=11.9 Hz, 3H), 1.18 (s, 6H), 1.09(s, 6H).

LC-MS (ES⁺): 820.60m/z [MH⁺], t_(R)=2.99 min, (4.8 minute run).

Synthetic Procedure for Compound 357 1. Synthesis of tert-butyl6-(2-ethoxy-2-oxoethylidene)-2-azaspiro[3.3]heptane-2-carboxylate)

A mixture of t-BuOK (3.98 g, 35.47 mmol, 2.498 equiv) and ethyl2-(bromotriphenyl-$1{circumflex over ( )}[5]-phosphanyl)acetate (15.2 g,35.41 mmol, 2.493 equiv) in THF (90 mL) in a 250-mL round-bottom flaskwas stirred for 1 hour at room temperature. Then tert-butyl6-oxo-2-azaspiro[3.3]heptane-2-carboxylate (3 g, 14.20 mmol, 1 equiv)was added and the reaction mixture was stirred for an additional 6 hoursat 35° C. Then filtered through Celite and filter cake was washed withTHF. The crude was subjected to a silica gel column with ethylacetate/petroleum ether (1:5). This resulted in 3.3 g (82.60%) oftert-butyl6-(2-ethoxy-2-oxoethylidene)-2-azaspiro[3.3]heptane-2-carboxylate as acolorless oil.

LC-MS (ES⁺): m/z 226.1 [M-(t-Bu)+H⁺], t_(R)=1.267 min, (2.0 minute run).

2. Synthesis of tert-butyl6-(2-ethoxy-2-oxoethyl)-2-azaspiro[3.3]heptane-2-carboxylate

To a solution of tert-butyl6-(2-ethoxy-2-oxoethylidene)-2-azaspiro[3.3]heptane-2-carboxylate (3.296g, 11.72 mmol, 1 equiv) in ethanol (330 mL) in a 500-mL 3-neckedround-bottom flask was added Pd/C (661.8 mg) under N₂ flow. The reactionflask was vacuumed and flushed with H₂ for three times. The resultingmixture was stirred for 3 hours at room temperature under H₂. Then themixture was filtered through a celite pad. The collected filtrate wasconcentrated under reduced pressure and dried under vacuum. Thisresulted in 3.12 g (93.99%) of tert-butyl6-(2-ethoxy-2-oxoethyl)-2-azaspiro[3.3]heptane-2-carboxylate as acolorless oil.

LC-MS (ES⁺): m/z 228.1 [M-(t-Bu)+H⁺], t_(R)=1.254 min, (2.0 minute run).

3. Synthesis of tert-butyl6-(2-hydroxyethyl)-2-azaspiro[3.3]heptane-2-carboxylate

Into a 250-mL round-bottom flask, was placed tert-butyl6-(2-ethoxy-2-oxoethyl)-2-azaspiro[3.3]heptane-2-carboxylate (3.08 g,10.87 mmol, 1 equiv), THF (120 mL), DIBAL-H in THF (1 M) (32.6 mL,229.28 mmol, 3 equiv). The resulting solution was stirred for 3 hours atroom temperature. The reaction was then quenched by the addition ofwater (60 mL×1). The resulting solution was extracted with ethyl acetate(120 mL×2). The resulting mixture was washed with brine (100 mL×1). Theorganic layer was dried over anhydrous sodium sulfate, concentrated anddried under vacuum. This resulted in 2.53 g (96.45%) of tert-butyl6-(2-hydroxyethyl)-2-azaspiro[3.3]heptane-2-carboxylate as a whitesolid.

LC-MS (ES⁺): m/z 186.1 [M-(t-Bu)+H+], t_(R)=1.061 min, (2.0 minute run).

4. Synthesis of 2-[2-azaspiro[3.3]heptan-6-yl]ethan-1-ol;trifluoroacetic acid

Into a 500-mL round-bottom flask, was placed a solution of tert-butyl6-(2-hydroxyethyl)-2-azaspiro[3.3]heptane-2-carboxylate (2.52 g, 10.44mmol, 1 equiv) in DCM (120 mL), trifluoroacetic acid (7.7 mL). Theresulting solution was stirred for 4 hours at room temperature. Theresulting mixture was evaporated to dryness and dried under vacuum. Thisresulted in 2.66 g (99.80%) of 2-[2-azaspiro[3.3]heptan-6-yl]ethan-1-ol;trifluoroacetic acid as light yellow oil.

5. Synthesis of tert-butyl4-[6-(2-hydroxyethyl)-2-azaspiro[3.3]heptan-2-yl]benzoate

To a solution of tert-butyl 4-fluorobenzoate (10.25 g, 52.24 mmol, 5.012equiv) in DMSO (50 mL) in a 250-mL round-bottom flask was added DIEA (14mL, 84.71 mmol, 8.128 equiv). The mixture was stirred for 5 minutes,then 2-[2-azaspiro[3.3]heptan-6-yl]ethan-1-ol; trifluoroacetic acid(2.66 g, 10.42 mmol, 1 equiv) was added. The resulting solution wasstirred for 16 hours at 130° C. After cooling to room temperature, thereaction was then quenched by addition of water (100 mL×1). Theresulting solution was extracted with ethyl acetate (100 mL×3). Thecombined organic layers were washed with water (50 mL×2) and brine (50mL×1). The organic layer was dried over anhydrous sodium sulfate. Thecrude was subjected to a silica gel column with ethyl acetate/petroleumether (1:2). This resulted in 311.5 mg (9.42%) of tert-butyl4-[6-(2-hydroxyethyl)-2-azaspiro[3.3]heptan-2-yl]benzoate as a lightyellow solid.

LC-MS (ES⁺): m/z 318.2 [MH⁺], t_(R)=1.314 min, (2.0 minute run).

6. Synthesis of tert-butyl4-[6-(2-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl]oxy]ethyl)-2-azaspiro[3.3]heptan-2-yl]benzoate

To a solution of PPh3 (361.7 mg, 1.38 mmol, 1.506 equiv) in THF (15 mL)was added DIAD (280.2 mg, 1.39 mmol, 1.513 equiv) dropwise with stirringat room temperature under N₂. To this was added tert-butyl4-[6-(2-hydroxyethyl)-2-azaspiro[3.3]heptan-2-yl]benzoate (290.7 mg,0.92 mmol, 1 equiv),2-(2,6-dioxopiperidin-3-yl)-5-hydroxy-2,3-dihydro-1H-isoindole-1,3-dione(377.4 mg, 1.38 mmol, 1.503 equiv). The resulting solution was stirredfor 4 hours at room temperature. The reaction was then quenched by theaddition of water (20 mL). The resulting solution was extracted withethyl acetate (30 mL×3) and the combined organic layers were washed withbrine (20 mL×1). The organic layer was dried over anhydrous sodiumsulfate. The crude was subjected to a silica gel column with ethylacetate/petroleum ether (1:1). This resulted in 90.8 mg (17.28%) oftert-butyl4-[6-(2-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl]oxy]ethyl)-2-azaspiro[3.3]heptan-2-yl]benzoateas a light brown solid.

LC-MS (ES⁺): m/z 574.05 [MH⁺], t_(R)=1.443 min, (2.0 minute run).

7. Synthesis of4-[6-(2-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl]oxy]ethyl)-2-azaspiro[3.3]heptan-2-yl]benzoicacid

To a solution of tert-butyl4-[6-(2-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl]oxy]ethyl)-2-azaspiro[3.3]heptan-2-yl]benzoate(70.2 mg, 0.12 mmol, 1 equiv) in DCM (2.0 mL) was added TFA (0.6 mL,8.08 mmol, 66.008 equiv). The resulting solution was stirred for 2 hoursat room temperature. The resulting mixture was evaporated to dryness anddried under vacuum. This resulted in 63.3 mg (99.95%) of4-[6-(2-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl]oxy]ethyl)-2-azaspiro[3.3]heptan-2-yl]benzoicacid as a light brown solid.

LC-MS (ES⁺): m/z 518.2 [MH⁺], t_(R)=1.166 min, (2.0 minute run).

8. Synthesis of4-[6-(2-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl]oxy]ethyl)-2-azaspiro[3.3]heptan-2-yl]-N-[(1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl]benzamide

To a solution of4-[6-(2-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl]oxy]ethyl)-2-azaspiro[3.3]heptan-2-yl]benzoicacid (63.3 mg, 0.12 mmol, 1 equiv) in DMF (3.4 mL) was added DIEA (0.32mL, 1.94 mmol, 15.830 equiv), then HATU (51.5 mg, 0.14 mmol, 1.107equiv), finally2-chloro-4-[(1r,3r)-3-amino-2,2,4,4-tetramethylcyclobutoxy]benzonitrilehydrochloride (43.4 mg, 0.14 mmol, 1.126 equiv). The resulting solutionwas stirred for 3 hours at room temperature. The reaction was thenquenched by the addition of water (10 mL). The resulting solution wasextracted with dichloromethane (20 mL×3); the combined organic layerswere washed with water (10 mL×2) and brine (10 mL×1). The organic layerwas dried over anhydrous sodium sulfate. The crude product was purifiedby Prep-HPLC with the following conditions: Column, XBridge Prep OBD C18Column, 19*250 mm, 5 um; mobile phase, Water(10 mmol/L NH₄HCO₃) andacetonitrile (20% Phase B up to 60% in 8 min); Detector, UV254/220. Thisresulted in 57.4 mg (60.30%) of4-[6-(2-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl]oxy]ethyl)-2-azaspiro[3.3]heptan-2-yl]-N-[(1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl]benzamideas a white solid.

¹H NMR (300 MHz, d6-DMSO) δ 1.13 (s, 6H), 1.22 (s, 6H), 1.88-2.01 (m,5H), 2.29 (d, J=5.7 Hz, 3H), 2.44-2.56 (m, 2H), 2.79-2.84 (m, 1H), 3.73(s, 2H), 3.84 (s, 2H), 3.98 (d, J=9.0 Hz, 1H), 4.07 (t, J=6.2 Hz, 2H),4.25 (s, 1H), 5.02-5.08 (m, 1H), 6.34 (d, J=8.4 Hz, 2H), 6.93 (dd,J1=2.1 Hz, J2=8.7 Hz, 1H), 7.13 (d, J=2.4 Hz, 1H), 7.26-7.29 (m, 1H),7.35-7.39 (m, 2H), 7.63-7.66 (m, 2H), 7.75-7.85 (m, 2H), 11.05 (s, 1H);LC-MS (ES⁺): m/z 778.30 [MH⁺], t_(R)=3.222 min, (4.60 minute run); LC-MS(ES⁺): m/z 778.30/780.30 [MH⁺], t_(R)=3.222 min, (4.60 minute run).

C₄₃H₄₄ClN₅O₇ [777.29/779.29].  Chemical formula:

Total H count from HNMR data: 44.

Synthetic Procedure for Compound 579 Synthesis of tert-butylN-[(1r,4r)-4-(3-chloro-4-cyanophenoxy)cyclohexyl]carbamate

Into a 50.0-mL round-bottom flask, was placed tert-butylN-[(1r,4r)-4-hydroxycyclohexyl]carbamate (500.0 mg, 2.32 mmol, 1.00equiv), N,N-dimethylformamide (10.0 mL), sodium hydride (82.8 mg, 3.45mmol, 1.50 equiv), 2-chloro-4-fluorobenzonitrile (432.6 mg, 2.78 mmol,1.20 equiv). The resulting solution was stirred for 2 hours at 0° C. ina water/ice bath. The reaction was then quenched by the addition of 20.0mL of water. The resulting solution was extracted with ethyl acetate(40.0 mL) and the organic layers combined. The resulting mixture waswashed with sodium chloride (40.0 mL). The mixture was dried overanhydrous sodium sulfate. The residue was applied onto a silica gelcolumn with ethyl acetate/petroleum ether (1/2). The collected fractionswere combined and concentrated under vacuum. This resulted in 470.0 mg(58%) of tert-butylN-[(1r,4r)-4-(3-chloro-4-cyanophenoxy)cyclohexyl]carbamate as yellowoil.

LC-MS (ES⁺): m/z 295.0 [MH⁺], t_(R)=1.199 min, (1.90 minute run).

C₁₈H₂₃ClN₂O₃[350.14]  Chemical formula:

2. Synthesis of 4-(((1r,4r)-4-aminocyclohexyl)oxy)-2-chlorobenzonitrilehydrochloride

Into a 50.0-mL round-bottom flask, was placed tert-butylN-[(1r,4r)-4-(3-chloro-4-cyanophenoxy)cyclohexyl]carbamate (470.0 mg,1.34 mmol, 1.00 equiv), methanol (5.0 mL), hydrogen chloride. Theresulting solution was stirred for 2 hours at room temperature. Theresulting mixture was concentrated under vacuum. This resulted in 340.0mg (88%) of 4-(((1r,4r)-4-aminocyclohexyl)oxy)-2-chlorobenzonitrilehydrochloride as a yellow solid.

LC-MS (ES⁺): m/z 250.90 [MH⁺], t_(R)=0.537 min, (1.90 minute run).

C₁₃H₁₅ClN₂O[250.09].  Chemical formula:

3. Synthesis of methyl5-(4-(hydroxymethyl)piperidin-1-yl)pyrazine-2-carboxylate

Into a 50-mL round-bottom flask, was placed methyl5-chloropyrazine-2-carboxylate (2 g, 11.59 mmol, 1 equiv), DMSO (15 mL,0.19 mmol, 0.017 equiv), DIEA (0.2 mL, 0.000 equiv),piperidin-4-ylmethanol (1.3 mg, 0.01 mmol, 1 equiv). The resultingsolution was stirred for 16 hours at 120° C. in an oil bath. Theresulting solution was extracted ethyl acetate (30 mL×3) and the organiclayers combined. The resulting mixture was washed with brine (10 mL×1).The resulting mixture was concentrated under vacuum. The residue wasapplied onto a silica gel column with dichloromethane/methanol (1:1).This resulted in 2.21 g (65%) of methyl5-[4-(hydroxymethyl)piperidin-1-yl]pyrazine-2-carboxylate as a whitesolid.

LC-MS (ES⁺): m/z 251.13 [MH⁺], t_(R)=0.61 min, (1.9 minute run).

4. Synthesis of 5-[4-(hydroxymethyl)piperidin-1-yl]pyrazine-2-carboxylicacid

Into a 100-mL round-bottom flask, was placed methyl5-[4-(hydroxymethyl)piperidin-1-yl]pyrazine-2-carboxylate (2.21 g, 8.79mmol, 1 equiv), methanol (40 mL), lithiumol (0.633 mg, 0.03 mmol, 0.003equiv), water (10 mL). The resulting solution was stirred for 16 hoursat room temperature. The resulting mixture was concentrated. The PH wasadjusted to 4 with 1M HCl. The resulting solution was extracteddichloromethane (30 mL×3) and the organic layers combined. The resultingmixture was washed with brine (10 mL×1). The resulting mixture wasconcentrated under vacuum. This resulted in 1.7042 g (81.67%) of5-[4-(hydroxymethyl)piperidin-1-yl]pyrazine-2-carboxylic acid as a whitesolid.

LC-MS (ES⁺): m/z 237.11 [MH⁺], t_(R)=0.75 min, (2.0 minute run).

5. Synthesis of5-[4-(hydroxymethyl)piperidin-1-yl]-N-[(s,4s)-4-(3-chloro-4-cyanophenoxy)cyclohexyl]pyrazine-2-carboxamide

Into a 100-mL round-bottom flask, was placed5-[4-(hydroxymethyl)piperidin-1-yl]pyrazine-2-carboxylic acid (310 mg),DMF (15 mL), DIEA (563.69 mg),2-chloro-4-[[(1s,4s)-4-aminocyclohexyl]oxy]benzonitrile (250 mg), BOP(386.28 mg). The resulting solution was stirred for 2 hours at roomtemperature. The resulting mixture was extracted with ethyl acetate (50mL×3) and the organic layer was washed with brine (30 mL×1). The organicwas dried over anhydrous sodium sulfate and concentrated under vacuum.The residue was applied onto a silica gel column withdichloromethane/methanol (10:1). The collected fractions were combinedand concentrated under vacuum. This resulted in 243.5 mg of5-[4-(hydroxymethyl)piperidin-1-yl]-N-[(1s,4s)-4-(3-chloro-4-cyanophenoxy)cyclohexyl]pyrazine-2-carboxamideas a white solid.

LC-MS (ES⁺): m/z 469.19 [MH⁺], t_(R)=0.99 min, (1.9 minute run).

6. Synthesis of5-(4-formylpiperidin-1-yl)-N-[(1r,4r)-4-(3-chloro-4-cyanophenoxy)cyclohexyl]pyrazine-2-carboxamide

Into a 100-mL round-bottom flask, was placed5-[4-(hydroxymethyl)piperidin-1-yl]-N-[(1r,4r)-4-(3-chloro-4-cyanophenoxy)cyclohexyl]pyrazine-2-carboxamide(150.1 mg, 0.32 mmol, 1 equiv), dichloromethane (15 mL, 0.18 mmol, 0.553equiv), Dess-martin (271.37 mg). The resulting mixture was extractedwith dichloromethane (50 mL×3) and the organic layer was washed withbrine (30 mL×1). The organic was dried over anhydrous sodium sulfate andconcentrated under vacuum. This resulted in 200 mg (crude) of5-(4-formylpiperidin-1-yl)-N-[(1r,4r)-4-(3-chloro-4-cyanophenoxy)cyclohexyl]pyrazine-2-carboxamideas a white solid.

LC-MS (ES⁺): m/z 467.17 [MH⁺], t_(R)=1.03 min, (1.9 minute run).

7. Synthesis of5-(4-[[(propan-2-yl)[(1r,3r)-3-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl]oxy]cyclobutyl]amino]methyl]piperidin-1-yl)-N-[(1r,4r)-4-(3-chloro-4-cyanophenoxy)cyclohexyl]pyrazin

Into a 100-mL round-bottom flask, was placed5-(4-formylpiperidin-1-yl)-N-[(1r,4r)-4-(3-chloro-4-cyanophenoxy)cyclohexyl]pyrazine-2-carboxamide(220 mg, 0.47 mmol, 1 equiv), dichloromethane (20 mL, 0.24 mmol, 0.501equiv), Titanium(IV)isopropoxide (2 mL, 0.01 mmol, 0.015 equiv),2-(2,6-dioxopiperidin-3-yl)-5-[(1r,3r)-3-[(propan-2-yl)amino]cyclobutoxy]-2,3-dihydro-1H-isoindole-1,3-dione(420 mg, 1.09 mmol, 2.318 equiv), NaH(OAc)₃ (340 mg). The resultingsolution was stirred for 16 hours at 60° C. in an oil bath. Theresulting mixture was extracted with dichloromethane (50 mL×3) and theorganic layer was washed with brine (30 mL×1). The crude product waspurified by Prep-HPLC with the following conditions: Column, XSelect CSHPrep C18 OBD Column, 5 um, 19×150 mm; mobile phase, water(10 mmol/LNH₄HCO₃) and acetonitrile (30% Phase B up to 55% in 8.5 min); DetectorUV254/220. This resulted in 26 mg (6.60%) of5-(4-[[(propan-2-yl)[(r,3r)-3-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl]oxy]cyclobutyl]amino]methyl]piperidin-1-yl)-N-[(1r,4r)-4-(3-chloro-4-cyanophenoxy)cyclohexyl]pyrazinas a light yellow solid.

¹H NMR (300 MHz, DMSO-d6) 11.09 (s, 1H), 8.56 (s, 1H), 8.23 (s, 1H),8.12-8.05 (m, 1H), 7.92-7.82 (m, 2H), 7.40-7.36 (s, 1H), 7.26-7.20 (m,2H), 7.12-7.09 (m, 1H), 5.12-5.10 (m, 1H), 4.90-4.81 (s, 1H), 4.51-4.48(m, 3H), 3.91-3.80 (s, 1H), 3.72-3.62 (m, 1H), 3.00-2.81 (m, 4H),2.79-2.68 (m, 1H), 2.50-2.42 (m, 3H), 2.30-2.00 (m, 7H), 1.99-1.81 (m,4H), 1.80-1.36 (m, 5H), 1.21-1.01 (m, 2H), 0.91-0.71 (m, 6H); LC-MS(ES⁺): m/z 837.30/839.30 [MH⁺], t_(R)=2.934 min, (4.80 minute run).

C₄₄H₄₉ClN₆O₇ [836.34/838.34].  Chemical formula:

Total H count from HNMR data: 49.

Synthetic Procedure for Compound 278 Step 1: [(R)-tert-butyl(1-(3-(3-chloro-4-cyanophenyl)-1H-pyrazol-1-yl)propan-2-yl)carbamate]

A mixture of (R)-2-((tert-butoxycarbonyl)amino)propyl4-methylbenzenesulfonate (12.6 g, crude),2-chloro-4-(1H-pyrazol-3-yl)benzonitrile (7.1 g, 34.9 mmol) and cesiumcarbonate (5.8 g, 48.8 mmol) in acetonitrile (100 ml) was stirred at 70°C. for 2 hours. TLC showed the reaction was complete. The reactionmixture was partitioned between water (50 ml) and ethyl acetate (100ml). The organic layer was collected and the aqueous layer was extractedwith ethyl acetate (50 ml×2). The combined organic layers were washedwith brine (100 ml), dried over magnesium sulfate and evaporated underreduced pressure to give a crude residue, which was purified by silicagel flash column chromatography (eluted with 50%-100% ethyl acetate inhexane) to afford tert-butyl 4-(prop-2-yn-1-yl)piperazine-1-carboxylate(7.0 g, yield 58%) as white solid.

¹H NMR (400 MHz, CDCl₃): δ 1.16 (d, J=6.8 Hz, 3H), 1.42 (s, 9H),4.02-4.11 (m, 1H), 4.16-4.30 (m, 2H), 6.61 (d, J=2.4 Hz, 1H), 7.46 (d,J=2.4 Hz, 1H), 7.67 (d, J=8.0 Hz, 1H), 7.74-7.80 (m, 1H), 7.96 (s, 1H).

C₁₈H₂₁ClN₄O₂; Molecular Weight: 360.84.  Chemical Formula:

Total H count from HNMR data: 20.

Step 2: [(R)-4-(1-(2-aminopropyl)-1H-pyrazol-3-yl)-2-chlorobenzonitrilehydrochloride]

A solution of (R)-tert-butyl(1-(3-(3-chloro-4-cyanophenyl)-1H-pyrazol-1-yl)propan-2-yl)carbamate(7.0 g, 19.4 mmol) in hydrogen chloride in dioxane (4M, 15 ml) wasstirred at room temperature for 2 hours. The volatiles were removedunder reduced pressure to give a crude residue, which was trituratedwith dichloromethane (25 ml). The resulting solid was collected byfiltration and dried under vacuum to afford(R)-4-(1-(2-aminopropyl)-1H-pyrazol-3-yl)-2-chlorobenzonitrilehydrochloride (4.3 g, yield 85%) as white solid which was used in nextstep without further purification.

Step 3: [tert-butyl 4-(prop-2-yn-1-yl)piperazine-1-carboxylate]

A mixture of tert-butyl piperazine-1-carboxylate (10 g, 53.7 mmol),N-ethyl-N-isopropylpropan-2-amine (12.6 g, 97.6 mmol) and3-bromoprop-1-yne (5.8 g, 48.8 mmol) in acetonitrile (50 ml) was stirredfor 2 hours. TLC showed the reaction was complete. The reaction mixturewas partitioned between ethyl acetate (80 ml) and water (80 ml). Theorganic layer was collected, and the aqueous layer was extracted withethyl acetate (45 ml×2). The combined organic layers were washed withbrine (100 ml), dried over anhydrous sodium sulfate, and concentratedunder reduced pressure to give a crude residue which was purified bysilica gel flash column chromatography (eluted with 50% ethyl acetate inhexane) to afford tert-butyl 4-(prop-2-yn-1-yl)piperazine-1-carboxylate(10.5 g, yield 96%) as pale yellow oil.

¹H NMR (400 MHz, CDCl₃): δ 1.46 (s, 9H), 2.26 (t, J=2.4 Hz, 1H), 2.51(t, J=4.8 Hz, 4H), 3.32 (d, J=2.4 Hz, 2H), 3.47 (t, J=4.8 Hz, 4H).

C₁₂H₂₀N₂O₂; Molecular Weight: 224.30.  Chemical Formula:

Total H count from HNMR data: 20.

Step 2: [tert-butyl4-((3-(ethoxycarbonyl)-1H-pyrazol-5-yl)methyl)piperazine-1-carboxylate]

A mixture of tert-butyl 4-(prop-2-yn-1-yl)piperazine-1-carboxylate (3.0g, 13.4 mmol), ethyl diazoacetate (2.3 g, 20.1 mmol) and zinctrifluoromethanesulfonate (974 mg, 2.68 mmol) in triethylamine (9.3 ml,67 mmol) was stirred at 100° C. overnight. TLC showed the reaction wascomplete. The reaction mixture was allowed to cool to room temperatureand partitioned between ethyl acetate (50 ml) and water (20 ml). Theorganic layer was collected, and the aqueous layer was extracted withethyl acetate (30 ml×2). The combined organic layers were washed withbrine (30 ml), dried over anhydrous sodium sulfate, and concentratedunder reduced pressure to afford a crude residue, which was purified bysilica gel flash chromatography (eluted with 100%-200% ethyl acetate inhexane) to afford tert-butyl4-((3-(ethoxycarbonyl)-1H-pyrazol-5-yl)methyl)piperazine-1-carboxylate(2.1 g, yield 47%) as yellow oil.

LC_MS: (ES⁺): m/z 339.5 [M+H]⁺, t_(R)=1.772 min.

Step 3:[5-((4-(tert-butoxycarbonyl)piperazin-1-yl)methyl)-1H-pyrazole-3-carboxylicacid]

A mixture of tert-butyl4-((3-(ethoxycarbonyl)-1H-pyrazol-5-yl)methyl)piperazine-1-carboxylate(500 mg, 1.48 mmol) and lithium hydroxide monohydrate (250 mg, 5.91mmol) in tetrahydrofuran (10 ml)-water (2.5 ml)-methanol (2.5 ml) wasstirred at 45° C. overnight. TLC showed the reaction was complete. Thereaction mixture was acidified with diluted hydrochloride acid (IN) tillpH 6-7, the resulting mixture was concentrated under reduced pressure toafford5-((4-(tert-butoxycarbonyl)piperazin-1-yl)methyl)-1H-pyrazole-3-carboxylicacid (1.1 g, crude) as yellow solid.

LC_MS: (ES⁺): m/z 311.3 [M+H]⁺, t_(R)=1.378 min.

Step 4: [(R)-tert-butyl4-((3-((1-(3-(3-chloro-4-cyanophenyl)-1H-pyrazol-1-yl)propan-2-yl)carbamoyl)-1H-pyrazol-5-yl)methyl)piperazine-1-carboxylate]

A mixture of5-((4-(tert-butoxycarbonyl)piperazin-1-yl)methyl)-1H-pyrazole-3-carboxylicacid (1.1 g, crude),(R)-4-(1-(2-aminopropyl)-1H-pyrazol-3-yl)-2-chlorobenzonitrilehydrochloride (336 mg, 1.29 mmol),N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (371 mg,1.94 mmol), 1-hydroxybenzotriazole (262 mg, 1.94 mmol) andN-ethyl-N-isopropylpropan-2-amine (835 mg, 6.5 mmol) in anhydrousN,N-dimethylformamide (8 ml) was stirred at room temperature for 2hours, and then2-(7-Aza-H-benzotriazole-1-yl)-1,1,3,3-tetramethyluroniumhexafluorophosphate (980 mg, 2.58 mmol) was added. The resulting mixturewas stirred at room temperature for 1 hour. TLC showed the reaction wascomplete. The mixture was partitioned between ethyl acetate (20 ml) andwater (10 ml). The organic layer was collected, washed with brine (20ml), dried over anhydrous sodium sulfate, and concentrated under reducedpressure to give a crude residue which was purified by silica gel flashchromatography (eluted with 100%-200% ethyl acetate in hexane) to afford(R)-tert-butyl4-((3-((1-(3-(3-chloro-4-cyanophenyl)-1H-pyrazol-1-yl)propan-2-yl)carbamoyl)-1H-pyrazol-5-yl)methyl)piperazine-1-carboxylate(300 mg, yield 37% over 2 steps) as white solid.

¹H NMR (400 MHz, CDCl₃): δ 1.21 (d, J=6.8 Hz, 3H), 1.46 (s, 9H), 2.42(t, J=4.8 Hz, 4H), 3.44 (t, J=4.8 Hz, 4H), 3.62 (s, 2H), 4.24-4.29 (m,1H), 4.40-4.46 (m, 1H), 6.63 (d, J=2.4 Hz, 1H), 6.68 (s, 1H), 7.50 (d,J=2.0 Hz, 1H), 7.68 (d, J=8.0 Hz, 1H), 7.74-7.78 (m, 1H), 7.97 (d, J=8.0Hz, 1H), 8.27 (d, J=1.2 Hz, 1H).

C₂₇H₃₃ClN₈O₃; Molecular Weight: 553.06.  Chemical Formula:

Total H count from HNMR data: 31.

LC_MS: (ES⁺): m/z 553.3 [M+H]⁺, t_(R)=2.181 min.

Step 5:[(R)—N-(1-(3-(3-chloro-4-cyanophenyl)-1H-pyrazol-1-yl)propan-2-yl)-5-(piperazin-1-ylmethyl)-1H-pyrazole-3-carboxamidedihydrochloride]

A solution of tert-butyl4-(2-(2-(4-(5-(((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)carbamoyl)pyridin-2-yl)piperazin-1-yl)ethoxy)ethyl)piperazine-1-carboxylate(160 mg, 0.29 mmol) in hydrogen chloride in dioxane (4M, 5 ml) wasstirred at room temperature for 2 hours. The volatiles were removedunder reduced pressure to give a crude residue which was triturated withdichloromethane (25 ml). The resulting solid was collected by filtrationand dried under vacuum to afford(R)—N-(1-(3-(3-chloro-4-cyanophenyl)-1H-pyrazol-1-yl)propan-2-yl)-5-(piperazin-1-ylmethyl)-1H-pyrazole-3-carboxamidedihydrochloride (130 mg, yield 86%) as white solid.

¹H NMR (400 MHz, CD₃OD): δ 1.31 (d, J=6.8 Hz, 3H), 3.50-3.62 (m, 8H),4.30-4.48 (m, 4H), 4.58-4.64 (m, 1H), 6.78 (d, J=2.0 Hz, 1H), 7.00-7.03(m, 1H), 7.73 (d, J=2.0 Hz, 1H), 7.81 (d, J=8.0 Hz, 1H), 7.90 (d, J=8.0Hz, 1H), 8.03 (s, 1H).

C₂₂H₂₇Cl₃N₈O; Molecular Weight: 525.86.  Chemical Formula:

Total H count from HNMR data: 23.

LC_MS: (ES⁺): m/z 453.3 [M+H]⁺, t_(R)=1.916 min.

Step 6: [4-chlorobutyl 4-methylbenzenesulfonate]

A mixture of 4-chlorobutan-1-ol (5 g, 46.05 mmol), triethylamine (9.3 g,92.1 mmol), N,N-dimethylpyridin-4-amine (562 mg, 4.61 mmol) and4-methylbenzene-1-sulfonyl chloride (9.63 g, 50.66 mmol) indichloromethane (40 ml) was stirred at room temperature for 1.5 hours.TLC showed the reaction was complete. The reaction mixture waspartitioned between water (50 ml) and ethyl acetate (100 ml). Theorganic layer was collected, and the aqueous layer was extracted withethyl acetate (100 ml). The combined organic layers were washed withbrine (100 ml), dried over sodium sulfate, and concentrated underreduced pressure to give a crude residue which was purified by silicagel flash column chromatography (eluted with 20% ethyl acetate inhexane) to afford 4-chlorobutyl 4-methylbenzenesulfonate (12.0 g, yield99%) as colorless oil.

¹H NMR (400 MHz, CDCl₃): δ 1.80-1.84 (m, 4H), 2.46 (s, 3H), 3.49-3.53(m, 2H), 4.04-4.08 (m, 2H), 7.35 (d, J=8.0 Hz, 2H), 7.79 (d, J=8.0 Hz,2H).

C₁₁H₁₅ClO₃S; Molecular Weight: 262.75.  Chemical Formula:

Total H count from HNMR data: 15.

LC_MS: (ES⁺): m/z 263.1 [M+H]⁺, t_(R)=2.888 min.

Step 7:[5-(4-chlorobutoxy)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione]

A mixture of 4-chlorobutyl 4-methylbenzenesulfonate (0.96 g, 3.65 mmol),2-(2,6-dioxopiperidin-3-yl)-5-hydroxyisoindoline-1,3-dione (1 g, 3.65mmol) and potassium carbonate (0.76 g, 5.47 mmol) inN,N-dimethylformamide (10 ml) was stirred at 70° C. overnight. TLCshowed the reaction was complete. The reaction mixture was partitionedbetween ethyl acetate (30 ml) and water (20 ml). The organic layer wascollected, and the aqueous layer was extracted with ethyl acetate (30ml×2). The combined organic layers were washed with brine (30 ml), driedover anhydrous sodium sulfate, and concentrated under reduced pressureto afford a crude residue which was purified by silica gel flashchromatography (eluted with 33%-50% ethyl acetate in hexane) to afford5-(4-chlorobutoxy)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione (220mg, yield 18%) as white solid.

LC_MS: (ES⁺): m/z 365.1 [M+H]⁺, t_(R)=2.547 min.

Step 8:[N—((R)-1-(3-(3-chloro-4-cyanophenyl)-1H-pyrazol-1-yl)propan-2-yl)-5-((4-(4-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)butyl)piperazin-1-yl)methyl)-1H-pyrazole-3-carboxamide]

A mixture of(R)—N-(1-(3-(3-chloro-4-cyanophenyl)-1H-pyrazol-1-yl)propan-2-yl)-5-(piperazin-1-ylmethyl)-1H-pyrazole-3-carboxamidedihydrochloride (130 mg, 0.25 mmol),5-(4-chlorobutoxy)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione (90mg, 0.25 mmol), and N-ethyl-N-isopropylpropan-2-amine (162 mg, 1.25mmol) and potassium iodide (124 mg, 0.75 mmol) in acetonitrile (3 ml)was stirred at 100° C. in sealed tube overnight. TLC showed the reactionwas complete. The mixture was partitioned between ethyl acetate (30 ml)and water (20 ml). The organic layer was collected, washed with brine(30 ml), dried over anhydrous sodium sulfate, and concentrated underreduced pressure to give a crude residue which was purified bypreparative TLC (eluted with 8% methanol in dichloromethane) to affordN—((R)-1-(3-(3-chloro-4-cyanophenyl)-1H-pyrazol-1-yl)propan-2-yl)-5-((4-(4-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)butyl)piperazin-1-yl)methyl)-1H-pyrazole-3-carboxamide(45 mg, yield 24%) as white solid.

¹H NMR (400 MHz, DMSO-d6): δ 1.11 (d, J=5.6 Hz, 3H), 1.23 (s, 1H), 1.57(s, 1H), 1.70-1.80 (m, 2H), 1.98-2.08 (m, 2H), 2.22-2.40 (m, 8H),2.52-2.68 (m, 2H), 2.84-2.94 (m, 1H), 3.30 (s, 1H), 3.51 (s, 2H), 4.18(t, J=6.4 Hz, 2H), 4.42-4.48 (m, 3H), 5.08-5.15 (m, 1H), 6.43 (s, 1H),6.94 (d, J=2.4 Hz, 1H), 7.32-7.6 (m, 1H), 7.42 (d, J=2.0 Hz, 1H),7.80-7.85 (m, 2H), 7.99 (s, 2H), 8.08 (s, 1H), 8.23 (d, J=8.0 Hz, 1H),11.1 (s, 1H), 13.1 (s, 1H).

C₃₉H₄₁ClN₁₀O₆; Molecular Weight: 781.26.  Chemical Formula:

Total H count from HNMR data: 41.

LC_MS: (ES⁺): m/z 781.4 [M+H]⁺, t_(R)=2.113 min.

Synthetic Procedure for Compound 612 Synthesis of tert-butyl4-[[-(2-fluoro-4-nitrophenyl)piperidin-4-yl]methyl]piperazine-1-carboxylate

Into a 20-30 mL sealed tube, was placed a solution of1,2-difluoro-4-nitrobenzene (977.5 mg, 6.1 mmol, 1.0 equiv) indimethylsulfoxide (10 mL), tert-butyl4-(piperidin-4-ylmethyl)piperazine-1-carboxylate (1.5 g, 5.1 mmol, 0.8equiv), N,N-Diisopropylethylamine (2.0 g, 15.3 mmol, 2.5 equiv). Theresulting solution was stirred overnight at 100° C. in an oil bath. Thereaction was then quenched by the addition of 10 mL of water/ice. Theresulting solution was extracted with ethyl acetate (20 mL×2) and theorganic layers combined and dried over anhydrous sodium sulfate andconcentrated under reduced pressure. The residue was applied onto asilica gel column with ethyl acetate/petroleum ether (1:0). Thisresulted in 1.5 g (58%) of tert-butyl 4-[[1-(2-fluoro-4-nitrophenyl)piperidin-4-yl] methyl]piperazine-1-carboxylate as a yellow solid.

LC-MS (ES⁺): m/z 423.30 [MH⁺], t_(R)=1.58 min (1.9 minute run).

Synthesis of tert-butyl4-[[-(4-amino-2-fluorophenyl)piperidin-4-yl]methyl]piperazine-1-carboxylate

To a solution of tert-butyl 4-[[1-(2-fluoro-4-nitrophenyl)piperidin-4-yl] methyl] piperazine-1-carboxylate (1.5 g, 3.6 mmol, 1.0equiv) in 15 mL i-PrOH was added Pd/C (10%, 40.0 mg) under nitrogenatmosphere in a 100 ml round bottom flask. The flask was then vacuumedand flushed with hydrogen. The reaction mixture was hydrogenated at roomtemperature for 4 hours under hydrogen atmosphere using a hydrogenballoon, then filtered through a Celite pad and concentrated underreduced pressure. The resulting mixture was concentrated under reducedpressure. This resulted in 1.2 g (86%) of tert-butyl4-[[1-(4-amino-2-fluorophenyl) piperidin-4-yl] methyl]piperazine-1-carboxylate as a pink solid.

LC-MS (ES⁺): m/z 393.10 [MH⁺], t_(R)=0.74 min (1.9 minute run).

3. Synthesis of tert-butyl4-[(1-[4-[(1-cyanocyclobutyl)amino]-2-fluorophenyl]piperidin-4-yl)methyl]piperazine-1-carboxylate

Into a 100 mL round-bottom flask, was placed a solution of tert-butyl4-[[1-(4-amino-2-fluorophenyl) piperidin-4-yl]methyl]piperazine-1-carboxylate (1.2 g, 3.1 mmol, 1.0 equiv) intetrahydrofuran (10 mL), cyclobutanone (428.6 mg, 6.1 mmol, 2.0equiv),ZnCl₂ (2.1 g, 15.4 mmol, 5.0 equiv), TMSCN (606.1 mg). The resultingsolution was stirred overnight at room temperature. The reaction wasthen quenched by the addition of 10 mL of 1 mmol/L FeSO₄ solvent. Theresulting solution was extracted with ethyl acetate (20 mL×2) and theorganic layers combined and dried over anhydrous sodium sulfate andconcentrated under reduced pressure. The residue was applied onto asilica gel column with dichloromethane/methanol (5:1). This resulted in990.0 mg (69%) of tert-butyl 4-[(1-[4-[(1-cyanocyclobutyl)amino]-2-fluorophenyl] piperidin-4-yl) methyl] piperazine-1-carboxylateas a black solid.

LC-MS (ES⁺): m/z 472.35 [MH⁺], t_(R)=1.50 min (1.9 minute run).

Synthesis of tert-butyl4-[(1-[4-[7-(5-chloro-6-cyanopyridin-3-yl)-8-imino-6-sulfanylidene-5,7-diazaspiro[3.4]octan-5-yl]-2-fluorophenyl]piperidin-4-yl)methyl]piperazine-1-carboxylate

Into a 100-mL round-bottom flask, was placed a solution of tert-butyl4-[(1-[4-[(1-cyanocyclobutyl)amino]-2-fluorophenyl]piperidin-4-yl)methyl]piperazine-1-carboxylate(402.6 mg, 1.3 mmol, 1.0 equiv) in toluene (10 mL),3-chloro-5-isothiocyanatopyridine-2-carbonitrile (200.0 mg, 1.5 mmol,1.2 equiv), 4-dimethylaminopyridine (156.4 mg, 1.9 mmol, 1.5 equiv). Theresulting solution was stirred overnight at 100° C. in an oil bath. Thereaction was then quenched by the addition of 5 mL of ice water. Theresulting solution was extracted with ethyl acetate (20 mL×2) and theorganic layers combined and dried over anhydrous sodium sulfate andconcentrated under reduced pressure. The residue was applied onto asilica gel column with ethyl acetate/petroleum ether (1:0). Thisresulted in 230.0 mg (30.4%) of tert-butyl4-[(1-[4-[7-(5-chloro-6-cyanopyridin-3-yl)-8-imino-6-sulfanylidene-5,7-diazaspiro[3.4] octan-5-yl]-2-fluorophenyl] piperidin-4-yl)methyl]piperazine-1-carboxylate as a yellow solid.

LC-MS (ES⁺): m/z 667.30 [MH⁺], t_(R)=1.52 min (1.9 minute run).

Synthesis3-chloro-5-(5-[3-fluoro-4-[4-(piperazin-1-ylmethyl)piperidin-1-yl]phenyl]-8-oxo-6-sulfanylidene-5,7-diazaspiro[3.4]octan-7-yl)pyridine-2-carbonitrilehydrochloride

Into a 100 mL round-bottom flask, was placed a solution of tert-butyl4-[(1-[4-[7-(5-chloro-6-cyanopyridin-3-yl)-8-imino-6-sulfanylidene-5,7-diazaspiro[3.4]octan-5-yl]-2-fluorophenyl]piperidin-4-yl)methyl]piperazine-1-carboxylate (230.0 mg, 0.3 mmol, 1.0equiv) in methanol (10 mL), hydrogen chloride (8 ml). The resultingsolution was stirred for 2 hours at 80° C. in an oil bath. The reactionwas then quenched by the addition of 5 mL of ice water. The resultingsolution was extracted with ethyl acetate (20 mL×2) and the organiclayers combined and dried over anhydrous sodium sulfate and concentratedunder reduced pressure. This resulted in 200.1 mg (96%) of3-chloro-5-(5-[3-fluoro-4-[4-(piperazin-1-ylmethyl)piperidin-1-yl]phenyl]-8-oxo-6-sulfanylidene-5,7-diazaspiro [3.4]octan-7-yl) pyridine-2-carbonitrile hydrochloride as a yellow solid.

LC-MS (ES⁺): m/z 568.25 [MH⁺], t_(R)=1.26 min (1.9 minute run).

6. Synthesis 3-chloro-5-(5-[4-[4-([4-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2, 3-dihydro-1H-isoindol-5-yl]piperazin-1-yl] methyl)piperidin-1-yl]-3-fluorophenyl]-8-oxo-6-sulfanylidene-5,7-diazaspiro[3.4]octan-7-yl)pyridine-2-carbonitrile

Into a 20-30 mL sealed tube, was placed a solution of3-chloro-5-(5-[3-fluoro-4-[4-(piperazin-1-ylmethyl)piperidin-1-yl]phenyl]-8-oxo-6-sulfanylidene-5,7-diazaspiro[3.4]octan-7-yl)pyridine-2-carbonitrilehydrochloride (100.0 mg, 0.2 mmol, 1.0 equiv) in dimethylsulfoxide (10mL),2-(2,6-dioxopiperidin-3-yl)-5-fluoro-2,3-dihydro-1H-isoindole-1,3-dione(40.6 mg, 0.2 mmol, 0.9 equiv), N,N-Diisopropylethylamine (56.9 mg, 0.44mmol, 2.66 equiv). The resulting solution was stirred for 2 hours at130° C. in an oil bath. The reaction was then quenched by the additionof 5 mL of water/ice. The resulting solution was extracted with of ethylacetate (20 mL×2) and the organic layers combined and dried overanhydrous sodium sulfate and concentrated under reduced pressure. Thecrude product was purified by Prep-HPLC with the following conditions:Mobile Phase A: Water (10 MMOUL ammonium bicarbonate), Mobile Phase B:acetonitrile; Flow rate: 20 mL/min; Gradient: 56% B to 76% B in 8 min;254 nm; Rt: 7.6 min; 5 mL product was obtained. This resulted in 72.7 mg(60%) of3-chloro-5-(5-[4-[4-([4-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl]piperazin-1-yl]methyl)piperidin-1-yl]-3-fluorophenyl]-8-oxo-6-sulfanylidene-5,7-diazaspiro[3.4]octan-7-yl)pyridine-2-carbonitrileas a yellow solid.

¹H NMR (300 MHz, DMSO-d₆) δ 11.10 (s, 1H), 8.90 (d, J=2.0 Hz, 1H), 8.54(d, J=1.9 Hz, 1H), 7.70 (d, J=8.5 Hz, 1H), 7.37 (s, 1H), 7.33-7.13 (m,4H), 5.09 (dd, J=12.6, 5.4 Hz, 1H), 3.50-3.45 (m, 6H), 2.90-2.81 (m,4H), 2.71-2.2.60 (m, 3H), 2.61-2.45 (m, 5H), 2.38-2.36 (m, 1H),2.30-2.28 (m, 2H), 2.05-1.99 (m, 2H), 1.89-1.80 (m, 2H), 1.76-1.72 (m,1H), 1.61-1.55 (m, 1H), 1.39-1.22 (m, 2H); LC-MS (ES⁺): m/z 824.35[MH⁺],t_(R)=1.27 min (2.9 minute run).

C₄₁H₃₉ClFN₉O₅S [823.25].  Chemical formula:

Total H count from HNMR data: 39.

Synthetic Procedure for Compound 603 1. Synthesis of4-fluoro-N-hydroxybenzene-1-carboximidamide

Into a 250-mL round-bottom flask, was placed 4-fluorobenzonitrile (5.00g, 41.28 mmol, 1 equiv), hydroxylamine hydrochloride (14.0 g, 201.47mmol, 4.880 equiv), ethanol (150 mL) andN-ethyl-N-isopropylpropan-2-amine (27.0 g, 208.90 mmol, 5.060 equiv).The resulting mixture was stirred for 4 hours at 85° C. in an oil bath.The resulting mixture was concentrated under reduced pressure. Theresidue was applied onto a silica gel column with methanol: ethylacetate (1:10). This resulted in 5.70 g (89.57%) of4-fluoro-N-hydroxybenzene-1-carboximidamide as a white solid.

LC-MS (ES⁺): m/z 155.30 [MH]⁺, t_(R)=0.60 min (2.00 minute run).

2. Synthesis of 3-(4-fluorophenyl)-5-methyl-1,2,4-oxadiazole

Into a 100-mL round-bottom flask, was placed4-fluoro-N-hydroxybenzene-1-carboximidamide (5.70 g, 36.98 mmol, 1.0equiv), acetyl acetate (54.1 g, 529.93 mmol, 14.3 equiv) and acetic acid(5 mL). The resulting solution was stirred for 16 hours at 120° C. in anoil bath. The reaction was then quenched by the addition of 150 mL ofwater. The pH value of the solution was adjusted to 7 withNaHCO₃solution. The resulting solution was extracted with ethyl acetate(30 mL×2) and the organic layers combined. The resulting mixture waswashed with brine (30 mL×2). The mixture was dried over with anhydroussodium sulfate and the solid was filtered out. The resulting mixture wasconcentrated under reduced pressure. The residue was applied onto asilica gel column with ethyl acetate/petroleum ether (1:1). Thisresulted in 6.10 g (92.59%) of3-(4-fluorophenyl)-5-methyl-1,2,4-oxadiazole as a white solid.

LC-MS (ES⁺): m/z 178.95 [MH]⁺, t_(R)=1.18 min (2.00 minute run).

3. Synthesis of tert-butyl4-([1-[4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl]azetidin-3-yl]methyl)piperazine-1-carboxylate

Into a 30-mL sealed tube, was placed3-(4-fluorophenyl)-5-methyl-1,2,4-oxadiazole (523.0 mg, 2.94 mmol, 1.5equiv), tert-butyl 4-(azetidin-3-ylmethyl)piperazine-1-carboxylate(500.0 mg, 1.96 mmol, 1 equiv), dimethyl sulphoxide (15 mL, 211.18 mmol,107.852 equiv) and Cs₂CO₃ (1.91 g, 5.86 mmol, 3.0 equiv). The resultingsuspension was stirred for 20 hours at 150° C. in an oil bath. Thereaction was then quenched by the addition of 150 mL of water. Theresulting solution was extracted with ethyl acetate (30 mL×2) and theorganic layers combined. The resulting mixture was washed with brine (30mL×2). The mixture was dried over anhydrous sodium sulfate. The solidswere filtered out. The resulting mixture was concentrated under reducedpressure. The residue was applied onto a silica gel column with ethylacetate/petroleum ether (1:1). This resulted in 380.0 mg (46.93%) oftert-butyl4-([1-[4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl]azetidin-3-yl]methyl)piperazine-1-carboxylateas a light yellow solid.

LC-MS (ES⁺): m/z 414.40 [MH]⁺, t_(R)=0.90 min (2.00 minute run).

4. Synthesis of tert-butyl4-[[1-(4-carbamimidoylphenyl)azetidin-3-yl]methyl]piperazine-1-carboxylate

Into a 100-mL round-bottom flask purged and maintained with an inertatmosphere of nitrogen, was placed tert-butyl4-([1-[4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl]azetidin-3-yl]methyl)piperazine-1-carboxylate(380.0 mg, 0.92 mmol, 1 equiv), methanol (50 mL), AcOH (2 mL, 34.90mmol, 37.981 equiv) and 10% Pd/C (300 mg). The flask was rapidlyevacuated and then recharged with hydrogen gas for three times, andfinally connected with a tyre containing H₂ (10 L). The resultingsuspension was stirred for 16 hours at room temperature. The solids werefiltered out and further washed successively with 200 mL methanol and200 ml of acetonitrile. The combined filtrate was concentrated underreduced pressure. This resulted in 100.0 mg (29.14%) of tert-butyl4-[[1-(4-carbamimidoylphenyl)azetidin-3-yl]methyl]piperazine-1-carboxylateas a white solid.

LC-MS (ES⁺): m/z 374.05 [MH]⁺, t_(R)=0.75 min (2.00 minute run).

5. Synthesis of2-chloro-4-[[(1r,4r)-4-(2-bromoacetyl)cyclohexyl]oxy]benzonitrile

Into a 100-mL three-necked round-bottom flask purged and maintained withan inert atmosphere of nitrogen, was placed(r,4r)-4-(3-chloro-4-cyanophenoxy)cyclohexane-1-carboxylic acid (400.0mg, 1.43 mmol, 1.0 equiv), dichloromethane (30 mL), oxalyl chloride(220.0 mg, 1.73 mmol, 1.2 equiv) and a drop of N,N-dimethylacetamide(30.0 mg, 0.41 mmol, 0.29 equiv). The resulting solution was stirred for4 hours at room temperature. The reaction mixture was concentrated underreduced pressure, and the residue was dissolved in acetonitrile (20 mL).Into the solution was added (Trimethylsilyl)diazomethane (2.2 mL, 4.4mmol, 3.0 equiv, 2M in hexane). The resulting solution was stirred for 2hours at room temperature, and then was cooled with an ice/water bath.Into the cooled mixture was added a solution of HBr in AcOH (40%) (1.05g, 5.17 mmol, 3.613 equiv), and then the cool bath was removed. Theresulting solution was allowed to react with stirring for an additional2 hours at room temperature. The reaction was then quenched by theaddition of 100 mL of water. The resulting solution was extracted withethyl acetate (30 mL×2) and the organic layers combined. The resultingmixture was washed with brine (30 mL×2). The mixture was dried overanhydrous sodium sulfate and the solid was filtered out. The resultingmixture was concentrated under reduced pressure. The residue was appliedonto a silica gel column with ethyl acetate/petroleum ether (1:5). Thisresulted in 380 mg (74.51%) of2-chloro-4-[[(1r,4r)-4-(2-bromoacetyl)cyclohexyl]oxy]benzonitrile as awhite solid.

LC-MS (ES⁺): m/z 355.85 [MH]⁺, t_(R)=1.05 min (1.90 minute run).

6. Synthesis of tert-butyl4-[[1-(4-[5-[(1r,4r)-4-(3-chloro-4-cyanophenoxy)cyclohexyl]-1H-imidazol-2-yl]phenyl)azetidin-3-yl]methyl]piperazine-1-carboxylate

Into a 50-mL 3-necked round-bottom flask, was placed tert-butyl4-[[1-(4-carbamimidoylphenyl)azetidin-3-yl]methyl]piperazine-1-carboxylate(100.0 mg, 0.27 mmol, 1.0 equiv), tetrahydrofuran (15 mL) and a solutionof NaHCO₃(113.0 mg, 1.35 mmol, 5.0 equiv) in water (3 mL). Afterstirring the mixture at room temperature for 5 minutes, into the flask,was added a solution of2-chloro-4-[[(1r,4r)-4-(2-bromoacetyl)cyclohexyl]oxy]benzonitrile (96.0mg, 0.27 mmol, 1 equiv) in THF (5 mL). The resulting solution wasstirred for 24 hours at 50° C. in an oil bath. The reaction was thenquenched by the addition of 150 mL of water. The resulting solution wasextracted with ethyl acetate (30 mL×2) and the organic layers combined.The resulting mixture was washed with brine (50 mL×2). The mixture wasdried over anhydrous sodium sulfate and the solid was filtered out. Theresulting mixture was concentrated under reduced pressure. The residuewas applied onto a silica gel column with methanol: ethyl acetate(1:10). This resulted in 50.0 mg (29.43%) of tert-butyl4-[[1-(4-[5-[(1r,4r)-4-(3-chloro-4-cyanophenoxy)cyclohexyl]-1H-imidazol-2-yl]phenyl)azetidin-3-yl]methyl]piperazine-1-carboxylateas an off-white solid.

LC-MS (ES⁺): m/z 631.15 [MH]⁺, t_(R)=0.94 min (2.00 minute run).

7. Synthesis of4-[[-(4-[5-[(1r,4r)-4-(3-chloro-4-cyanophenoxy)cyclohexyl]-1H-imidazol-2-yl]phenyl)azetidin-3-yl]methyl]piperazin-1-iumtrifluoroacetate

Into a 100-mL round-bottom flask, was placed tert-butyl4-[[1-(4-[5-[(1r,4r)-4-(3-chloro-4-cyanophenoxy)cyclohexyl]-1H-imidazol-2-yl]phenyl)azetidin-3-yl]methyl]piperazine-1-carboxylate(50.0 mg, 0.08 mmol, 1 equiv), dichloromethane (20 mL, 314.60 mmol,3971.566 equiv) and 2,2,2-trifluoroacetaldehyde (5 mL). The resultingsolution was stirred for 2 hours at room temperature. The resultingmixture was concentrated under vacuum. This resulted in 50.0 mg (97.84%)of4-[[1-(4-[5-[(1r,4r)-4-(3-chloro-4-cyanophenoxy)cyclohexyl]-1H-imidazol-2-yl]phenyl)azetidin-3-yl]methyl]piperazin-1-iumtrifluoroacetate as an off-white solid.

8. Synthesis of2-chloro-4-[[(1r,4r)-4-(2-[4-[3-([4-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl]piperazin-1-yl]methyl)azetidin-1-yl]phenyl]-1H-imidazol-5-yl)cyclohexyl]oxy]benzonitrile

Into a 8-mL sealed tube, was placed4-[[1-(4-[5-[(1r,4r)-4-(3-chloro-4-cyanophenoxy)cyclohexyl]-1H-imidazol-2-yl]phenyl)azetidin-3-yl]methyl]piperazin-1-iumtrifluoroacetate (50.0 mg, 0.08 mmol, 1 equiv),2-(2,6-dioxopiperidin-3-yl)-5-fluoro-2,3-dihydro-1H-isoindole-1,3-dione(54.0 mg, 0.20 mmol, 2.522 equiv), dimethyl sulphoxide (4 mL, 56.31mmol, 726.583 equiv) and N-ethyl-N-isopropylpropan-2-amine (2 mL, 12.10mmol, 156.134 equiv). The resulting solution was stirred for 3 hours at130° C. in an oil bath. The reaction was then quenched by the additionof 150 mL of water. The resulting solution was extracted with ethylacetate (30 mL×2) and the organic layers combined. The resulting mixturewas washed with brine (50 mL×2). The mixture was dried over anhydroussodium sulfate and the solid was filtered out. The resulting mixture wasconcentrated under reduced pressure. The residue was applied onto asilica gel column with methanol: ethyl acetate (1:10). The crude productwas further purified by Prep-HPLC (Column: XBridge Prep C18 OBD Column,5 um, 19*150 mm; Mobile Phase A: Water (10 mmoL/L NH₄HCO₃), Mobile PhaseB: ACN; Flow rate: 20 mL/min; Gradient: 45% B to 63% B in 8 min; 254 nm;Rt: 7.8 min). This resulted in 31.5 mg (51.62%) of2-chloro-4-[[(1r,4r)-4-(2-[4-[3-([4-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl]piperazin-1-yl]methyl)azetidin-1-yl]phenyl]-1H-imidazol-5-yl)cyclohexyl]oxy]benzonitrileas a yellow solid.

¹H NMR (300 MHz, Me₂SO-d₆): δ 11.08 (s, 1H), 7.86 (d, J=8.8 Hz, 1H),7.71-7.67 (m, 3H), 7.39-7.25 (m, 3H), 7.13 (dd, J=8.8, 2.3 Hz, 1H), 6.74(s, 1H), 6.45 (d, J=8.4 Hz, 2H), 5.07 (dd, J=12.7, 5.5 Hz, 1H), 4.60(brs, 1H), 3.98 (t, J=7.6 Hz, 2H), 3.54-3.30 (m, 7H), 3.29-3.120 (m,5H), 3.11-2.79 (m, 3H), 2.67-2.55 (m, 3H), 2.18-2.01 (m, 5H), 1.75-1.35(m, 4H); LC-MS (ES⁺): m/z 787.50 [MH⁺], HPLC: t_(R)=5.13 min (10.00minute run).

C₄₃H₄₃ClN₈O₅ [787.31].  Chemical Formula:

Total H count from HNMR data: 43.

Synthetic Procedure for Compound 609 1. Synthesis of tert-butylN-[(1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl]carbamate

Into a 100-mL 3-necked round-bottom flask purged and maintained with aninert atmosphere of nitrogen, was placed a solution of tert-butylN-[(1r,3r)-3-hydroxy-2,2,4,4-tetramethylcyclobutyl]carbamate (600.0 mg,2.47 mmol, 1.00 equiv) in N,N-dimethylformamide (10.0 mL). This wasfollowed by the addition of sodium hydride (198.0 mg, 8.25 mmol, 2.00equiv), in portions at 0° C. After 30 minutes, to this was added2-chloro-4-fluorobenzonitrile (459.0 mg, 2.95 mmol, 1.20 equiv). Theresulting solution was stirred for 1 hour at 70° C. The reaction mixturewas cooled to room temperature with a water bath. The reaction was thenquenched by the addition of water (20 mL). The resulting solution wasextracted with ethyl acetate (20 mL×3) and the organic layers combined.The residue was applied onto a silica gel column with ethylacetate/petroleum ether (1/5). This resulted in 100.0 mg (11%) oftert-butylN-[(1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl]carbamateas colorless oil.

LC-MS (ES⁺): m/z 279.10 [MH-100]⁺, t_(R)=1.20 min (2.5 minute run).

2. Synthesis of2-chloro-4-[(1r,3r)-3-amino-2,2,4,4-tetramethylcyclobutoxy]benzonitrile

Into a 100-mL round-bottom flask purged and maintained with an inertatmosphere of nitrogen, was placed tert-butylN-[(1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl]carbamate(500.0 mg, 1.32 mmol, 1.00 equiv), hydrogen chloride/dioxane (3 mL, 4M),1,4-dioxane (3 mL). The resulting solution was stirred for 1 hour atroom temperature. The resulting mixture was concentrated under vacuum.This resulted in 447.0 mg (87%) of2-chloro-4-[(1r,3r)-3-amino-2,2,4,4-tetramethylcyclobutoxy]benzonitrileas a white solid.

3. Synthesis of tert-butyl4-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl]piperazine-1-carboxylate

Into a 100-mL a flask, was placed a solution of2-(2,6-dioxopiperidin-3-yl)-5-fluoro-2,3-dihydro-1H-isoindole-1,3-dione(5 g, 18.10 mmol, 1.00 equiv) in methyl sulfoxide (30 mL), methylsulfoxide (30 mL), N,N-diisopropylethylamine (12.5 mL, 2.00 equiv),tert-butyl piperazine-1-carboxylate (3.75 g, 20.13 mmol, 1.10 equiv).The resulting solution was stirred for 16 hours at 110° C. in an oilbath. The reaction was then quenched by the addition of water (100 mL).The resulting solution was extracted with ethyl acetate (100 mL×3) andthe organic layers combined. The resulting mixture was washed with brine(200 mL). The mixture was dried over anhydrous sodium sulfate andconcentrated under vacuum. This resulted in 6.5 g (81%) of tert-butyl4-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl]piperazine-1-carboxylateas a yellow solid.

LC-MS (ES⁺): m/z 443.00 [MH⁺], t_(R)=1.156 min, (2.0 minute run).

4. Synthesis of tert-butyl4-[2-(2,6-dioxopiperidin-3-yl)-3-hydroxy-3-methyl-1-oxo-2,3-dihydro-1H-isoindol-5-yl]piperazine-1-carboxylate

Into a 50-mL sealed tube purged and maintained with an inert atmosphereof nitrogen, was placed tert-butyl4-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl]piperazine-1-carboxylate(2 g, 4.52 mmol, 1.00 equiv), tetrahydrofuran (30 mL). This was followedby the addition of Methylmagnesium bromide (6 mL) dropwise with stirringat −75° C. in 20 minutes. The resulting solution was stirred for 4 hoursat 60° C. The reaction was then quenched by the addition of water (50mL). The resulting solution was extracted with ethyl acetate (30 mL×3)and the organic layers combined. The resulting mixture was washed withsaturated sodium chloride aqueous solution (50 mL). The mixture wasdried over anhydrous sodium sulfate and concentrated under vacuum. Theresidue was applied onto a silica gel column with ethylacetate/petroleum ether (1:0). This resulted in 1.5 g (72%) oftert-butyl4-[2-(2,6-dioxopiperidin-3-yl)-3-hydroxy-3-methyl-1-oxo-2,3-dihydro-1H-isoindol-5-yl]piperazine-1-carboxylateas yellow crude oil.

5. Synthesis of3-[3-methyl-1-oxo-5-(piperazin-1-yl)-2,3-dihydro-1H-isoindol-2-yl]piperidine-2,6-dione

Into a 100-mL round-bottom flask, was placed tert-butyl4-[2-(2,6-dioxopiperidin-3-yl)-3-hydroxy-3-methyl-1-oxo-2,3-dihydro-1H-isoindol-5-yl]piperazine-1-carboxylate(1.5 g, 3.27 mmol, 1.00 equiv), dichloromethane (20 mL), triethylsilane(15 mL). This was followed by the addition of Boron trifluoride etherate(15 mL) dropwise with stirring. The resulting solution was stirred for16 hours at 25° C. The resulting solution was diluted with water (35mL). The resulting solution was extracted with ethyl acetate (15 mL×3)and the aqueous layers combined and concentrated under vacuum. Thisresulted in 1.12 g (100%) of3-[3-methyl-1-oxo-5-(piperazin-1-yl)-2,3-dihydro-1H-isoindol-2-yl]piperidine-2,6-dioneas yellow crude oil.

LC-MS (ES⁺): m/z 343.00 [MH⁺], t_(R)=0.658 min, (2.0 minute run).

6. Synthesis of tert-butyl4-[2-(2,6-dioxopiperidin-3-yl)-3-methyl-1-oxo-2,3-dihydro-1H-isoindol-5-yl]piperazine-1-carboxylate

Into a 100-mL round-bottom flask, was placed3-[3-methyl-1-oxo-5-(piperazin-1-yl)-2,3-dihydro-1H-isoindol-2-yl]piperidine-2,6-dione(1.12 g, 3.27 mmol, 1.00 equiv), dichloromethane (50 mL), (Boc)₂O (1.5g, 6.87 mmol, 2.10 equiv). This was followed by the addition oftriethylamine (4 mL) dropwise with stirring. The resulting solution wasstirred for 16 hours at 25° C. The resulting solution was diluted withwater (50 mL). The resulting solution was extracted with dichloromethane(20 mL×3) and the organic layers combined. The resulting mixture waswashed with saturated sodium chloride aqueous solution (15 mL×2). Themixture was dried over anhydrous sodium sulfate and concentrated undervacuum. The residue was applied onto a silica gel column with ethylacetate/petroleum ether (8:2). The crude product was purified byPrep-HPLC with the following conditions: Column, XBridge Prep C18 OBDColumn, 5 um, 19*150 mm; mobile phase, Water (10 MMOUL NH₄HCO₃) and ACN(32.0% ACN up to 41.0% in 9 min); Detector, UV 254 nm. This resulted in435 mg (30%) of tert-butyl4-[2-(2,6-dioxopiperidin-3-yl)-3-methyl-1-oxo-2,3-dihydro-1H-isoindol-5-yl]piperazine-1-carboxylateas yellow oil.

LCMS42-PH-ARV-LS-046-E-20-3(60861-135Q)1T.

LC-MS (ES⁺): m/z 443.40 [MH⁺], t_(R)=2.034 min, (4.6 minute run).

7. Synthesis of3-[3-methyl-1-oxo-5-(piperazin-1-yl)-2,3-dihydro-1H-isoindol-2-yl]piperidine-2,6-dione;trifluoroacetic acid

Into a 50-mL round-bottom flask, was placed tert-butyl4-[2-(2,6-dioxopiperidin-3-yl)-3-methyl-1-oxo-2,3-dihydro-1H-isoindol-5-yl]piperazine-1-carboxylate(435 mg, 0.98 mmol, 1.00 equiv), dichloromethane (30 mL),trifluoroacetic acid (1 mL). The resulting solution was stirred for 3hours at 25° C. The resulting mixture was concentrated under vacuum.This resulted in 500 mg (1.11%) of3-[3-methyl-1-oxo-5-(piperazin-1-yl)-2,3-dihydro-1H-isoindol-2-yl]piperidine-2,6-dione;trifluoroacetic acid as yellow crude oil.

8. Synthesis of4-[4-(hydroxymethyl)piperidin-1-yl]-N-[(1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl]benzamide

Into a 25-mL round-bottom flask, was placed4-[4-(hydroxymethyl)piperidin-1-yl]benzoic acid (250 mg, 1.06 mmol, 1.00equiv), N,N-dimethylformamide (6 mL), HATU (485 mg, 1.28 mmol, 1.20equiv). This was followed by the addition of N,N-diisopropylethylamine(550 mg, 4.26 mmol, 4.01 equiv) in 5 minutes. To this was added2-chloro-4-[(1r,3r)-3-amino-2,2,4,4-tetramethylcyclobutoxy]benzonitrilehydrochloride (335 mg, 1.06 mmol, 1.00 equiv). The resulting solutionwas stirred for 2 hours at 25° C. The resulting solution was dilutedwith water (25 mL). The resulting solution was extracted with ethylacetate (15 mL×3) and the organic layers combined. The resulting mixturewas washed with saturated sodium chloride aqueous solution (20 mL). Themixture was dried over anhydrous sodium sulfate and concentrated undervacuum. The residue was applied onto a silica gel column withdichloromethane/methanol (10:1). This resulted in 514 mg (98%) of4-[4-(hydroxymethyl)piperidin-1-yl]-N-[(1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl]benzamideas a off-white solid.

LC-MS (ES⁺): m/z 496.05 [MH⁺], t_(R)=1.133 min, (2.0 minute run).

9. Synthesis of4-(4-formylpiperidin-1-yl)-N-[(1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl]benzamide

Into a 50-mL round-bottom flask, was placed4-[4-(hydroxymethyl)piperidin-1-yl]-N-[(1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl]benzamide(600 mg, 1.21 mmol, 1.00 equiv), dichloromethane (20 mL). This wasfollowed by the addition of Dess-Martin (1.02 g), in portions at 0° C.The resulting solution was stirred for 2 hours at 25° C. The reactionwas then quenched by the addition of saturated sodium bicarbonatesolution (50 mL) and sodium thiosulfate solution (50 mL). The resultingsolution was extracted with dichloromethane (30 mL×3) and the organiclayers combined. The resulting mixture was washed with saturated sodiumchloride aqueous solution (50 mL). The mixture was dried over anhydroussodium sulfate and concentrated under vacuum. The residue was appliedonto a silica gel column with ethyl acetate/petroleum ether (1:1). Thisresulted in 450 mg (75%) of4-(4-formylpiperidin-1-yl)-N-[(1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl]benzamideas a off-white solid.

LC-MS (ES⁺): m/z 494.10 [MH⁺], t_(R)=1.074 min, (1.9 minute run).

10. Synthesis of4-[4-([4-[2-(2,6-dioxopiperidin-3-yl)-3-methyl-1-oxo-2,3-dihydro-1H-isoindol-5-yl]piperazin-1-yl]methyl)piperidin-1-yl]-N-[(1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl]benzamide

Into a 50-mL round-bottom flask, was placed4-(4-formylpiperidin-1-yl)-N-[(1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl]benzamide(130 mg, 0.26 mmol, 1.00 equiv),3-[3-methyl-1-oxo-5-(piperazin-1-yl)-2,3-dihydro-1H-isoindol-2-yl]piperidine-2,6-dione;trifluoroacetic acid (110 mg, 0.24 mmol, 0.92 equiv), dichloromethane(20 mL). This was followed by the addition of DIEA (0.3 mL) dropwisewith stirring in 16 hours. To this was added sodiumtriacetoxyborohydride (550 mg), in portions. The resulting solution wasstirred for 16 hours at 25° C. The reaction was then quenched by theaddition of water (20 mL). The resulting solution was extracted withdichloromethane (15 mL×3) and the organic layers combined. The resultingmixture was washed with saturated sodium chloride aqueous solution (20mL). The mixture was dried over anhydrous sodium sulfate andconcentrated under vacuum. The crude product was purified by Prep-HPLCwith the following conditions: Column, XBridge Prep C18 OBD Column, 5um, 19*150 mm; mobile phase, Water (10 MMOL/L NH₄HCO₃) and ACN (53.0%ACN up to 72.0% in 8 min); Detector, UV 254 nm. This resulted in 53.4 mg(25%) of4-[4-([4-[2-(2,6-dioxopiperidin-3-yl)-3-methyl-1-oxo-2,3-dihydro-1H-isoindol-5-yl]piperazin-1-yl]methyl)piperidin-1-yl]-N-[(1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl]benzamideas a white solid.

H-NMR-PH-ARV-LS-046-E-0: (300 MHz, DMSO, ppm) δ 10.90-10.88 (br, 1H),7.92-7.89 (d, J=9 Hz, 1H), 7.75-7.72 (d, J=9 Hz, 2H), 7.51-7.44 (m, 2H),7.21 (br, 1H), 7.10-6.94 (m, 5H), 4.65-4.64 (m, 1H), 4.54-4.52 (m, 1H),4.32 (s, 1H), 4.06-4.03 (d, J=9 Hz, 1H), 3.88-3.84 (m, 2H), 3.31-3.28(m, 4H), 2.83-2.75 (m, 3H), 2.63-2.58 (m, 6H), 2.22-2.20 (m, 2H),1.96-1.94 (m, 1H), 1.83-1.79 (m, 3H), 1.43-1.38 (m, 3H), 1.21 (s, 6H),1.18-1.17 (m, 2H), 1.12 (s, 6H); LC-MS (ES⁺): m/z 820.30/822.30 [MH⁺],t_(R)=2.042 min, (3.0 minute run).

C₄₆H₅₄ClN₇O₅ [819.39/821.39].  Chemical Formula:

Total H count from HNMR data: 54.

Synthetic Procedure for Compound 88 Synthesis of4-(6-[4-[2-(2,6-dioxopiperidin-3-yl)-6-fluoro-3-hydroxy-1-oxo-2,3-dihydro-1H-isoindol-5-yl]piperazin-1-yl]hexyl)-N-[(1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl]benzamide

Into a 100-mL round-bottom flask, was placed a solution of4-(6-[4-[2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl]piperazin-1-yl]hexyl)-N-[(1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl]benzamide(330 mg, 0.40 mmol, 1.00 equiv) in acetic acid (20 mL), Zn (100 mg, 3.00equiv). The resulting solution was stirred for 30 minutes at roomtemperature. The resulting solution was diluted with 100 of methylalcohol. The resulting mixture was concentrated under vacuum. Thisresulted in 320 mg (97%) of4-(6-[4-[2-(2,6-dioxopiperidin-3-yl)-6-fluoro-3-hydroxy-1-oxo-2,3-dihydro-1H-isoindol-5-yl]piperazin-1-yl]hexyl)-N-[(1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl]benzamideas white oil, m/z 827.40 [MH⁺], t_(R)=0.799 min (1.90 minute run).

2. Synthesisof-(6-[4-[2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1-oxo-2,3-dihydro-1H-isoindol-5-yl]piperazin-1-yl]hexyl)-N-[(1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl]benzamide

Into a 100-mL round-bottom flask, was placed a solution of4-(6-[4-[2-(2,6-dioxopiperidin-3-yl)-6-fluoro-3-hydroxy-1-oxo-2,3-dihydro-1H-isoindol-5-yl]piperazin-1-yl]hexyl)-N-[(1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl]benzamide(320 g, 386.76 mmol, 1.00 equiv) in trifluoroacetic acid (10 mL),triethylsilane (3 mL, 0.30 equiv). The resulting solution was stirredfor 30 minutes at room temperature. The resulting mixture wasconcentrated under vacuum. The crude product (100 mg) was purified byColumn: XBridge Prep OBD C18 Column 19*250 mm, 5 um; Mobile Phase A:Water (0.1% FA), Mobile Phase B: ACN; Flow rate: 20 mL/min; Gradient:55% B to 75% B in 8 min; 220 nm; Rt: 6.05 min. This resulted in 49.2 mgof4-(6-[4-[2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1-oxo-2,3-dihydro-1H-isoindol-5-yl]piperazin-1-yl]hexyl)-N-[(1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl]benzamideas a white solid.[(1r,3r)-3-[4-cyano-3-(trifluoromethyl)phenoxy]-2,2,4,4-tetramethylcyclobutyl]benzamideas a white solid.

¹H NMR (300 MHz, CD₃OD): δ 7.81-7.69 (m, 3H), 7.53-7.46 (m, 1H),7.35-7.27 (m, 3H), 7.15 (s, 1H), 6.97-6.94 (m, 1H), 5.17-5.04 (m, 1H),4.52-4.39 (m, 2H), 4.27 (s, 1H),4.16 (s, 1H), 3.84-3.55 (m, 4H), 3.36(s, 2H), 3.27-3.11 (m, 4H), 3.01-2.61 (m, 4H), 2.22-2.07 (m, 1H),1.87-1.63 (m, 4H), 1.52-1.38 (m, 4H), 1.33-1.16 (m, 12), m/z811.45[MH⁺], t_(R)=2.415 min (3.20 minute run).

C45H52ClFN6O5 [810.37].  Chemical formula:

Total H count from HNMR data: 52.

Synthetic Procedure for Compound 571 1. Synthesis of5-bromo-3-fluorobenzene-1,2-dicarboxylic acid

Into a 100-mL round-bottom flask, was placed4-bromo-2-fluoro-6-methylbenzoic acid (2.5 g, 10.73 mmol, 1.00 equiv),sodium hydroxide (1.72 g, 43.00 mmol, 4.00 equiv), water (20 mL), KMnO₄(3.41 g, 2.00 equiv). The resulting solution was stirred for 16 hours at100° C. in an oil bath. The solids were filtered out. The pH value ofthe solution was adjusted to 3 with hydrogen chloride (2 mol/L). Theresulting solution was extracted with dichloromethane (10 mL×1) and theorganic layers combined. The resulting solution was extracted with ethylacetate:methanol=10:3 (10 mL×3) and the organic layers combined anddried over anhydrous sodium sulfate and concentrated under vacuum. Thisresulted in 518 mg (18%) of 5-bromo-3-fluorobenzene-1,2-dicarboxylicacid as a white solid and 1.365 g material as a white solid.

LC-MS (ES⁺): m/z 264.75 [MH⁺], t_(R)=0.675 min (2.0 minute run).

2. Synthesis of 1,2-dimethyl 5-bromo-3-fluorobenzene-1,2-dicarboxylate

Into a 100-mL round-bottom flask, was placed5-bromo-3-fluorobenzene-1,2-dicarboxylic acid (1.4 g, 5.32 mmol, 1.00equiv), methanol (40 mL), sulfuric acid (2 mL). The resulting solutionwas stirred for 16 hours at 70° C. The reaction was then quenched by theaddition of water (10 mL). The pH value of the solution was adjusted to7 with sodium carbonate. The resulting solution was extracted with ethylacetate (20 mL×3) and the organic layers combined and dried overanhydrous sodium sulfate and concentrated under vacuum. The residue wasapplied onto a silica gel column with ethyl acetate/hexane (1:10). Thisresulted in 1.15 g (74%) of 1,2-dimethyl5-bromo-3-fluorobenzene-1,2-dicarboxylate as colorless oil.

LC-MS (ES⁺): m/z 292.80 [MH⁺], t_(R)=0.939 min (2.0 minute run).

3. Synthesis of 1,2-dimethyl5-[4-[(tert-butoxy)carbonyl]piperazin-1-yl]-3-fluorobenzene-1,2-dicarboxylate

Into a 50-mL round-bottom flask, was placed 1,2-dimethyl5-bromo-3-fluorobenzene-1,2-dicarboxylate (500 mg, 1.72 mmol, 1.00equiv), tert-butyl piperazine-1-carboxylate (481 mg, 2.58 mmol, 1.50equiv), Rouphos Pd (66 mg, 0.09 mmol, 0.05 equiv), Cs₂CO₃ (1.66 g, 5.09mmol, 3.00 equiv), Toluene (20 mL). The resulting solution was stirredfor 12 hours at 100° C. in an oil bath. The resulting solution wasdiluted with water (40 mL). The resulting solution was extracted withethyl acetate (30 mL×3) and the organic layers combined and dried overanhydrous sodium sulfate and concentrated under vacuum. The residue wasapplied onto a silica gel column with ethyl acetate/petroleum ether(1:1). This resulted in 600 mg (88%) of 1,2-dimethyl5-[4-[(tert-butoxy)carbonyl]piperazin-1-yl]-3-fluorobenzene-1,2-dicarboxylateas a solid.

LC-MS (ES⁺): m/z 397.25 [MH⁺], t_(R)=1.238 min (2.0 minute run).

4. Synthesis of5-[4-[(tert-butoxy)carbonyl]piperazin-1-yl]-3-fluorobenzene-1,2-dicarboxylicacid

Into a 100-mL round-bottom flask, was placed 1,2-dimethyl5-[4-[(tert-butoxy)carbonyl]piperazin-1-yl]-3-fluorobenzene-1,2-dicarboxylate(800 mg, 2.02 mmol, 1.00 equiv), methanol/water/THF (16 mL), sodiumol(242.4 mg, 6.06 mmol, 3.00 equiv). The resulting solution was stirredfor 16 hours at 25° C. The resulting solution was diluted with 16 mL ofwater (30 mL). The pH value of the solution was adjusted to 8 withhydrogen chloride (2 mol/L). Citric acid monohydrate was employed toadjust the pH to 3. The resulting solution was extracted with ethylacetate/methanol=10:1 (30 mL×3) and the organic layers combined anddried over anhydrous sodium sulfate and concentrated under vacuum. Thisresulted in 740 mg (100%) of5-[4-[(tert-butoxy)carbonyl]piperazin-1-yl]-3-fluorobenzene-1,2-dicarboxylicacid as a yellow solid.

LC-MS (ES⁺): m/z 369.00 [MH⁺], t_(R)=0.804 min (2.0 minute run).

5. Synthesis of tert-butyl4-[2-(2,6-dioxopiperidin-3-yl)-7-fluoro-,3-dioxo-2,3-dihydro-1H-isoindol-5-yl]piperazine-1-carboxylate

Into a 100-mL round-bottom flask, was placed5-[4-[(tert-butoxy)carbonyl]piperazin-1-yl]-3-fluorobenzene-1,2-dicarboxylicacid (560 mg, 1.52 mmol, 1.00 equiv) in acetonitrile (25 mL), CDI (986.6mg, 6.08 mmol, 4.00 equiv), DIEA (785.6 mg, 6.08 mmol, 4.00 equiv),3-aminopiperidine-2,6-dione (375.5 mg, 2.93 mmol, 1.50 equiv). Theresulting solution was stirred for 5 hours at 70° C. in an oil bath. Theresulting solution was diluted with water (40 mL). The resultingsolution was extracted with ethyl acetate (30 mL×3) and the organiclayers combined and dried over anhydrous sodium sulfate and concentratedunder vacuum. The residue was applied onto a silica gel column withethyl acetate/hexane (1:1). This resulted in 700 mg (100%) of tert-butyl4-[2-(2,6-dioxopiperidin-3-yl)-7-fluoro-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl]piperazine-1-carboxylateas a yellow solid.

LC-MS (ES⁺): m/z 483.05 [MNa⁺], t_(R)=0.884 min (2.0 minute run).

6. Synthesis of2,2,2-triluoroacetaldehyde-2-(2,6-dioxopiperidin-3-yl)-4-fluoro-6-(piperazin-1-yl)-2,3-dihydro-1H-isoindole-1,3-dione

Into a 100-mL round-bottom flask, was placed tert-butyl4-[2-(2,6-dioxopiperidin-3-yl)-7-fluoro-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl]piperazine-1-carboxylate(710 mg, 1.54 mmol, 1.00 equiv), dichloromethane (10 mL),trifluoroacetic acid (3 mL). The resulting solution was stirred for 2hours at 25° C. The resulting mixture was concentrated under vacuum. Thecrude product was purified by re-crystallization from ethanol. Thisresulted in 320 mg (45%) of2,2,2-trifluoroacetaldehyde-2-(2,6-dioxopiperidin-3-yl)-4-fluoro-6-(piperazin-1-yl)-2,3-dihydro-1H-isoindole-1,3-dioneas a yellow solid.

LC-MS (ES⁺): m/z 361.2 [MH⁺], t_(R)=0.210 min (2.0 minute run).

7. Synthesis of2-[4-([4-[2-(2,6-dioxopiperidin-3-yl)-7-fluoro-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl]piperazin-1-yl]methyl)piperidin-1-yl]-N-[(1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl]pyrimidine-5-carboxamide

Into a 100-mL round-bottom flask, was placed2-(4-formylpiperidin-1-yl)-N-[(1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl]pyrimidine-5-carboxamide(110 mg, 0.22 mmol, 1.00 equiv), 2,2,2-trifluoroacetaldehyde;2-(2,6-dioxopiperidin-3-yl)-4-fluoro-6-(piperazin-1-yl)-2,3-dihydro-1H-isoindole-1,3-dione(104 mg, 0.23 mmol, 1.30 equiv), dichloromethane (10 mL), acetylethaneperoxoate sodioboranyl acetate (70.67 mg, 0.33 mmol, 1.50 equiv).The resulting solution was stirred for 15 minutes at 25° C. Theresulting solution was allowed to react, with stirring, for anadditional 1 hour at 25° C. The resulting solution was allowed to react,with stirring, for an additional 2 hours at 25° C. The resultingsolution was diluted with dichloromethane (30 mL). The resulting mixturewas washed with water (30 mL x 1. The mixture was dried over anhydroussodium sulfate and concentrated under vacuum. The residue was appliedonto a silica gel column with dichloromethane/ethyl acetate (3:1). Thecrude product was purified by Prep-HPLC with the following conditions:Column, XBridge Prep C18 OBD Column, 5 um, 19*150 mm; mobile phase,water (10 mmol/L NH₄HCO₃) and acetonitrile (32.0% acetonitrile up to75.0% in 8 min); Detector, UV 254/220 nm. This resulted in 145 mg (78%)of2-[4-([4-[2-(2,6-dioxopiperidin-3-yl)-7-fluoro-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl]piperazin-1-yl]methyl)piperidin-1-yl]-N-[(1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl]pyrimidine-5-carboxamideas a yellow solid.

¹H NMR (300 MHz, DMSO-d6) δ 11.10 (s, 1H), 8.75 (s, 2H), 7.90 (d, J=8.7Hz, 1H), 7.71 (d, J=9.0 Hz, 1H), 7.24-7.21 (m, 2H), 7.07-6.99 (m, 2H),5.10 (m, 1H), 4.74 (d, J=13.2 Hz, 2H), 4.29 (s, 1H), 4.04 (d, J=9.0 Hz,1H), 3.50 (s, 4H), 3.00-2.95 (m, 3H), 2.53-2.50 (m, 5H), 2.21-2.19 (m,2H), 2.08-1.81 (m, 5H), 1.21-1.04 (m, 14H); LC-MS (ES⁺): m/z840.30/842.30 [MH⁺], t_(R)=3.099 min (5.0 minute run).

Chemical Formula: C₄₃H₄₇ClFN₉O₆ [839.33/841.33].

Total H count from HNMR data: 47.

Synthetic Procedure for Compound 358 1. Synthesis of ethyl4,6-dimethyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate

Into a 500-mL round-bottom flask, was placed a solution of ethyl3-oxobutanoate (10 g, 76.84 mmol, 1.00 equiv) in ethanol (200 mL), urea(6.9 g, 114.89 mmol, 1.50 equiv), acetaldehyde (5 g, 113.50 mmol, 1.50equiv), hydrogen chloride (2 mL, 0.30 equiv). The resulting solution wasstirred for 5 hours at 85° C. in an oil bath. The resulting mixture wasconcentrated under vacuum. This resulted in 12 g (79%) of ethyl4,6-dimethyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate as a whitesolid, m/z: 199.13[MH⁺], t_(R)=0.865 min (2.00 minute run).

2. Synthesis of ethyl4,6-dimethyl-2-oxo-1,2-dihydropyrimidine-5-carboxylate

Into a 100-mL round-bottom flask, was placed Nitric acid (20 mL, 5.00equiv) over a period of 5 minutes. This was followed by the addition ofethyl 4,6-dimethyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate (2g, 10.09 mmol, 1.00 equiv) dropwise with stirring. The resultingsolution was stirred for 3 hours at 0° C. in a water/ice bath. Theresulting mixture was concentrated under vacuum. The residue was appliedonto a silica gel column with dichloromethane/methanol (1:7). Thecollected fractions were combined and concentrated under vacuum. Thisresulted in 1.1 g (56%) of ethyl4,6-dimethyl-2-oxo-1,2-dihydropyrimidine-5-carboxylate as yellow oil,m/z: 197.14[MH⁺], t_(R)=0.477 min (1.80 minute run).

3. Synthesis of ethyl 2-chloro-4,6-dimethylpyrimidine-5-carboxylate

Into a 100-mL round-bottom flask, was placed a solution of ethyl4,6-dimethyl-2-oxo-1,2-dihydropyrimidine-5-carboxylate (300 mg, 1.53mmol, 1.00 equiv) in phosphoroyl trichloride (10 mL), N,N-Diethylaniline(0.1 mL, 0.10 equiv). The resulting solution was stirred for 3 hours at105° C. in an oil bath. The reaction was then quenched by the additionof water. The resulting solution was extracted with ethyl acetate andthe organic layers combined and concentrated under vacuum. This resultedin 100 mg (30%) of ethyl 2-chloro-4,6-dimethylpyrimidine-5-carboxylateas a yellow solid, m/z: 214.85[MH⁺], t_(R)=0.842 min (1.90 minute run).

4. Synthesis of ethyl2-[4-[(tert-butoxy)carbonyl]piperazin-1-yl]-4,6-dimethylpyrimidine-5-carboxylate

Into a 100-mL round-bottom flask, was placed a solution of ethyl2-chloro-4,6-dimethylpyrimidine-5-carboxylate (100 mg, 0.47 mmol, 1.00equiv) in tetrahydrofuran (20 mL), triethylamine (0.3 mL, 0.30 equiv),tert-butyl piperazine-1-carboxylate (104 mg, 0.56 mmol, 1.20 equiv). Theresulting solution was stirred for 2 hours at room temperature. Theresulting mixture was concentrated under vacuum. The residue was appliedonto a silica gel column with ethyl acetate/petroleum ether (1:4). Thecollected fractions were combined and concentrated under vacuum. Thisresulted in 180 mg (94%) of ethyl2-[4-[(tert-butoxy)carbonyl]piperazin-1-yl]-4,6-dimethylpyrimidine-5-carboxylateas a yellow solid, m/z: 365.13[MH⁺], t_(R)=1.418 min (2.00 minute run).

5. Synthesis of2-[4-[(tert-butoxy)carbonyl]piperazin-1-yl]-4,6-dimethylpyrimidine-5-carboxylicacid

Into a 100-mL round-bottom flask, was placed a solution of ethyl2-[4-[(tert-butoxy)carbonyl]piperazin-1-yl]-4,6-dimethylpyrimidine-5-carboxylate(170 mg, 0.47 mmol, 1.00 equiv) in methanol/water (50/10 mL), sodiumhydroxide (93 mg, 2.33 mmol, 5.00 equiv). The resulting solution wasstirred for 12 hours at 50° C. in an oil bath. The resulting mixture wasconcentrated under vacuum. The pH value of the solution was adjusted to5-6 with hydrogen chloride (1 mol/L). The resulting solution wasextracted with ethyl acetate and the organic layers combined. Theresidue was applied onto a silica gel column withdichloromethane/methanol (4:1). The collected fractions were combinedand concentrated under vacuum. This resulted in 150 mg (89%) of2-[4-[(tert-butoxy)carbonyl]piperazin-1-yl]-4,6-dimethylpyrimidine-5-carboxylicacid as a white solid, m/z 337.24[MH⁺], t_(R)=1.106 min (2.00 minuterun).

6. Synthesis of tert-butyl4-(4,6-dimethyl-5-[[(1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl]carbamoyl]pyrimidin-2-yl)piperazine-1-carboxylate

Into a 100-mL round-bottom flask, was placed a solution of2-[4-[(tert-butoxy)carbonyl]piperazin-1-yl]-4,6-dimethylpyrimidine-5-carboxylicacid (130 mg, 0.39 mmol, 1.00 equiv) in N,N-dimethylformamide (30 mL),N,N,N′,N′-Tetramethyl-O-(7-azabenzotriazol-1-yl)uroniumhexafluorophospate (220 mg, 1.50 equiv), N,N-Diisopropylethylamine(0.3mL,0.30equiv),2-chloro-4-[(1r,3r)-3-amino-2,2,4,4-tetramethylcyclobutoxy]benzonitrilehydrochloride (129 mg, 0.41 mmol, 1.20 equiv). The resulting solutionwas stirred for 30 minutes at room temperature. The resulting solutionwas extracted with ethyl acetate and the organic layers combined. Theresulting mixture was washed with of brine. The mixture was dried overanhydrous sodium sulfate and concentrated under vacuum. The residue wasapplied onto a silica gel column with ethyl acetate (100%). Thecollected fractions were combined and concentrated under vacuum. Thisresulted in 150 mg (63%) of tert-butyl4-(4,6-dimethyl-5-[[(1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl]carbamoyl]pyrimidin-2-yl)piperazine-1-carboxylateas a yellow solid, m/z 597.13[MH⁺], t_(R)=1.428 min (2.00 minute run).

7. Synthesis of4,6-dimethyl-2-(piperazin-1-yl)-N-[(1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl]pyrimidine-5-carboxamidehydrochloride

Into a 100-mL round-bottom flask, was placed tert-butyl4-(4,6-dimethyl-5-[[(1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl]carbamoyl]pyrimidin-2-yl)piperazine-1-carboxylate(140 mg, 0.23 mmol, 1.00 equiv), dioxane/HCl (20 mL, 3.00 equiv). Theresulting solution was stirred for 2 hours at room temperature. Theresulting mixture was concentrated under vacuum. This resulted in 160 mg(122%) of4,6-dimethyl-2-(piperazin-1-yl)-N-[(1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl]pyrimidine-5-carboxamidehydrochloride as a yellow solid, m/z: 497.22[MH⁺], t_(R)=1.046 min (2.00minute run).

8. Synthesis of2-[4-(3-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl]oxy]propyl)piperazin-1-yl]-4,6-dimethyl-N-[(1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl]pyrimidine-5-carboxamide

Into a 25-mL sealed tube, was placed a solution of4,6-dimethyl-2-(piperazin-1-yl)-N-[(1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl]pyrimidine-5-carboxamidehydrochloride (140 mg, 0.26 mmol, 1.00 equiv) in acetonitrile (10 mL),potassium carbonate (181 mg, 1.31 mmol, 5.00 equiv), Sodium iodide (51mg, 1.50 equiv),5-(3-bromopropoxy)-2-(2,6-dioxopiperidin-3-yl)-2,3-dihydro-1H-isoindole-1,3-dione(125 mg, 0.32 mmol, 1.20 equiv). The resulting solution was stirred for12 hours at 70° C. in an oil bath. The resulting solution was dilutedwith 20 mL of acetonitrile. The resulting mixture was concentrated undervacuum. The crude product (50 mL) was purified by Prep-HPLC with thefollowing conditions: Mobile Phase A: Water (0.1% Formic acid), MobilePhase B: acetonitrile; Flow rate: 20 mL/min; Gradient: 30% B to 48% B in8 min; 254 nm; Rt: 7.83 min. This resulted in 51 mg (28%) of2-[4-(3-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl]oxy]propyl)piperazin-1-yl]-4,6-dimethyl-N-[(1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl]pyrimidine-5-carboxamideas a off-white solid.

1H NMR (300 MHz, CDCL3) δ 8.29 (s, 1H), 7.81 (d, J=8.3 Hz, 1H), 7.60 (d,J=8.6 Hz, 1H), 7.36 (d, J=2.2 Hz, 1H), 7.22 (dd, J=8.3, 2.3 Hz, 1H),6.99 (d, J=2.4 Hz, 1H), 6.83 (dd, J=8.8, 2.4 Hz, 1H), 5.96 (d, J=8.6 Hz,1H), 4.99 (dd, J=11.9, 5.5 Hz, 1H), 4.24 (dt, J=11.9, 7.0 Hz, 7H), 4.08(s, 1H), 3.09 (s, 9H), 2.98-2.77 (m, 5H), 2.40 (s, 2H), 2.21-2.14 (m,1H), 1.27 (d, J=3.9 Hz, 12H); LC-MS (ES⁺): m/z: 811.32 [MH⁺],t_(R)=6.278 min (10.00 minute run).

Chemical formula: C₄₂H₄₇ClN₈O₇ [810.33].

Total H count from HNMR data: 46.

Synthetic Procedure for Compound 584 1. Synthesis of5-bromo-3-methoxybenzene-1,2-dicarboxylic acid)

Into a 100-mL round-bottom flask, was placed4-bromo-2-methoxy-6-methylbenzonitrile (800 mg, 3.54 mmol, 1.00 equiv),water (10 mL), sodium hydroxide (708 mg, 17.70 mmol, 5.00 equiv),KMnO₄(1.12 g, 7.09 mmol, 2.00 equiv). The resulting solution was stirredfor 16 hours at 100° C. in an oil bath. The solids were filtered out.The pH value of the solution was adjusted to 3 with hydrogen chloride (2mol/L). The resulting solution was extracted with dichloromethane (15mL×3) and the aqueous layers combined. The resulting solution wasextracted with ethyl acetate/methanol=10:1 (15 mL×3) and the organiclayers combined and dried in an oven under reduced pressure,concentrated under vacuum. This resulted in 330 mg (34%) of5-bromo-3-methoxybenzene-1,2-dicarboxylic acid as a white solid.

2. Synthesis of 1,2-dimethyl 5-bromo-3-methoxybenzene-1,2-dicarboxylate)

Into a 100-mL round-bottom flask, was placed5-bromo-3-methoxybenzene-1,2-dicarboxylic acid (330 mg, 1.20 mmol, 1.00equiv), methanol (20 mL), sulfuric acid (5 mL). The resulting solutionwas stirred for 16 hours at 70° C. in an oil bath. The resultingsolution was diluted with water (40 mL). The pH value of the solutionwas adjusted to 8 with sodium carbonate. The resulting solution wasextracted with ethyl acetate (30 mL×3) and the organic layers combinedand dried over anhydrous sodium sulfate and concentrated under vacuum.The residue was applied onto a silica gel column with ethylacetate/petroleum ether (1:10). This resulted in 340 mg (93%) of1,2-dimethyl 5-bromo-3-methoxybenzene-1,2-dicarboxylate as a whitesolid.

LC-MS (ES⁺): m/z 302.85 [MH⁺], t_(R)=0.906 min (2.0 minute run).

3. Synthesis of 1,2-dimethyl5-[4-[(tert-butoxy)carbonyl]piperazin-1-yl]-3-methoxybenzene-1,2-dicarboxylate

Into a 100-mL round-bottom flask, was placed 1,2-dimethyl5-bromo-3-methoxybenzene-1,2-dicarboxylate (300 mg, 0.99 mmol, 1.00equiv), tert-butyl piperazine-1-carboxylate (277 mg, 1.49 mmol, 1.50equiv), RouphosPd (39 mg, 0.05 mmol, 0.05 equiv), Cs₂CO₃ (978 mg, 3.00mmol, 3.00 equiv), toluene (15 mL). The resulting solution was stirredfor 12 hours at 100° C. in an oil bath. The resulting solution wasdiluted with water (30 mL). The resulting solution was extracted withethyl acetate (30 mL×3) and the organic layers combined and dried overanhydrous sodium sulfate and concentrated under vacuum. The residue wasapplied onto a silica gel column with dichloromethane/ethyl acetate(10:1). This resulted in 340 mg (84%) of 1,2-dimethyl5-[4-[(tert-butoxy)carbonyl]piperazin-1-yl]-3-methoxybenzene-1,2-dicarboxylateas light yellow oil.

LC-MS (ES⁺): m/z 409.05 [MH⁺], t_(R)=0.963 min (2.0 minute run).

4. Synthesis of5-[4-[(tert-butoxy)carbonyl]piperazin-1-yl]-3-methoxybenzene-1,2-dicarboxylicacid

Into a 100-mL round-bottom flask, was placed 1,2-dimethyl5-[4-[(tert-butoxy)carbonyl]piperazin-1-yl]-3-methoxybenzene-1,2-dicarboxylate(340 mg, 0.83 mmol, 1.00 equiv), methanol/H₂O/THF (8 mL), sodiumol (100mg, 2.50 mmol, 3.00 equiv). The resulting solution was stirred for 12hours at 25° C. The resulting solution was diluted with water (30 mL).The pH value of the solution was adjusted to 8 with hydrogen chloride (2mol/L), citric acid monohydrate was employed to adjust the pH to 3. Theresulting solution was extracted with ethyl acetate (30 mL×3) and theorganic layers combined and dried over anhydrous sodium sulfate andconcentrated under vacuum. This resulted in 300 mg (95%) of5-[4-[(tert-butoxy)carbonyl]piperazin-1-yl]-3-methoxybenzene-1,2-dicarboxylicacid as colorless oil.

LC-MS (ES⁺): m/z 306.95 [MH⁺], t_(R)=0.853 min (2.0 minute run).

5. Synthesis of tert-butyl4-[2-(2,6-dioxopiperidin-3-yl)-7-methoxy-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl]piperazine-1-carboxylate

Into a 100-mL round-bottom flask, was placed tert-butyl4-(7-methoxy-1,3-dioxo-1,3-dihydro-2-benzofuran-5-yl)piperazine-1-carboxylate(260 mg, 0.72 mmol, 1.00 equiv), 3-aminopiperidine-2,6-dionehydrochloride (153.6 mg, 0.93 mmol, 1.30 equiv), pyridine (10 mL). Theresulting solution was stirred for 4 hours at 120° C. in an oil bath.The resulting solution was diluted with water (30 mL). The resultingsolution was extracted with ethyl acetate (30 mL×3) and the organiclayers combined and dried over anhydrous sodium sulfate and concentratedunder vacuum. The residue was applied onto a silica gel column withdichloromethane/methanol (100:1). This resulted in 280 mg (83%) oftert-butyl4-[2-(2,6-dioxopiperidin-3-yl)-7-methoxy-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl]piperazine-1-carboxylateas a yellow solid.

LC-MS (ES⁺): m/z 417.05 [MH⁺], t_(R)=0.852 min (2.0 minute run).

6. Synthesis of2-(2,6-dioxopiperidin-3-yl)-4-methoxy-6-(piperazin-1-yl)isoindoline-1,3-dione

Into a 50-mL round-bottom flask, was placed tert-butyl4-[2-(2,6-dioxopiperidin-3-yl)-7-methoxy-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl]piperazine-1-carboxylate(270 mg, 0.57 mmol, 1 equiv), dichloromethane (6 mL, 0.07 mmol, 0.124equiv), TFA (2 mL, 0.02 mmol, 0.031 equiv). The resulting solution wasstirred for 2 hours at 25° C. The resulting mixture was concentrated togive2-(2,6-dioxopiperidin-3-yl)-4-methoxy-6-(piperazin-1-yl)isoindoline-1,3-dioneas a brown oil.

LC-MS (ES⁺): m/z 373.05 [MH⁺], t_(R)=0.155 min (2.0 minute run).

7. Synthesis of6-[4-([4-[2-(2,6-dioxopiperidin-3-yl)-7-methoxy-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl]piperazin-1-yl]methyl)piperidin-1-yl]-N-[(1r,4r)-4-(3-chloro-4-cyanophenoxy)cyclohexyl]pyridazine-3-carboxamide

Into a 100-mL round-bottom flask, was placed2,2,2-trifluoroacetaldehyde;2-(2,6-dioxopiperidin-3-yl)-4-methoxy-6-(piperazin-1-yl)-2,3-dihydro-1H-isoindole-1,3-dione(130 mg, 0.28 mmol, 1.078 equiv), dichloromethane (10 mL, 0.12 mmol),6-(4-formylpiperidin-1-yl)-N-[(1r,4r)-4-(3-chloro-4-cyanophenoxy)cyclohexyl]pyridazine-3-carboxamide(120 mg, 0.26 mmol, 1 equiv), NaBH(OAc)₃ (163.4 mg, 0.77 mmol, 3.006equiv). The resulting solution was stirred for 2 hours at 25° C. Theresulting solution was diluted with dichloromethane (30 mL). Theresulting mixture was washed with H₂O (30 mL×3). The mixture was driedover anhydrous sodium sulfate and concentrated under vacuum. Theresulting mixture was concentrated under vacuum. The residue was appliedonto a silica gel column with dichloromethane/ethyl acetate (3:1). Thecrude product was purified by Prep-HPLC with the following conditions:Column, XBridge Prep C18 OBD Column, 5 um, 19*150 mm; mobile phase,Water (10 mmol/L NH₄HCO₃) and acetonitrile (43% Phase B up to 65% in 8min); Detector, uv. This resulted in 70 mg (33.11%) of6-[4-([4-[2-(2,6-dioxopiperidin-3-yl)-7-methoxy-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl]piperazin-1-yl]methyl)piperidin-1-yl]-N-[(1r,4r)-4-(3-chloro-4-cyanophenoxy)cyclohexyl]pyridazine-3-carboxamideas a yellow solid.

¹H NMR (400 MHz, DMSO-d6) δ 11.04 (s, 1H), 8.57 (d, J=8.4 Hz, 1H),7.87-7.79 (m, 2H), 7.39-7.32 (m, 2H), 7.15-7.12 (m, 1H), 6.96 (s, 1H),6.68 (s, 1H), 5.04-4.98 (m, 1H), 4.50-4.47 (m, 3H), 4.93-3.85 (m, 4H),3.35-3.33 (m, 5H), 3.07-2.81 (m, 3H), 2.51 (s, 3H), 2.27-22.1 (m, 2H),2.09-2.01 (m, 2H), 2.00-1.49 (m, 11H), 1.23-1.11 (m, 3H); LC-MS (ES⁺):m/z 824.25/826.25 [MH⁺], t_(R)=182 min (3.0 minute run).

C₄₂H₄₆ClN₉O₇ [823.32/825.32].  Chemical Formula:

Total H count from HNMR data: 46.

Synthetic Procedure for Compound 618 1. Synthesis ofN-(2,2-dimethoxyethyl)-3,4-dihydro-2H-pyrrol-5-amine

Into a 250-mL round-bottom flask, was placed5-methoxy-3,4-dihydro-2H-pyrrole (4.4 g, 1 equiv), MeOH (50 mL),2,2-dimethoxyethan-1-amine (4.6 g). The resulting solution was stirredfor 12 hours at 60° C. in an oil bath. The resulting mixture wasconcentrated under vacuum. This resulted in 5.7 g ofN-(2,2-dimethoxyethyl)-3,4-dihydro-2H-pyrrol-5-amine as brown oil.

LC-MS (ES⁺): m/z 173.00[MH⁺], t_(R)=0.17 min (1.9 minute run).

2. Synthesis of 5H,6H,7H-pyrrolo[1,2-a]imidazole

Into a 250-mL round-bottom flask, was placedN-(2,2-dimethoxyethyl)-3,4-dihydro-2H-pyrrol-5-amine (5.72 g, 33.21mmol, 1 equiv), formic acid (100 mL). The resulting solution was stirredfor 16 hours at 100° C. in an oil bath. The resulting mixture wasconcentrated under vacuum. This resulted in 3.1 g (86.31%) of5H,6H,7H-pyrrolo[1,2-a]imidazole as a brown solid.

LC-MS (ES⁺): m/z 108.95[MH⁺], t_(R)=0.15 min (1.9 minute run).

3. Synthesis of [5H,6H,7H-pyrrolo[1,2-a]imidazol-3-yl]boronic acid

Into a 100-mL round-bottom flask purged and maintained with an inertatmosphere of nitrogen, was placed 5H,6H,7H-pyrrolo[1,2-a]imidazole (1.0g, 9.25 mmol, 1 equiv). This was followed by the addition of THF (20 mL,246.86 mmol, 26.696 equiv). The resulting solution was turned to −78° C.To this was added n-BuLi (10 mL, 106.16 mmol, 11.480 equiv). Theresulting solution was stirred for 10 minutes at −78° C. To the mixturewas added B(Oi-Pr)₃ (5.0 g, 26.59 mmol, 2.875 equiv). The resultingsolution was stirred for 6 hours at room temperature. The PH wasadjusted to 2 with 2 M HCL. The resulting mixture was concentrated undervacuum. This resulted in 2.1 g (crude) of[5H,6H,7H-pyrrolo[1,2-a]imidazol-3-yl]boronic acid as a brown solid.

LC-MS (ES⁺): m/z 512.4 [MH⁺], t_(R)=1.27 min (1.9 minute run).

4. Synthesis of tert-butyl4-[[-(4-nitrophenyl)piperidin-4-yl]methyl]piperazine-1-carboxylate

Into a 250-mL round-bottom flask, was placed a solution of1-fluoro-4-nitrobenzene (3 g, 21.26 mmol, 1.00 equiv) in DMSO (80 mL).This was followed by the addition of DIEA (2.7 g, 20.89 mmol, 1.00equiv) in several batches in 2 minutes. To this was added tert-butyl4-(piperidin-4-ylmethyl)piperazine-1-carboxylate (6 g, 21.17 mmol, 1.00equiv). The resulting solution was stirred for 6 hours at 100° C. in anoil bath. The reaction was then quenched by the addition of water (100mL). The resulting solution was extracted with ethyl acetate (100 mL×2)and the organic layers combined. The resulting mixture was washed withbrine (30 mL×2). The resulting solution was concentrated under vacuum.The residue was applied onto a silica gel column with ethylacetate/petroleum ether (1:1). This resulted in 8.0 g (93%) oftert-butyl4-[[1-(4-nitrophenyl)piperidin-4-yl]methyl]piperazine-1-carboxylate as alight yellow solid.

LC-MS (ES⁺): m/z 405.10 [MH⁺], t_(R)=0.65 min (1.9 minute run).

5. Synthesis of tert-butyl4-[[-(4-aminophenyl)piperidin-4-yl]methyl]piperazine-1-carboxylate

Into a 250-mL round-bottom flask, was placed a solution of tert-butyl4-[[1-(4-nitrophenyl)piperidin-4-yl]methyl]piperazine-1-carboxylate (4.8g, 11.87 mmol, 1.00 equiv) in methanol (60 mL) under nitrogenatmosphere. This was followed by the addition of Pd/C (0.96 g, 0.20equiv). The flask was then vacuumed and flushed with hydrogen. Thereaction mixture was hydrogenated at room temperature for 3 hours underhydrogen atmosphere using a hydrogen balloon, then filtered through aCelite pad and concentrated under reduced pressure. This resulted in 2.7g (61%) of tert-butyl4-[[1-(4-aminophenyl)piperidin-4-yl]methyl]piperazine-1-carboxylate as alight yellow solid.

LC-MS (ES⁺): m/z 375.10 [MH⁺], t_(R)=0.73 min (2.0 minute run).

6. Synthesis of tert-butyl4-[[1-(4-bromophenyl)piperidin-4-yl]methyl]piperazine-1-carboxylate

Into a 250-mL round-bottom flask purged and maintained with an inertatmosphere of nitrogen, was placed tert-butyl4-[[1-(4-aminophenyl)piperidin-4-yl]methyl]piperazine-1-carboxylate (2.0g), acetonitrile (100 mg). This was followed by the addition oftert-butyl nitrite (770 mg). It was stirred for 30 minutes. To this wasadded dibromocopper (1.4 g). The resulting solution was stirred for 3hours at O t in a water/ice bath. The residue was applied onto a silicagel column with ethyl acetate/petroleum ether (0:100-1:2). This resultedin 320 mg of tert-butyl4-[[1-(4-bromophenyl)piperidin-4-yl]methyl]piperazine-1-carboxylate as awhite solid.

LC-MS (ES⁺): m/z 438.15 [MH⁺], t_(R)=0.69 min (1.9 minute run).

7. Synthesis of tert-butyl4-([-[4-(1,2-dimethyl-1H-imidazol-5-yl)phenyl]piperidin-4-yl]methyl)piperazine-1-carboxylate

Into a 25-mL sealed tube purged and maintained with an inert atmosphereof nitrogen, was placed tert-butyl4-[[1-(4-bromophenyl)piperidin-4-yl]methyl]piperazine-1-carboxylate (230mg), [5H,6H,7H-pyrrolo[1,2-a]imidazol-3-yl]boronic acid (1.0 g),dioxane/H₂O (8 mL/2 mL), Na₂CO₃ (170 mg), Pd(dppf)Cl₂ (50 mg). Theresulting solution was stirred for 3 hours at 90° C. in an oil bath. Theresidue was applied onto a silica gel column withdichloromethane/methanol (10:1). This resulted in 150 mg of tert-butyl4-([1-[4-(1,2-dimethyl-1H-imidazol-5-yl)phenyl]piperidin-4-yl]methyl)piperazine-1-carboxylateas brown oil.

LC-MS (ES⁺): m/z 466.30 [MH⁺], t_(R)=0.61 min (1.9 minute run).

8. Synthesis of1-[[1-(4-[5H,6H,7H-pyrrolo[1,2-a]imidazol-3-yl]phenyl)piperidin-4-yl]methyl]piperazine

Into a 100-mL round-bottom flask, was placed tert-butyl4-[[1-(4-[5H,6H,7H-pyrrolo[1,2-a]imidazol-3-yl]phenyl)piperidin-4-yl]methyl]piperazine-1-carboxylate(100 mg, 0.21 mmol, 1 equiv), trifluoroacetyl (4 mL), dichloromethane(20 mL). The resulting solution was stirred for 4 hours at roomtemperature. The resulting mixture was concentrated under reducedpressure. This resulted in 80 mg (90.91%) of1-[[1-(4-[5H,6H,7H-pyrrolo[1,2-a]imidazol-3-yl]phenyl)piperidin-4-yl]methyl]piperazineas brown oil.

LC-MS (ES⁺): m/z 366.00 [MH⁺], t_(R)=0.63 min (2.0 minute run).

9. Synthesis of2-(2,6-dioxopiperidin-3-yl)-5-(4-[[1-(4-[5H,6H,7H-pyrrolo[1,2-a]imidazol-3-yl]phenyl)piperidin-4-yl]methyl]piperazin-1-yl)-2,3-dihydro-H-isoindole-1,3-dione

Into a 25-mL sealed tube purged and maintained with an inert atmosphereof nitrogen, was placed1-[[1-(4-[5H,6H,7H-pyrrolo[1,2-a]imidazol-3-yl]phenyl)piperidin-4-yl]methyl]piperazine(100 mg, 0.27 mmol, 1 equiv), DMSO (5 mL), DIEA (1.5 m),2-(2,6-dioxopiperidin-3-yl)-5-fluoro-2,3-dihydro-1H-isoindole-1,3-dione(80 mg, 0.29 mmol, 1.059 equiv). The resulting solution was stirred for3 hours at 130° C. in an oil bath. The resulting solution was extractedwith ethyl acetate (30 mL×3). The resulting mixture was washed withbrine (30 mL×1). The resulting mixture was concentrated under reducedpressure. The crude product was purified by Prep-HPLC with the followingconditions: Column, XB ridge Prep C18 OBD Column, 5 um, 19*150 mm;mobile phase, Water (10 mmol/L NH₄HCO₃) and acetonitrile (38% Phase B upto 55% in 8 min); Detector, UV. This resulted in 30.6 mg (17.99%) of2-(2,6-dioxopiperidin-3-yl)-5-(4-[[1-(4-[5H,6H,7H-pyrrolo[1,2-a]imidazol-3-yl]phenyl)piperidin-4-yl]methyl]piperazin-1-yl)-2,3-dihydro-1H-isoindole-1,3-dioneas a yellow solid.

¹H NMR (300 MHz, DMSO-d₆) δ 11.07 (s, 1H), 7.67 (d, J=8.5 Hz, 1H),7.37-7.25 (m, 4H), 7.04-6.89 (m, 3H), 5.06 (dd, J=12.7, 5.4 Hz, 1H),4.09 (t, J=7.0 Hz, 2H), 3.70 (d, J=12.2 Hz, 2H), 3.43-3.41 (m, 5H),2.90-2.49 (m, 12H), 2.20-2.10 (m, 2H), 2.00-1.90 (m, 1H), 1.80-1.73 (m,3H), 1.21-1.17 (m, 2H); LC-MS (ES⁺): m/z 622.35 [M+H⁺], t_(R)=0.68 min,(2.90 minute run).

C₃₅H₃₉N₇O₄ [621.31].  Chemical Formula:

Total H count from HNMR data: 39.

Synthetic Procedure for Compound 77 Step 1:[6-(4-(tert-butoxycarbonyl)piperazin-1-yl)nicotinic acid]

A mixture of tert-butyl4-(5-((benzyloxy)carbonyl)pyridin-2-yl)piperazine-1-carboxylate (2.0 g,5.03 mmol) and palladium on carbon (10%, 200 mg) in ethanol (20 ml) wasstirred at 30° C. overnight under hydrogen atmosphere (hydrogenballoon). TLC showed the reaction was complete. Palladium on carbon wasremoved through filtration and washed with ethanol (20 ml×2). Thecombined filtrates were concentrated under reduced pressure to give6-(4-(tert-butoxycarbonyl)piperazin-1-yl)nicotinic acid (1.6 g, crude)as colorless oil which was used in next step without purification.

Step 2: [tert-butyl4-(5-(((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)carbamoyl)pyridin-2-yl)piperazine-1-carboxylate]

To a stirred solution of6-(4-(tert-butoxycarbonyl)piperazin-1-yl)nicotinic acid (300 mg, 0.97mmol),4-((1r,3r)-3-amino-2,2,4,4-tetramethylcyclobutoxy)-2-chlorobenzonitrilehydrochloride (306 mg, 0.97 mmol), and N-ethyl-N-isopropylpropan-2-amine(309 mg, 2.4 mmol) in anhydrous N,N-dimethylformamide (8 ml) was addedHATU (2-(7-Aza-1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluroniumhexafluorophosphate) (684 mg, 1.8 mmol) at 0° C., the resulting mixturewas allowed to warm to room temperature and stirred for 20 minutes. TLCshowed the reaction was complete. The mixture was partitioned betweenethyl acetate (50 ml) and water (80 ml). The organic layer wascollected, washed with brine (10 ml), dried over anhydrous sodiumsulfate, and concentrated under reduced pressure to give a crude residuewhich was purified by silica gel flash chromatography (eluted with 10%methanol in dichloromethane) to afford tert-butyl4-(5-(((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)carbamoyl)pyridin-2-yl)piperazine-1-carboxylate(400 mg, yield 72%) as white solid.

Step 3[N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-6-(piperazin-1-yl)nicotinamide]

A mixture of tert-butyl4-(5-(((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)carbamoyl)pyridin-2-yl)piperazine-1-carboxylate(80 mg, 0.14 mmol) in hydrogen chloride in dioxane solution (4M, 2 ml)was stirred at room temperature for 2 hours. TLC showed the reaction wascomplete. The volatiles were evaporated under reduced pressure. Theresidue was taken up in dichloromethane (20 ml) and washed with aqueoussodium bicarbonate solution (IN, 5 ml), dried over anhydrous sodiumsulfate, and concentrated under reduced pressure to give a crude residuewhich was purified by pre-TLC (eluted with 10% methanol indichloromethane) to afford[N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-6-(piperazin-1-yl)nicotinamide(32 mg, yield 50%) as white solid.

LC_MS: (ES⁺): m/z 468.6 [M+H]⁺, t_(R)=2.285 min.

¹HNMR (400 MHz, CD₃OD): δ 1.07-1.38 (m, 12H), 3.12-3.40 (m, 4H),3.51-3.86 (m, 1H), 3.94 (br, 3H), 4.17-4.30 (m, 2H), 6.99-7.15 (m, 2H),7.74 (s, 1H), 8.05 (s, 1H), 8.48-8.68 (m, 2H).

C₂₅H₃₀ClN₅O₂; Molecular Weight: 467.99.  Chemical Formula:

Total H count from HNMR data: 28.

Step4:[2-(2,6-dioxopiperidin-3-yl)-5-(4-(2-hydroxyethyl)piperazin-1-yl)isoindoline-1,3-dione]

A mixture of 2-(piperazin-1-yl)ethanol (235.6 mg, 1.8 mmol),2-(2,6-dioxopiperidin-3-yl)-5-fluoroisoindoline-1,3-dione (500 mg, 1.8mmol) and N-ethyl-N-isopropylpropan-2-amine (468 mg, 3.6 mmol) in1-methylpyrrolidin-2-one (5 ml) was stirred at 90° C. for 12 hours. TLCshowed the reaction was complete. The reaction mixture was partitionedbetween ethyl acetate (30 ml) and water (50 ml). The organic layer wascollected, washed with brine (20 ml), dried over anhydrous sodiumsulfate, and concentrated under reduced pressure to give a crude residuewhich was purified by silica gel flash chromatography (eluted with 2-3%methanol in dichloromethane) to afford2-(2,6-dioxopiperidin-3-yl)-5-(4-(2-hydroxyethyl)piperazin-1-yl)isoindoline-1,3-dione(370 mg, 62%) as yellow oil.

Step 2:[2-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)ethyl4-methylbenzenesulfonate]

To a solution of2-(2,6-dioxopiperidin-3-yl)-5-(4-(2-hydroxyethyl)piperazin-1-yl)isoindoline-1,3-dione(370 mg, 0.96 mmol), N,N-dimethylpyridin-4-amine (12 mg, 0.1 mmol) andtriethylamine (291 mg, 2.87 mmol) in dichloromethane (10 ml) was added4-toluenesulfonyl chloride (201 mg, 1.05 mmol) at 0° C. The reactionmixture was allowed to warm up to room temperature and stirred at roomtemperature overnight. TLC showed the reaction was complete. Thereaction mixture was diluted with dichloromethane (10 ml), washed withwater (10 ml×2) then brine (10 ml), dried over anhydrous sodium sulfateand concentrated under reduced pressure to give2-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)ethyl4-methylbenzenesulfonate (200 mg, 38%) as yellow solid which was used innext step without further purification.

LC_MS: (ES⁺): m/z 541.20 [M+H]⁺, t_(R)=1.965 min.

Step 3:[N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-6-(4-(2-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)ethyl)piperazin-1-yl)nicotinamide]

A mixture of2-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)ethyl4-methylbenzenesulfonate (139 mg, 0.25 mmol),N-ethyl-N-isopropylpropan-2-amine (55.3 mg, 0.43 mmol) andN-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-6-(piperazin-1-yl)nicotinamide(100 mg, 0.21 mmol) in dry N,N-dimethylformamide (2 ml) was stirred at50° C. for 16 hours. TLC showed the reaction was complete. The mixturewas partitioned between ethyl acetate (20 ml) and water (20 ml). Theorganic layer was collected, washed with brine (10 ml), dried overanhydrous sodium sulfate, and concentrated under reduced pressure togive a crude residue which was purified by pre-TLC (eluted with 10%methanol in dichloromethane) to affordN-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-6-(4-(2-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)ethyl)piperazin-1-yl)nicotinamide(40 mg, 18%) as yellow solid.

¹H NMR (400 MHz, S6-DMSO): δ 1.12 (s, 6H), 1.22 (s, 6H), 1.99-2.05 (m,1H), 2.54-2.73 (m, 12H), 2.84-2.92 (m, 1H), 3.41-3.70 (m, 10H), 4.06 (d,J=9.2 Hz, 1H), 4.30 (s, 1H), 5.05-5.10 (m, 1H), 6.89 (d, J=9.2 Hz, 1H),6.99-7.02 (m, 1H), 7.21 (d, J=2.4 Hz, 1H), 7.25-7.30 (m, 1H), 7.37 (br,1H), 7.63 (d, J=9.2 Hz, 1H), 7.69 (d, J=8.4 Hz, 1H), 7.90 (d, J=8.4 Hz,1H), 7.96-7.99 (m, 1H), 8.63 (d, J=2.0 Hz, 1H), 11.08 (s, 1H).

C₄₄H₅₀ClN₉O₆; Molecular Weight: 836.38.  Chemical Formula:

Total H count from HNMR data: 50.

LC_MS: (ES⁺): m/z 836.40 [M+H]⁺, t_(R)=2.408 min.

Synthetic Procedure for Compound 383 Synthesis of tert-butyl4-[(4-bromo-2-fluorophenyl)carbonyl]piperazine-1-carboxylate

Into a 100.0-mL round-bottom flask, was placed 4-bromo-2-fluorobenzoicacid (5.0 g, 22.83 mmol, 1.00 equiv), N,N-dimethylformamide (20.0 mL),HATU (10.5 g, 27.61 mmol, 1.20 equiv), DIEA (11.9 g, 92.08 mmol, 4.00equiv), tert-butyl piperazine-1-carboxylate (4.3 g, 23.09 mmol, 1.00equiv). The resulting solution was stirred overnight at roomtemperature. The reaction was then quenched by the addition of 20.0 mLof water. The resulting solution was extracted with ethyl acetate (40.0mL) and the organic layers combined. The resulting mixture was washedwith sodium chloride (40.0 mL). The mixture was dried over anhydroussodium sulfate. The residue was applied onto a silica gel column withethyl acetate/petroleum ether (1/4). The collected fractions werecombined and concentrated under vacuum. This resulted in 8.82 g (100%)of tert-butyl4-[(4-bromo-2-fluorophenyl)carbonyl]piperazine-1-carboxylate as a yellowsolid.

2. Synthesis of2-[[4-([4-[(tert-butoxy)carbonyl]piperazin-1-yl]carbonyl)-3-fluorophenyl]amino]-2-methylpropanoicacid

Into a 100.0-mL round-bottom flask, was placed tert-butyl4-[(4-bromo-2-fluorophenyl)carbonyl]piperazine-1-carboxylate (4.0 g,10.33 mmol, 1.00 equiv), N,N-dimethylformamide (10.0 mL), potassiumcarbonate (3.58 g, 25.90 mmol, 2.50 equiv), CuI (393.8 mg, 2.07 mmol,0.20 equiv), 2-acetylcyclohexan-1-one (261.0 mg, 1.86 mmol, 0.20 equiv),2-amino-2-methylpropanoic acid (1.6 g, 15.52 mmol, 1.50 equiv). Theresulting solution was stirred overnight at 105.0° C. in an oil bath.The reaction was then quenched by the addition of 20.0 mL of water. Theresulting solution was extracted with ethyl acetate (40.0 mL) and theorganic layers combined. The pH value of the solution was adjusted to 8with hydrogen chloride (1.0 mol/L). The resulting solution was extractedwith ethyl acetate (40.0 mL) and the organic layers combined and driedover anhydrous sodium sulfate and concentrated under vacuum. Thisresulted in 3.9 g (92%) of2-[[4-([4-[(tert-butoxy)carbonyl]piperazin-1-yl]carbonyl)-3-fluorophenyl]amino]-2-methylpropanoicacid as a yellow solid.

LC-MS (ES⁺): m/z 410.2 [MH⁺], t_(R)=1.049 min, (2.0 minute run).

C₂₀H₂₈FN₃O₅ [409.20].  Chemical formula:

3. Synthesis of tert-butyl4-([2-fluoro-4-[(1-methoxy-2-methyl-1-oxopropan-2-yl)amino]phenyl]carbonyl)piperazine-1-carboxylate

Into a 250.0-mL round-bottom flask, was placed2-[[4-([4-[(tert-butoxy)carbonyl]piperazin-1-yl]carbonyl)-3-fluorophenyl]amino]-2-methylpropanoicacid (2.7 g, 6.59 mmol, 1.00 equiv), N,N-dimethylformamide (20.0 mL),potassium carbonate (2.7 g, 19.54 mmol, 3.00 equiv), CH3I (2.8 g, 19.73mmol, 3.00 equiv). The resulting solution was stirred overnight at roomtemperature. The reaction was then quenched by the addition of 20.0 mLof water. The resulting solution was extracted with ethyl acetate (40.0mL) and the organic layers combined. The resulting mixture was washedwith sodium chloride (40.0 mL). The mixture was dried over anhydroussodium sulfate. The residue was applied onto a silica gel column withethyl acetate/petroleum ether (1/1). The collected fractions werecombined and concentrated under vacuum. This resulted in 2.2 g (79%) oftert-butyl4-([2-fluoro-4-[(1-methoxy-2-methyl-1-oxopropan-2-yl)amino]phenyl]carbonyl)piperazine-1-carboxylateas a yellow solid.

LC-MS (ES⁺): m/z 424.05 [MH⁺], t_(R)=0.920 min, (1.90 minute run).

C₂₁H₃₀FN₃O₅ [423.22].  Chemical formula:

4. Synthesis of tert-butyl4-[(4-[3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-sulfanylideneimidazolidin-1-yl]-2-fluorophenyl)carbonyl]piperazine-1-carboxylate

Into a 100.0-mL round-bottom flask, was placed tert-butyl4-([2-fluoro-4-[(1-methoxy-2-methyl-1-oxopropan-2-yl)amino]phenyl]carbonyl)piperazine-1-carboxylate(500.0 mg, 1.18 mmol, 1.00 equiv), N,N-dimethylformamide (5.0 mL),4-isothiocyanato-2-(trifluoromethyl)benzonitrile (404.3 mg, 1.77 mmol,1.50 equiv), t-BuOK (198.24 mg, 1.77 mmol, 1.50 equiv). The resultingsolution was stirred overnight at 100.0° C. in an oil bath. The reactionwas then quenched by the addition of 20.0 mL of water. The resultingsolution was extracted with ethyl acetate (40.0 mL) and the organiclayers combined. The resulting mixture was washed with sodium chloride(40.0 mL). The mixture was dried over anhydrous sodium sulfate. Theresidue was applied onto a silica gel column with ethylacetate/petroleum ether (1/1). The collected fractions were combined andconcentrated under vacuum. This resulted in 500.0 mg (68%) of tert-butyl4-[(4-[3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-sulfanylideneimidazolidin-1-yl]-2-fluorophenyl)carbonyl]piperazine-1-carboxylateas a yellow solid.

5. Synthesis of4-(3-[3-fluoro-4-[(piperazin-1-yl)carbonyl]phenyl]-4,4-dimethyl-5-oxo-2-sulfanylideneimidazolidin-1-yl)-2-(trifluoromethyl)benzonitrilehydrochloride

Into a 50.0-mL round-bottom flask, was placed tert-butyl4-[(4-[3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-sulfanylideneimidazolidin-1-yl]-2-fluorophenyl)carbonyl]piperazine-1-carboxylate(120.0 mg, 0.19 mmol, 1.00 equiv), methanol (3.0 mL), hydrogen chloride(0 mg). The resulting solution was stirred for 2 hours at roomtemperature. The crude product (mL) was purified by Prep-HPLC with thefollowing conditions (2#-AnalyseHPLC-SHIMADZU(HPLC-10)): Column, XBridgePrep C18 OBD Column, 5 um, 19*150 mm; mobile phase, Water(0.1% FA) andacetonitrile (25.0% acetonitrile up to 62.0% in 8 min); This resulted in89.9 mg (83%) of4-(3-[3-fluoro-4-[(piperazin-1-yl)carbonyl]phenyl]-4,4-dimethyl-5-oxo-2-sulfanylideneimidazolidin-1-yl)-2-(trifluoromethyl)benzonitrilehydrochloride as a yellow solid.

H-NMR (300 MHz, CD3OD) δ 8.17-8.15 (d, J=5.4 Hz, 2H), 8.01-7.98 (d,J=8.4 Hz, 1H), 7.64-7.58 (m, 1H), 7.41-7.37 (m, 2H), 5.49 (s, 1H), 3.83(s, 2H), 3.46 (s, 2H), 3.01-2.92 (d, J=28.5 Hz, 4H), 1.60 (s, 6H), 1.38(s, 1H).

LC-MS (ES⁺): m/z 520.05 [MH⁺], t_(R)=1.315 min, (3.0 minute run).

C₂₄H₂₁F₄N₅O₂S [519.14].  Chemical formula:

Total H count from HNMR data: 22.

6. Synthesis of4-[3-(4-[[4-(4-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl]oxy]butyl)piperazin-1-yl]carbonyl]-3-fluorophenyl)-4,4-dimethyl-5-oxo-2-sulfanylideneimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile

Into a 50.0-mL round-bottom flask, was placed4-(3-[3-fluoro-4-[(piperazin-1-yl)carbonyl]phenyl]-4,4-dimethyl-5-oxo-2-sulfanylideneimidazolidin-1-yl)-2-(trifluoromethyl)benzonitrilehydrochloride (150.0 mg, 0.27 mmol, 1.00 equiv), CH3CN (5.0 mL),potassium carbonate (149.1 mg, 1.08 mmol, 4.00 equiv), NaI (40.5 mg,1.00 equiv),5-(4-bromobutoxy)-2-(2,6-dioxopiperidin-3-yl)-2,3-dihydro-1H-isoindole-1,3-dione(220.0 mg, 0.54 mmol, 2.00 equiv). The resulting solution was stirredovernight at 70.0° C. in an oil bath. The crude product (mL) waspurified by Prep-HPLC with the following conditions(2#-AnalyseHPLC-SHIMADZU(HPLC-10)): Column, XBridge Prep C18 OBD Column,5 um, 19*150 mm; mobile phase, Water(0.1% FA) and acetonitrile (25.0%acetonitrile up to 62.0% in 8 min); Detector, UV 254 nm, mL product wasobtained. This resulted in 27.2 mg (12%) of4-[3-(4-[[4-(4-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl]oxy]butyl)piperazin-1-yl]carbonyl]-3-fluorophenyl)-4,4-dimethyl-5-oxo-2-sulfanylideneimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrileas a white solid.

H-NMR (300 MHz, CDCl3) δ 8.04-7.95 (m, 3H), 7.84-7.77 (m, 2H), 7.60-7.55(m, 1H), 7.34-7.33 (d, J=1.8 Hz, 1H), 7.21-7.09 (m, 3H), 4.98-4.93 (m,1H), 4.14-4.10 (m, 2H), 3.91 (s, 2H), 3.49 (s, 2H), 2.94-2.72 (m, 3H),2.67-2.56 (m, 5H), 2.25-2.13 (m, 2H), 1.92-1.88 (m, 2H), 1.76 (s, 2H),1.68 (s, 6H).

LC-MS (ES⁺): m/z 848.20 [MH⁺], t_(R)=3.304 min, (5.0 minute run).

C₄₁H₃₇F₄N₇O₇S [847.24].  Chemical formula:

Total H count from HNMR data: 37.

Synthetic Scheme for Compound 450

Experiments Step 1: [chloromethyl 2,5,8,11-tetraoxatridecan-13-ylcarbonate]

To a stirred solution of chloromethyl carbonochloridate (2.6 g, 20 mmol)in dichloromethane (40 mL) was added a mixture of2,5,8,11-tetraoxatridecan-13-ol (4.16 g, 20 mmol) and triethylamine (2g, 20 mmol) in dichloromethane (5 ml) dropwise at 0° C. The resultingreaction mixture was stirred at 0° C. for 0.5 hour. TLC showed thereaction was completed. The reaction mixture was partitioned betweentert-Butyl methyl ether (100 ml) and water (60 ml). The organic layerwere collected, washed with brine (50 ml), dried over anhydrous sodiumsulfate, and concentrated under reduced pressure to give a crude residuewhich was purified by silica gel flash chromatography (eluted with 30%ethyl acetate in hexane) to afford chloromethyl2,5,8,11-tetraoxatridecan-13-yl carbonate (2.2 g, yield 35.2%) ascolorless oil.

1H NMR (400 MHz, CDCl₃): δ 3.38 (s, 3H), 3.54-3.56 (m, 2H), 3.64-3.66(m, 10H), 3.74-3.76 (m, 2H), 4.36-4.38 (m, 2H), 5.74 (s, 2H).

C₁₁H₂₁ClO₇; Molecular Weight: 300.73;  Chemical Formula:

Total H count from HNMR data: 21.

Step 2:[(3-(5-(4-((1-(4-(((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)carbamoyl)phenyl)piperidin-4-yl)methyl)piperazin-1-yl)-1,3-dioxoisoindolin-2-yl)-2,6-dioxopiperidin-1-yl)methyl2,5,8,11-tetraoxatridecan-13-yl carbonate]

A mixture ofN-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)benzamide(320 mg, 0.39 mmol), cesium carbonate (190 mg, 0.58 mmol) andchloromethyl 2,5,8,11-tetraoxatridecan-13-yl carbonate (140 mg, 0.47mmol) in N,N-dimethylformamide (6 mL) was stirred at room temperaturefor 2 hours. TLC showed the reaction was completed. The mixture waspartitioned between ethyl acetate (50 ml) and water (40 ml). The organiclayer were collected, washed with brine (30 ml), dried over anhydroussodium sulfate, and concentrated under reduced pressure to give a cruderesidue which was purified by silica gel flash chromatography (elutingwith 2.5% methanol in dichloromethane) to afford(3-(5-(4-((1-(4-(((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)carbamoyl)phenyl)piperidin-4-yl)methyl)piperazin-1-yl)-1,3-dioxoisoindolin-2-yl)-2,6-dioxopiperidin-1-yl)methyl2,5,8,11-tetraoxatridecan-13-yl carbonate (160 mg, yield 38%) as yellowsolid.

LC_MS: (ES⁺): m/z 1084.7 [M+H]⁺, t_(R)=2.550 min.

¹H NMR (400 MHz, DMSO-d6): δ 1.13 (s, 6H), 1.18-1.27 (m, 2H), 1.22 (s,6H), 1.77-1.83 (m, 3H), 2.04-2.12 (m, 1H), 2.21-2.22 (m, 2H), 2.31-2.45(m, 1H), 2.58-2.67 (m, 3H), 2.73-2.85 (m, 3H), 3.01-3.12 (m, 1H), 3.23(s, 3H), 3.31-3.33 (m, 2H), 3.40-3.52 (m, 15H), 3.59-3.62 (m, 2H), 3.86(d, J=12.4 Hz, 2H), 4.05 (d, J=9.2 Hz, 1H), 4.19-4.21 (m, 2H), 4.32 (s,1H), 5.25-5.29 (m, 1H), 5.67-5.69 (m, 2H), 6.96 (d, J=8.8 Hz, 2H), 7.00(dd, J=2.4, 8.8 Hz, 1H), 7.21 (d, J=2.4 Hz, 1H), 7.28 (d, J=8.8 Hz, 1H),7.36 (s, 1H), 7.50 (d, J=9.2 Hz, 1H), 7.68 (d, J=8.4 Hz, 1H), 7.74 (d,J=8.4 Hz, 2H), 7.92 (d, J=8.8 Hz, 1H).

C₅₆H₇₀ClN₇O₁₃; Molecular Weight: 1084.65;  Chemical Formula:

Total H count from HNMR data: 70.

Synthetic Scheme for Compound 448

Experiments Step 1: [benzyl (2-aminoethyl)carbamate]

To a stirred solution of ethane-1,2-diamine (10 g, 166 mmol) inanhydrous dichloromethane (50 ml) was added benzyl chloroformate (2.83g, 16.6 mmol) in dichloromethane (10 ml) dropwise at 0° C. over 30 min.The reaction mixture was stirred at 0° C. for 3 hours. TLC showed thereaction was complete. The mixture solution was acidified with dilutedhydrochloride acid (IN) till pH 4-5, and extracted with ethyl acetate(100 ml). The aqueous layer was collected, acidified with saturatedsodium hydroxide solution till pH 9-10, and extracted with ethyl acetate(50 ml×2). The combined organic layers were collected, dried overanhydrous sodium sulfate, and concentrated under reduced pressure togive benzyl (2-aminoethyl)carbamate (1.31 g, yield 40%) as colorless oilwhich was used in next step without further purification.

LC_MS: (ES⁺): m/z 195.2 [M+H]⁺, t_(R)=1.198 min.

¹H NMR (400 MHz, CDCl₃): 2.787 (t, J=6.0 Hz, 2H), 3.14-3.28 (m, 2H),5.07 (s, 2H), 7.27-7.35 (m, 5H).

C₁₀H₁₄N₂O₂; Molecular Weight: 194.23;  Chemical Formula:

Total H count from HNMR data: 11.

Step 2

To a stirred solution of benzyl (2-aminoethyl)carbamate (400 mg, 2.06mmol), (S)-2-((tert-butoxycarbonyl)amino)-3-methylbutanoic acid (447 mg,2.06 mmol), and N-ethyl-N-isopropylpropan-2-amine (797 mg, 6.18 mmol) inanhydrous N,N-dimethylformamide (4 ml) was added HATU(2-(7-Aza-1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluroniumhexafluorophosphate) (1.56 g, 4.12 mmol) at room temperature and stirredfor 20 min. TLC showed the reaction was complete. The mixture waspartitioned between ethyl acetate (40 ml) and water (20 ml). The organiclayer was collected, washed with brine (30 ml), dried over anhydroussodium sulfate, and concentrated under reduced pressure to give a cruderesidue which was purified by silica gel flash chromatography (elutingwith 5% methanol in dichloromethane) to afford Compound 448-2 (670 mg,yield 83%) as white solid.

¹H NMR (400 MHz, CDCl₃): 0.88 (d, J=6.8 Hz, 3H), 0.93 (d, J=6.8 Hz, 3H),1.43 (s, 9H), 2.07-2.15 (m, 1H), 3.33-3.38 (m, 4H), 3.85 (t, J=1.2 Hz,3H), 5.08 (s, 2H), 7.30-7.35 (m, 5H).

C₂₀H₃₁N₃O₅; Molecular Weight: 393.48;  Chemical Formula:

Total H count from HNMR data: 28.

Step 3: [(S)-tert-butyl(1-((2-aminoethyl)amino)-3-methyl-1-oxobutan-2-yl)carbamate]

Palladium on carbon (10%, 200 mg) was added to a stirred solution ofCompound 448-2 (670 mg, 1.70 mmol) in methanol (20 ml). The reactionmixture was stirred under hydrogen atmosphere (hydrogen balloon) at roomtemperature overnight. TLC showed the reaction was complete. Palladiumon carbon was removed through filtration and washed with methanol (5ml×2). The combined filtrates were concentrated under reduced pressureto afford (S)-tert-butyl(1-((2-aminoethyl)amino)-3-methyl-1-oxobutan-2-yl)carbamate (470 mg,crude) as colorless oil which was used in next step directly withoutpurification.

¹H NMR (400 MHz, CDCl₃): 0.92 (d, J=6.8 Hz, 3H), 0.96 (d, J=6.8 Hz, 3H),1.44 (s, 9H), 2.08-2.20 (m, 1H), 2.84 (t, J=5.6 Hz, 2H), 3.27-3.38 (m,2H), 3.85-3.89 (m, 1H).

C₁₂H₂₅N₃O₃; Molecular Weight: 259.35;  Chemical Formula:

Total H count from HNMR data: 21.

Step 4:(3-(5-(4-((1-(4-(((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)carbamoyl)phenyl)piperidin-4-yl)methyl)piperazin-1-yl)-1,3-dioxoisoindolin-2-yl)-2,6-dioxopiperidin-1-yl)methyl(2-((S)-2-((tert-butoxycarbonyl)amino)-3-methylbutanamido)ethyl)carbamate

To a stirred solution ofN-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)benzamide(300 mg, 0.36 mmol), and cesium carbonate (179 mg, 0.55 mmol) indichloromethane (8 ml) and acetonitrile (1 ml) was added chloromethyl(4-nitrophenyl) carbonate (102 mg, 0.44 mmol) under nitrogen. Thereaction mixture was stirred at room temperature under nitrogen for 3hours. TLC showed the reaction was complete. To the reaction mixture wasadded (S)-tert-butyl(1-((2-aminoethyl)amino)-3-methyl-1-oxobutan-2-yl)carbamate (93 mg, 0.36mmol), and the resulting mixture was continued stirring under nitrogenfor 2 hours. TLC showed the reaction was complete. The mixture waspartitioned between ethyl acetate (30 ml) and water (20 ml). The organiclayer was collected, washed with brine (30 ml), dried over anhydroussodium sulfate, and concentrated under reduced pressure to give a cruderesidue which was purified by silica gel flash chromatography (elutedwith 2.5% methanol in dichloromethane) to afford desired product (240mg, yield 59%) as yellow solid.

LC_MS: (ES⁺): m/z 1135.7 [M+H]⁺, t_(R)=2.578 min.

Step 5:[(3-(5-(4-((1-(4-(((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)carbamoyl)phenyl)piperidin-4-yl)methyl)piperazin-1-yl)-1,3-dioxoisoindolin-2-yl)-2,6-dioxopiperidin-1-yl)methyl(2-((S)-2-amino-3-methylbutanamido)ethyl)carbamate]

A solution of(3-(5-(4-((1-(4-(((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)carbamoyl)phenyl)piperidin-4-yl)methyl)piperazin-1-yl)-1,3-dioxoisoindolin-2-yl)-2,6-dioxopiperidin-1-yl)methyl(2-((S)-2-((tert-butoxycarbonyl)amino)-3-methylbutanamido)ethyl)carbamate(230 mg, 0.20 mmol) in dichloromethane (6 ml) in 4M hydrogen chloride indioxane (2 ml) was stirred at room temperature for 2 hours. TLC showedthe reaction was complete. The mixture solution was acidified withsaturated sodium bicarbonate solution till pH 9-10, and extracted withdichloromethane (15 ml×2). The organic layers were combined, washed withbrine (30 ml), dried over sodium sulfate and concentrated under reducedto give a crude residue which was purified by silica gel flashchromatography (eluted with 2.5% methanol in dichloromethane) to afford(3-(5-(4-((1-(4-(((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)carbamoyl)phenyl)piperidin-4-yl)methyl)piperazin-1-yl)-1,3-dioxoisoindolin-2-yl)-2,6-dioxopiperidin-1-yl)methyl(2-((S)-2-amino-3-methylbutanamido)ethyl)carbamate (140 mg, yield 67%)as yellow solid.

LC_MS: (ES⁺): m/z 1035.6 [M+H]⁺, t_(R)=2.215 min.

¹H NMR (400 MHz, DMSO-d6): δ 0.76 (d, J=6.8 Hz, 3H), 0.84 (d, J=6.8 Hz,3H), 1.12 (s, 6H), 1.18 (s, 2H), 1.22 (s, 6H), 1.80-1.87 (m, 4H),2.07-2.09 (m, 2H), 2.21 (d, J=6.0 Hz, 2H), 2.50 (s, 4H), 2.58-2.62 (m,2H), 2.76-2.85 (m, 3H), 2.90 (d, J=5.2 Hz, 1H), 3.00-3.06 (m, 3H), 3.11(t, J=6.0 Hz, 2H), 3.45 (s, 4H), 3.86 (d, J=12.0 Hz, 2H), 4.05 (d, J=9.2Hz, 1H), 4.32 (s, 1H), 5.20-5.24 (m, 1H), 5.55-5.61 (m, 2H), 6.95 (d,J=9.2 Hz, 2H), 6.99-7.02 (m, 1H), 7.20 (d, J=2.4 Hz, 1H), 7.27 (d, J=8.8Hz, 1H), 7.32-7.35 (m, 2H), 7.48 (d, J=9.2 Hz, 1H), 7.69 (d, J=8.4 Hz,1H), 7.73 (d, J=8.8 Hz, 2H), 7.90 (d, J=8.8 Hz, 2H).

C₅₄H₆₇ClN₁₀O₉; Molecular Weight: 1035.62;  Chemical Formula:

Total H count from HNMR data: 67.

Synthesis of ABM MoietiesABM-1:2-chloro-4-(3-(4-hydroxyphenyl)-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl)benzonitrile

Step 1: Synthesis of 2-chloro-4-isothiocyanatobenzonitrile (B)

To a stirred solution of 4-amino-2-chlorobenzonitrile (A, 1 g, 6.55mmol) in dichloromethane (9 mL) was added sodium bicarbonate (2.21 g,26.31 mmol) and water (9 mL). The resulting mixture was cooled to 0° C.,to which thiophosgene (817 mg, 7.11 mmol) was added in drop wise in 30min at 0° C. The resulting mixture was then warmed up to roomtemperature and stirred at room temperature for 1 hour. The reactionmixture was diluted with dichloromethane (200 mL), washed with brine (50mL×2), dried over anhydrous sodium sulfate and then concentrated underreduced pressure to give a crude residue. The residue was purified byflash silica gel chromatography (eluent: ethyl acetate/petroleum ether(v:v=1:30)) to give desired product (yield: 71%) ¹HNMR (400 MHz, CDCl₃):δ 7.69 (d, J=8.0 Hz, 1H), 7.38 (s, 1H), 7.28 (m, 1H);

Step 2: Synthesis of2-chloro-4-[3-(4-hydroxyphenyl)-5-imino-4,4-dimethyl-2-sulfanylideneimidazolidin-1-yl]benzonitrile(D)

To a stirred solution of 2-chloro-4-isothiocyanatobenzonitrile (B, 399mg, 2.05 mmol) in toluene (5 mL) was added2-[(4-hydroxyphenyl)amino]-2-methylpropanenitrile (C, 300 mg, 1.70 mmol)and 4-dimethylaminopyridine (312 mg, 2.55 mmol). The resulting solutionwas then heated in an oil bath to 100° C. and stirred at the sametemperature for 16h. LC-MS indicated formation of the desired product.The reaction mixture was concentrated under vacuum to give a crudereside which was purified by flash silica gel chromatography (eluent:ethyl acetate/petroleum ether (v:v=1:1)) to give desired product (yield:48%) as a brown solid. LC-MS (ES⁺): m/z 370.95 [MH⁺], t_(R)=0.74 min(2.0 minute run);

Step 3: Synthesis of2-chloro-4-[3-(4-hydroxyphenyl)-4,4-dimethyl-5-oxo-2-sulfanylideneimidazolidin-1-yl]benzonitrile(ABM-1)

To a stirred solution of 2-chloro-4-[3-(4-hydroxyphenyl)-5-imino-4,4-dimethyl-2-sulfanylideneimidazolidin-1-yl]benzonitrile (D, 300 mg,0.81 mmol) in methanol (6 mL) was added aqueous hydrogen chloride (2N,3.0 mL). The resulting solution was then heated in an oil bath to 100°C. and stirred at the same temperature for 2h. The reaction mixture wasdiluted with water (30 mL), extracted with ethyl acetate (60 mL×3),washed with water (50 mL), dried over anhydrous sodium sulfate andconcentrated under vacuum to give titled product (yield: 93%) as ayellow solid, which was used for the next step without any furtherpurifications. LC-MS (ES⁺): m/z 372.00 [MH⁺], t_(R)=0.97 min (2.0 minuterun).

Unless otherwise noted, the following intermediates and their analogs(for examples, but not limited to, analogs with substitutions such ashalogens) were synthesized according to similar procedures describedabove for the synthesis of ABM-1, by utilizing corresponding startingmaterials and reagents.

ABM-2:2-fluoro-4-(3-(4-hydroxyphenyl)-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl)benzonitrile

ABM-3:4-(3-(4-hydroxyphenyl)-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl)-2-(trifluoromethyl)benzonitrile

ABM-4:5-(3-(4-hydroxyphenyl)-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl)-3-(trifluoromethyl)picolinonitrile

ABM-5:4-(3-(4-hydroxyphenyl)-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl)-2-methoxybenzonitrile

ABM-6:4-(3-(4-hydroxyphenyl)-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl)-2-methylbenzonitrile

ABM-7:3-chloro-5-(3-(4-hydroxyphenyl)-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl)picolinonitrile

ABM-8:4-(1-(4-hydroxyphenyl)-4-oxo-2-thioxo-8-oxa-1,3-diazaspiro[4.5]decan-3-yl)-2-(trifluoromethyl)benzonitrile

ABM-9:4-(1-(4-hydroxyphenyl)-8-methyl-4-oxo-2-thioxo-1,3,8-triazaspiro[4.5]decan-3-yl)-2-(trifluoromethyl)benzonitrile

ABM-10:4-(5-(4-hydroxyphenyl)-8-oxo-6-thioxo-5,7-diazaspiro[3.4]octan-7-yl)-2-(trifluoromethyl)benzonitrile

ABM-11:5-(5-(4-hydroxyphenyl)-8-oxo-6-thioxo-5,7-diazaspiro[3.4]octan-7-yl)-3-(trifluoromethyl)picolinonitrile

ABM-12:4-(4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)phenyl)butanoicacid

ABM-13:2-chloro-4-(3-(4′-hydroxybiphenyl-4-yl)-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl)benzonitrile

ABM-14:4-(3-(4′-hydroxybiphenyl-4-yl)-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl)-2-(trifluoromethyl)benzonitrile

ABM-15:5-(3-(4′-hydroxybiphenyl-4-yl)-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl)-3-(trifluoromethyl)picolinonitrile

ABM-16:4-(3-(3-fluoro-4-hydroxyphenyl)-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl)-2-(trifluoromethyl)benzonitrile

ABM-17:1-(4-hydroxyphenyl)-5,5-dimethyl-3-(4-nitro-3-(trifluoromethyl)phenyl)-2-thioxoimidazolidin-4-one

ABM-18:4-(3-(3,5-difluoro-4-hydroxyphenyl)-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl)-2-(trifluoromethyl)benzonitrile

ABM-19:4-(3-(4-hydroxyphenyl)-4,4-dimethyl-2,5-dioxoimidazolidin-1-yl)-2-(trifluoromethyl)benzonitrile

ABM-20:4-(3-(6-hydroxypyridin-3-yl)-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl)-2-(trifluoromethyl)benzonitrile

ABM-21:2-chloro-4-(3-(3-fluoro-4-hydroxyphenyl)-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl)benzonitrile

ABM-22:4-(3-(3-fluoro-4-hydroxyphenyl)-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl)-2-methoxybenzonitrile

ABM-23:5-(3-(3-fluoro-4-hydroxyphenyl)-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl)-3-(trifluoromethyl)picolinonitrile

ABM-24:5-(3-(2-fluoro-4′-hydroxybiphenyl-4-yl)-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl)-3-(trifluoromethyl)picolinonitrile

ABM-25:4-(4,4-dimethyl-5-oxo-3-(4-(piperidin-4-yl)phenyl)-2-thioxoimidazolidin-1-yl)-2-(trifluoromethyl)benzonitrile

ABM-26:trans-2-Chloro-4-[3-amino-2,2,4,4-tetramethylcyclobutoxy]benzonitrile

ABM-27:cis-2-Chloro-4-[3-amino-2,2,4,4-tetramethylcyclobutoxy]benzonitrile

ABM-28: trans6-Amino-N-[3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl]pridazine-3-carboxamide

ABM-29: trans tert-ButylN-[3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl]carbamate

ABM-30: trans4-Amino-N-[3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl]benzamide

Step 1: Synthesis of tert-butyl(4-((trans-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)carbamoyl)phenyl)carbamate

A suspension of 4-((tert-butoxycarbonyl)amino)benzoic acid (1.50 g, 6.34mmol) in methylene dichloride (40 mL) was charged withN,N-diisopropylethylamine (3.30 mL, 19.0 mmol), followed by4-(trans-3-amino-2,2,4,4-tetramethylcyclobutoxy)-2-chlorobenzonitrilehydrochloride (2.0 g, 6.34 mmol). The mixture was stirred for severalminutes and then charged with HATU (2.41 g, 6.34 mmol). The reactionmixture was allowed to stir at room temperature for 2 hours. The mixturewas diluted with methylene dichloride (40 mL), washed with aqueous 1NHCl (2 x), saturated aqueous sodium bicarbonate (2 x), brine, and driedover anhydrous Na₂SO₄. The crude product was used in next step;

Step 2: synthesis of trans4-Amino-N-[3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl]benzamide

4M HCl in Dioxane (1.38 mL, 40.0 mmol) was added to a pre-mixed solutionof tert-butyl(4-((trans-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)carbamoyl)phenyl)carbamate(2.00 g, 4.01 mmol) in MeOH (2 mL) and left to stir at room temperaturefor 1 hour till completion. The reaction mixture was concentrated invacuo to a solid, which was dissolved with 5% MeOH in DCM. The organiclayer was washed with sodium bicarbonate (2 x), filtered through aBiotage Universal Phase Separator and then concentrated in vacuo to asolid. The crude product was recrystallized from EtOH/Heptanes to affordthe desired product as a white solid, 1.2 g, 75% yield. H NMR (400 MHz,METHANOL-d4) δ 7.72 (d, J=8.80 Hz, 1H), 7.61 (d, J=8.61 Hz, 2H), 7.13(d, J=2.35 Hz, 1H), 6.98 (dd, J=2.45, 8.71 Hz, 1H), 6.69 (d, J=8.61 Hz,2H), 4.28 (s, 1H), 4.12 (s, 1H), 1.27 (s, 6H), 1.22 (s, 6H). LC-MS(ES⁺): m/z 398.16/400.15 [MH⁺].

Unless otherwise noted, the following intermediates and their analogs(for examples, but not limited to, analogs with substitutions such ashalogens) were synthesized according to similar procedures describedabove for the synthesis of ABM-30, by utilizing corresponding startingmaterials and reagents.

ABM-31: trans5-Amino-N-[3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl]pyrazine-2-carboxamide

ABM-32: trans2-Amino-N-[3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl]pyrimidine-5-carboxamid

ABM-33:4-Methoxy-N-[(1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl]benzamide

ABM-34: trans1-(2-Hydroxyethyl)-N-[3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl]-1H-pyrazole-4-carboxamide

ABM-35: trans6-Amino-N-[3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl]pyridine-3-carboxamide

ABM-36: trans4-[(5-Hydroxypentyl)amino]-N-[3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl]benzamide

ABM-37: trans tert-Butyl2-({5-[(4-{[3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl]carbamoyl}phenyl)aminopentyl}oxy)acetate

ABM-38:N-((1r,3r)-3-(4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-methylbenzamide

ABM-39:N-((1r,4r)-4-(3-chloro-4-cyanophenoxy)cyclohexyl)-6-methylpyrdazine-3-carboxamide

ABM-40:N-((1r,4r)-4-(3-chloro-4-cyanophenoxy)cyclohexyl)-6-methylpyridazine-3-carboxamide

Synthesis of CLM Moieties

Some non-limiting exemplary methods to generate the CLMs as describedherein are summarized as shown below.

wherein R comprises 1-4 independently selected functional groups oratoms, and optionally, one of which is modified to be covalently joinedto a ABM, a chemical linker group (L), a ULM, CLM (or CLM′) orcombination thereof.

As shown in representative reaction 1, dimethyl phthalate derivativescan be condensed with glutamine (racemate or enantiomer) or glutamineanalogs then further reacted with agents such as carbonyl diimidazole toform 2-(2,6-dioxopiperidin-3-yl)-2,3-dihydro-1H-isoindole-1,3-dionederivatives.

Alternatively as shown in representative reaction 2, the intermediatephthalimide produced in the initial condensation described above may beseparately prepared and/or isolated and then reacted with dehydratingagents such as trifluoroacetamide, POCl₃ or acetic anhydride to form thedesired 2-(2,6-dioxopiperidin-3-yl)-2,3-dihydro-1H-isoindole-1,3-dionederivatives. The same type of intermediate phthalimide can also bereacted with Lawesson's reagent prior to the dehydration step to providethio analogs such as that shown in representative reactions 8 and 9.

Protected examples of2-(2,6-dioxopiperidin-3-yl)-2,3-dihydro-1H-isoindole-1,3-dionederivatives such as the N-BOC species shown in representative example 3can be deprotected to reveal the target2-(2,6-dioxopiperidin-3-yl)-2,3-dihydro-1H-isoindole-1,3-dionederivatives by using, in this case, reagents such as TFA or silica.

Phthalic anhydrides such as that shown in representative example 4 canbe ring-opened by reaction with amines such as3-aminopiperidine-2,6-dione to form an intermediate carboxylate species,that on treatment with carbonyldiimidazole and benzotriazole will formthe target2-(2,6-dioxopiperidin-3-yl)-2,3-dihydro-1H-isoindole-1,3-dionederivatives. Alternatively, the two components may be combined in thepresence of acetic acid to provide desired product as shown inrepresentative reaction 13.

In an analogous reaction, anhydride derivatives like those shown inrepresentative reaction 5 may be reacted with amines (ammonia in theexample shown) then carbonyldiimidazole to form the desired2-(2,6-dioxopiperidin-3-yl)-2,3-dihydro-1H-isoindole-1,3-dionederivatives.

Where phthaloyl chlorides are available, direct condensation withglutamine (racemate or enantiomer) or glutamine analogs is possible,followed by further reaction with agents such as carbonyl diimidazole toform 2-(2,6-dioxopiperidin-3-yl)-2,3-dihydro-1H-isoindole-1,3-dionederivatives as shown in representative reaction 6.

o-Bromobenzamides can be reacted with a source of CO such as the acidchloride shown in representative reaction 7 in the presence of apalladium catalyst and associated phosphine ligand to produce thedesired 2-(2,6-dioxopiperidin-3-yl)-2,3-dihydro-1H-isoindole-1,3-dionederivatives. Alternatively CO gas itself may be used in conjunction withrhodium (II) catalysts and silver carbonate to provide the desiredproducts.

2-(2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-2,3-dihydro-1H-isoindole-1,3-dione,and5-(1,3-dioxo-2,3-dihydro-1H-isoindol-2-yl)-1,3-diazinane-2,4,6-trionederivatives can be prepared by analogous means to some of the methodsdescribed above for2-(2,6-dioxopiperidin-3-yl)-2,3-dihydro-H-isoindole-1,3-dionederivatives. In representative reactions 20 and 21, a phthalic anhydridecan be reacted with 5-amino-1,2,3,4-tetrahydropyrimidine-2,4-dione or5-amino-1,3-diazinane-2,4,6-trione derivatives, respectively, in thepresence of acetic acid to form the desired products.

Alternatively,5-(1,3-dioxo-2,3-dihydro-1H-isoindol-2-yl)-1,3-diazinane-2,4,6-trionederivatives can be prepared by reaction of5-amino-1,3-diazinane-2,4,6-trione derivatives with phthalic acid monotert-butyl esters in the presence of Hunig's base, a carbodiimide andbenzotriazole as shown in representative reaction 12. Similar conditionscan be employed for the preparation of2-(2,6-dioxopiperidin-3-yl)-2,3-dihydro-1H-isoindole-1,3-dionederivatives from phthalic acid mono tert-butyl esters as shown inrepresentative reaction 14.

Compounds such as3-(2,6-dioxopiperidin-3-yl)-1,2,3,4-tetrahydroquinazoline-2,4-dione canbe prepared from anthranilic acid derivatives by reaction of3-aminopiperidine-2,6-diones with a carbodiimide as in representativereaction 16. The intermediate benzamide product may be isolated (orseparately produced) and further reacted with a carbodiimide to produce3-(2,6-dioxopiperidin-3-yl)-1,2,3,4-tetrahydroquinazoline-2,4-dionederivatives as shown in representative reaction 15.

3-(2,6-Dioxopiperidin-3-yl)-3,4-dihydro-2H-1,3-benzoxazine-2,4-dioneanalogs can be prepared by activation of salicylic acids withchloroformates then condensation with 3-aminopiperidine-2,6-diones asshown in representative reaction 17.

3,3-Dichloro-2,1)-benzoxathiole-1,1-diones as shown in representativereaction 18 can be prepared by reaction of 2-sulfobenzoic acids withPOCl₃ and PCl₅. These compounds can be reacted with amino derivatives toproduce, for example, desired2-(2,6-dioxopiperidin-3-yl)-2,3-dihydro-1λ⁶,2-benzothiazole-1,1,3-trionederivatives.

As shown in representative reaction 19, anions of saccharin derivativescan be alkylated with electrophiles such as the3-bromo-3-methylpiperidin-2-one to produce targeted2-(3-methyl-2-oxopiperidin-3-yl)-2,3-dihydro-1λ⁶,2-benzothiazole-1,1,3-trionederivatives.

Analogs of2-(2,6-dioxopiperidin-3-yl)-2,3-dihydro-1λ⁶,2-benzothiazole-1,1,3-trionemay also be prepared by reaction of methyl2-[(2,6-dioxopiperidin-3-yl)sulfamoyl]benzoate with strong bases such assodium hydride (see representative reaction 20).

Deprotonation of 2-methyl-2,3-dihydro-1H-indene-1,3,dione derivativeswith sodium ethoxide then reaction with electrophiles such as3-bromopiperidin-2,6-dione affords3-(2-methyl-1,3-dioxo-1H-inden-2-yl)piperidine-2,6-dione as shown inrepresentative reaction 21.

Preparation of N¹-substituted compounds such as2-[1-(benzyloxy)-2,6-dioxopiperidin-3-yl]-2,3-dihydro-1H-isoindole-1,4-dione(representative reaction 22) can be achieved by reaction of2-(1,3-dioxo-2,3-dihydro-1H-isoindol-2-yl)pentanedioic acid withN-benzylhydroxylamine and with trifluoroacetic anhydride.

In turn, molecules such as2-[1-(benzyloxy)-2,6-dioxopiperidin-3-yl]-2,3-dihydro-1H-isoindole-,4-dione(representative reaction 23) may be subject to benzyl removal underhydrogenation conditions to yield N¹-hydroxy analogs such as2-(1-hydroxy-2,6-dioxopiperidin-3-yl)-2,3-dihydro-1H-isoindole-1,3-dione.

In representative reaction 24, methyl1,3-dioxo-2,3-dihydro-1H-isoindole-2-carboxylate (and analogs) isreacted with 3-aminopiperidin-2-one to provide2-(2-oxopiperidin-3-yl)-2,3-dihydro-1H-isoindole-1,3-diones.

The same amine can also be reacted with phthalic anhydride derivativesin the presence of a Lewis acid such as zinc bromide and trimethylsilylether to yield the same type of product as shown in representativereaction 25. Intermediate products from this reaction if isolated orotherwise prepared (representative reaction 26) can be pushed to fullcyclization through use of a dehydrating agent.

The isomeric derivatives such as2-(6-oxopiperidin-3-yl)-2,3-dihydro-1H-isoindole-1,3-dione shown inrepresentative reaction 27 are attainable through reaction of phthalicacid with 5-aminopiperidin-2-one.

Preparation of N¹-substituted compounds such as2-(1-benzyl-2,6-dioxopiperidin-3-yl)-2,3-dihydro-1H-isoindole-,4-dione(representative reactions 28 and 29) can be achieved through multipleroutes. For example the anhydride(2-(2,6-dioxooxan-3-yl)-2,3-dihydro-1H-isoindole-1,3-dione) can becondensed with 3-aminopiperidine-2,6-dione in the presence of DMAP andcarbonyldiimidazole (representative reaction 28), or2-(2,6-dioxopiperidin-3-yl)-2,3-dihydro-1H-isoindole-1,3-dionederivatives can be alkylated with electrophiles such as benzyl bromidein the presence of base as shown in representative reaction 29.

In some instances, protecting group strategies and/or functional groupinterconversions (FGIs) may be required to facilitate the preparation ofthe desired materials. Such chemical processes are well known to thesynthetic organic chemist and many of these may be found in texts suchas “Greene's Protective Groups in Organic Synthesis” Peter G. M. Wutsand Theodora W. Greene (Wiley), and “Organic Synthesis: TheDisconnection Approach” Stuart Warren and Paul Wyatt (Wiley).

Synthesis of Linker Chemistry, L L-1:2-(3-(5-(tosyloxy)pentyloxy)propoxy)acetic acid

Step 1: Synthesis of ({[5-(prop-2-en-1-yloxy)pentyl]oxy}methyl)benzene

To a stirred solution of 5-(benzyloxy)pentan-1-ol (W, 4.0 g, 20.59 mmol)in N,N-dimethylformamide (50 mL) was added sodium hydride (1.24 g, 51.67mmol) in portions at 0° C. under an atmosphere of nitrogen. Theresulting mixture was then stirred at room temperature for 1 hour. Tothis mixture was added 3-bromoprop-1-ene (3.71 g, 30.67 mmol), thereaction mixture was stirred overnight at 60° C. in an oil bath. LC-MSindicated formation of the desired product. The reaction mixture wascooled to 0° C. and then quenched by water (100 mL), the resultingmixture was extracted with ethyl acetate (200 mL×2). The organic layerswere combined, washed with saturated aqueous solution of sodium chloride(60 mL), dried over anhydrous sodium sulfate and then concentrated underreduced pressure to give a crude residue. The residue was purified by aflash silica gel chromatography (eluent: ethyl acetate/petroleum ether(v:v=1:40)) to give 4.57 g of X. ¹H NMR (300 MHz, CDCl₃): δ 7.36 (s,4H), 7.32 (m, 1H), 5.98 (m, 1H), 5.33 (m, 1H), 5.21 (m, 1H), 4.53 (s,2H), 3.99 (m, 2H), 3.53 (m, 4H), 1.72 (m, 4H), 1.52 (m, 2H). LC-MS(ES⁺): m/z 235.00 [MH⁺], t_(R)=1.18 min (2.0 minute run).

Step 2: Synthesis of 3-{[5-(benzyloxy)pentyl]oxy}propan-1-ol (Y)

To a 250-mL round-bottom flask with 9-BBN (0.5 M in THF, 77 mL) wasadded a solution of ({[5-(prop-2-en-1-yloxy)pentyl]oxy}methyl)benzene(X, 3.0 g, 12.80 mmol) in anhydrous tetrahydrofuran (20 mL) withstirring at 0° C. under an atmosphere of nitrogen. The resultingsolution was stirred overnight at room temperature. LC-MS indicatedformation of the desired product. Methanol (15 mL, with 30% sodiumhydroxide and 30% H₂O₂) was added to the reaction and the resultingmixture was stirred at room temperature for 2 hours. This mixture wasthen extracted with ethyl acetate (20 mL×3). The organic layers werecombined, washed with saturated aqueous solution of sodium chloride (100mL), dried over anhydrous sodium sulfate and then concentrated underreduced pressure to give a crude residue. The residue was purified by aflash silica gel chromatography (eluent: ethyl acetate/petroleum ether(v:v=1:1)) to provide 1.96 g of Y as light yellow oil. H NMR (300 MHz,CDCl₃): δ7.34 (m, 5H), 4.49 (s, 2H), 3.75 (m, 2H), 3.59 (m, 2H), 3.49(m, 4H), 2.65 (bs, 1H), 1.84 (m, 2H), 1.68 (m, 4H), 1.50 (m, 2H). LC-MS(ES⁺): m/z 253.17 [MH⁺], t_(R)=1.44 min (2.6 minute run).

Step 3: Synthesis of tert-butyl2-(3-{[5-(benzyloxy)pentyl]oxy}propoxy)acetate (Z)

To a stirred solution of 3-{[5-(benzyloxy)pentyl]oxy}propan-1-ol (Y, 3.7g, 14.66 mmol) in dichloromethane (30 mL) was added a solution of NaOHin water (37%, 30 mL) followed by tert-butyl 2-bromoacetate (11.39 g,58.39 mmol) and TBACl (4.17 g). The resulting mixture was stirred atroom temperature overnight. LC-MS indicated formation of the desiredproduct. The reaction mixture was then extracted with ethyl acetate (50mL×3). The organic layers were combined, washed with saturated aqueoussolution of sodium chloride (60 mL), dried over anhydrous sodium sulfateand then concentrated under reduced pressure to give a crude residue.The residue was purified by a flash silica gel chromatography (eluent:ethyl acetate/petroleum ether (v:v=1:2) to give 3.2 g of Z as a yellowoil. ¹H NMR (400 MHz, CDCl₃): δ 7.34 (s, 4H), 7.29 (m, 1H), 4.50 (s,4H), 4.3 (m, 2H), 3.51 (m, 4H), 3.42 (m, 2H), 1.98 (m, 2H), 1.67 (m,4H), 1.48 (s, 9H), 1.46 (m, 2H). LC-MS (ES⁺): m/z 367.25 [MH⁺],t_(R)=1.28 min (2.0 minute run).

Step 4: Synthesis of tert-butyl2-[3-[(5-hydroxypentyl)oxy]propoxy]acetate (AA)

To a stirred solution of tert-butyl2-(3-{[5-(benzyloxy)pentyl]oxy}propoxy)acetate (Z, 3.2 g, 8.73 mmol) inmethanol (30 mL) was added AcOH (1.5 mL), palladium on carbon (1.5 g)under an atmosphere of nitrogen. Hydrogen was then introduced to thereaction mixture via a hydrogen balloon, and the reaction was stirred atroom temperature for 3 hours. The solid material was removed byfiltration, the solution was concentrated under vacuum to provide 2.3 gof AA as light yellow oil, which was used for the next step without anyfurther purifications. LC-MS (ES⁺): m/z 277.10 [MH⁺], t_(R)=0.86 min(2.0 minute run).

Step 5: Synthesis of tert-butyl2-[3-({5-[(4-methylbenzenesulfonyl)oxy]pentyl}oxy)propoxy]acetate (AB)

To a stirred solution of tert-butyl2-[3-[(5-hydroxypentyl)oxy]propoxy]acetate (AA, 2.3 g, 8.32 mmol) indichloromethane (30 mL) was added 4-methylbenzene-1-sulfonyl chloride(3.17 g, 16.63 mmol), triethylamine (2.52 g, 24.90 mmol) and4-dimethylaminopyridine (203 mg, 1.66 mmol) at room temperature. Theresulting mixture was stirred overnight at room temperature. Theresulting mixture was concentrated under reduced pressure to give acrude residue, which was purified by a flash silica gel chromatography(eluent: ethyl acetate/petroleum ether (v:v=1:2) to give 2.6 g of AB asa yellow oil. ¹H NMR (300 MHz, CDCl₃): δ 7.77 (d, J=8.1 Hz, 2H), 7.36(d, J=8.1 Hz, 2H), 4.51 (s, 2H), 4.31 (m, 2H), 4.13 (m, 2H), 3.52 (m,4H), 2.05 (s, 3H), 1.97 (m, 2H), 1.69 (m, 4H), 1.48 (s, 9H), 1.46 (m,2H). LC-MS (ES⁺): m/z 431.20 [MH⁺], t_(R)=1.21 min (2.0 minute run).

Step 1: Synthesis of2-[3-({5-[(4-methylbenzenesulfonyl)oxy]pentyl}oxy)propoxy]acetic acid(L-1)

To a stirred solution of tert-butyl2-[3-({5-[(4-methylbenzenesulfonyl)oxy]pentyl}oxy)propoxy]acetate (AB,1.3 g, 3.02 mmol) in dichloromethane (10 mL) was added trifluoroaceticacid (10 mL) at room temperature. The resulting solution was stirred atroom temperature for 3 hours. The reaction mixture was then concentratedunder vacuum to give 1.5 g (crude) of L-1, which was used for next stepwithout any further purification. LC-MS (ES⁺): m/z 375.34 [MH⁺],t_(R)=1.39 min (2.6 minute run).

The following Linkers (L) were prepared in a similar manner as for thepreparation of L-1.

L-2: 2-(3-(3,3-dimethyl-5-(tosyloxy)pentyloxy)propoxy)acetic acid

L-3:2-(3-(3-hydroxy-5-(tosyloxy)pentyloxy)propoxy)acetic acid

L-4:2-(2-(2-(2-(tosyloxy)ethoxy)ethoxy)ethoxy)acetic acid

To a stirred solution of ethyl2-[2-(2-{2-[(4-methylbenzenesulfonyl)oxy]ethoxy}ethoxy)ethoxy]acetate(AC, 2 g, 5.12 mmol, 1.00 equiv) in methanol (20 mL) was added asolution of NaOH (500 mg, 12.50 mmol) in water (4 mL), and the resultingmixture was stirred at room temperature for 2 hours. Aqueous hydrogenchloride (1 M) was then added to the reaction mixture to adjust pH to˜5. Solids precipitated were collected by filtration to give L-4 (yield:98%). Mass (ES⁺): m/z 363, [MH+].

The following Linkers (L) were prepared in a similar manner as for thepreparation of L-4.

L-5: 2-(2-((2R,3R)-3-(2-(tosyloxy)ethoxy)butan-2-yloxy)ethoxy)aceticacid

L-6: 2-(2-((2S,3S)-3-(2-(tosyloxy)ethoxy)butan-2-yloxy)ethoxy)aceticacid

L-7: 2-(4-(4-(tosyloxy)butoxy)butoxy)acetic acid

Step 1: Synthesis of4-{4-[(4-methylbenzenesulfonyl)oxy]butoxy}butan-1-ol (AE)

To a stirred solution of 4-(4-hydroxybutoxy)butan-1-ol (AD, 2 g, 12.33mmol) in dichloromethane (20 mL) was added Ag₂O (4.25 g, 18.49 mmol), KI(409 mg, 2.46 mmol) and TsCl (2.345 g, 12.30 mmol). The resultingmixture was stirred at room temperature for 12 hours. The inorganic saltformed was removed by filtration and the organic solution wasconcentrated under reduced pressure to give a crude residue. The residuewas purified by flash silica gel chromatography (eluent: ethylacetate/petroleum ether (v:v=1:1)) to give AE (yield: 28%) as acolorless oil.

Step 2: Synthesis of ethyl2-(4-{4-[(4-methylbenzenesulfonyl)oxy]butoxy)butoxy}acetate (AF)

To a stirred solution of4-{4-[(4-methylbenzenesulfonyl)oxy]butoxy}butan-1-ol (AE, 1.1 g, 3.48mmol) in dichloromethane (10 mL) was slowly added BF₃.Et₂O (49.4 mg,0.35 mmol) followed by ethyl 2-diazoacetate (794 mg, 6.96 mmol) at 0° C.The resulting mixture was stirred overnight at room temperature. Thereaction was then quenched by water (2.0 mL). The resulting mixture wasextracted with dichloromethane (50 mL×3), the organic layers werecombined, dried over anhydrous sodium sulfate and then concentratedunder reduced pressure to give a crude residue. The residue was purifiedby flash silica gel chromatography (eluent: ethyl acetate/petroleumether (v:v=1:4) to give AF (yield: 93 as light yellow oil. Mass (ES⁺):m/z 403.10 [MH⁺].

Step 3: Synthesis of2-(4-{4-[(4-methylbenzenesulfonyl)oxy]butoxy}butoxy)acetic acid (L-7)

To a stirred solution of ethyl2-(4-{4-[(4-methylbenzenesulfonyl)oxy]butoxy}butoxy)acetate (AF, 1.3 g,3.23 mmol) in methanol (25 mL) was added a solution of NaOH (388 mg,9.70 mmol) in water (6 mL) at room temperature. The resulting solutionwas stirred at room temperature for 4 hours. The bulk of organic solventwas removed under reduced pressure, to the resulting mixture was addedaqueous hydrogen chloride (1.0 M) to adjust the pH=˜5. The solution wasthen extracted with ethyl acetate (250 mL×3), the organic layers werecombined and dried over anhydrous sodium sulfate, concentrated underreduced pressure to give I-7 (yield: 93%) as light yellow oil. Mass(ES⁺): m/z 375.05 [MH⁺].

L-8: tert-butyl 2-(3-(4-(tosyloxy)butoxy)propoxy)acetate

Step 1. Synthesis of 3-[4-(benzyloxy)butoxy]propan-1-ol (AH)

To a stirred solution of propane-1, 3-diol (1.52 g, 19.98 mmol) in N,N-dimethylformamide (20 mL) was added sodium hydride (840 mg, 35.00mmol) at room temperature, the resulting mixture was stirred at roomtemperature for 30 minutes. Then to the mixture was added 4-(benzyloxy)butyl 4-methylbenzene-1-sulfonate (AG, 6.68 g, 19.97 mmol) and thereaction was stirred overnight at 50° C. TLC indicated formation of thedesired product, at this time the reaction was allowed to cool down toroom temperature. Water (10 mL) was added slowly to quench the reaction;the resulting mixture was then extracted with ethyl acetate (80 mL×2).The organic layers were combined, washed with saturated aqueous solutionof sodium chloride (20 mL), dried over anhydrous sodium sulfate and thenconcentrated under reduced pressure to give a crude residue, which waspurified by flash silica gel chromatography (eluent: ethylacetate/petroleum ether (v:v=1:2)) to give AH (yield: 67%) as a lightyellow oil. ¹H NMR (300 MHz, CDCl₃) δ 7.38-7.29 (m, 5H), 4.52 (m, 2H),3.80 (m, 2H), 3.61 (m, 2H), 3.49-3.46 (m, 4H), 2.04 (m, 2H), 1.82 (m,2H), 1.68 (m, 2H); Mass (ES⁺): m/z 239.05 [MH⁺].

Step 2. Synthesis of tert-butyl2-[3-[4-(benzyloxy)butoxy]propoxy]acetate (AI)

To a stirred solution of 3-[4-(benzyloxy)butoxy]propan-1-ol (AH, 2.38 g,9.99 mmol) in dichloromethane (15 mL) was added tert-butyl2-bromoacetate (7.76 g, 39.78 mmol), TBAC (2.78 g, 10.00 mmol) followedby aqueous sodium hydroxide (37%, 15 mL). The resulting mixture wasstirred overnight at room temperature. The reaction mixture was thenextracted with dichloromethane (100 mL×3), the organic layers werecombined, washed with saturated aqueous solution of sodium chloride (20mL), dried over anhydrous sodium sulfate and then concentrated underreduced pressure to give a crude residue. The residue was purified byflash silica gel chromatography (eluent:ethyl acetate/petroleum ether(v:v=1:5)) to give AI (yield 57%) as a yellow oil. Mass (ES⁺): m/z353.10 [MH⁺].

Step 3. Synthesis of tert-butyl 2-[3-(4-hydroxybutoxy)propoxy]acetate(AJ)

To a stirred mixture of tert-butyl2-[3-[4-(benzyloxy)butoxy]propoxy]acetate (AI, 1 g, 2.84 mmol),palladium on carbon (10%, 200 mg) in methanol (20 mL) was added aceticacid (0.05 mL) under a nitrogen atmosphere. Hydrogen was then introducedto the reaction mixture via a balloon, the reaction was then stirredovernight at room temperature. The insoluble solids were removed byfiltration and the solution phase was concentrated under reducedpressure to give the desired product (yield: 94%) as a yellow oil. Mass(ES⁺): m/z 263.05 [MH+].

Step 4. Synthesis of tert-butyl2-(3-{4-[(4-methylbenzenesulfonyl)oxy]butoxy}propoxy)acetate (L-8)

To a stirred solution of tert-butyl2-[3-(4-hydroxybutoxy)propoxy]acetate (AJ, 700 mg, 2.67 mmol) indichloromethane (10 mL) was added 4-methylbenzene-1-sulfonyl chloride(558.4 mg, 2.93 mmol), TEA (539.5 mg, 5.33 mmol) and4-dimethylaminopyridine (32.6 mg, 0.27 mmol). The resulting mixture wasstirred overnight at room temperature. The bulk of solvent was removedunder reduced pressure to give a crude residue, which was purified byflash silica gel chromatography (eluent: ethyl acetate/petroleum ether(v:v=1:2)) to give titled product (yield: 52%) as a yellow oil. ¹H NMR(300 MHz, CDCl₃) 7.79 (d, J=8.4 Hz, 2H), 7.35 (d, J=8.0 Hz, 2H), 4.05(m, 2H), 3.95 (s, 2H), 3.59 (m, 2H), 3.48 (m, 2H), 3.38 (m, 2H), 2.46(s, 3H), 1.82 (m, 2H), 1.70 (m, 2H), 1.57 (m, 2H), 1.50 (s, 9H); Mass(ES⁺): m/z 417.05 [MH⁺].

L-9: tert-butyl 2-(4-(3-(tosyloxy)propoxy)butoxy)acetate

L-9 was prepared in a similar manner as that used to prepare L-8, exceptthat AK was used in place of AG. Mass (ES⁺): m/z 439.15 [MNa⁺].

L-10: tert-butyl 2-(6-(tosyloxy)hexa-2,4-diynyloxy)acetate

Step 1: Synthesis of tert-butyl2-[(6-hydroxyhexa-2,4-diyn-1-yl)oxy]acetate (AP)

To a stirred solution of hexa-2, 4-diyne-1, 6-diol (AO, 100 mg, 0.91mmol) in N, N-dimethylformamide (5 mL) was added sodium hydride (32 mg,1.33 mmol) at 0° C. The resulting mixture was then warmed up to roomtemperature and stirred at room temperature for 30 minutes. The reactionmixture was cooled to 0° C. followed by addition of tert-butyl2-bromoacetate (176 mg, 0.90 mmol), and the resulting mixture wasstirred at 0° C. for 2h. LC-MS indicated formation of the desiredproduct. The reaction was then quenched by water (10 mL, added slowly)at 0° C., and was extracted with ethyl acetate (20×2 mL). The organiclayers were combined, dried over anhydrous sodium sulfate and thenconcentrated under reduced pressure to give a crude residue, which waspurified by flash silica gel chromatography (eluent: ethylacetate/petroleum ether (v:v=1:2)) to give AP (yield: 49%) as a yellowoil.

Step 2. Synthesis of tert-butyl2-({6-[(4-methylbenzenesulfonyl)oxy]hexa-2,4-diyn-1-yl}oxy)acetate(L-10)

To a stirred solution of tert-butyl 2-[(6-hydroxyhexa-2, 4-diyn-1-yl)oxy] acetate (AP, 50 mg, 0.22 mmol) in ether (2 mL) was added4-toluenesulfonyl chloride (51 mg, 0.27 mmol) at 0° C., followed bypotassium hydroxide (125 mg, 2.23 mmol) in several batches at 0° C. Theresulting mixture was stirred at 0° C. for 4 hours. LC-MS indicatedformation of the desired product. Water (10 mL) was added to thereaction, and the resulting mixture was extracted with ethyl acetate (20mL×2). The organic layers were combined, dried over anhydrous sodiumsulfate and then concentrated under reduced pressure to give a cruderesidue, which was purified by flash silica gel chromatography (eluent:ethyl acetate/petroleum ether (v:v=1:2)) to give L-10 (yield: 71%) as ayellow oil. ¹H NMR (300 MHz, CDCl₃): δ 7.83 (d, J=6.0 Hz, 2H), 7.39 (d,J=6.0 Hz, 2H), 4.79 (s, 2H), 4.37 (s, 2H), 4.05 (s, 2H), 2.48 (s, 3H),1.51 (s, 9H); LC-MS (ES⁺): m/z 401.05 [MNa⁺], t_(R)=1.71 min (2.6 minuterun).

The following Linkers (L) were prepared in a similar manner as for thepreparation of L-10.

L-11: tert-butyl 3-(6-(tosyloxy)hexa-2,4-diynyloxy)propanoate

L-12: tert-butyl 4-(6-(tosyloxy)hexa-2,4-diynyloxy)butanoate

L-13: ethyl 2-(2-(2-aminoethoxy)ethoxy)acetate hydrochloride

Step 1: Synthesis of tert-butyl N-[2-(2-hydroxyethoxy)ethyl]carbamate(AR)

To a stirred solution of 2-(2-aminoethoxy)ethan-1-ol (AQ, 5.25 g, 49.94mmol) in tetrahydrofuran (100 mL) was added aqueous solution of sodiumbicarbonate (20% (w/w), 40 ml) and (Boc)₂O (11.4 g, 52.23 mmol, added inseveral batches) at 0° C. The resulting mixture was then warmed upslowly to room temperature and stirred at room temperature for 5 hours.The bulk of organic solvent was removed under reduced pressure and theresulting residue was diluted with water (300 mL), extracted with ofethyl acetate (100 mL×3). The organic layers were combined, washed withsaturated aqueous solution of sodium chloride (20 mL×2), dried overanhydrous sodium sulfate and then concentrated under reduced pressure togive AR (yield: 98%) as colorless oil.

Step 2: Synthesis of ethyl2-[2-(2-{[(tert-butoxy)carbonyl]amino}ethoxy)ethoxy]acetate (AS)

To a stirred solution of tert-butylN-[2-(2-hydroxyethoxy)ethyl]carbamate (AR, 4.0 g, 19.49 mmol) indichloromethane (30 mL) was added 1-diazo-3-methoxypropan-2-one (3.34 g,29.27 mmol) and BF₃-Et₂O (0.2 mL) at room temperature. The resultingsolution was stirred at room temperature for 2 hours. Water (20 mL) wasadded to the reaction mixture, organic layer was separated and washedwith brine (20 mL), dried over anhydrous sodium sulfate and concentratedunder reduced pressure to give a crude residue. The residue was purifiedby flash silica gel chromatography (eluent: ethyl acetate/petroleumether (v:v=1:2)) to give AS (yield: 18%) as yellow solid. ¹H NMR (400MHz, CDCl₃): δ 4.25-4.22 (q, J=7.2 Hz, 2H), 4.14 (s, 2H), 3.74 (b, 2H),3.72 (b, 1H), 3.67-3.32 (m, 4H), 1.414 (s, 9H), 1.31 (t, J=7.2 Hz, 3H).

Step 3: Synthesis of ethyl 2-[2-(2-aminoethoxy)ethoxy]acetatehydrochloride (L-13)

To a stirred solution of ethyl2-[2-(2-{[(tert-butoxy)carbonyl]amino}ethoxy)ethoxy]acetate (AS, 500 mg,1.72 mmol) in 1,4-dioxane (10 mL) was introduced hydrogen chloride (gas)via bubbling at room temperature for 2 hours. The solvent was thenremoved under vacuum to give L-13 (yield: 99%). LC-MS (ES⁺): m/z 192.00[MH⁺], t_(R)=0.41 min (2.0 minute run).

L-14: ethyl 2-(5-aminopentyloxy)acetate

Step 1: Synthesis of tert-butyl 5-hydroxypentylcarbamate (AU)

To a stirred solution of 5-aminopentan-1-ol (AT, 3.1 g, 30.05 mmol) indichloromethane (30 mL) was added di-tert-butyl dicarbonate (6.56 g,30.06 mmol) at 0° C. The resulting mixture was then stirred at roomtemperature for 4 hours. The solvent was removed under reduced pressureto give a crude residue which was purified by flash silica gelchromatography (eluent: ethyl acetate/petroleum ether (v:v=1:2)) to giveAU (yield: 98%) as a colorless oil. LC-MS (ES⁺): m/z 204.00 [MH⁺],t_(R)=1.29 min (2.6 minute run).

Step 2: Synthesis of ethyl2-[(5-{[(tert-butoxy)carbonyl]amino}pentyl)oxy]acetate (AV)

To a stirred solution of tert-butyl N-(5-hydroxypentyl)carbamate (AU,1.5 g, 7.38 mmol) in dichloromethane (10 mL) was added BF₃-Et₂O (0.1 mL)at 0° C. To this mixture was then added a solution of ethyl2-diazoacetate (850 mg, 7.45 mmol) in dichloromethane (2 mL) at 0° C.The resulting mixture was allowed to warm up to room temperature andstirred at room temperature for 2 hours. Saturated aqueous sodiumbicarbonate (30 mL) was added to the reaction, the resulting mixture wasextracted with ethyl acetate (150 mL×3). The organic layers werecombined, dried over anhydrous sodium sulfate and then concentratedunder reduced pressure to give a crude residue, which was purified byflash silica gel chromatography (eluent: ethyl acetate/petroleum ether(v:v=1:7)) to give AV (yield: 15%) as a colorless oil. LC-MS (ES⁺): m/z290.05 [MH⁺], t_(R)=1.55 min (2.6 minute run).

Step 3: Synthesis of ethyl 2-(5-aminopentyloxy)acetate (L-14)

To a stirred solution of ethyl ethyl2-[(5-{[(tert-butoxy)carbonyl]amino}pentyl)oxy]acetate (AV, 400 mg, 1.38mmol) in dichloromethane (5 mL) was added trifluoroacetic acid (5 mL) atroom temperature. The resulting solution was stirred at room temperaturefor 2 hours. The reaction mixture was then concentrated under vacuum togive L-14 (yield: 84%) as a yellow oil. LC-MS (ES⁺): m/z 190.00 [MH⁺],t_(R)=1.01 min (2.6 minute run).

L-15: methyl 2-(2-(2-(methylamino)ethoxy)ethoxy)acetate

Step 1: Synthesis of 2-[2-(benzylamino)ethoxy]ethan-1-ol (AX)

To a stirred solution of 2-(2-aminoethoxy)ethan-1-ol (AW, 5.0 g) andbenzaldehyde (5.0 g) in THF (50 mL) was added sodiumtriacetoxyborohydride (15.8 g, 74.5 mmol) at 0° C. The resultingsolution was then stirred at room temperature for 4 hours. Water (50 mL)was added to the reaction and the resulting mixture was extracted withethyl acetate (50 mL×2). The organic layers were combined, dried overanhydrous sodium sulfate and then concentrated under reduced pressure togive a crude residue, which was purified by flash silica gelchromatography (eluent: dichloromethane/methanol (v:v=3:1) to give AX(yield: 85%) as a white solid. LC-MS (ES⁺): m/z 195.95[MH⁺], t_(R)=0.22min (2.0 minute run).

Step 2: Synthesis of 2-{2-[benzyl(methyl)amino]ethoxy}ethan-1-ol (AY)

To a stirred solution of of 2-[2-(benzylamino)ethoxy]ethan-1-ol (AX,10.0 g) in methanol (200 mL) was added formaldehyde (38% in water) (4.9mL) and triacetoxyborohydride (17.0 g) at room temperature. Theresulting solution was stirred at room temperature for 2 hours.Saturated aq. sodium bicarbonate (100 mL) was added to the reaction, andbulk of organic solvent was then removed under reduced pressure. Theresulting mixture was extracted with ethyl acetate (200 mL×3). Theorganic layers were combined, dried over anhydrous sodium sulfate andthen concentrated under reduced pressure followed by high vacuum pump togive AY (yield: 33%) as a yellow oil. LC-MS (ES⁺): m/z 210.00 [MH⁺],t_(R)=0.43 min (2.0 minute run).

Step 3: Synthesis of methyl2-(2-{2-[benzyl(methyl)amino]ethoxy}ethoxy)acetate (AZ)

To a stirred solution of 2-{2-[benzyl(methyl)amino]ethoxy}ethan-1-ol(AY, 2 g) in dichloromethane (20 mL) was added a solution of sodiumhydroxide (37%) in water (20 mL) followed by tert-butyl 2-bromoacetate(7.76 g) and TBAC (2.78 g) at room temperature. The resulting mixturewas stirred at room temperature for 15 hours. The aqueous layer wasseparated, and to which aq. hydrogen chloride (4N) was added to adjustthe pH to ˜3 before it was concentrated under reduced pressure to give acrude residue. Methanol (20 mL) was then added to this residue andinsoluble salts were filtered out. The solution was concentrated undervacuum to give 2-(2-[2-[benzyl(methyl)amino]ethoxy]ethoxy)acetic acid(yield: 78%) as a yellow oil. To a stirred solution of2-(2-{2-[benzyl(methyl)amino]ethoxy}ethoxy)acetic acid (2 g, 7.48 mmol,1.00 equiv) prepare above in methanol (50 mL) was slowly added sulfuricacid (2 mL) at room temperature. The resulting solution was stirred at70° C. in an oil bath for 3 hours. The bulk of solvent was removed underreduced pressure to give a residue, which was diluted with H₂O (30 mL).Sodium carbonate was then added to the mixture to adjust the pH to ˜8.The mixture was then extracted with ethyl acetate (50 mL×2), the organiclayers were combined, dried over anhydrous sodium sulfate and thenconcentrated under reduced pressure followed by high vacuum pump to giveAZ (yield: 29%) as a yellow oil. LC-MS (ES⁺): m/z 281.95 [MH⁺],t_(R)=0.30 min (2.0 minute run).

Step 4: Synthesis of methyl 2-{2-[2-(methylamino)ethoxy]ethoxy}acetate(L-15)

To a stirred mixture of methyl2-(2-{2-[benzyl(methyl)amino]ethoxy}ethoxy)acetate (AZ, 600 mg, 2.13mmol) and palladium on carbon (300 mg) in methanol (30 mL) under anitrogen atmosphere was charged with hydrogen gas via a balloon. Theresulting mixture was stirred at room temperature for 15 hours. Thesolid material was removed by filtration and the solution wasconcentrated under vacuum to give L-15 (400 mg) as yellow oil, which wasused for next step without any further purifications. LC-MS (ES⁺): m/z191.95 [MH⁺], t_(R)=0.31 min (2.0 minute run).

L-16: ethyl 2-(5-(methylamino)pentyloxy)acetate

Step 1: Synthesis of ethyl2-[(5-{[(tert-butoxy)carbonyl](methyl)amino}pentyl)oxy]acetate (BB)

To a stirred solution of ethyl2-[(5-{[(tert-butoxy)carbonyl]amino}pentyl)oxy]acetate (BA, 1.1 g, 3.8mmol) in N,N-dimethylformamide (10 mL) was added CH₃I (0.71 mL, 11.4mmol) at 0° C., followed by sodium hydride (304 mg, 7.60 mmol, 60% inmineral oil) in several portions at 0° C. The resulting mixture wasstirred at room temperature for 16 hours. Water (1.0 mL) was added andthe resulting mixture was extracted with ethyl acetate (50 mL×2). Theorganic layers were combined, washed with saturated aqueous solution ofsodium chloride (100 mL), dried over anhydrous sodium sulfate and thenconcentrated under reduced pressure to give a crude residue which waspurified by a flash silica gel chromatography (eluent: ethylacetate/petroleum ether (v:v=1:10)) to give BB (yield: 21%) as a yellowoil. LC-MS (ES⁺): m/z 326.20 [MNa⁺], t_(R)=1.55 min (2.6 minute run).

Step 2: Synthesis of ethyl 2-{[5-(methylamino)pentyl]oxy}acetate (L-16)

To a stirred solution of ethyl2-[(5-{[(tert-butoxy)carbonyl](methyl)amino}pentyl)oxy]acetate (BB, 240mg, 0.79 mmol) in dichloromethane (5 mL) was added trifluoroacetic acid(0.5 mL). The resulting solution was stirred at room temperature for 16hours. The solvents were removed under recued pressure followed by highvacuum pump to give L-16 (yield: 99%) as a yellow oil. LC-MS (ES⁺): m/z204.20 [MH⁺], t_(R)=0.56 min (2.0 minute run).

L-17: 2-(3-(2-(tosyloxy)ethoxy)propoxy)acetic acid

Step 1: Synthesis of tert-butyl2-{3-[2-(benzyloxy)ethoxy]propoxy}acetate (BD)

To a stirred solution of 3-[2-(benzyloxy)ethoxy]propan-1-ol (BC, 1.8 g,8.56 mmol) and tert-butyl 2-bromoacetate (6.6 g, 33.84 mmol, 4.00 equiv)in dichloromethane (40 mL) was added TBAC (2.4 g) and aq. Solution ofsodium hydroxide (37%, 40 mL). The resulting mixture was stirred at roomtemperature overnight. LC-MS indicated formation of the desired product.The reaction mixture was then extracted with ethyl acetate (150×3 mL),the organic layers combined, dried over anhydrous sodium sulfate andconcentrated under reduced pressure to give a crude residue, which waspurified by a flash silica gel chromatography (eluent: ethylacetate/petroleum ether (v:v=1:2) to give BD (yield: 90%) as a colorlessoil. H NMR (300 MHz, CDCl₃): δ 7.35-7.27 (m, 5H), 4.57 (s, 2H), 3.94 (s,2H), 3.63-3.57 (m, 8H), 1.96-1.87 (m, 2H), 1.47 (s, 9H); LC-MS (ES⁺):m/z 347.10 [MNa⁺], t_(R)=1.72 min (2.6 minute run).

Step 2: Synthesis of tert-butyl 2-[3-(2-hydroxyethoxy)propoxy]acetate(BE)

To a stirred mixture of tert-butyl2-{3-[2-(benzyloxy)ethoxy]propoxy}acetate (BD, 2.5 g, 7.71 mmol) andpalladium on carbon (2.0 g) in methanol (20 mL) under a nitrogenatmosphere was introduced hydrogen gas via a balloon. The resultingmixture was stirred overnight at room temperature under hydrogen gasatmosphere. LC-MS indicated completion of the reaction. The solids wereremoved by filtration, the solution was concentrated under vacuum togive BE (yield: 99%) as a colorless oil. LC-MS (ES⁺): m/z 257.10 [MNa⁺],t_(R)=1.21 min (2.6 minute run).

Step 3: Synthesis of tert-butyl2-(3-{2-[(4-methylbenzenesulfonyl)oxy]ethoxy}propoxy)acetate (BF)

To a stirred solution of tert-butyl2-[3-(2-hydroxyethoxy)propoxy]acetate (BE, 1.8 g, 7.68 mmol) indichloromethane (50 mL) was added 4-toluenesulfonyl chloride (2.2 g,11.54 mmol), triethylamine (2.33 g, 23.03 mmol) and4-dimethylaminopyridine (95 mg, 0.78 mmol). The resulting mixture wasstirred overnight at room temperature. LC-MS indicated formation of thedesired product. The reaction mixture was concentrated under reducedpressure to give a crude residue, which was purified by a flash silicagel chromatography (eluent: ethyl acetate/petroleum ether (v:v=1:2) togive BF (yield: 80%) as a yellow oil. ¹H NMR (400 MHz, CDCl₃): δ 7.80(d, J=8.0 Hz, 2H), 7.34 (d, J=8.4 Hz, 2H), 4.15 (t, J=3.6 Hz, 2H), 3.93(s, 2H), 3.61 (t, J=3.6 Hz, 2H), 3.55-3.49 (m, 4H), 2.45 (s, 3H),1.85-1.78 (m, 2H), 1.48 (s, 9H); LC-MS (ES⁺): m/z 411.00 [MNa⁺],t_(R)=1.12 min (2.0 minute run).

Step 4: Synthesis of2-(3-{2-[(4-methylbenzenesulfonyl)oxy]ethoxy}propoxy)acetic acid (L-17)

To a stirred solution of tert-butyl2-(3-{2-[(4-methylbenzenesulfonyl)oxy]ethoxy}propoxy)acetate (BF, 400mg, 1.03 mmol) in dichloromethane (3 mL) was added trifluoroacetic acid(1 mL) at room temperature. The resulting solution was stirred at roomtemperature for 1 hour. LC-MS indicated completion of the reaction. Thereaction mixture was concentrated under reduced pressure to give L-17(350 mg) as a yellow oil, which was used for next step without furtherpurifications. LC-MS (ES⁺): m/z 332.90 [MH⁺], t=0.81 min (2.0 minuterun).

Unless otherwise noted, the following intermediates and their analogs(for examples, but not limited to, analogs with substitutions such ashalogens) were synthesized according to similar procedures describedabove for the synthesis of L-17, by utilizing corresponding startingmaterials and reagents.

L-18: 2-(2-hydroxyethoxy)ethyl 4-methylbenzenesulfonate

L-19: ethyl 2-(2-(2-(tosyloxy)ethoxy)ethoxy)acetate

L-20: ethyl 3-(2-(2-(tosyloxy)ethoxy)ethoxy)propanoate

L-21: ethyl 5-(tosyloxy)pentanoate

L-22: ethyl 3-(2-(tosyloxy)ethoxy)propanoate

L-23: ethyl 2-(5-(tosyloxy)pentyloxy)acetate

L-24: ethyl 3-(5-(tosyloxy)pentyloxy)propanoate

L-25: 5-hydroxypentyl 4-methylbenzenesulfonate

L-26: ethyl 2-(5-(tosyloxy)pentyloxy)acetate

L-27: ethyl 2-(3-(tosyloxy)propoxy)acetate

L-28: ethyl 2-(2-(tosyloxy)ethoxy)acetate

L-29: ethyl 2-(4-(2-(tosyloxy)ethoxy)butoxy)acetate

L-30: 2-(2-(2-hydroxyethoxy)ethoxy)ethyl 4-methylbenzenesulfonate

L-31: 2-((2R,3R)-3-(2-hydroxyethoxy)butan-2-yloxy)ethyl4-methylbenzenesulfonate

L-32: 1-methyl-4-((1-methylpiperidin-4-yl)methyl)piperazine

When referring to the specific exemplary compounds presented herein, thespecification uses the terms “example #.” For example, compound 1 (Table2 of FIG. 2) is also referred to as Example 1. DC50 (μM) categories(degradation of AR ELISA in LNCaP and/or VCaP cells) of Table 2-7 are asfollows: A<1 nM; B: 1-10 nM; C: 10-100 nM; D: >100 nM. Dmax categories(degradation of AR-maximum inhibition (%) AR ELISA in LNCaP and/or VCaPcells): A>50%; B<50%.

Androgen Receptor ELISA Assay. Compounds have been evaluated in thisassay in LNCaP and/or VCaP cells utilizing similar protocols. Theprotocols used with VCaP cells are described below. The androgenreceptor ELISA assay was performed using PathScan AR Sandwich ELISA(Cell Signaling Catalog#1280 according to the following assay steps:

VCaP cells are seeded at 40,000 cells/well at a volume of 100 μL/well inVCaP assay medium [Phenol red free RPMI (Gibco Cat#11835-030); 5%Charcoal Stripped (Dextran treated) FBS (Omega Scientific, Cat#FB-04);1% penstrep (Life Technologies, Gibco Cat#: 10378-016)] in Corning 3904plates. The cells are grown for a minimum of 3 days.

First, cells are dosed with compounds diluted in 0.01% DMSO-use apolypropylene plate avoiding the use of outer columns according to thefollowing protocol: (1)(i) make 1000× stock plate in DMSO; (ii) 20 mMstock diluted 1/6.7 with DMSO (5 μL+28.3 μL DMSO)=3 mM into row H; (iii)perform serial dilutions in % log doses (10 μL of PROTAC+20 μL DMSO)from row H towards row B. Reserve row A for DMSO; (iv) 7 doses total(final concentration in this 1000× plate will be 3 mM, 1 mM, 333 μM, 111μM, etc). (2)(i) Make 10× stock plate in media; (ii) transfer 2.5 μL ofthe 1000× stock to a new 10× stock plate (use 12 channel pipet, start atA (DMSO control) work thru H. When 247.5 μL of media is added to thisplate, it will serve as a Ox stock; (iii) make media+1 nM R1881 formaking 10× stock plate; (iv) add 247.5 μL of media with 1 nM R1881 toeach well of the 10× stock plate, mix.

Then 22 μL of 10× stock is added to cells and incubated for 5 hours. 1×Cell Signaling Cell lysis buffer is made (Catalogue #9803; comes withthe kit)—prepare for 50 μL/well. Keep on ice. Media is aspirated, and100 μL 1× cell lysis buffer/well is added. The cells are placed on ashaker located in a cold room for 10 minutes and shaken at speek of 7.The lysate mixture is mix and 20 μL transferred to 100 μl of Diluent inELISA plate (0.15 μg/ml-0.075 μg/ml). The lysate-diluent mixture isstore at 4° C. overnight on a shaker located in a cold room at speed 5(gentle swirl).

The lysate-diluent mixture is shaken for 30 minutes at 37° C. Allowmouse AR antibody, anti-mouse antibody, TMB, and STOP solution to cometo room temperature. Make 1×ELISA buffer included in kit, load inreservoir. Run primer program on plate washer. Media from the plates isdiscarded, the ELISA plate tapped hard on paper towel, and washed 4×200μl ELISA wash buffer using a plate washer for the first three washes andan eight channel aspirator for the fourth wash to more thoroughlyaspirate the solution.

Add 100 μL/well mouse AR detection Ab; cover and shake, 37° C. for 1hour; media is discarded from the places, tap the plates on a papertowel, wash 4×200 μL ELISA wash buffer with a plate washer for the firstthree washed and an eight channel aspirator for the fourth wash; add 100μL/well anti-mouse—HRP conjugated Ab (comes with the kit); cover andshake, 37° C. for 30 minutes; allow TMB reagent to come to roomtemperature; discard media from the plate, tap plates on paper towl,wash 4×200 μL ELISA wash buffer with a plate washer for the first threewashed and an eight channel aspirator for the fourth wash; tap theplates on paper towl; add 100 μL TMB and shake for 2 minutes—whilewatching color. Add 100 μL Stop solution when light blue color develops.Shake plates and read at 450 nM.

Progression of prostate cancer in patients treated with anti-androgentherapy usually involves one of several mechanisms of enhanced AndrogenReceptor (AR) signaling, including increased intratumoral androgensynthesis, increased AR expression and AR mutations. PROTACs(PROteolysis TArgeting Chimera), which uses bi-functional molecules thatsimultaneously bind a target of choice and an E3 ligase, causeubiquitination via induced proximity and degradation of the targeted,pathological protein. As opposed to traditional target inhibition, whichis a competitive process, degradation is a progressive process. As such,it is less susceptible to increases in endogenous ligand, targetexpression, or mutations in the target. Thus this technology seems idealfor addressing the mechanisms of AR resistance in patients with prostatecancer.

Data is analyzed and plotted using GraphPad Prism software. Compoundsdescribed in this application were assayed and c-myc suppression potencyis listed in the Table 2-7.

Apoptosis in VCaP cells. VCaP cells may be cultured in Charcoal StrippedSerum containing media supplemented with 0.1 nM R1881 for 48 hours. Thedegree of apoptosis can then be ascertained with CaspaseGlo assay(Promega).

Anti-proliferation in LNCaP F876L. LNCaP cells transduced with an ARconstruct were cultured in Charcoal Stripped Serum containing media.Indicated doses of enzalutamide or Exemplary Compounds can be added for7 days. CellTiterGlo reagent (Promega) can be employed to assessproliferation.

PSA suppression in LNCaP F876L. LNCaP F876L cells transduced with an ARconstruct were cultured in Charcoal Stripped Serum containing mediasupplemented with 0.1 nM R1881 for 7 days. Secreted PSA in the media wasdetected by PSA ELISA (Sigma).

Prostate involution in C57B6 mouse model. 12-week old male C57BL/6 miceare treated with an AR PROTAC and its inactive epimer analog which isunable to bind to cereblon E3 ligase. Compounds are administered for 10days, upon which the prostates were isolated and weighed.

Tumor Growth Inhibition in VCaP Xenograft Model.

VcaP Xenograft and Drug Treatment. Three million VCaP cells 75%MatriGel/25% RPMI suspension are implanted into CB17 scid micesubcutaneously. Once the tumors reach about 200-300 mm³, the mice aresurgically castrated, leading to temporary tumor stasis. Allow the miceto recover for at least one week. The mice are then dosed withenzalutamide (PO, QD, 30 mpk) or AR PROTAC (IP, QD, at 30, 10 and 3 mpk)as indicated by oral gavage. Sixteen hours after the last does, the miceare sacrificed and the tumors excised.

Tissue lysis buffer. Final concentrations: 25 mM HEPES (pH 7.4), 50 mMNaCl, 1% NP-40, 0.1% SDS, protease inhibitor tablets/EDTA free mini(A32955) 1/10 ml (if DNA is a problem, protease inhibitor tablets withEDTA is used); if phospho-proteins are observed at end point—aphosphatase inhibitor is added. One p per mg of tissue is utilized.Protease Inhibitor Cocktail mini is added fresh to the lysis bufferprior to homogenization.

Tissue lysis. Five mm stainless steel bead in 2 ml tube or 2.5 mm beadfor 1.5 ml tubes is added to frozen tumor chunk on dry ice. Bead andtumor is transferred to wet ice. Add 1 μl of tissue lysis buffer per mgof tissue to the tumor and beads mixture. Bead milling of the tissue wasperformed for for 4 minutes, 25 Hz, 4° C. The beads are removed with amagnet. The lysates are spun for 15 minutes 14,000×g, 4° C. The totallysate volume is transferred to block plate. The tumor lysate isnormalized, usually ˜50 μg/μl.

Western blotting. 10 μg/lane are used for LnCAP lysates and 5 ug/lanefor VCaP lysates. Samples are run at 150 V for 85 minutes. Transfer tonitrocellulose membrane. Block the nitrocellulose membrane for 1 hour atroom temperature with 3% BSA. Primary antibody: Cell Signaling antibodyAR #5153 1/2000 o.n., mitoC abcam #ab92824 1:1000, ERG antibody Abcam #ab92513 1:1000. Secondary antibody: Cell signaling antibody #7074/70761/20000 for 1 hour (Anti-mouse/rabbit HRP). Detect with Femto (THERMOFISHER) or Clarity (BIO-RAD).

Xenograft data is shown below in Table 8.

TABLE 8 Xenograft data for select compounds of the present disclosurePD_AR_castrated_VCaP % AR degraded Ex. # @10 mg_kg @16 hr (%) 382 C 378C 265 C 177 C 124 C 263 C 400 B 134 B 133 B 183 B 293 B 316 B 193 B 377B 289 B 185 B 41 A 91 A 127 A 178 A 180 A 315 A 359 A 288 A 131 A 179 A440 A 126 A 310 A 182 A 346 A 132 A 181 A 420 A 270 A 240 A 343 A 426 A145 A 215 A 114 A 158 A 210 A 234 A 122 A 129 A 247 A 406 A

AR degradation of PROTAC is E3 ligase dependent. An AR PROTAC is addedto LNCaP cells at indicated concentrations for 24 hours in the presenceor absence of 10 uM cereblon E3 ligase ligand. (A) AR decradationactivity of the AR PROTAC is examined to determine if there isdiminished degradation as a result of competition from the cereblon E3ligase ligand with AR PROTAC in cereblon E3 ligase binding. (B) LNCaPcells are treated with an AR PROTAC and its inactive epimer analog whichis unable to bind to cereblon E3 ligase.

PROTAC Prodrug Oral Pharmacokinetics and PROTAC SubcutaneousPhamacokinetics.

Representative Pharmacokinetic Procedure

Male CD-1 mice (6-8 weeks old, weighing 20-30 g, 3 per study) with freeaccess to food and water are administered with the test article at 10mg/kg either by oral gavage or sub-cutaneous injection in theformulation specified in tables 20 and 21, at 10 mL/kg.

Approximately 0.04 mL blood samples are collected from the dorsalmetatarsal vein serially at 0.25, 0.5, 1, 2, 4, 8 and 24 hourstimepoints; heparin is used as the anticoagulant. The samples arecentrifuged at 4000 g for 5 minutes at 4° C. then stored at −75° C.prior to analysis.

The plasma samples are analysed via an LC/MS/MS method quantitating forunchanged, administered test article, and/or a derivative species asappropriate. WinNonlin (PhoenixTM) is used for the pharmacokineticcalculations and modeling, to generate parameters such as Cmax and AUC.

SPECIFIC EMBODIMENTS

In certain embodiments, the description provides a compound having astructure selected from the group consisting of Examples 1-452 and528-625 (see Tables 2-7), a salt, a polymorph, and prodrug thereof. Incertain additional embodiments, the description provides a compositioncomprising at least one of the compounds of Examples 1-452 and 528-625including a salt, polymorph, and prodrug thereof. In still additionalembodiments, the description provides a therapeutic compositioncomprising at least one of the compounds of Examples 1-452 and 528-625including a salt, a polymorph, and a prodrug thereof, and apharmaceutically acceptable carrier.

An aspect or the present disclosure provides a compound having thestructure:

ABM-L-CLM,

wherein ABM is an androgen receptor (AR) binding moiety, L is a chemicallinker moiety, CLM is a cereblon E3 ubiquintin ligase binding moiety,wherein the ABM comprises a structure selected from the group consistingof:

wherein:

-   -   W¹ is aryl, heteroaryl, bicyclic, or biheterocyclic, each        independently substituted by 1 or more H, halo, hydroxyl, nitro,        CN, C≡CH, C₁₋₆ alkyl (linear, branched, optionally substituted;        for example, optionally substituted by 1 or more halo, C₁₋₆        alkoxyl), C₁₋₆ alkoxyl (linear, branched, optionally        substituted; for example, optionally substituted by 1 or more        halo), C₂₋₆ alkenyl, C₂₋₆alkynyl, or CF₃;    -   Y¹, Y² are each independently NR^(Y1), O, S, SO₂, heteroaryl, or        aryl;    -   Y³, Y⁴, Y⁵ are each independently a bond, O, NR^(Y2),        CR^(Y1)R^(Y2), C═O, C═S, SO, SO₂, heteroaryl, or aryl;    -   Q is a 3-6 membered ring with 0-4 heteroatoms, optionally        substituted with 0-6 R^(Q), each R^(Q) is independently H, C₁₋₆        alkyl (linear, branched, optionally substituted; for example,        optionally substituted by 1 or more halo, C₁₋₆ alkoxyl),        halogen, C₁₋₆ alkoxy, or 2 R^(Q) groups taken together with the        atom they are attached to, form a 3-8 membered ring system        containing 0-2 heteroatoms);    -   R¹, R², R^(a), R^(b), R^(Y1), R^(Y2) are each independently H,        C₁₋₆ alkyl (linear, branched, optionally substituted; for        example, optionally substituted by 1 or more halo, C₁₋₆        alkoxyl), halogen, C₁₋₆ alkoxy, cyclic, heterocyclic, or R¹, R²        together with the atom they are attached to, form a 3-8 membered        ring system containing 0-2 heteroatoms);    -   W² is a bond, C₁₋₆ alkyl, C₁₋₆ heteroalkyl, O, aryl, heteroaryl,        alicyclic, heterocyclic, biheterocyclic, biaryl, or        biheteroaryl, each optionally substituted by 1-10 R^(W2); each        R^(W2) is independently H, halo, C₁₋₆ alkyl (linear or branched        optionally substituted; for example, optionally substituted by 1        or more F), —OR^(W2A), C₃₋₆ cycloalkyl, C₄₋₆ cycloheteroalkyl,        C₁₋₆ alicyclic (optionally substituted), heterocyclic        (optionally substituted), aryl (optionally substituted), or        heteroaryl (optionally substituted), bicyclic hereoaryl or aryl,        OC₁₋₃alkyl(optionally substituted; for example, optionally        substituted by 1 or more —F), OH, NH₂, NR^(Y1)R^(Y2), CN; and    -   R^(W2A) is H, C₁₋₆ alkyl (linear, branched), or C₁₋₆ heteroalkyl        (linear, branched), each optionally substituted by a cycloalkyl,        cycloheteroalkyl, aryl, heterocyclic, heteroaryl, halo, or        OC₁₋₃alkyl.

In any aspect or embodiment described herein, W¹ is selected from thegroup consisting of:

In any aspect or embodiment described herein, W² is selected from thegroup consisting of:

In any aspect or embodiment described herein, the CLM comprises achemical group derived from an imide, a thioimide, an amide, or athioamide that binds to the cereblon E3 ubiquitin ligase.

In any aspect or embodiment described herein, the chemical group is aphthalimido group, or an analog or derivative thereof.

In any aspect or embodiment described herein, the CLM is thalidomide,lenalidomide, pomalidomide, analogs thereof, isosteres thereof, orderivatives thereof.

In any aspect or embodiment described herein, the CLM has a chemicalstructure represented by:

wherein

W is selected from the group consisting of CH₂, CHR, C═O, SO₂, NH, andN-alkyl;

each X is independently selected from the group consisting of O, S, andH₂;

Y is selected from the group consisting of NH, N-alkyl, N-aryl,N-hetaryl, N-cycloalkyl, N-heterocyclyl, O, and S;

Z is selected from the group consisting of O, S, and H₂;

G and G′ are each independently selected from the group consisting of H,alkyl (linear, branched, optionally substituted), OH, R′OCOOR,R′OCONRR″, CH₂-heterocyclyl optionally substituted with R′, and benzyloptionally substituted with R′;

Q₁, Q₂, Q₃, and Q₄ represent a carbon C optionally substituted with agroup independently selected from R′, N or N-oxide;

A is selected from the group consisting of H, alkyl, cycloalkyl, Cl andF;

R is selected from the group consisting of —CONR′R″, —OR′, —NR′R″, —SR′,—SO₂R′, —SO₂NR′R″, —CR′R″—, —CR′NR′R″—, -aryl, -hetaryl, -alkyl (linear,branched, optionally substituted), -cycloalkyl, -heterocyclyl,—P(O)(OR′)R″, —P(O)R′R″, —OP(O)(OR′)R″, —OP(O)R′R″, —Cl, —F, —Br, —I,—CF₃, —CN, —NR′SO₂NR′R″, —NR′CONR′R″, —CONR′COR″, —NR′C(═N—CN)NR′R″,—C(═N—CN)NR′R″, —NR′C(═N—CN)R″, —NR′C(═C—NO₂)NR′R″, —SO₂NR′COR″, —NO₂,—CO₂R′, —C(C═N—OR′)R″, —CR′═CR′R″, —CCR′, —S(C═O)(C═N—R′)R″, —SF₅,—R′NR′R″, (—R′O)_(n)R″, or and —OCF₃;

R′ and R″ are each independently selected from the group consisting of abond, H, alkyl (linear, branched), cycloalkyl, aryl, hetaryl,heterocyclyl, or —C(═O)R, each of which is optionally substituted;

represents a bond that may be stereospecific ((R) or (S)) ornon-stereospecific; and

R_(n) is a functional group or an atom,

wherein n is an integer from 1-10 (e.g., 1-4, 1, 2, 3, 4, 5, 6, 7, 8, 9,or 10), and wherein

-   -   when n is 1, R_(n) is modified to be covalently joined to the        linker group (L), and    -   when n is 2, 3, or 4, then one R_(n) is modified to be        covalently joined to the linker group (L), and any other R_(n)        is optionally modified to be covalently joined to a ABM, a CLM,        a second CLM having the same chemical structure as the CLM, a        CLM′, a second linker, or any multiple or combination thereof.

In any aspect or embodiment described herein, the CLM or ULM has achemical structure represented by:

wherein:

W is independently selected from the group CH2, C═O, NH, and N-alkyl;

R is independently selected from a H, methyl, alkyl;

represents a bond that may be stereospecific ((R) or (S)) ornon-stereospecific; and

Rn comprises 1-4 independently selected functional groups or atoms, andoptionally, one of which is modified to be covalently joined to a ABM, achemical linker group (L), a ULM, CLM (or CLM′) or combination thereof.

Another aspect of the present disclosure provides a bifunctionalcompound comprising the chemical structure: ABM-L-CLM, wherein ABM is anandrogen receptor (AR) binding moiety, L is absent (a bond) or achemical linker, and CLM is a cereblon E3 ubiquitin ligase bindingmoiety is a chemical group derived from an imide, a thioimide, an amide,or a thioamide, wherein the ABM comprises a structure selected from thegroup consisting of:

wherein:

-   -   W¹ is aryl, heteroaryl, bicyclic, or biheterocyclic, each        independently substituted by 1 or more H, halo, hydroxyl, nitro,        CN, C≡CH, C₁₋₆ alkyl (linear, branched, optionally substituted;        for example, optionally substituted by 1 or more halo, C₁₋₆        alkoxyl), C₁₋₆ alkoxyl (linear, branched, optionally        substituted; for example, optionally substituted by 1 or more        halo), C₂₋₆ alkenyl, C₂₋₆ alkynyl, or CF₃;    -   Y¹, Y² are each independently NR^(Y1), O, S;    -   Y³, Y⁴, Y⁵ are each independently a bond, O, NR^(Y2),        CR^(Y1)R^(Y2), C═O, C═S, SO, SO₂, heteroaryl, or aryl;    -   Q is a 3-6 membered ring with 0-4 heteroatoms, optionally        substituted with 0-6 R^(Q), each R^(Q), is independently H, C₁₋₆        alkyl (linear, branched, optionally substituted; for example,        optionally substituted by 1 or more halo, C₁₋₆ alkoxyl),        halogen, C₁₋₆ alkoxy, or 2 R^(Q) groups taken together with the        atom they are attached to, form a 3-8 membered ring system        containing 0-2 heteroatoms);    -   R¹, R², R^(a), R^(b), R^(Y1), R^(Y2) are each independently H,        C₁₋₆ alkyl (linear, branched, optionally substituted; for        example, optionally substituted by 1 or more halo, C₁₋₆        alkoxyl), halogen, C₁₋₆ alkoxy, cyclic, heterocyclic, or R¹, R²        together with the atom they are attached to, form a 3-8 membered        ring system containing 0-2 heteroatoms);    -   W² is a bond, C₁₋₆ alkyl, C₁₋₆ heteroalkyl, O, aryl, heteroaryl,        alicyclic, heterocyclic, biheterocyclic, biaryl, or        biheteroaryl, each optionally substituted by 1-10 R^(W2);    -   each R^(W2) is independently H, halo, C₁₋₆ alkyl (linear or        branched optionally substituted; for example, optionally        substituted by 1 or more F), —OR^(W2A), C₃₋₆ cycloalkyl, C₄₋₆        cycloheteroalkyl, C₁₋₆ alkyl (optionally substituted), C₁₋₆        alicyclic (optionally substituted), heterocyclic (optionally        substituted), aryl (optionally substituted), or heteroaryl        (optionally substituted), bicyclic hereoaryl or aryl, OC₁₋₃alkyl        (optionally substituted; for example, optionally substituted by        1 or more —F), OH, NH₂, NR^(Y1)R^(Y2), CN; and    -   RW2A is H, C₁₋₆ alkyl (linear, branched), or C₁₋₆ heteroalkyl        (linear, branched), each optionally substituted by a cycloalkyl,        cycloheteroalkyl, aryl, heterocyclic, heteroaryl, halo, or        OC1-3alkyl.

In any aspect or embodiment described herein, W¹ is selected from thegroup consisting of:

In any aspect or embodiment described herein, W² is selected from thegroup consisting of:

In any aspect or embodiment described herein, CLM comprises a chemicalgroup derived from an imide, a thioimide, an amide, or a thioamide thatbinds cereblon E3 ubiquitin ligase.

In any aspect or embodiment described herein, the chemical group is aphthalimido group, or an analog or derivative thereof.

In any aspect or embodiment described herein, the CLM is thalidomide,lenalidomide, pomalidomide, analogs thereof, isosteres thereof, orderivatives thereof.

In any aspect or embodiment described herein, the CLM has a chemicalstructure represented by:

wherein

W is selected from the group consisting of CH₂, CHR, C═O, SO₂, NH, andN-alkyl;

each X is independently selected from the group consisting of O, S, andH₂;

Y is selected from the group consisting of CH₂, —C═CR′, NH, N-alkyl,N-aryl, N-hetaryl, N-cycloalkyl, N-heterocyclyl, O, and S;

Z is selected from the group consisting of O, S, and H₂;

G and G′ are independently selected from the group consisting of H,alkyl (linear or branched optionally substituted; for example optionallysubstituted with R′), OH, R′OCOOR, R′OCONRR″, CH₂-heterocyclyloptionally substituted with R′, and benzyl optionally substituted withR′;

Q₁, Q₂, Q₃, and Q₄ are independently a carbon C optionally substitutedwith a group independently selected from R′, N or N-oxide;

A is independently selected from the group H, alkyl, cycloalkyl, Cl andF;

R comprises —CONR′R″, —OR′, —NR′R″, —SR′, —SO₂R′, —SO₂NR′R″, —CR′R″—,—CR′NR′R″—, (—CR′O)_(n)R″, -aryl, -hetaryl, -alkyl, -cycloalkyl,-heterocyclyl, —P(O)(OR′)R″, —P(O)R′R″, —OP(O)(OR′)R″, —OP(O)R′R″, —Cl,—F, —Br, —I, —CF₃, —CN, —NR′SO₂NR′R″, —NR′CONR′R″, —CONR′COR″,—NR′C(═N—CN)NR′R″, —C(═N—CN)NR′R″, —NR′C(═N—CN)R″, —NR′C(═C—NO₂)NR′R″,—SO₂NR′COR″, —NO₂, —CO₂R′, —C(C═N—OR′)R″, —CR′═CR′R″, —CCR′,—S(C═O)(C═N—R′)R″, —SF₅ or —OCF₃;

R′ and R″ are independently selected from the group consisting of abond, H, alkyl, cycloalkyl, aryl, hetaryl, heterocyclyl, —C(═O)R, eachof which is optionally substituted;

represents a bond that may be stereospecific ((R) or (S)) ornon-stereospecific; and

R_(n) comprises a functional group or an atom,

wherein n is an integer from 1-10 (e.g., 1-4, 1, 2, 3, 4, 5, 6, 7, 8, 9,or 10), and wherein

-   -   when n is 1, R_(n) is modified to be covalently joined to the        linker group (L), and    -   when n is 2, 3, or 4, then one R_(n) is modified to be        covalently joined to the linker group (L), and any other R_(n)        is optionally modified to be covalently joined to a ABM, a CLM,        a second CLM having the same chemical structure as the CLM, a        CLM′, a second linker, or any multiple or combination thereof.

In any aspect or embodiment described herein, the CLM or ULM has achemical structure represented by:

wherein:

W is independently selected from the group CH2, C═O, NH, and N-alkyl;

R is independently selected from a H, methyl, alkyl;

represents a bond that may be stereospecific ((R) or (S)) ornon-stereospecific; and

Rn comprises 1-4 independently selected functional groups or atoms, andoptionally, one of which is modified to be covalently joined to a ABM, achemical linker group (L), a ULM, CLM (or CLM′) or combination thereof.

In any aspect or embodiment described herein, the linker group L is agroup comprises a chemical structural unit represented by the formula:

-A_(q)-

wherein A is a group coupled to at least one of CLM, ABM, or both; and

q is an integer greater than or equal to 1,

wherein Aq is selected from the group consisting of, a bond,CR^(L1)R^(L2), O, S, SO, SO₂, NR^(L3), SO₂NR^(L3), SONR^(L3), CONR^(L3),NR^(L3)CONR^(L4), NR^(L3)SO₂NR^(L4), CO, CR^(L1)═CR^(L2), C≡C,SiR^(L1)R^(L2), P(O)R^(L1), P(O)OR^(L1), NR^(L3)C(═NCN)NR^(L4),NR^(L3)C(═NCN), NR^(L3)C(═CNO₂)NR^(L4), C3-11cycloalkyl optionallysubstituted with 0-6 RL1 and/or RL2 groups, C₅₋₁₃ spirocycloalkyloptionally substituted with 0-9 R^(L1) and/or R groups,C3-11heterocyclyl optionally substituted with 0-6 R^(L1) and/or R^(L2)groups, C5-13 spiroheterocycloalkyl optionally substituted with 0-8R^(L1) and/or R^(L2) groups, aryl optionally substituted with 0-6 R^(L1)and/or R^(L2) groups, heteroaryl optionally substituted with 0-6 R^(L1)and/or R^(L2) groups, where R^(L1) or R^(L2), each independently areoptionally linked to other groups to form cycloalkyl and/or heterocyclylmoiety, optionally substituted with 0-4 R^(L5) groups;

R^(L1), R^(L2), R^(L3), R^(L4) and R^(L5) are, each independently, H,halo, C₁₋₈alkyl, OC₁₋₈alkyl, SC₁₋₈alkyl, NHC₁₋₈alkyl, N(C₁₋₈alkyl)₂,C₃₋₁₁cycloalkyl, aryl, heteroaryl, C₃₋₁₁heterocyclyl, OC₁₋₈cycloalkyl,SC₁₋₈cycloalkyl, NHC₁₋₈cycloalkyl, N(C₁₋₈cycloalkyl)₂,N(C₁₋₈cycloalkyl)(C₁₋₈alkyl), OH, NH₂, SH, SO₂C₁₋₈alkyl,P(O)(OC₁₋₈alkyl)(C₁₋₈alkyl), P(O)(OC₁₋₈alkyl)₂, CC—C₁₋₈alkyl, CCH,CH═CH(C₁₋₈alkyl), C(C₁₋₈alkyl)═CH(C₁₋₈alkyl),C(C₁₋₈alkyl)═C(C₁₋₈alkyl)₂, Si(OH)₃, Si(C₁₋₈alkyl)₃, Si(OH)(C₁₋₈alkyl)₂,COC₁₋₈alkyl, CO₂H, halogen, CN, CF₃, CHF₂, CH₂F, NO₂, SF₅,SO₂NHC₁₋₈alkyl, SO₂N(C₁₋₈alkyl)₂, SONHC₁₋₈alkyl, SON(C₁₋₈alkyl)₂,CONHC₁₋₈alkyl, CON(C₁₋₈alkyl)₂, N(C₁₋₈alkyl)CONH(C₁₋₈alkyl),N(C₁₋₈alkyl)CON(C₁₋₈alkyl)₂, NHCONH(C₁₋₈alkyl), NHCON(C₁₋₈alkyl)₂,NHCONH₂, N(C₁₋₈alkyl)SO₂NH(C₁₋₈alkyl), N(C₁₋₈alkyl) SO₂N(C₁₋₈alkyl)₂, NHSO₂NH(C₁₋₈alkyl), NH SO₂N(C₁₋₈alkyl)₂, NH SO₂NH₂.

In any aspect or embodiment described herein, the linker (L) comprises agroup represented by a general structure selected from the groupconsisting of:—N(R)—(CH2)_(m)-O(CH2)_(n)-O(CH2)_(o)-O(CH2)_(p)-O(CH2)_(q)-O(CH2)_(r)-OCH2-,—O—(CH2)_(m)-O(CH2)_(n)-O(CH2)_(o)-O(CH2)_(p)-O(CH2)_(q)-O(CH2)_(r)-OCH2-,—O—(CH2)_(m)-O(CH2)_(n)-O(CH2)_(o)-O(CH2)_(p)-O(CH2)_(q)-O(CH2)_(r)-O—;—N(R)—(CH2)_(m)-O(CH2)_(n)-O(CH2)_(o)-O(CH2)_(p)-O(CH2)_(q)-O(CH2)_(r)-O—;—(CH2)_(m)-O(CH2)_(n)-O(CH2)_(o)-O(CH2)_(p)-O(CH2)_(q)-O(CH2)_(r)-O—;—(CH2)_(m)-O(CH2)_(n)-O(CH2)_(o)-O(CH2)_(p)-O(CH2)_(q)-O(CH2)_(r)-OCH2-;

wherein m, n, o, p, q, and r are each independently 0, 1, 2, 3, 4, 5, 6,with the provision that when the number is zero, there is no N—O or O—Obond, R is selected from the group H, methyl or ethyl, and X is selectedfrom the group H or F.

In any aspect or embodiment described herein, the linker (L) comprises agroup represented by a general structure:

wherein m can be 2, 3, 4, 5.

In any aspect or embodiment described herein, the linker (L) comprises agroup represented by a general structure selected from the groupconsisting of:

wherein n and m are each independently 0, 1, 2, 3, 4, 5, 6, and X is H,or F.

In any aspect or embodiment described herein, linker (L) is selectedfrom the group consisting of:

In any aspect or embodiment described herein, L is a polyethylene groupoptionally substituted with aryl or phenyl comprising from 1 to 10ethylene glycol units.

In any aspect or embodiment described herein, the compound comprisesmultiple LCMs, multiple ABMs, multiple linkers or any combinationsthereof.

In any aspect or embodiment described herein, the compound is a memberselected from the group consisting of Examples 1-452 and 528-625 (e.g.,a compound from Tables 2-7), a salt, a polymorph, isotopic derivative,and a prodrug thereof.

In any aspect or embodiment described herein, the compound is selectedfrom Tables 2-7 (i.e., Exemplary Compounds 1-452 and 528-625).

In any aspect or embodiment described herein, the ABM is selected fromthe group consisting of:

wherein:

-   -   R^(Q2) is a H, halogen, CH₃ or CF₃;    -   RQ3 is a H, halo, hydroxyl, nitro, CN, C≡CH, C₁₋₆ alkyl (linear,        branched, optionally substituted by 1 or more halo, C₁₋₆        alkoxyl), C₁₋₆ alkoxyl (linear, branched, optionally substituted        by 1 or more halo), C₂₋₆ alkenyl, C₂₋₆ alkynyl, or CF₃;    -   Y³, Y⁴, Y⁵ are each independently a bond, O, NR^(Y2),        CR^(Y1)R^(Y2), C═O, heteroaryl, or aryl;    -   R^(Y1), R^(Y2) are each independently H, or C₁₋₆alkyl (linear,        branched, optionally substituted by 1 or more halo, C₁₋₆alkoxyl,        cyclic, or heterocyclic);    -   R^(Q) each independently is H, C₁-C₆ alkyl (linear, branched,        optionally substituted by 1 or more halo, or C₁₋₆alkoxyl), or        two R^(Q) together with the atom they are attached to, form a        3-8 membered ring system containing 0-2 heteroatoms; and    -   X is N or C.

In any aspect or embodiment described herein, each R^(Q) isindependently H or CH₃.

In any aspect or embodiment described herein, R^(Q3) is CN;

In any aspect or embodiment described herein, the ABM is selected fromthe group consisting of:

A further aspect of the present disclosure provides a compositioncomprising an effective amount of a compound or bifunctional compound ofany of claims 1-25, and a pharmaceutically acceptable carrier.

In any aspect or embodiment described herein, the composition furthercomprises at least one additional bioactive agent.

In any aspect or embodiment described herein, the bioactive agent is ananti-cancer agent.

An additional aspect of the present disclosure provides a therapeuticcomposition comprising an effective amount of at least two differentcompounds as described in any of claims 1-25.

Another aspect of the present disclosure provides a method of treating adisease or disorder in a subject comprising the steps of administering acomposition comprising a pharmaceutically acceptable carrier and aneffective amount of a compound or bifunctional compound as described inany of claims 1-25 to a subject in need thereof, wherein the compound iseffective in treating or ameliorating at least one symptom of thedisease or disorder.

In any aspect or embodiment described herein, the disease or disorder iscancer or Kennedy's Disease or both.

In any aspect or embodiment described herein, the cancer is prostatecancer.

In any aspect or embodiment described herein, the composition furthercomprises an effective amount of at least one additional anti-canceragent.

The contents of all references, patents, pending patent applications andpublished patents, cited throughout this application are herebyexpressly incorporated by reference. Except in the Examples, or whereotherwise explicitly indicated, all numerical quantities in thisdescription specifying amounts of materials, and the like, are to beunderstood as modified by the word “about”. It is to be understood thatthe upper and lower amount, range, and ratio limits set forth herein maybe independently combined. Similarly, the ranges and amounts for eachelement of the disclosure can be used together with ranges or amountsfor any of the other elements.

Those skilled in the art will recognize, or be able to ascertain usingno more than routine experimentation, many equivalents to the specificembodiments and methods described herein. Such equivalents are intendedto be encompassed by the scope of the following claims.

It is understood that the detailed examples and embodiments describedherein are given by way of example for illustrative purposes only, andare in no way considered to be limiting to the disclosure. Variousmodifications or changes in light thereof will be suggested to personsskilled in the art and are included within the spirit and purview ofthis application and are considered within the scope of the appendedclaims. For example, the relative quantities of the ingredients may bevaried to optimize the desired effects, additional ingredients may beadded, and/or similar ingredients may be substituted for one or more ofthe ingredients described. Additional advantageous features andfunctionalities associated with the systems, methods, and processes ofthe present disclosure will be apparent from the appended claims.Moreover, those skilled in the art will recognize, or be able toascertain using no more than routine experimentation, many equivalentsto the specific embodiments of the disclosure described herein. Suchequivalents are intended to be encompassed by the following claims.

What is claimed is:
 1. A compound having the structure: CLM-L-ABM, wherein: (a) CLM is a cereblon E3 ubiquitin ligase binding moiety; (b) L is a chemical linker group that is covalently bound to the PTM and the CLM and has the chemical structure -(A^(L))_(q)-, wherein: q is greater than or equal to 1; each A^(L) is selected from the group consisting of CR^(L1)R^(L2), O, NR^(L3), CONR^(L3), CO, C₃₋₁₁ cycloalkyl optionally substituted with 1-6 R^(L1) and/or R^(L2) groups, and C₃₋₁₁ heterocyclyl optionally substituted with 1-6 R^(L1) and/or R^(L2) groups; and R^(L1), R^(L2), R^(L3), R^(L4) and R^(L5) are, each independently, H, halo, C₁₋₈alkyl, OC₁₋₈alkyl, NHC₁₋₈alkyl, OH, or NH₂; and (c) ABM is an androgen receptor (AR) binding moiety having the structure:

wherein: W¹ is aryl or heteroaryl, each independently substituted by 1 or more: H; halo; hydroxyl; nitro; CN; C≡CH; CF₃; linear or branched C₁₋₆ alkyl optionally substituted by 1 or more halo or C₁₋₆ alkoxyl; or linear or branched C₁₋₆ alkoxyl optionally substituted by 1 or more halo; Y¹ and Y² are each independently O or S; R¹, R², R^(Y1), and R^(Y2) are each independently: H; halogen; C₁₋₆ alkoxy, linear or branched C₁₋₆ alkyl optionally substituted by 1 or more halo; or R¹ and R² together with the atom they are attached to, form a 3-8 membered ring system containing 0-2 heteroatoms; W² is aryl or heteroaryl, each optionally substituted by 1-10 R^(W2); each R^(W2) is independently: H; halo; C₁₋₆ alkyl optionally substituted by 1 or more F; C₃₋₆ cycloalkyl; C₄₋₆ cycloheteroalkyl; OH; NH₂; NR^(Y1)R^(Y2); CN; or OC₁₋₃alkyl optionally substituted by 1 or more —F; and

is the point of attachment of the ABM to the chemical linker group (L).
 2. The bifunctional compound according to claim 1, wherein W¹ is:

each R₂₂ is independently halo, H, linear or branched C₁₋₆ alkyl optionally substituted by 1 or more halo, or cyano; and each R₂₃ is independently H, halo, CF₃, linear or branched C₁₋₆ alkyl, C₁₋₆ alkoxy, or cyano.
 3. The compound of claim 1, wherein at least one of: W¹ is selected from the group consisting of:

and W² is selected from the group consisting of:


4. The compound of claim 1, wherein at least one of: W¹ is selected from the group consisting of:

and W² is selected from the group consisting of:


5. The bifunctional compound according to claim 1, wherein the ABM has the chemical structure:

wherein: W¹ is

each R₂₂ is independently H or —CN; each R₂₃ is independently H, halo, or —CF₃; Y¹, Y² are each independently O or S; R¹, R², are each independently H or a methyl group; and W² is aryl or heteroaryl, each optionally substituted by 1, 2 or 3 R^(W2); and each R^(W2) is independently H, halo, C₁₋₆ alkyl optionally substituted by 1 or more F, C₃₋₆ cycloalkyl, C₄₋₆ cycloheteroalkyl, or OC₁₋₃alkyl optionally substituted by 1 or more —F.
 6. The bifunctional compound according to claim 1, wherein the ABM is selected from the group consisting of:


7. The bifunctional compound according to claim 1, wherein the chemical linker group (L) has the chemical structure:

wherein m, n, o, p, q, and r are each independently 0, 1, 2, 3, 4, 5, or
 6. 8. The bifunctional compound according to claim 1, wherein linker (L) comprises a group represented by a general structure selected from the group consisting of:


9. The compound of claim 1, wherein the chemical linker group (L) is a substituted or unsubstituted polyethylene glycol group having 1 to 10 ethylene glycol units (e.g., 1 to 8 ethylene glycol units or 1 to 6 ethylene glycol units).
 10. The compound of claim 1, wherein the CLM comprises a chemical group derived from an amide or a thioamide that binds to the cereblon E3 ubiquitin ligase.
 11. The compound of claim 1, wherein the CLM comprises a chemical group derived from an imide or a thioimide that binds to the cereblon E3 ubiquitin ligase.
 12. The compound of claim 1, wherein the CLM comprises an amide or a thioamide derived moiety.
 13. The compound of claim 1, wherein the CLM comprises an imide or a thioimide derived moiety.
 14. A compound having the structure:

wherein: CLM is a thalidomide analog comprising a substituted glutaramide moiety; L is a chemical linker group that is covalently bound to the PTM and the CLM and has the chemical structure -(A^(L))_(q)-, wherein: q is greater than or equal to 1; each A^(L) is selected from the group consisting of CR^(L1)R^(L2), O, NR^(L3), CONR^(L3), CO, C₃₋₁₁ cycloalkyl optionally substituted with 1-6 R^(L1) and/or R^(L2) groups, and C₃₋₁₁ heterocyclyl optionally substituted with 1-6 R^(L1) and/or RU groups, where R^(L1) and R, together with the carbon they are linked optionally form a cycloalkyl and/or heterocyclyl group; and R^(L1), R^(L2), R^(L3), R^(L4) and R^(L5) are, each independently, H, halo, C₁₋₈alkyl, OC₁₋₈alkyl, NHC₁₋₈alkyl, OH, or NH₂; W¹ is aryl or heteroaryl, each independently substituted by 1 or more: H; halo; hydroxyl; nitro; CN; C═CH; CF₃; linear or branched C1.6 alkyl optionally substituted by 1 or more halo or C₁₋₆ alkoxyl; or linear or branched C₁₋₆ alkoxyl optionally substituted by 1 or more halo; Y¹ and Y² are each independently O or S; R¹, R², R^(Y1), and R^(Y2) are each independently: H; halogen; C₁₋₆ alkoxy, linear or branched C₁₋₆ alkyl optionally substituted by 1 or more halo; or R¹ and R² together with the atom they are attached to, form a 3-8 membered ring system containing 0-2 heteroatoms; W² is aryl or heteroaryl, each optionally substituted by 1-10 R^(W2); and each R^(W2) is independently: H; halo; C₁₋₆ alkyl optionally substituted by 1 or more F; C₃₋₆ cycloalkyl; C₄₋₆cycloheteroalkyl; OH; NH₂; NR^(Y1)R^(Y2); CN; or OC₁₋₃alkyl optionally substituted by 1 or more —F.
 15. The compound of claim 14, wherein the linker comprises at least one group selected from an optionally substituted:

or a combination thereof, wherein m, and n are each independently 0, 1, 2, 3, 4, 5, or
 6. 16. A composition comprising an effective amount of a bifunctional compound of claim 1, and a pharmaceutically acceptable carrier.
 17. The composition of claim 16, wherein the composition further comprises at least one bioactive agent.
 18. The composition of claim 17, wherein the bioactive agent is an anti-cancer agent.
 19. A method for treating a disease or disorder in a subject, the method comprising administering a composition comprising a pharmaceutically acceptable carrier and an effective amount of at least one compound of claim 1, wherein the compound is effective in treating or ameliorating at least one symptom of the disease or disorder.
 20. The method according to claim 19, wherein the disease or disorder is associated with androgen receptor accumulation and aggregation.
 21. The method according to claim 19, wherein the disease or disorder is cancer or a neoplasia associated with androgen receptor accumulation and aggregation.
 22. The method according to claim 19, wherein the disease or disorder is prostate cancer.
 23. The method according to claim 19, wherein the disease or disorder is Kennedy's Disease.
 24. A compound having the structure:

wherein: CLM is a cereblon E3 ubiquitin ligase binding moiety; L is a chemical linker group that is covalently bound to the PTM and the CLM and has the chemical structure

W¹ is an aryl or heteroaryl substituted with CN and optionally substituted with CF₃; R¹ and R² are each a C1 alkyl, or R¹ and R², together with the atom to which they are attached, form a 4 membered cycloalkyl; and W² is aryl substituted with an ethyl. 